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Abstract
The research discussed in this thesis focuses on the development and characterisation 
o f  immunoassays for the detection o f  aflatoxin B i (AFBi), a toxic fungal metabolite, 
and for the diagnosis o f  bovine brucellosis, a highly contagious disease o f  cattle 
caused by B ru ce lla  abortus.
An AFBi-specific single chain fragment variable (scFv) was isolated from a pre­
immunised phage display library and the gene encoding it sub-cloned into a range o f 
different vectors for soluble expression o f  monomeric, dimeric and bifunctional 
scFvs. The genetically-derived scFvs w ere then applied to the development o f  
competitive ELIS As and BIAcore-based inhibition assays for the detection o f  AFBi. 
A  lateral flow im munoassay (LFIA) was developed for the detection o f  AFBi using 
an AFBi-specific monoclonal antibody. Each immunoassay format described was 
suitable for the detection o f  AFBi, with high levels o f  sensitivity, specificity and 
reproducibility achieved.
Several immunoassay form ats for the diagnosis o f  bovine brucellosis, in serum 
samples, w ere investigated. Four antigens were selected as diagnostic markers for 
brucellosis and included w hole B. a b o rtu s  cells, a crude cytoplasmic lysate, an 18kDa 
cytoplasmic protein ( p i8) and a 26kDa periplasmic protein (bp26). Recombinant 
forms o f  the p i 8 and bp26 proteins were cloned and expressed using a high-level 
expression vector in E. co li. Two polyclonal antibodies, directed against whole B. 
a b o rtu s  cells and the crude cytoplasmic lysate, w ere developed and a naive phage 
display library was used to  isolate scFvs directed against the recombinant bp26. 
Feasibility studies w ere carried out on the indirect ELISAs incorporating the four 
antigens and on the sandwich ELISAs w ith the polyclonal antibodies. The indirect 
and sandwich ELISAs, for the diagnosis o f  bovine brucellosis, were then validated 
using a panel o f  B ru ce lla - positive and negative serum samples.
CHAPTER 1
I n t r o d u c t i o n
1
1.1 Immunity to infection
Two cooperative defence systems have evolved to  encounter foreign invasion from 
potentially dangerous viruses, bacteria and other pathogens. Firstly, the non-specific 
innate immunity provides tw o lines o f  defence and secondly the highly specific 
acquired immunity provides the third line o f  defence.
1.1.1 Innate immunity
Non-specific innate immunity is present from birth and fundamentally is not affected 
by prior contact with foreign particles. Several factors, including physiological and 
chemical barriers, phagocytic white blood cells, the inflammatory response and 
complement pathway play critical roles in innate immunity.
The skin and mucous membranes act as the first line o f  defence against foreign 
invasion and prevent micro-organisms gaining entry. W hen intact, the skin is 
impermeable to  infectious agents. The low pH o f  sweat and sebaceous secretions and 
the presence o f  hydrolytic enzymes and fatty acids inhibit microbial growth. Mucous 
membranes lining the inner surfaces o f  the body, such as the respiratory and 
gastrointestinal tracks, trap foreign particles, which are removed from the body by 
ciliary movement, coughing and sneezing. Pulmonary and alveolar macrophages in 
the respiratory tract and the hostile conditions within the gastrointestinal tract, such as 
presence o f  hydrolytic enzym es in saliva, the low pH  o f the stomach and proteoltytic 
enzymes in bile, all aid in the elimination o f  micro-organisms.
Following penetration o f  the physiological and chemicals barriers the second line o f 
defence confronts the invading micro-organism. This involves various specialised 
cells that destroy the foreign micro-organism by phagocytosis or extracellular killing. 
Polymorphonuclear leukocytes, which include basophils, mast cells, eosinophils and 
neutrophils, facilitate in the destruction o f  invading micro-organisms. These short­
lived phagocytic cells contain enzyme-rich lysosomes and produce toxic peroxide and 
superoxide radicals. M acrophages derived from  blood monocytes also play a critical 
role in phagocytosis and subsequent destruction o f  the invading micro-organism. 
Natural killer cells lyse infected cells and tum our cells following the release o f  
cytotoxic molecules.
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The inflammatory response plays a critical role in both innate and acquired immunity. 
It is a complex process initiated by tissue damage that activates clotting, kinin­
formation and fibrolytic pathways. It also induces fever, increased white blood cell 
production, increased synthesis o f  hydrocortisone and adrenocorticotropic hormones 
and production o f  acute-phase proteins.
The com plement system is also involved in innate immunity either by killing invading 
micro-organisms directly or stimulating ingestion and killing by phagocytic cells.
1.1.2 Acquired Immunity
In contrast to innate immunity, acquired immunity is more specialized and specific. 
Two main cells types participate in acquired immunity, B-lymphocytes, which 
differentiate in the bone m arrow and T-lymphocytes, which differentiate in the 
thymus. Acquired immunity can be further divided into cell-mediated immunity, 
which involves T-lymphocytes, and humoral immunity, w hich is mediated by B- 
lymphocytes.
1.1.2.1 Cell-mediated immunity
Follow ing maturation o f  T-lymphocytes in the thymus they migrate to lymphoid 
organs such as the spleen and lymph nodes. T-lymphocytes or T-cells can be 
subdivided into CD4+ and CD8+ T-cells. CD4+ T-cells, w ith  specific T-cell receptors 
(TCRs) recognise and bind foreign antigens presented on the surface o f  antigen 
presenting cells (APCs) in conjunction w ith an M HC class II molecule (Fig. 1.1). 
Stimulation o f  the CD4+ T-cell by the peptide-M HC complex results in the release 
cytokines, which affect the function o f  several cell types, including CD4+ and CD8+ 
T-cells, B-cells, macrophages and eosinophils. Based on the different cytokines 
secreted CD4+ T-cells, which are also known as T helper cells (Th), can be further 
divided into three subsets, ThO, Th I and Th2. ThO cells synthesise IL-2, interferon y 
(IFN-y) and IL-4. ThI and T h2 cells are produced following the antigen driven 
differentiation o f  ThO cells. Th I cells release IL-2, IFN-y and tum our necrosis factor 
beta (TNF-P). These cytokines result in the activation o f  CD8+ T-cells, natural killer 
cells and macrophages, w hich are involved in cell-mediated immunity. Th2 cells
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synthesise IL-4, IL-5, IL-10 and IL-13. The cytokines released by Th2 cells trigger B- 
cells to  class switch to  IgE production and result in the activation o f eosinophils.
In contrast to CD4+ T-cells, the CD8+ T-cells function in the direct killing o f  infected 
cells. CD8+ T-cells or cytotoxic T lymphocytes (CTLs) recognise a foreign peptide in 
conjunction with an M HC class I molecule. Interaction between the TCR, on the 
CD8+ T-cell, and the peptide-M HC class I complex results in the direct killing o f  the 
antigen-presenting cell. Activated CD8+ CTLs release perforin and granzymes, which 
perforate the target-cell membrane and induce apoptosis, respectively. C D 8f T-cells 
also synthesise the cytokines IFN-y and TNF-J3, which are associated with a TH1 
response, and IL-4, which is linked with a Th2 response.
Following antigen stimulation, CD4+ and CD8+ T-cells divide into effector cells (as 
discussed above) and memory cells. The memory cells persist within the body and 
will multiply and m ature if  they are re-exposed to the antigen-M HC complex.
1.1.2.2 Humoral Immunity
Humoral immunity is mediated by B-cells and circulating antibodies. Interaction 
between membrane bound immunoglobulins (Ig), on the surface o f  B-cells, and a 
specific antigen results in the activation o f  B-cells, which start secreting antigen- 
specific antibodies (Fig. 1.2). CD4+ T-cells also play a role in the activation o f  a 
humoral immune response. Following antigen binding at the B-cell surface the 
antigen-immunoglobulin complex is internalised and degraded in acid compartments. 
In conjunction w ith an M HC class II molecule the processed peptides o f  the antigen 
are displayed on the surface o f  the B-cell and, therefore, enable interaction with a 
CD4+ T-cell, expressing the appropriate TCR. Interaction between the peptide-M HC 
class II complex on the B-cell surface and the TCR on the CD4^ T-cell is 
accompanied by key cell surface interactions at the surface o f  the B and T-cells, 
which result in activation o f  the B and T-cells. The activated T-cells synthesise and 
release cytokines and B-cell activation results in the synthesis and release o f  antigen- 
specific antibodies. Several paired interactions are involved in T-cell/B-cell (T-B) 
cooperation. One im portant interaction occurs between CD40 on the surface o f  the B- 
cell and CD154 on the T-cell surface. This interaction promotes upregulation o f  B7, a
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co-stimulatory molecule on the B-cell surface, which in turn interacts with CD28 on 
the T-cell surface increasing the effectiveness o f  the B-cell as an APC. CD40-CD154 
interaction also promotes proliferation and antibody class switching. Following T-cell 
activation, the B-cells differentiate into either antibody secreting plasma cells or 
memory B-cells, which are capable o f  being activated for a subsequent and more 
rapid response to the antigen. B-cell activation can also occur in the absence o f T- 
cells and cytokines produced by T-cells. Generally only large polymeric antigens such 
as bacterial cell wall components are capable o f  these T-independent responses. The 
B-cells are activated following extensive cross-linking between the multivalent 
antigen and B-cell surface immunoglobulins. However, T-independent responses 
primarily generate IgM  antibodies and fail to  give rise to memory.
1.2 Lymphatic system
The lymphatic system comprises the organs in w hich lymphocyte maturation, 
differentiation and proliferation occur. The lymphatic organs are subdivided into 
primary lymphoid organs, in which B-cell and T-cell maturation occurs, and 
secondary lymphoid organs where antigen driven proliferation and differentiation 
occurs (Male e t  al., 1996). The primary lymphoid organs include the bone marrow 
and thymus where B-cells and T-cells develop, respectively. Embryonic B-cell 
differentiation occurs in hem atopoietic stem cells. However, following birth this 
function migrates to  the bone marrow, where mature B-lymphocytes, expressing 
antigen-specific immunoglobulins, are developed. T-cell differentiation occurs in the 
thymus, following migration o f  progenitor cells from the bone marrow. The thymus 
consists o f  epithelial cells organised into cortical and medullary areas, which contain 
thymocytes. Following T-cell maturation, in the cortex, they m igrate to the medulla, 
where they encounter macrophages and dentritic cells. Developm ent o f  mature T-cells 
is completed following thym ic selection. M ature T-cells are capable o f  responding to 
specific foreign epitopes using specific T-cell receptors. Antigen stimulation o f 
mature T-cells and B-cells occurs in the secondary lymphoid organs, which include 
the spleen, lymph nodes, tonsils, appendix, Peyer’s Patches (small intestine), and 
lymphoid aggregates throughout the mucosal tissue. The secondary lymphoid organs 
function in trapping foreign particles and are the main areas for antibody production 
and activation o f  antigen-specific T-lymphocytes.
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IL-2, IFN-y, TNF-P IL-4, IL-5, IL -10, IL -13
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Kill infected cell
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com plex
CD8+ T-cell
I
In fec ted  c e ll
T -ce ll recep to r
F ig u re  1 .1 : O verv iew  o f  the c e ll-m e d ia te d  im m unity. The c e ll-m e d ia te d  immune 
resp o n se  o p era tes  through  the g en era tio n  o f  cy to tox ic  T -cells  f r o m  C D 8 + T -cells a n d  
T -h elper ce lls  (Th)  f r o m  C D 4 + T-cells. F o llo w in g  in teraction  betw een  the T -cell 
recep tor, on  the C D 4 + T-cells, a n d  the an tigen-M H C  c la ss  I I  com plex, on  the an tigen-  
p re se n tin g  cell, the C D 4 + T -ce ll d ifferen tia tes in to  ThI  o r  Th2 cells, w hich secre te  
d iffe ren t cytokines. The C D 8 + T -ce ll d ifferen tia tes in to  a  cy to to x ic  T-cell, fo llo w in g  
in tera c tio n  betw een  its  T -ce ll re c e p to r  a n d  the a n tigen -M H C  c la ss  I  com plex  on  the 
in fec te d  cell.
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F ig u re  1 .2 : O verv iew  o f  T -ce ll d ep en d en t hum oral immunity. In itia lly  an  an tigen- 
p re se n tin g  c e ll  in tern a lises the fo r e ig n  a n tigen  by p h a g o cyto sis . The an tigen  is  then  
p r o c e s s e d  a n d  d isp la y e d  on  the c e ll  su rface  co m p lex ed  w ith  an  M H C  c la ss  I I  
m olecu le. Th c e lls  d irec tly  a c tiva te  B -c e ll d ifferen tia tion  through  ce ll- to -ce ll con tac t 
v ia  s e v e r a l p a ir e d  in te ra c tio n s o r  in d irec tly  through the re lea se  o f  Th2 cy tok in es  
fo llo w in g  in teraction  b e tw een  the T -ce ll recep to r  on  the C D 4 + T -cell a n d  the an tigen- 
M H C  c la ss  I I  com plex  on  the su rface  o f  a  m acrophage. U ltim ately  B -ce ll  
d ifferen tia tion  resu lts  in  the fo rm a tio n  o f  m em ory ce lls  a n d  a n tib o d y-secre tin g  p la sm a  
cells.
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1.3 Antibody structure
Antibodies comprise a class o f  glycoproteins known as the immunoglobulins (Igs) 
that are produced by the immune system in response to  foreign antigens. Five major 
structural classes o f  immunoglobulins exist, which include IgG, IgM, IgA, IgD and 
IgE. The five classes differ from each other depending on the type o f  heavy chain they 
possess. However, IgG  is generally used to  represent the typical antibody structure 
(Fig. 1.3).
IgG  is a monomeric subunit composed o f  four polypeptide chains, two identical y 
heavy chains and tw o identical k  or X. light chains. The IgG  molecule has an apparent 
molecular weight o f  150kDa, with each light chain weighing 25kDa and each heavy 
chain 50kDa. A  heavy chain consists o f  one variable domain (Vh) and three constant 
domains (ChI, Ch2 and Ch3). Each light chain is composed o f  one variable domain 
(V l) and one constant domain (Cl). The light chain consists o f  212 amino acid 
residues and each heavy chain is composed o f  450 amino acid residues (Killard e t a l., 
1995). The hinge region is a short amino acid sequence positioned on the heavy chain 
between the ChI and Ch2 domains, w hich permits flexibility between the antigen- 
binding arms. Each monomeric antibody molecule has tw o antigen binding sites that 
bind to an epitope or antigenic determinant on the corresponding antigen.
The variable regions o f  the immunoglobulin are important for antigen-antibody 
binding and the generation o f  diversity. W ithin the variable region is a considerable 
amount o f  amino acid sequence diversity. The sequence variability is concentrated in 
several hypervariable regions known as complementarity-determining regions 
(CDRs). Each variable light domain and each variable heavy region contains three 
CDRs (CDR1, CDR2 and CDR3). Each CDR is flanked on either side by framework 
regions (FRs), which have little or no sequence variability. The CDRs on the heavy 
and light chain result in the formation o f  a specific 3-D structure, which acts as an 
antigen-binding site, Electrostatic forces, hydrogen bonds, hydrophobic interactions 
and V an der W aals forces are the main non-covalent forces, which give rise to 
antibody-antigen interactions.
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Intra-chain disulphide bonds are present on the heavy and light chains w ith inter-chain 
disulphide bridges linking the tw o heavy chains and linking the heavy chain and light 
chain. The inter-chain and intra-chain disulphide bonds play an important role in the 
globular nature o f  the immunoglobulin. The individual domains o f the 
immunoglobulin chains all form globular structures, which are constructed o f  a P- 
Barrel. P-Barrels consist o f  specific arrangement o f  tw o P-Sheets packed together and 
linked by a disulphide bond resulting in the formation a cylindrical shape. These 
specific P-Barrels are known as the im munoglobulin fold, a structure that plays 
im portant roles in antibody function (Rees e t a l., 1994). The immunoglobulin folds 
are also found in several other molecules o f  the immune and nervous systems as well 
as in other proteins (Porter, 1991).
Immunoglobulins are glycosylated at conserved positions in the constant regions o f  
the heavy chain with each isotype possessing a distinct array o f  N-linked carbohydrate 
structures. The carbohydrates protect against proteoltytic degradation and affect 
protein assembly, secretion and functional activity (W right and Morrison, 1997). In 
the case o f  IgG i there are tw o carbohydrate-binding domains located on the Ch2 
fragment.
The stem o f  the antibody (or the Fc portion) is responsible for the effector function o f  
the antibody and it allows contact with the rest o f  the immune system. The 
im munoglobulin communicates w ith the rest o f  the immune system via Fc receptors, 
which are located on the majority o f  cells involved in the immune response. The Fc 
receptors enable accessory cells (e.g. macrophage, mast cells, eosinophils etc.) to 
detect pathogens through antibody-bound molecules. Different cells express different 
types o f  Fc receptors, which in turn bind different immunoglobulin isotypes. FcyRII 
receptors are found on mast cells, B-cells and neutrophils. Aggregated binding o f IgG 
molecules to FcyRII receptors triggers phagocytosis and the oxidative burst in 
neutrophils. FcyRIII receptors on the surface o f  natural killer cells, eosinophils, 
macrophages, neutrophils and mast cells mediate phagocytosis or antibody dependent 
cellular cytotoxicity following the binding o f  aggregated IgG or IgG  antigen 
complexes. Binding o f  antigen to  IgE-FcsR l complexes on the surface o f  mast cells, 
eosinophils and basophils triggers the release o f  histamines and various inflammatory
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mediators. FcaR I receptors on the surface o f macrophages, eosinophils and 
neutrophils bind IgA  and are involved in antibody dependent cell killing and in the 
clearance o f  immune complexes.
There are five distinct types o f  heavy chains, y, (x, a, 5, and e, which define the five 
classes o f  immunoglobulins, IgG, IgM, Ig A  IgD and IgE, respectively. IgG  is the 
m ost abundant antibody found circulating in the serum and accounts for 70 -75%  of 
the total Ig pool (Roitt e t a l ,  1998). There are four subclasses o f  IgG  in humans, IgGi, 
IgG2, IgG 3 and IgG 4 , and four subclasses in mice, IgGi, IgG 2a, IgGib and IgG 3. The 
number o f  inter-chain disulphide bonds distinguishes the different subtypes o f  IgG. 
IgG  functions in activation o f  the classical complement pathway, thereby attracting 
phagocytic cells. IgG  molecules also bind to  Fc receptors on the surface o f  
macrophages and polymorphs and cross the placenta by passive transfer, thus 
conferring immunity to  the foetus. IgM  occurs naturally as a pentamer, with an 
additional J-chain for polymerisation, and has a molecular w eight o f  900 kDa. IgM  is 
involved in the activation o f  the complement cascade and in the activation o f 
macrophages. IgA exists as a dimer and is mainly produced at mucosal surfaces. 
There are tw o IgA  isotypes, IgAi and IgA2 . IgAi is predominant in the serum where 
IgA2 is found in secretions such as saliva and tears. IgA  functions in preventing the 
attachm ent o f  viruses and bacteria to  the epithelial. IgD appears in the serum as a 
m onom er and is a surface com ponent o f  B-cells. Although the function o f  IgD is still 
poorly understood it is believed to  act as an antigen receptor on B-cells and be 
involved in lymphocyte differentiation. IgE also appears as a monom er in the serum 
and defends the body against parasitic invasion. IgE interacts with mast cells and 
eosinophils and stimulates mast cells to  release histamine. However, the interaction 
between IgE and the mast cells and eosinophils can lead to hypersensitivity reactions 
such as hay fever, asthma, hives and anaphylaxis.
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F ig u re  1 .3 : D ia g ra m m a tic  rep resen ta tio n  o f  an  im m unoglobulin  G  (IgG ) m olecule. 
The Ig G  m olecu le  is  co m p o sed  o f  tw o id en tic a l lig h t ch ains a n d  tw o  id en tica l h eavy  
chains. The lig h t ch a in s co m p rise  o f  a  va r ia b le  (V\) a n d  con stan t (Ci) dom ain. The 
h ea vy  ch ain  co n sis ts  o f  one va ria b le  (V h ) cm d three co n sta n t (ChI  Ch2 a n d  Ch3) 
dom ain s w ith  a  h inge reg io n  con n ectin g  the C h I a n d  Ch2 regions. The h ea vy  a n d  
ligh t ch a in s a re  co n n ec ted  v ia  d isu lph ide  b o n d s; d isu lph ide bon ds a re  a lso  p r e s e n t in 
the con stan t a n d  va ria b le  reg ions. The C D R s w ith in  the va ria b le  dom ain s confer  
a n tig en ic  sp ec if ic ity  a n d  con ta in  co n sid era b le  am ino a c id  sequ en ce variation .
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1.4 Genetic basis of antibody diversity
In humans, there is an estimated 108 antibody molecules, each with a different 
antigenic specificity (French e t ah , 1989). The variable regions o f  the antibody encode 
the diversity. The k  and X light chains and the heavy chains are encoded by separate 
m ulti-gene families, which are situated on different chromosomes. The gene family 
encoding the k  light chain are located on chromosome 2 ,  those for the X chain are 
located on chromosome 22 and the gene segments encoding the heavy chain are 
positioned on chromosome 14. In all cells, except B cells and lymphocytes, a 
considerable distance separates the genes encoding the variable and constant domains 
o f  an immunoglobulin. During B-cell differentiation DNA rearrangements occur that 
bring the constant and variable regions closer together (Davies e t ah , 1999).
The variable regions o f  the k  and X light chains are encoded by tw o separate gene 
fragments. The Vi, (variable) segment encodes the first 95 amino acids and the J l  
(joining) segment encodes 13 amino acids amino acids at the carboxy-terminal. (Fig. 
4). During D N A  rearrangement the V l and Jl gene segments are combined (VJ 
recombination) to produce a continuous piece o f  D NA that encodes for the variable 
domain o f  the light chain. Following transcription, RN A  splicing combines the V-J 
segment and constant (Cl) domain.
The gene arrangement o f  the heavy chain is similar to that o f  the light chain (Fig. 1.5). 
In contrast with the light chain four gene segments, Ch, Vh, Jh and Dh, encode the 
heavy chain. Thus, in addition to  the V and J segments, genes encoding the variable 
region o f  the heavy chain also include a D h (diversity) segment. The D H gene 
segment is situated between the Vh and the Jh gene segments. M ultiple genes 
encoding the Ch domain are also present in the germline, which determine the 
antibody class. There are tw o recombination steps involved in the generation o f  the 
heavy chain, firstly the D h segment is joined to the Jh segment and then the Vh 
segment is joined to the DJ segment, which gives rise to  the Vh domain. RN A 
splicing then joins the Vh segment to the C h region (Lewis, 1994).
Although the molecular events leading to recombination are not completely 
understood several factors involved in the rearrangement o f  the antibody gene
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segments have been identified. An enzyme complex, V(D)J recombinase, mediates 
the rearrangement o f receptor genes in B and T cells. Two recombination activation 
genes (RAG), RAG-1 and RAG-2 have been identified, the products o f  which are 
exclusively expressed in lymphocytes and critical for the development o f T and B- 
cells. RAG-1 and RAG-2 proteins cut double stranded D N A  at recombinational signal 
sequences (RSS) forming double-stranded breaks. The RSS are non-coding DNA 
sequences, which are critical for recom bination o f  antibody genes. The RSS are 
conserved sequences located at the 3' side o f  the V segments, the 5' side o f the J 
segments and on both sides o f  the D h segments. Each RSS consists o f  seven 
nucleotides (heptamer) and a block o f  nine nucleotides (nonamer), which are 
separated by a 12 or 23 base pair spacer. The heptamer is a conserved sequence, 
which can be CACAGTG or the inverse complement and the conserved nonamer 
sequence can be ACAAAAACC or the inverse complement.
Several factors, such as the presence o f  multiple variable (V) genes, combinatorial 
association, random assortm ent o f  heavy (H) and light (L) chains, junctional and 
insertional diversity and somatic hypermutations are all involved in generating 
antibody diversity. The num ber o f  different genes encoding the variable region in the 
germ line constitutes the baseline from which antibodies are derived. Initially, 
diversity results from the form ation o f  a complete variable-region gene following the 
random recombination o f  separate V, D  and J gene segments. Additional diversity is 
introduced during random assortm ent o f  the H  and L chains during which any H  chain 
may associate with any L  chain. Inaccuracies also occur at the precise positions at 
which the V, D and J segments join, resulting in junctional diversity. The absence o f  
precision in joining the gene segments during DNA rearrangement leads to  deletions 
or amino acid changes, which result in the generation o f  diversity. In addition small 
sets o f  nucleotides can also be inserted at the V-D and D -J junctions. This is referred 
to as insertional diversity and is mediated by the enzyme terminal 
deoxynucleotidyltransferase (TdT). Somatic hypermutations, w hich occur in the V 
genes o f  heavy and / or light chains during the lifetime o f  the B cell, also increase 
antibody diversity. These somatic hypermutations are predominantly point mutations 
in the V(D)J recombined segment o f  the antibody V  genes, and lead to amino acid 
changes. These mutations occur at a rate at least ten-fold higher than the normal rate
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o f mutation and results in the generation o f  antibodies with increased affinities 
(Benjamini e t a l., 2000).
Following antigenic stimulation, a B-cell can rearrange its DNA  and switch to  make a 
different class o f  antibody, which retains the same antigenic specificity. This 
phenomenon is known as class or isotype switching and involves further DNA 
rearrangement, combining the VDJ genes w ith different heavy chain C genes. Each 
Ch region gene contains a 5' end stretch o f  repeating bases called the switch (S) 
region, which permits any Ch gene (except 5, which contains no S region) to associate 
with the VDJ segment. Following stimulation a B-cell with a VDJ segment linked to 
C(x rearranges its DNA to link the VDJ region to  an S region in front o f  an alternative 
C gene. In doing so the intervening C region DNA  is removed, and therefore, the B- 
cell loses its ability to  revert to  making this class o f  antibody. This mechanism is 
regulated by antigen and T-cell derived cytokines and allows an antibody with a 
single antigenic specificity to  associate with a variety o f  different effector functions.
k  light chain genes
A. light chain genes
Vx, Vu m Vju* JjU
- Cm Cu
Heavy chain genes
Vu, V»-* Dm Dn ¡o - •Ini JJT6 C, ca c .
F ig u re  1 .4 : G erm line D N A  a rra n g em en t o f  the g en es en co d in g  the h ea vy  a n d  ligh t 
chains. The three se ts  o f  g e n e s  a re  en co d e d  f o r  on  d is tin c t chrom osom es. M o d if ie d  
fr o m  B en jam in i e ta l .  (2000).
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F ig u re  1 .5 : S chem atic represen ta tion  o f  the even ts lea d in g  up to  h ea vy  chain  synthesis. G erm line D N A  is  rea rra n g ed  in to  B -ce ll D N A fo llo w in g  
tw o-recom bin ation  steps, w hich  resu lt in VJD jo in in g . The D N A is then tra n scr ib ed  in to  mRNA, which is  tra n sla ted  in to  the h ea vy  chain  
p o lyp ep tid e . M o d ified fro m  B enjam in i e t a l . (2000).
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1.5 Antibody production
1.5.1 Polyclonal antisera
Following immunisation o f  an animal w ith a particular immunogen, an immune 
response is induced against the foreign antigen. Polyclonal antiserum can be 
recovered from the immunized subject and should contain several antibody 
populations, with different epitope specificities, against the particular immunogen. 
Relatively large animals such as rabbits, goats, sheep, guinea pigs, donkeys and fowl 
have all been used for the generation o f  polyclonal antisera. The chosen subject used 
for the immunization depends on the type and quantity o f  antiserum required, on the 
previous success o f  the particular animal and on the cost and welfare o f  the animal. 
Rabbits are frequently used for the production o f  polyclonal antiserum because they 
are cheap and easy to handle for im munisation and bleeding purposes. Polyclonal 
antisera production is relatively cost effective and does not involve laborious 
techniques. However, the heterogeneous antibody population may cross-react with 
structurally related molecules and there is little consistency between batches. Small 
molecules or haptens (i.e. < 1000 D altons) must be covalently attached to a large 
carrier molecule such as bovine serum albumin (BSA), prior to immunisation, to  elicit 
an im mune response against it. The protein conjugate is required during the 
production, screening and characterisation o f  antibodies.
1.5.2 Monoclonal antibody production
The first system for the production o f  monoclonal antibodies was reported by Kohler 
and M ilstein (1975). It provided an alternative method for antibody production, 
resulting in the isolation o f  a homogenous antibody population. Plasma cells are the 
end product o f  B cell differentiation and they produce antibodies o f a single 
specificity. However, plasm a cells can only last a few days under cultured conditions. 
On the other hand myelom a cells are immortalised cancerous cells that can survive 
extended periods o f  time in culture and are non-antibody producers. Somatic cell 
hybridisation allows the fusion o f  the antibody secreting plasma cell and the 
im m ortalised myeloma cell. The resulting hybridoma (h yb rid -m ye io m a )  displays 
characteristics from both parental cell types. It exhibits the immortality o f  the
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myeloma cell and the antibody producing properties o f  the splenocyte, resulting in a 
virtually unlimited supply o f  the specific antibody.
The B-lym phocytes are generally isolated from an immunised animal, such as a 
mouse or rat. Following several intra-peritoneal and a final intravenous immunisation 
with the specific antigen or hapten-carrier conjugate the spleen, which is then rich in 
antibody-secreting B-lymphocytes, is removed and the spleenocytes recovered.
The myeloma cells used are derived from tum ourogenic murine plasma cells (Van 
Em on e t  a l., 1989). Commonly used myeloma cell lines include X63-Ag8.653 and 
Sp2/0-agl4. The myeloma cells lack the enzyme hypoxanthine guanine 
phosphoribosyl transferase (HGPRT). The absence o f  this enzyme renders the 
myeloma cell incapable o f  synthesising purines and pyrimidines when grown in the 
presence o f  HAT (hypoxanthine, aminopterin and thymidine)-supplemented media. 
The aminopterin blocks D N A  synthesis via the d e  n ovo  pathway and in the absence o f 
the enzyme HGPRT, the myeloma cells are unable to  synthesise purines and 
pyrimidines using the salvage pathway (Fig. 1.6). Spleenocytes have the enzyme 
HGPRT and in the presence o f  aminopterin convert to  the salvage pathway for DNA 
synthesis. However, in v itro  the splenocytes are unable to  proliferate and die o ff 
within days. Following the myeloma and spleenocyte fusion the resulting hybridoma 
will proliferate in the presence o f  HAT, as it will have inherited the HGPRT enzyme 
from the spleenocyte. This H A T selection system, employed by Kohler and M ilstein 
(1975), was previously described by Littlefield (1964).
Figure 1.7 outlines the principle o f  monoclonal antibody production. The splenocytes 
and myeloma cells are fused in the presence o f  polyethylene glycol (PEG), which is a 
polywax that promotes cell fusion and transfer o f  nuclei. The resulting hybridomas are 
immortalised and produce specific antibodies, expressing properties from both 
parental cell lines. However, the fusion event occurs w ith an extremely low frequency 
o f  10'5. This means that approximately 108 spleen cells are required to  produce 1000 
hybrid cells and out o f  the hybrid cells produced only a  small number will secrete the 
desired antibody (Wild and Davies, 1994). After the fusion has taken place, a mixed 
population o f  hybridomas, unfused lymphocytes and unfused myelomas remain. The 
hybridom a cells are positively selected for when grown in the presence o f  HAT. The
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myeloma cells, lacking the enzyme HGPRT, die o ff in the presence o f  HAT and the 
spleenocytes die within a few days in culture, regardless o f  the growth medium. Then, 
using limiting dilution, hybridomas from a single cell parent, secreting the specific 
antibody, are isolated (Goding, 1996).
Alternatively, monoclonal antibodies can be produced following an in v itro  
immunisation (Borrebaeck e ta l . ,  1983). Naive spleenocytes are isolated from a non­
immunised mouse and exposed to  the antigen in culture for a period o f  5 -  9 days. 
The activated spleenocytes are then fused w ith the myeloma cells as described above. 
An in  v itro  im munisation leads to  a primary im mune response and the resulting 
antibodies produced are predominately IgM, which have lower affinities than IgG  
antibodies. Previously, an initial in v ivo  immunisation, prior to  the secondary in v itro  
boost, has lead to  an increase in the production o f  IgG  antibodies (De Boer e t al., 
1989).
F ig u re  1 .6 : The d e  n o vo  b iosyn th esis  o f  p u r in es  a n d  p yr im id in es  is  b lo ck ed  in the 
p re se n c e  o f  am inopterin . In  the a bsen ce o f  d e  n o vo  syn thesis, ce lls  con ta in in g  the 
en zym es h ypoxan th ine-guan ine p h o sp h o r ib o sy l tran sferase  (H G PR T) a n d  thym idine  
kinase (TK), co n vert to  the sa lva g e  p a th w a y  f o r  n u cle ic  a c id  synthesis, in the p re se n c e  
o f  hypoxan th ine a n d  thym idine. H ow ever, ce lls  la ck in g  the enzym e H G P R T  w ill  d ie  
o f f  in  the p re se n c e  H A T  b e c a m e  th ey  a re  unable to  p ro d u c e  p u r in es  a n d  p yr im id in es  
f o r  n u c le ic  a c id  synthesis.
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p ro d u ctio n .
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1.6 A ntibody fragm ents
The Ig molecule can be broken into several fragments using chemical, enzymatic or 
genetic means. Research conducted by Porter and associates (1966) demonstrated 
that proteoltytic treatm ent o f  the Ig w ith the enzyme papain resulted in the formation 
o f  three fragments. Papain cleaves the tw o heavy chains above the interchain 
disulphide bridge, resulting in the formation o f  tw o individual antibody-binding 
fragments (Fab) and the Fc portion. Treatment o f  the Ig  with the enzyme, pepsin, 
cleaves the tw o heavy chains below the interchain disulphide bond and results in the 
formation o f  an antibody fragment containing two binding arms (F(ab ')2).
Various antibody fragments, including the Fab, Fv and scFv, can also be produced 
using recombinant D N A  technology. The smallest antibody fragment required for 
complete antigen binding is the Fv fragment. This truncated Fab fragment consists o f 
one V l domain and one Vh domain. The Fv fragment can be very unstable for use in 
therapeutics or imunnoanalysis because it lacks the inter-chain disulphide bond, which 
is present in the Fab fragment. A  synthetic peptide linker, or in some cases the 
insertion o f  cysteine residues to  form a disulphide bridge, has been incorporated into 
the Fv fragment to  produce a more stable single chain Fv fragment (scFv) (Brinkmann 
e t ah, 1993; Reiter e t  ah, 1994 and Young e t  ah , 1995). Other antibody fragments 
have been engineered that have the ability to  bind antigen, these include the Fd, which 
consists o f  one Vh and one ChI domain, and CDR, the smallest antibody fragment 
capable o f binding to  an antigen (Fig. 1.8).
The scFv is one o f  the m ost commonly used antibody fragments, with many analytical 
and therapeutic applications. Recom binant scFvs w ith specific affinities have been 
produced and applied to  the detection o f  illicit drugs (Brennan e t  a l ,  2002 and Dillon 
e t  ah, 2003), residues (Garrett e t ah, 1997; A lcocer e t ah, 2000 and Strachan e t  a l  
2000) and food contaminants (Daly e t  ah, 2001). The small size and stability o f  the 
scFv fragments makes it particularly applicable to  therapeutics (Arakawa e t ah, 2002 
and Suzuki e t ah, 2003). The attachm ent o f  a toxin or label has also enabled the use o f 
scFv in drug therapy (Sun e t ah , 2003) and tum our imaging (Demartis e t ah, 2001).
Recom binant phage display technology (Section 1.7) is now  routinely utilised in the 
generation o f  scFv antibody fragments.
2 0
scFv
C D R
F d
F ig u re  1 .8 : S tructure o f  the va rio u s Ig G  a n tib o d y  fra g m en ts , w hich  m a y be g en era ted  
through  gen etic , en zym atic  o r  ch em ica l m anipulations. The F (a b  )2  con sists  o f  tw o  
a n tigen  b in d in g  fra g m e n ts  lin k e d  a t  the h inge regions, w ith  the F ab  fra g m e n t  
co n sis tin g  o f  on e an tigen  b in d in g  dom ain  a n d  the F d  co m p ris in g  one Vh  a n d  one Ch  
dom ain. The F v  fra g m e n t co n sis ts  o f  one Vh a n d  one Vl, w hich  fo llo w in g  
s ta b ilisa tio n  b y  a  syn th e tic  lin k er re su lts  in  the fo rm a tio n  o f  the scF v  fragm en t. The 
C D R  rep re sen ts  the sm a lle s t a n tib o d y  fra g m e n t ca p a b le  o f  an tigen  binding.
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1.7 Phage display technology
The introduction o f  phage display technology, in 1985 by Smith, paved the way for an 
alternative method o f  antibody production in  v itro  (Smith e t al., 1985). Phage display 
technology enabled the expression o f  antibody fragments on the surface o f  
filamentous phage as a fusion partner to a phage coat protein. Phage particles 
displaying an antibody fragment o f  interest could then be subsequently selected using 
a method known as panning (See Section 1.7.5), which has enabled the isolation o f  
high affinity antibodies (Barbas, e t a l ., 1991; Breitling e t a l., 1991; Garrard e t a l ,  
1991; Hoogenboom  e t a l., 1991 and M cCafferty e t a l., 1990). Fab (Hoogenboom e t  
al., 1991) and single chain Fv (scFv) (M cCafferty e t  al., 1990) antibody fragments 
have been displayed on filamentous phage attached to either the N-terminus 
(M cCafferty e t  al., 1991) or C-terminus (Barbas e t al., 1991) o f  the minor phage coat 
protein g3p. Large antibody repertoire libraries can be generated from a variety o f 
naive, immunized and synthetic sources.
1.7.1 The Filamentous Phage
The filamentous phage are routinely used in phage display technology. They belong to 
the genus In virus  and infect a variety o f  gram-negative bacteria. They are 
metabolically inactive in their extra-cellular form and only capable o f  reproduction 
within their host. The F f  bacteriophage ( f l ,  fd and M l 3) are the most extensively 
studied and, as their name would suggest, they infect host cells via attachment to the F 
pili, present on male E. co li such as TGI.  The phage particle is comprised o f  a single 
strand o f  circular D N A  encapsulated in a protein coat. The single stranded genome 
contains 11 genes, which encode the proteins required for D NA  replication, the 
protein capsid and phage assembly. The filamentous phage replicate within the host 
cells w ithout inducing a lytic infection. The F f  bacteriophage attach to  the F pilus on 
the E . co li host via the gene Ill-encoded coat protein (g3p) and the single stranded 
D NA  enters the cell. W ithin the host the single stranded D NA is replicated via a 
double stranded intermediate, which is produced using the host’s genetic machinery. 
The replicated single stranded genome serves as a template for expression o f  the 
phage proteins. The phage coat proteins are expressed as integral membrane proteins 
and the single stranded phage genom e is packaged into the protein capsid at the 
bacterial membrane and released. Figure 1.9 represents the structure o f  a phage 
particle displaying an scFv fused to the p in  coat protein.
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F ig u re  1 .1 9 : S ch em atic  represen ta tion  o f  a  f ila m en to u s  p h a g e  p a r tic le  d isp la y in g  an  
scF v a n tib o d y  fra g m en t. The scF v is  d isp la y e d  a tta c h e d  to  the p i l l  p h a g e  c o a t p ro tein , 
w ith  the g en es  en co d in g  the va ria b le  h ea vy  a n d  lig h t chains en co d ed  f o r  on  an  
expression  vector, w ith in  the fila m en to u s  ph a g e.
1.7.2 Expression vectors
There are a variety o f  phage and phagemids vectors available for the expression o f 
antibody fragments on the surface o f  filamentous phage. Phage vectors encode the 
g3p-antibody fusion along with all the genes required for replication, packaging and 
bacterial infection. Phagem ids vectors encode the g3p-antibody fusion, the phage and 
E. co li origins o f  replication and an antibiotic resistance for selection. However, 
unlike the phage vector, they lack all structural and non-structural genes. Therefore, 
they require rescue with a helper phage that encodes the appropriate proteins for 
phage replication and packaging. Suitable helper phage that are routinely used in 
phage display are VCSM13 and M 13K07, which both encode a kanamycin resistance 
gene for selection. Rondot and associates (2001) have described a helper phage called 
hyperphage that increased antibody phage display particles by more then tw o fold. 
These hyperphage have a w ild-type p il l  phenotype and are capable o f  infecting F ' E. 
co li cells w ith high efficiency. However, they lack a functional p ill  gene so that the 
phagemid-encoded p in  antibody fusion is the sole source o f  p il l  in phage assembly. 
Therefore, this results in a considerable increase in the number o f phage displaying
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the antibody fragment on their surface. Prom oter regions and tags, to aid in 
purification and detection, are also coded for on the phagemid vector.
1.7.3 Library construction
Initial stages o f  library construction involve the isolation o f  a genetic source from 
which total RNA is extracted (Fig. 1.10). The genetic material can be sourced from a 
variety o f  locations including peripheral blood lymphocytes, lymph nodes, the spleen, 
bone marrow and hybridomas. The mRNA is then reverse transcribed into cDNA and 
the V h  and V l  genes PCR amplified using universal primer sets that in theory enable 
the amplification o f  the entire antibody repertoire. Several universal prim er sets have 
been described for the production o f  antibody phage display libraries, which have 
been species specific and degenerate, and have enabled the construction o f  V-gene 
repertoires from several species including humans (Marks e t al., 1991) and mice 
(Clackson e t  a l., 1991; Kettleborough e t a l., 1993 and Krebber e t  al., 1997). The V h  
and V l chains are then assembled into the scFv fragment by SOE-PCR (slicing by 
overlap polym erase chain reaction). The SOE-PCR is carried out using specific 
primers w ith restriction sites that aid in the later stages o f  cloning. Depending on the 
cloning strategy and display vector o f  choice, the restriction sites may be engineered 
outside the V-region or within the scFv sequence. The scFv fragment is then cloned 
into the appropriate vector, following restriction o f  the scFv insert and display vector. 
The vector containing the scFv insert is transformed into CaCl2 competent or electro- 
competent E. co li cells, for antibody expression. The ligation and transformation 
efficiency are crucial steps in library construction and they can directly influence 
library size (Azzazy and Highsmith, 2002). The transformed bacterial cells are then 
infected with a helper phage (VCSM13 or M13K07), which results in the production 
o f  antibody displaying phage particles. Transformation efficiencies o f  bacterial cells 
have limited library size to  approximately 1x10s. However, larger phage repertoires 
o f  approximately lx lO 10 clones have been reported (Griffiths e t a l ,  1994) following 
combinatorial infection and in  v ivo  recom bination (W aterhouse e t a l., 1993). More 
recently, techniques involving in v itro  display and the introduction o f  mutagenesis 
steps into the antibody-encoding RN A sequence (See Section 1.7.8.5) have enabled 
the construction o f  antibody libraries containing > 1012 clones (Hanes e ta l . ,  2000).
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1.7.4 A ntibody repertoires
1.7.4.1 Naïve repertoires
Naïve antibody repertoires are constructed using B-lym phocytes from non-immunised 
human or animal donors. The IgM  mRNA is isolated from peripheral blood 
lymphocytes, bone marrow or spleen cells. Naïve antibody repertoires enable the 
isolation o f  high affinity antibodies against self, non-immunogenic and toxic antigens 
and they can be used for the isolation o f  antibodies against numerous antigens in a 
relatively short period o f  time.
Numerous large naïve repertoires have been reported and have enabled the isolation 
o f  antibodies against a variety o f  antigens. Non-immunised human donors (43) were 
used to  construct a repertoire o f  1 .4x l010 scFv-phage display particles (Vaughan e t  
al., 1996). This library provided a source o f  specific, high affinity human monoclonal 
antibodies against a variety o f  antigens including fluorescein, and the haptens DTPA 
and oestradiol. A  naïve human Fab repertoire containing 3 .7 x l0 10 clones has also 
been reported (de Haard e t a l ,  1999). Naïve human repertoires have also enabled the 
isolation o f  antibody fragments against antigens associated w ith C hlam ydia  
trach om atis  (Lindquist e t  al., 2002) and small haptens such as aflatoxin Bi 
(M oghaddam e t a l ,  2001).
1.7.4.2 Immunised repertoires
A ntibody repertoires can also been constructed from IgG genes isolated from  B- 
lymphocytes from  immunised animals and immune donors. Pre-immunised libraries 
are enriched with antigen-specific antibodies, some o f  which will have been affinity 
matured within the host. However, this method o f library construction may be time­
consuming if  animal im munisation if  required, antibodies against self or toxic 
antigens cannot be isolated, individual libraries must be constructed for different 
antigens and the immune response against different antigens is unpredictable.
Immunised or pre-immunised repertoires have been constructed following 
immunisation o f  mice (Daly e t  al., 2002 and D illon e t a l ,  2003), chicken (Davies et 
al., 1995 and Yamanaka e t  a l., 1996), rabbits (Lang e t al., 1996), sheep (Charlton e t 
al., 2001), camels (Arbabi e t  al., 1997) and sharks (Dooley e t  a l ., 2003). Immunised
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phage display libraries have been used for the isolation o f  antibody fragments against 
small haptens such as morphine-3-glucuronide (Dillon e t al., 2003), the mycotoxins 
zearalenone (Yuan e t a l ,  1997) and aflatoxin Bi (Daly e t  al., 2002) and bacterial cells 
including B. m eliten sis  (Hayhurst e t  al., 2003).
1.7.4.3 Synthetic repertoires
Synthetic antibody libraries are constructed artificially by in  v itro  assembly o f  V gene 
fragments and D /J segments. Synthetic repertoires are made following randomisation 
o f  the CDR regions using oligonucleotide-directed mutagenesis or PCR-based 
techniques. The CDR3 o f  the heavy chain is most central to the antigen-binding site 
and encodes the majority o f  the structural and sequence diversity, with the other five 
CDRs encoding limited variation. Therefore, it has been targeted for introducing 
diversity in synthetic libraries. Synthetic repertoires have been constructed using 
randomised light and heavy chain CDR3s (Akamatsu e t  a l ,  1993) and V-gene 
segments in which all three CDRs have been diversified (Garrard and Henner, 1993). 
Synthetic libraries enable control over the contents, local variability and overall 
diversity o f  the antibody repertoire.
Hoogenboom and W inters (1992) reported the construction o f  one o f the first 
synthetic antibody repertoires. Human Vh fragments (49), containing short CDR3 
regions encoding either 5 or 8 amino acids and a J-region, w ere assembled using PCR 
and cloned for scFv display w ith a human lambda light chain. Subsequently, more 
diversity was introduced following enlargement o f  the CDR3-region, which ranged 
from 4 - 1 2  amino acids (Nissim e t al., 1994). The largest synthetic library 
constructed to date consists o f  6 .5 x l0 10 Fab-displaying phage (Griffiths e t al., 1994). 
This library w as constructed using the 49 human VH fragments (Hoogenboom and 
W inters, 1992), which w ere combined w ith 47 human kappa and lambda light chain 
fragments containing partially randomised CDR3 regions. Synthetic libraries have 
been reported for the isolation o f  antibody fragments against a variety o f  antigens 
such as haptens, foreign antigens and human antigens (Griffiths e t a l ,  1994) and 
environmental contaminants including microcystin-LR a cyanobacterial hepatotoxins 
(M cElhiney e t a l ,  2000) and S trep to co ccu s su is  (de G reeff e t a l ,  2000).
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1.7.5 Isolation of specific antibody fragments from antibody repertoires
The isolation o f  specific-phage clones, expressing the antibody fragment o f  interest, 
enables the sequential enrichment o f  specific binding phage from  a large repertoire o f  
non-binding clones. Figure 1.11 outlines the bio-panning process, which involves 
m ultiple rounds o f  selection during which specific phage are bound to the 
immobilised antigen and non-specific phage are washed away. Bound phage are 
eluted and reinfected into bacteria for further rounds o f  selection and enrichment. 
Selection can be performed against the antigen absorbed onto plastic surfaces such as 
immunotubes and ELISA  plates (Marks e t a l ,  1991) or against the antigen 
immobilised on a Biacore sensor surface (M alm borg e t a l ,  1996). The bound phage 
can be eluted from the specific antigen using acidic solutions such as HC1 or glycine 
buffer (Krebber e t al., 1997), with basic solutions, such as triethylamine (Marks e t a l ,  
1991 and de Bruin e t al., 1999), following enzymatic cleavage o f  a protease-sensitive 
site engineered between the antibody and gp3 (W ard e t  a l ,  1996) or by competition 
with excess antigen (Clackson e t  a l ,  1991).
Selection using antigens in solution have also been described (Hawkins e t a l ,  1992 
and Griffiths e t a l ,  1994). Following incubation o f  the phage antibody repertoire with 
biotinylated antigen, phage bound to  the labelled antigen are recovered using avidin or 
streptavidin-coated paramagnetic beads. Panning can also be performed on 
monolayers o f  adherent cells or on cells in suspension for the isolation o f  antibodies 
against cell surface antigens (de K ruif e t  a l ,  1995 and Cai and Garen, 1995). In  v ivo  
selection methods have also been described, which involves the direct injection o f 
antibody repertoires into animals followed by tissue isolation and examination o f  
bound phage (Pasqualini and Ruoslahti, 1996).
Following each round o f  selection, eluted phage are analysed for specific-antigen 
binding. Phage ELISAs are commonly used during which the antigen o f  interest is 
immobilised on an im munoplate and incubated with the antibody-displaying phage 
clones. Bound phage particles are then detected using an enzyme-labelled secondary 
antibody specific for either the phage o f  a phagemid-encoded tag (e.g. c-myc).
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F ig u re  1 .1 1 : S ch em atic  rep resen ta tio n  o f  the se lec tio n  p r o c e s s  f o r  the iso la tio n  o f  
sp ec ific  p h a g e  clones. The p h a g e  rep er to ire  is  in cu b a ted  w ith  the an tigen  o f  interest. 
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w a sh e d  aw ay. P o s itiv e  p h a g e  a re  then  e lu te d  a n d  re in fec ted  in to  b a c te r ia l f o r  fu r th er  
rou nds o f  se lec tio n  a n d  enrichm ent.
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1.7.6 Soluble expression of antibody fragments
Following selection, the antigen-positive phage are infected into a non-suppressor E. 
co li strain (e.g. TG I and JM83) for soluble scFv production. These bacterial strains 
recognise the phagemid encoded amber stop codon situated between the scFv gene 
segment and the g3p coat protein. Therefore, they express the scFv w ithout the g3p 
protein. Phagem id vectors can also encode tags such as 6xHis and c-myc tags, that 
following soluble expression, are fused to  the scFv to  aid in detection and purification. 
Depending on the isolated clone, the soluble antibodies can be expressed into the 
culture supernatant, the bacterial periplasm or both. Phagemids incorporating pelB 
leader sequences enable the E. co li cell m imic the eukaryotic secretory pathway for 
proteins resulting in appropriate refolding and relocation o f  the expressed antibody to 
the periplasm (Leumeulle e t al., 1998).
Bacterial expression systems are most commonly used for the soluble production o f 
functional antibody fragments because they are easy to manipulate, fermentation is 
rapid and inexpensive and high-levels o f  protein production can be achieved (up to 
several hundred milligrams). Fully functional antibody fragments can be expressed in 
E. c o li  because, unlike whole antibody molecules, they do not require any complex 
post-translational modifications.
Eukaryotic expression systems have also been described for expression o f  antibody 
fragments and are capable o f  performing post-translational modifications such as 
glycosylation. Yeast expression systems offer the distinct advantage that their codon 
usage and protein folding pathways mimic that o f  mammalian cells. Expression o f 
scFvs has been reported in several strains o f  yeast including S ch izosacch arom yces  
p o m b e  (Davis e t al., 1991), Pichia pastoris (Freyre e t a l ,  2000), T richoderm a reese i 
(Eldin e t  al., 1997) and Saccharomyces cerevisiae (Shusta e t al., 1998). Insect 
expression systems in conjunction w ith the baculovirus have also enabled the 
expression and secretion o f  correctly folded scFvs (Kretzschmar e t  al., 1996; Brocks 
e ta l . ,  1997 and Lem eulle e ta l . ,  1998). M ammalian cells have provided an alternative 
system for high-level expression o f  antibody fragments. Antibody fragments have 
been successfully expressed in Chinese Ham ster ovary (CHO) cells (Dorai e t al., 
1994), myeloma cells (Dorai e t  al., 1994) and COS cells (Jost e t al., 1994 and Ridder 
e ta l . ,  1995). Rapid eukaryotic expression vectors have also enabled the conversion o f
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scFv and Fab fragments into fully assembled and functional whole antibody 
molecules (M ahler e t  ah, 1997; Persic e t  ah, 1997 and Boel e t ah, 2000). Plant 
expression systems have also proved useful for the expression o f  antibody fragments. 
Plant expression systems do not require large sterile fermentation processes, the 
expressed fragments are free from bacterial toxins and mammalian viruses and the 
plants are capable o f  storing the expressed antibody fragments for a short period o f 
time within the leaf and over a longer time period within the seeds. The tobacco plant 
using A g ro b a cteriu m -m ed ia ted  transfection has been widely reported for soluble 
expression o f  antibody fragments (Owen e t  al., 1992; Fiedler and Conrad, 1995 and 
Hendy e ta l . ,  1999).
1.7.7 Purification of antibody fragments
Several purification strategies have been described for scFvs, which include antigen 
affinity chromatography (Owen e t ah, 1992; Casey e t  ah, 1995 and Cho e t ah, 2000), 
ion exchange and size exclusion chromatography (Kretzschmar e t ah, 1996), human 
constant light chain tagging (Ridder e t  ah, 1995 and Longstaff e t ah, 1998) and 
immobilised metal affinity chromatography (IM AC) (Kipriyanov e t ah, 1997 and 
Freyre e t a l . ,  2000).
IMAC is now routinely used for the purification o f  recom binant proteins including 
antibody fragments. This method ensures high ligand stability, high protein loading, 
mild elution conditions, relatively low cost, and complete ligand recovery following 
regeneration (Arnold e t  ah, 1991). The theory behind IM AC is discussed further in 
Section 4.1.3. K ipriyanov and associates (1997) demonstrated that IMAC could be 
successfully applied for the purification o f  functional scFvs from E. co li periplasmic 
lysates. IMAC is now frequently used for the purification o f  his-tagged scFvs and it 
has recently been applied to  the purification o f  scFvs against the mycotoxin 
deoxynivalenol (Choi e t ah, 2004) and scFvs against the transmembrane envelope 
glycoproteins gp46 o f  maedi-visna virus (MVV) (Blazek e t  ah, 2004).
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1.7.8 Affinity maturation of antibody fragments
Although antibody fragments selected from immune and single-pot repertoires have 
proven to be extremely useful, their affinity is often not sufficient for therapeutic 
applications in immunotherapy, viral neutralisation, or for use in sensitive diagnostics 
(Hoogenboom e t a l ,  1998). To date, several methods have been described for affinity 
maturation o f  antibody fragments.
1.7.8.1 Multivalent molecules
Decreases in apparent affinity have been reported w ith scFvs, when compared to  the 
parental monoclonal antibody (H uston e t  al., 1988). The reduced levels o f  affinity 
observed can be due to  the decrease in the number o f  antibody binding sites. One o f  
the easiest methods to improve scFv-binding affinity is the creation o f  a multimer. 
Several multivalent scFv-based structures have been reported, including 
mini antibodies (Pack and Pluckthun, 1992), dimeric miniantibodies (M uller e t al., 
1998), minibodies (Hu e t  a l ,  1996), diabodies (Holliger e t al., 1993) and triabodies 
(Iliades e t al., 1998; Law rence e t al., 1998; Hudson and Kortt, 1999). Non-covalent 
diabodies and triabodies are among the easiest to engineer and are produced by 
shortening the polypeptide linker connecting the variable heavy and light chains from 
15 amino acids to  5 for the diabodies and 0 -  3 for the triabodies. The compatible 
vector series described by K rebber and associates (1997) allows for the production o f  
dimeric scFvs (as discussed in Section 1.7.9).
1.7.8.2 Site-directed mutagenesis
Site-directed mutagenesis involves amino acid substitutions within one or more o f  the 
CDRs followed by the subsequent selection o f  clones w ith higher affinity for the 
target antigen. Schier and associates (1996) reported a 16-fold increase in affinity o f 
an scFv directed against H ER2/neu following randomisation o f  the light chain CDR3. 
The resulting affinity mutant was then used as a starting molecule for the 
manipulation o f  the heavy chains. Following selection on the subsequent Vh CDR3 
libraries, containing randomised amino acids, a 1200-fold increase in affinity over the 
parental scFv was observed. An alternative method o f  site-directed mutagenesis, 
termed “parsimonious m utagenesis” was described by Balint and Larrick (1993). This 
method involves screening the entire CDR sequence and identifying the amino acids 
that are actively involved in antigen binding. First, the number o f  codons introduced is
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limited so that each amino acid is only coded for by a single codon. The amino acids 
at each position are then manipulated to favour the parental sequence, conservative 
changes and those that appear more frequently in CDR regions o f  the antibody. PCR- 
based site-directed mutagenesis has been described for the affinity maturation o f an 
scFv against Venezuelan equine encephalitis virus (VEE), during which a five-fold 
increase in reactivity against VEE was observed in ELISA  over the parental clone 
(Alvi e t a l ,  2003).
1.7.8.3 Error-prone PCR
Error-prone PCR is a random mutagenesis technique used to  introduce amino acid 
changes into proteins. M utations are deliberately introduced during PCR amplification 
o f  the specific genes through the use o f  error-prone D NA  polymerase reaction 
conditions. Taq D NA  polym erase is commonly used because it lacks proofreading 
activity and the error rate is further increased by employing reaction buffers 
containing M n2+ and unbalanced dNTP concentrations (Leung e t  a l ,  1989; Cadwell 
and Joyce, 1992). Error-prone PCR has been successfully applied to  the affinity 
m aturation o f  an scFv directed against cardiac glycoside digoxigenin (Daugherty et  
a l ,  2000). M ore recently error-prone PCR has been described in conjunction with an 
additional affinity maturation process. Zahnd and associates (2004) have described a 
method involving ribosomal display, error-prone PCR and DNA  shuffling for the 
affinity maturation o f  a peptide binding scFv, which lead to  a 500-fold affinity 
im provem ent over its potential germ line precursor.
1.7.8.4 Chain shuffling
Chain shuffling mutagenesis involves alterations to  the intrinsic affinity o f  the 
m onovalent antibody fragment. During chain shuffling the scFv is subjected to a 
series o f  manipulations during which the gene for one chain (e.g. V h )  o f the scFv is 
cloned into a repertoire for the second chain (e.g. V l )  (Marks et  a l ,  1992). The 
resulting antibody library consists o f  phage encoding an scFv containing V h  chains 
specific for the target antigen and random V l chains. The resulting library is then 
panned against the specific antigen and clones w ith improved binding properties are 
identified. The cycle is then repeated except this tim e the new V l gene is shuffled into 
a  V h  repertoire. However, in order to  maintain the specificity o f  the parent scFv, the 
CDR3 (that contains m ost o f  the contact residues to the antigen) is conserved.
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Therefore, only the Vh segment from frameworks 1 to 3, including CDRs 1 and 2 are 
replaced. Using this method the affinity o f  a naive human scFv directed against the 
glycoproteins tum our antigen c-erbB-2 was increased six-fold following light chain 
shuffling and five-fold by heavy-chain shuffling (Schier e t a l ,  1996).
1.7.8.5 Ribosomal display
Ribosomal display is an in v itro  technique aimed at the simultaneous selection and 
evolution o f  proteins from diverse libraries w ithout the need for any bacterial 
transformations. Ribosomal display o f  scFv antibody fragments has been described in 
prokaryotic (Hanes and Pluckthun, 1997) and eukaryotic (He and Taussig, 1997) 
systems.
Figure 1.12 illustrates the principal o f  in  v itro  ribosomal display. Initially the D NA  
encoding the scFv library is PCR amplified, whereby a T7 promoter, a ribosome- 
binding site and stem loops are introduced, and then transcribed, in vitro , into mRNA. 
The T7 prom oter ensures efficient transcription by T7 RNA polymerase, the ribosome 
binding sites enable initiation o f  translation in  v itro  and the stem loop structure 
prevents RNAse E degradation. Following purification the mRNA is translated in 
vitro, whereby the mRNA is retained on the ribosome as a result o f  an absent stop 
codon (Hanes and Pluckthun, 1997 and H e e t  ah, 1999) resulting in the formation o f  a 
tertiary mRNA-ribosome-scFv complex. The tertiary complex is stabilised at low 
temperature (4°C) and in buffer containing magnesium (Hanes and Pluckthun, 1997 
and Schaffitzel e t ah, 1999). The mRNA-ribosome-scFv complexes are then affinity 
selected from the translation mixture through binding o f  the native scFv to  the specific 
immobilised antigen. Non-specific binders are eliminated following stringent wash 
steps and specific binders are eluted following dissociation with EDTA or upon 
addition o f  free antigen (Hanes and Pluckthun, 1997 and Schaffitzel e t ah, 1999). The 
mRNA can then be isolated from the specific binder and reverse transcribed into 
cDNA for use in the next enrichment cycle. Ribosomal display is an entirely cell free 
system that does not require the need for bacterial transformations. Therefore, large 
antibody repertoires can be constructed and used for selection. Further diversity can 
be introduced either before starting or in between ribosomal display cycles via D N A  
shuffling (Stemmer, 1994) or error-prone PCR (Cadwell and Joyce, 1994). Ribosome
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display methods have been successfully applied to in v itro  affinity maturation o f an 
scFv against bovine insulin during which up to a 40-fold increase in affinity was 
observed (Hanes e t  al., 2000).
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F ig u re  1 .1 2 : Illu stra tion  o f  the p r in c ip a l o f  r ib o so m a l p h a g e  d isp la y  technology. 
D N A  en co d in g  the scF v lib ra ry  is  P C R  am plified , a n d  tra n sc r ib e d  in to  mRNA (1). The 
m RNA is  then tra n sla ted  in v itro  in such  a  w a y  th a t a  m R N A -ribosom e-scF v com plex  
is  fo r m e d  (2). R ib o so m e com plexes, con ta in in g  the scF v  o f  interest, a re  affin ity  
se lec ted , w ith  n on -spec ific  co m p lex es  b e in g  re m o v e d  fo llo w in g  strin gen t w ash  s tep s
(3). A ffin ity  se le c te d  co m p lex es  a re  e lu te d  u sin g  f r e e  an tigen  (4a) o r  fo llo w in g  E D TA  
d isso c ia tio n  (4b). The m RNA is  iso la te d  (5) a n d  reverse  tra n scr ib ed  in to  cD NA (6) f o r  
the n ex t ro u n d  o f  se lec tio n  /en rich m en t. (M o d ified fro m  H a n es a n d  Pluckthun, 1997.)
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1.7.9 Krebber scFv phage display system
Krebber and co-workers (1997) have developed and optimised a phage display system 
for the expression o f scFv antibody fragments. This system offers robustness, vector 
stability and tight control o f  scFv expression fused to  the wild type genelll coat 
protein o f  filamentous phage, primer usage for PCR amplification o f  variable region 
genes, scFv assembly strategy and subsequent directional cloning using a single rare 
cutting restriction enzyme (Sfil). The Krebber system also offers a compatible vector 
series to simplify modification, detection, multimerization and rapid purification. The 
pAK vector series, described by Krebber e t al. (1997), consists o f  6 vectors (pAKlOO
-  pAK600), which can be used for the expression o f  scFvs on the surface o f  phage 
(pAK100/200) or in soluble form (pAK300 -  600) (Fig. 1.13).
Each vector contains a chloramphenicol resistance marker and a tetracycline 
resistance gene. The tetracycline gene is flanked on either side by an Sfil restriction 
site that allows the te t gene to be removed and replaced w ith the genes encoding the 
variable heavy and light genes o f  the antibody. All vectors also contain p e lB  leader 
sequence, a strong upstream  tHP terminator, between the la c l  gene and the lac  
promoter/operator region, w hich in combination with glucose repression o f the lac  
prom oter prevents background expression prior to  IPTG induction. The pAKlOO 
vector contains a truncated version o f  g il l  phage coat protein in order to avoid 
immunity to  superinfection, a c-myc tag for detection and an amber codon, that allows 
the switching between phage-bound and soluble scFv expression by simply changing 
the expression host. The primers engineered for the amplification o f  the variable 
regions encode a truncated version o f  the FLA G sequence, which enables detection 
and purification o f  the expressed scFv. The pAK400 vector contains a C-terminal 
hexa-His tag for purification using immobilised metal affinity chromatography 
(IM AC) and detection using an anti-His tag antibody and a strong Shine Dalgarno 
sequence (SD T 7gl0) for increased scFv expression. The pAK500 vector contains a 
single chain double helix (dHLX) for scFv dimerisastion followed by a penta-His tag. 
The pAK600 contains a bacterial alkaline phosphatase gene that allows direct 
detection and results in dim erisastion o f  the scFv. A schematic representation o f  the 
soluble scFvs expressed from  pAK400/500/600 can be seen in Figure 1.14.
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F ig u re  1 .1 3 : p A K  co m p a tib le  vec to r  series. P h a g e  d isp la y  vec to r  (pAKlOO) a n d  its  
r e la te d  vec to rs  (pA K 400  -  600) a re  u se d  to  co n stru c t va rio u s scF v  m odifications. The 
p A K  vec to rs  con ta in  the sa m e elem en ts a s  d e ta ile d  f o r  pA K lO O  ex cep t f o r  the 
m o d ified  ca sse tte s  sh ow n  above . The p A K  vec to rs  en co d e  te tracyclin e a n d  
ch loram ph en ico l a n tib io tic  res is ta n ce  gen es, the la c l  rep re sso r  g en e  (LacI), a  s tro n g  
u pstream  term in a to r (Thi), the la c  p ro m o te r  /  o p e ra to r  (L ac p /o ), the p e lB  lea d er  
sequ en ce (pelB), m o d ified  to  con ta in  an  S f il  s ite  a n d  a  dow n stream  term in a tor (t\p). 
A ddition a lly , pA K lO O  en co d es  a  tru n ca ted  versio n  o f  the g i l l  p h a g e  co a t p ro te in  
(g ffl25o - 40$), a  c-m yc ta g  (m yc) a n d  an  a m b er codon  (*). p A K 4 0 0  en codes hexa-H is  
ta g  f o r  p u rifica tio n  a n d  d e tec tio n  a n d  a  s tro n g  Shine D a lg a rn o  sequ en ce (SD T 7glO ) 
f o r  in c rea sed  scF v  expression . pAKSOO en co d es p en ta -H is  ta g  a n d  a  h elix  f o r  
d im erisa tio n  (P ark  e t a l .. 1993). p A K 6 0 0  en co d es an  a lka lin e p h o sp h a ta se  la b e l f o r  
d ire c t d e tec tio n  a n d  d im erisa tio n  (L indner e t a l.. 1997). M o d ifie d fro m  K reb b er  e t a l .. 
1997.
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F ig u re  1 .1 4 ; S ch em atic  rep resen ta tio n  o f  the m onom eric  (A), d im eric  (B) a n d  
bifu n ction a l scF vs (C). The m on om eric  scF v  co n sis ts  o f  a  va ria b le  h ea vy  a n d  ligh t 
ch ain  dom ain  s ta b ilis e d  w ith  a  serin e-g lyc in e  linker; the d im eric  scF v com prises tw o  
scF v  fra g m e n ts  d im e r ise d  v ia  a  d ou b le  h elix  a n d  the b ifu n ction a l scF v con sists  o f  tw o  
a lk a lin e  p h o sp h a ta se - la b e lle d  scF vs fu s e d  v ia  the a lka lin e  p h o sp h a ta se  (AP).
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1.8 Immunoassays
An immunoassay is an analytical technique that relies on the use o f  antibody 
molecules for the detection o f  a specific compound present in a complex sample or 
matrix. The first immunoassay was introduced by Yalow and Berson (1959) and it 
was used to  detect the presence o f  insulin in blood samples.
Immunoassays have numerous advantages over the conventional analytical methods 
such as mass spectrometry, gas chromatography and liquid chromatography. In 
contrast to  such techniques, immunoassays do not require the use o f  expensive 
equipment, which requires highly skilled technical expertise to  operate and the 
analysis o f  samples using immunoassays is relatively quick. Immunoassays can be 
performed easily, they are relatively economical, sensitive and highly specific. The 
selectivity o f  an im munoassay is based on the innate selectivity o f  the antibody- 
antigen reaction and the sensitivity is determined by the detection limit o f  the label 
and by the affinity o f  the specific antibody (Van Em on e t  a l ,  1989).
Immunoassay can be defined as homogeneous or heterogeneous depending on 
w hether the assay is carried out in solution (fluid phase) or on the surface o f  plastic 
(solid-phase). Homogeneous immunoassays are performed in a single step, in 
solution, and do not require the separation o f  the free and bound labelled antibody. 
However, heterogeneous immunoassays involve the immobilisation o f  either the 
antigen or antibody onto a solid support matrix, in such a way that the 
im munogenicity o f  the molecule is not affected. Immunoassays can also be further 
classified depending on the label used to  detect the antibody-antigen interaction. 
Radioisotopes are used in a radioimmunoassay form at (RIA), enzymes in an enzyme 
im munoassay format (EIA or ELISA) and fluorescent labels are used in a fluorescent 
im munoassay format (FIA).
Several different im munoassay formats have been described with the most commonly 
used including the non-competitive o r indirect and the competitive immunoassays. 
Non-com petitive im munoassays can be used to  determine the concentration o f  an 
antibody in the sample being analysed during which the analyte is adsorbed onto the 
solid support matrix and the antiserum allowed to react with the immobilised analyte. 
Antibody-antigen interactions can then be indirectly quantified using a labelled
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secondary antibody. However, a competitive immunoassay measures competition in 
binding to  antibody between a fixed amount o f antigen and an unknown quantity o f  
antigen (analyte) in the sample. In a competitive immunoassay format the response 
obtained is inversely proportional to  the concentration o f  analyte in the sample 
mixture
1.8.1 Enzyme-linked immunosorbent assay (ELISA)
The ELISA  technique is one o f  the most commonly used immunoassay formats for 
detecting antigen-antibody interaction and is routinely used for the detection o f  many 
im portant analytes including dangerous residues in m eat products (Pou e t a t ,  1994) 
and pesticide residues in food (Franek e t  al., 1995). In this type o f  immunoassay 
format either the antigen or antibody is immobilised onto a solid support matrix in 
such a way that the im munogenicity o f  the molecule is not affected. The 
im munosorbent refers to the solid support onto which the antigen or antibody is 
adsorbed. An enzyme label is attached to the antigen or antibody and this is used to 
detect bound antigen-antibody complexes. The most commonly used enzymes in 
ELISAs are horseradish peroxidase and alkaline phosphatase.
Figure 1.15 illustrates a schematic representation o f  an indirect non-competitive 
ELISA. Initially, the antigen o f  interest is absorbed onto the solid support matrix 
through hydrophobic interactions. Following suitable incubation (i.e. 1 hour at 37°C) 
the plate is washed three tim es with phosphate-buffered saline (PBS) and 3 times with 
PBS -  0.05% (v/v) tween. Non-specific binding interactions are then eliminated 
following blocking w ith m ilk marvel dissolved in PBS, which binds any uncoated 
absorption sites. Following appropriate incubation the plate is washed, as before, and 
serial dilutions o f  the specific antibody /  serum samples are added to each well and 
allowed interact with the immobilised antigen. After incubation any unbound 
antibodies are removed following a wash step. An enzyme-labelled anti-species 
secondary antibody is added and incubated. The plate is then washed and following 
addition o f  a chromogenic substrate the colour intensity is determined at the 
appropriate wavelength use a  spectrophotometer. The colour produced is directly 
proportional to  the concentration o f  the specific antibody and can be used to 
quantitatively measure antigen -  antibody binding.
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Figure 1.16 displays a schematic representation o f a competitive ELISA. This assay 
format is similar to that o f  the indirect non-competitive ELISA. The antigen o f 
interest, in this case an aflatoxin B i-B SA  conjugate, is absorbed onto an immunoplate, 
which is blocked using milk marvel. A  solution containing a constant amount o f the 
specific antibody and varying concentrations o f  free antigen (AFBi) is added to the 
wells o f  the immunoplate and incubated. The immunoplate is washed and the enzyme­
labelled anti-species secondary antibody added. Follow ing incubation the plate is 
washed and the chromogenic substrate added. The colour produced in this assay 
form at is inversely proportional to  the concentration o f  free antigen added. Therefore, 
this assay format can be used for the quantitative detection o f  an antigen following 
reference to a standard curve.
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F ig u re  1 .1 5 : S ch em atic  rep resen ta tio n  o f  an  in d irec t n on -com petitive  ELISA. E ach
step  req u ires  a n  a p p ro p r ia te  incubation  p e r io d  a n d  a n y  unbou n d  m a ter ia l is  rem o ve d
fo llo w in g  a  w a sh  p ro ced u re . The p la te  is  c o a te d  w ith  the an tigen  o f  in te rest (1) a n d
an y unbou n d s ite s  a re  b lo ck ed  w ith  ca se in  to  p re v e n t an y  n on -specific  in teraction s
(2). The sp ec if ic  a n tib o d y  is  then in cu b a ted  w ith  the im m o b ilised  an tigen  (3) a n d  any
a n tigen  -  a n tib o d y  in te ra c tio n s a re  d e te c te d  u sin g  an  en zym e-la b e led  sp ec ie s-sp ec if ic
a n tib o d y  (4) fo llo w in g  a d d itio n  o f  the ch rom ogen ic  su bstra te  (5).
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F ig u re  1 .1 6 : S ch em atic  rep resen ta tio n  o f  an  in d irec t co m p etitive  ELISA. E ach  s tep
req u ires  an  a p p ro p ria te  incubation  p e r io d  a n d  an y  u nbound m a te r ia l is  rem o ved  
fo llo w in g  a  w ash  p ro ced u re . The p la te  is  c o a te d  w ith  the an tigen  o f  in te rest (1) a n d  
a n y unbou n d  s ite s  a re  b lo ck ed  w ith  ca se in  to  p re v e n t an y  n on -specific  in teraction s
(2). F ree  a n d  im m o b ilised  an tigen  co m p ete  f o r  b in d in g  to  the sp ec ific  a n tib o d y  (3) 
a n d  a n y  a n tib o d ies  bo u n d  to  the im m o b ilised  an tigen  a re  d e te c te d  u sin g  an  enzym e­
la b e le d  sp ec ie s -sp ec if ic  a n tib o d y  (4) fo l lo w in g  a d d itio n  o f  the ch rom ogen ic su bstra te
(5).
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1.8.2 Lateral-flow immunoassay (LFIA)
The lateral flow immunoassay (LFIA) is an immunochromatographic technique 
studying antibody-antigen interaction as components o f a sample are separated using a 
chromatographic technique. These membrane immunoassays have been developed for 
a variety o f  applications including the detection o f  several antigens including 
aflatoxins (Sibanda e t a l ,  1999 and N iessen e t  a l ,  1998); human chorionic 
gonadotropin (van Amerongen e t a l ,  1994); cannabinoids, cocaine and opiates in 
urine (W enning e t al., 1998) and F usariu m  T-2 toxin in wheat (de Saeger and 
Peteghem, 1996). The first commercially successful LFIA was the pregnancy test, 
which was based on the rapid detection o f  human chorionic gonadotropin in urine 
(May, 1991).
LFIAs involve the unidirectional flow  o f  pre-impregnated antibody or antigen-coated 
particles (e.g. latex, carbon, colloidal gold or silica) along a membrane. Interactions 
between the particle-coated antigen / antibody and the target molecule occur as the 
sample flows along the membrane and, if  present, are subsequently detected and 
captured by a specific antibody immobilised in a defined area on the membrane. 
Figure 1.17 illustrates the principal behind the lateral flow immunoassay whereby the 
capture ligand is spotted or immobilised onto the nitrocellulose strips in a line-format. 
The sample droplet containing a detection ligand coupled to colloidal carbon particles 
is applied to the tip o f  the strip and allowed chromatographically run through the 
membrane by capillary action. U pon passing the immobilised capture ligand the 
detection ligand, bound to  the specific antigen, can specifically bind, resulting in the 
formation o f  a visual signal (i.e. a black line).
Surface-modified hydrophilic membrane supports that covalently bind protein are 
used in a LFIA  format. These retain the immobilised protein in its native 
conformation (Pfund and Bourdage, 1990). The basic chemistry o f  the solid phase 
can affect the immobilisation o f  the capture reagent and the release and flow o f the 
mobile samples (Price e t a l ,  1997). Nitrocellulose is the most suitable membrane for 
LFIA  development because it posses high protein binding, low non-specific binding, a 
smooth white surface that gives better visibility o f  results and, typically, it is o f 
uniform thickness. Protein binds to  nitrocellulose by electrostatic mechanisms. The 
porosity o f  the nitrocellulose can influence protein binding with increasing pore size
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resulting in a decrease in the polymer surface area and consequently the membrane 
binds less protein. Increased pore size can however result in increased flow rates 
(Harvey, 1991). Although faster flow rates decrease the assay time the sensitivity o f  
the assay may be affected, as the molecules in the sample have less time to  interact.
>c y &  Y
Antigen Immobilised antibody Colloidal carbon Carbon-labelled
particles antibody conjugate
it (b)
(c)
F ig u re  1 .1 7 : S ch em atic  rep resen ta tio n  o f  a  la te ra l f lo w  im m u n oassay device. 
F o llo w in g  sa m p le  a d d itio n  (a) the c a rb o n -la b e lled  a n tib o d y  in te ra c ts  w ith  the an tigen  
a s  the sam ple  f lo w s  a lo n g  the m em brane. The a n tig en -a n tib o d y  in teraction  is  then  
ca p tu red  b y  the a n tib o d y  im m o b ilised  on  the m em brane (c). C oncen tra tion  o f  the 
a n tig en -a n tib o d y-co a ted  p a r tic le  co m p lex  in a  d e fin ed  a re a  on  the m em brane resu lts  
in  the g en era tio n  o f  a  signal, w h ich  is  v isib le  b y  the n a k ed  eye  (d).
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1.9 Biacore
The B iacore is a commercially available biosensor system that has been applied to the 
development immunoassays for the detection o f  several analytes including aflatoxin 
Bi (Van der Gaag e t a l ,  1998 and Daly e t a l ,  2000) and morphine 3-glucuronide 
(Brennan e t  a l ,  2002 and D illon e t a l ,  2003). Biacore systems detect binding events 
using the phenomenon o f  surface plasm on resonance (SPR) (Liedberg e t al., 1995; 
Salamon e t  al., 1999 and Quinn and O ’Kennedy, 1999). The Biacore sensor uses 
continuous flow technology that enables biospecific interaction analysis (BIA) such as 
antigen-antibody binding in “real-tim e” . The Biacore system offers several 
advantages over conventional biom olecular interaction techniques. It provides real­
time monitoring, label free detection, a reusable sensor surface, flexible-experimental 
design, rapid analysis, exact sample handling and a complete integrated analytical 
system.
SPR is an optical technique that utilises the principle o f  total internal reflection (TIR). 
W hen a plane-polarized light beam propagates a medium o f higher refractive index 
(e.g. glass prism) and meets an interface w ith a medium o f  lower refractive index (e.g. 
sample solution) the light is totally internally reflected, above a certain critical angle. 
Under these conditions an evanescent wave, an electromagnetic field component o f 
the light, penetrates into the low refract re media to a magnitude o f  one wavelength 
(Fig. 1.18). I f  the TIR interface is coated with a thin metal film (which is gold in the 
case o f  the Biacore) and the light is monochromatic and p-polarised (i.e. the electric 
vector component is parallel to  the plane o f  incidence) the evanescent wave interacts 
with the electrons on the metal layer. The electron clouds on the surface o f  the metal 
layer are also known as plasmons and following propagation o f  the evanescent wave 
the plasmons begin to  resonate forming a quantum mechanical wave known as the 
surface plasm on wave. At a particular angle o f  incidence, some o f  the energy o f  the 
reflected light causes excitation o f  the surface plasmons, resulting in a decrease in 
intensity o f  the reflected light. The specific angle at which SPR occurs is known as 
the SPR angle. The SPR angle is dependent on the refractive index o f  the medium 
close to  metal film. Therefore, changes in the refractive index o f  the buffer solution 
(i.e. an increase in the surface concentration o f  solutes) can alter the SPR angle. 
Continuous monitoring o f  the SPR angle enables the quantification o f  changes in the 
refractive index o f  the medium adjacent to the metal layer. Therefore, SPR can be
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used to monitor biological interactions on the metal film because changes in the 
refractive index o f  the media are directly proportional to changes in mass or 
concentration on the surface o f  the metal layer.
F ig u re  1 .1 8 : P r in c ip a l o f  su rface p la sm o n  resonance. U nder con dition s o f  to ta l  
in tern a l reflec tio n  a t  a  m e ta l-co a ted  in terface an  e lec trom agn etic  f i e l d  com ponen t o f  
the light, known a s  the eva n escen t w ave, p ro p a g a te s  in to  the m edium  o f  lo w er  
re fra c tive  index on the n on -illu m in a ted  side.
The SPR angle is dependent on a number o f  factors, including the properties o f  the 
metal film (e.g. thickness, optical constants and uniformity), the wavelength o f  the 
incident light and the refractive index o f  the media on either side o f  the metal film. 
The refractive index o f  the medium into which the evanescent wave propagates, on 
the non-illuminated side o f  the surface, is affected by the surface concentration o f  
solutes, so that monitoring the SPR angle provides a real-time measure o f  changes in 
the surface concentration. A  shift in the SPR angle is observed when biomolecules 
bind to  the immobilised surface and changes the refractive index o f the surface layer 
(Fig. 1.19). The change in SPR angle is plotted against time in a sensogram, which 
displays the progress o f  the interaction at the sensor surface as it occurs (Fig. 1.20).
B iacore systems utilise a high-efficiency near-infrared light emitting diode, at a 
w avelength o f  760nm, which focuses light, in a wedge-shaped beam, onto the sensor 
surface providing a fixed range o f  incident angles. The SPR response in the reflected 
light is monitored using a fixed array o f  light-sensitive 2-dimensional diodes, from 
which the angle at which minimal reflection occurs (the SPR angle or resonance) is 
calculated.
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F ig u re  1 .1 9 : D ia g ra m m a tic  rep resen ta tio n  o f  su rface p la sm o n  reson an ce occu rrin g  
a t  the su rface  o f  a  B ia co re  sen so r chip. (A) The sen sor su rface is  im m o b ilised  w ith  an  
a n tib o d y  (Y) using E D C  N H S chem istry. L ig h t from  a  Ugh- em ittin g  d io d e  is  fo cu sed  
on the sen so r a n d  the r e f le c te d  lig h t is  d e te c te d  u sin g  a  2 -d im en sion a l p h o to -d io d e  
array. U nder co n d itio n s o f  to ta l in tern a l reflec tion  an  eva n escen t w ave p ro p a g a te s  
in to  the m edium  o f  lo w er re fra c tive  index, w hich  resu lts  in a  d ip  in the in tensity o f  the 
re f le c te d  lig h t a t  a  p a r tic u la r  an g le  know n a s  the SP R  an g le  (a). (B) F o llow in g  
in jection  o f  the an tigen  ( + ) ,  a  sh ift in the surface p la sm o n  reson an ce an gle (b) occu rs  
fo llo w in g  sp ec ific  in teraction  b e tw een  the im m o b ilised  a n tib o d y  a n d  antigen. The 
ch an ge in the SP R  an g le  is  a s  a  d ir e c t  re su lt o f  ch an ges in the m ass con cen tra tion  a t  
the im m o b ilised  sen sor surface.
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Reflected intensity Resonance signal (RU)
F ig u re  1 .2 0 : The sen sogram  is  u se d  to  d isp la y  the p r o g r e s s  o f  in teraction s a t the 
sen so r  surface. C hanges in  the SP R  a n g le  (0) a re  con tinu ou sly m o n ito red  a n d  
d isp la y e d  a s  a  fu n c tio n  o f  tim e on  a  sen sogram  a s  the cm tibody-an tigen  in teraction s  
occur. B in d in g  in terac tion s on  the sen so r  su rface  resu lt in a  change in the m ass  
concentration , w hich  ca u ses a n  in crea se  in the SPR  angle. The increase in the SPR  
an g le  is  see n  a s  a  g ra d u a l in crea se  in s ig n a l on  the sensogram . R eson an ce units (RU) 
a re  u se d  to  ex p ress the S P R  s ig n a l on  the sensogram .
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Changes in the SPR angle occur due to changes in the refractive index o f  the surface 
layer, which in turn is as a result o f  both the bulk solution and interactions on the 
surface matrix. In the majority o f  Biacore applications the contribution o f  the bulk 
solution is eliminated because the measured param eter is either the rate o f  change o f 
the signal, which is the case in binding kinetics, or the difference in signal between 
response units before and after injection is used, as w ith binding interaction studies. 
Figure 1.21 represents a schematic sensogram after sample injection. Following 
injection a significant increase in the refractive index is observed due to  the bulk 
solution. A steady increase in the binding response is then seen as the antigen interacts 
with the immobilised antibody and, on completion o f  sample injection, a large 
decrease in the refractive index is observed as running buffer begins to  pass over the 
surface. The difference between the resonance units before and after sample injection 
is used to  determine binding interactions on the immobilised surface, A binding 
response o f  1000 R U  is equivalent to a change o f  approximately lng/m m 2 in surface 
protein concentration or o f  about 6mg/ml in bulk protein concentration (Stenberg e t 
al., 1991).
The quantitative analysis on the binding interactions between biomolecules is 
dependent on the immobilisation o f  a target molecule on the sensor chip surface (Fig. 
1.22). The sensor chip surface consists o f  a  glass layer coated with a thin gold film. 
Gold is selected because o f  its chemical inertness and good SPR response. The gold 
layer is covered w ith a covalently attached matrix (attached through a linker layer), 
onto which biom olecules can be immobilised. The CM5 sensor chip is the most 
widely used and consists o f  the gold surface modified w ith a carboxymethylated 
dextran layer. The carboxymethylated dextran provides a hydrophilic environment for 
the im mobilisation o f  biomolecules. Sensor chips for specialised applications are also 
available. These include Sensor Chip SA, which is covalently immobilised with 
streptavidin to  capture biotinylated molecules, Sensor Chip NTA, for the capture o f  
His-tagged molecules and the Sensor Chip H P A, which enables the attachment o f 
lipid monolayers for membrane biochemistry and the study o f  membrane-associated 
receptors.
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F ig u re  1 .2 1 : S ch em atic  rep resen ta tio n  o f  a  sen sogram  fo llo w in g  in jection  o f  an tigen  
o ve r  an  a n tib o d y  im m o b ilised  surface. In itia lly  a  s te a d y  baselin e is  o b se rv e d  a s  
running buffer is  b a se d  o ve r  the surface. F o llo w in g  in jection  o f  the sam ple  an  in itia l 
change in the re fra c tive  index  is  o b se rv e d  du e to  the bu lk  solution. This is  fo l lo w e d  by  
a  s tea d y  increase  in the SP R  sig n a l a s  b in d in g  in teraction s occu r a t  the sen sor  
surface. O n com ple tion  o f  sa m p le  in jection  there is  a  r a p id  d ecrea se  in the hulk  
refra c tive  index a s  runn ing buffer is  p a s s e d  o v e r  the surface. The am oun t o f  bou n d  
an tigen  is  then d e te rm in ed  a s  the d ifferen ce in respon se units o b se rv e d  before a n d  
a fter  sa m p le  injection.
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Gold film 
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F ig u re  1 .22 : D ia g ra m m a tic  represen ta tion  o f  the su rface  o f  a  ca rb o x ym eth y la ted  5 
(CM S) sen so r chip. Ih e  ch ip  co n sis ts  o f  three layers: g lass, a  thin g o ld  f i lm  a n d  a  
m atrix  layer. The m atrix  la y e r  is  a tta c h e d  to  the g o ld  film  through an  in ert linker  
layer, h i the ca se  o f  the C M S ch ip  the m atrix  la yer  is  ca rb o x ym eth y la ted  dextran, 
w hich a llo w s  the co va len t im m obilisa tion  o f  m o lecu les on to  the sen so r surface.
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1.10 Aims of research
The main aims o f  this research project were the development o f  rapid immunoassays 
for the detection o f  aflatoxin Bi, using novel antibody fragments, and the 
development o f  a highly sensitive and specific immunoassay for the detection o f a 
B ru cella  infection in bovine serum samples.
Chapter 3 describes the production and characterisation o f  a monomeric, a dimeric 
and an alkaline phosphatase-labelled scFv against aflatoxin Bi. The scFvs were 
applied to  the development o f  competitive ELISAs and Biacore inhibition 
immunoassays for the detection o f  aflatoxin Bi. A rapid sol particle immunoassay was 
also developed for the detection o f  aflatoxin B i, using a monoclonal antibody 
obtained from collaborators (IFR Norwich, UK.).
Chapter 4 describes the production and characterisation o f  tw o B ru ce lla -specific 
recombinant proteins, p i 8, an 18kDa cytoplasmic protein, and bp26, a 26kDa 
periplasmic protein, w ere cloned from B. a b o rtu s  45/20 cells. Following high-level 
expression, the recom binant proteins w ere purified using immobilised metal affinity 
chromatography (IMAC), characterised and investigated for use as serological 
diagnostic markers o f  bovine brucellosis.
Chapter 5 described the production and characterisation o f  polyclonal and 
recom binant B ru ce lla -specific antibodies. Polyclonal antibodies were raised against
B. a b o r tu s  45/20 cells, and following purification the antibodies were applied to  the 
development o f a competitive immunoassay for the detection o f  whole B. a b o rtu s  
cells. A naive human phage display library was also panned against the p i 8 and bp26 
recom binant proteins.
Chapter 6 describes the optimisation and validation o f  immunoassays for the detection 
o f  a B ru ce lla  infection in bovine serum samples. Several indirect and sandwich 
im munoassay formats w ere developed, using the antigens and antibodies described in 
chapters 4 and 5, and validated using a pool o f  known positive and negative serum 
samples.
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CHAPTER 2
M a t e r i a l s  a n d  M e t h o d s
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2.1 M aterial and equipm ent
2.1.1 Material
All reagents and chemicals w ere o f  analytical grade and supplied by Sigma-Aldrich 
Co. (Poole, Dorset, U.K.), unless listed below  (Table 2.1).
T ab le  2 .1 : R ea g en ts  a n d  ch em ica ls  u sed  a n d  the re leva n t suppliers.
Reagent Supplier
Acetic acid Riedel de-Haen AG, W unstorfer, Strabe 40, D-
Hydrochloric acid 30926, Hannover, Germany.
Anti-bovine-HRP antibody DakoCytomation D enm ark A/S, Golstrup, 
Denmark.
B am H l enzyme Biosciences, 13 Charlemont Tee., Crofton Rd.,
N co l enzyme 
T4 D N A  ligase
Dun Laoghaire, Co. Dublin.
Bicinchoninic acid assay (BCA) kit Pierce and W arner (UK) Ltd., Chester UK.
Colloidal carbon ATO BV, Postbus 17, NL-6700, AA, 
W ageningen, The Netherlands.
M 13K07 H elper phage Stratagene, N orth Torrey Pines Rd., La Jolla, 
USA.
N i-N TA  resin QIAgen, QIAgen House, Flem ing Way,
pQE-60 Crawley, W est Sussex, UK.
Nitrocellulose membrane Schleicher and Schuell Bioscience GmbH, 
Hahnestrasse 3, D-37586, Dassel, Germany.
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PCR primers 
Sequencing
M W G-Biotech Ltd., Milton Keynes, MK12 
5RD, UK.
Sfil enzyme 
TA cloning kit
N ew  England Biolabs, 73 Knowl Piece, 
W ibury Way, Hitchin, Hertfordshire, UK.
Invitrogen, 9704-CH-Groningen, Netherlands.
2.1.2 Equipment
T a b le  2 .2 : L is t  d e ta ilin g  equ ipm en t u sed  a n d  the re leva n t suppliers.
Equipment Supplier
3015 pH meter Jenway Ltd., Gransmore Green, Felsted, 
Dunmow, Essex, UK.
Atto dual minislab AE-6450 M edical Supply Company (MSC),
Atto Ae-6100 Damastown, M ulhuddart, Dublin 15,
Titertek Twinreader PLUS 
Sterile universal tubes 
Hybrid PCR express
Ireland.
Beckm an ultracentrifuge (L8-70M ) Beckm an-Coulter Inc., 430QN Harbour
Beckm an centrifuge (J2-21) Boulevard, Fullerton, CA 92834-3100, 
USA.
BIACORE 3000 Biacore International AB, Uppsala, 
Sweden.
Biom etra PCR machine Anachem Ltd., Anachem House, Charles 
St., Luton, Bedfordshire, UK.
56
BioRad w et blotter
Eppendorf centrifuge (5810 R)
Eppendorf tubes 
Grant waterbath (Y6)
Hermle centrifuge Z 200 M /H)
Image M aster VSD gel documentation 
system
Linomat 5
Sintered glass filtration system 
NUNC M axisorb plates
BioRad, BioRad House, M aylands Ave., 
Hemel Hempstead, Hertfordshire, UK.
Eppendorf AG, 10 Signet Court, Swann 
Rd., Cambridge, UK.
Sarstedt, Wexford, Ireland.
Grant Instruments (Cambridge) Ltd., 29 
Station Rd., Shepreth, Royston,
Hertfordshire, UK.
Hermle Labortechnik, 78564-W ehingen, 
Gosheimerstr. 56, Germany.
Pharm acia Biotech, Uppsala, Sweden.
Camag, M uttenz, Switzerland.
Millipore, 900 M iddlesex Tpk., 
Billerica, M A 01821, USA.
NUNC, Kamstrup DK, Roskilde,
Denmark.
Orbital incubator Sanyo Gallenkamp pic., M onarch Way, 
Belton Park, Loughborough, Leicester, 
UK
SB 1 blood tube rotator Stuart Scientific, Holmethrope Industrial 
Est., Redhill, Surrey, UK.
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Stuart platform shaker (STR 6) Lennox, John F Kennedy Industrial Est.,
N aas Rd., Dublin 12, Ireland.
Tomy autoclave (SS 325) M ason Technology, Greenville Hall, 228
South Circular Rd., Dublin 8, Ireland.
U V-160A spectrophotometer Shimadzu Corp., Albert-Hahn-Str. 6-10,
47269 Duisburg, Germany.
2.1.3 Composition of culture media
T a b le  2 .3 : C o m position  o f  cu ltu re  m ed ia  used.
2x Tryptone yeast extract (2x TY) medium Tryptone 16g/l
Yeast extract 10g/l
NaCl 5g/l
Luria broth (LB) medium Tryptone 10g/l
Yeast extract 5g/l
NaCl 10g/l
Super optimal catabolite (SOC) medium Tryptone 20g/l
Yeast extract 5g/l
NaCl 0.5g/l
KC1 2.5mM
*MgCl2 20mM
*Glucose 20mM
pH 7.0
* Added separately following autoclaving
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2 . 1 . 4  B u f f e r s
Table 2.4 : C om position o f  buffers used.
Hepes buffered saline (HBS) lOmM HEPES
ISOmMNaCI
3.4m M EDTA
0.05% (v/v) Tween 20
pH 7.4
Phosphate buffered saline (PBS) 0.15M NaCl
2.5mM KC1
lOmM Na2H P 0 4
1.8mM KH2PO4
pH 7.3
Tris-acetate /  EDTA electrophoresis 40mM Tris-acetate
buffer (TAE) ImM EDTA
pH 8.0
Tris-EDTA sucrose buffer (TES) lOOniM Tris-HCl,
0.5M Sucrose
0.5mM EDTA
pH 8.0
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2 . 1 . 5  B a c t e r i a l  s t r a i n s
Table 2. 5: B acteria l host s tra ins a n d  their genotypes.
B a c t e r i a l  s t r a i n  G e n o t y p e
XL-1 Blue E. coli RecA endAl gyrA96 thi-1 hsdR17 supE44 relAl lac [F'proAB
lacP ZSM15 TnlO (Tef)]
JM83 E. coli Ara Alac-proAB rpsL <j>80 dlacZAM15
IN V aF ' E. coli F'endAl recAl hsdR17 fa , m^) supE44 thi-1 gyrA96
relA 1 <f)80lacZAM15 A(lacZYA-argF)U16 X  
X L-10 Gold E. coli TeP \(mcrA) 183A(mcrCB-hsdSMR-mrr) 173 endAl supE44
thi-1 recAl gyrA96 relAl lac Hte [F ’proAB lacPZhM15 TnlO 
(Tef) Amy CarrP]
D H 5a E. coli F  $80 dlacZAM15 A(lacZTA-argF)U 169 deoR recAl endAl
hsdR17fa, mk ) phoa supE44 X  thi-1 gyrA96 relAl
6 0
2 . 2  T h e  p r o d u c t i o n  o f  g e n e t i c a l l y  d e r i v e d  a n t i - a f l a t o x i n  B i  s c F v s
2.2.1 Aflatoxin Bi (AFBi) scFv Phage Display Library
A  pre-immunised phage display library was constructed by Dr. Stephen Daly, Dublin 
City University. An AFBj-specific clone was isolated (following third round panning 
on the pre-immunised phage display library). The clone consisted o f  XL-1 Blue E. 
coli harbouring pAKlOO plasmid D N A  encoding an AFB]-specific scFv.
2.2.2 Plasmid DNA purification using W izard Plus SV miniprep DNA 
purification system
Single colonies o f  E. coli cells harbouring the appropriate plasmid were inoculated in 
5ml o f  2x TY, containing the appropriate antibiotics, and grown while shaking at 
37°C overnight. The overnight culture was centrifuged at 4000rpm for 20 min. The 
supernatant was discarded and the tube was blotted on tissue paper to remove any 
remaining supernatant. The bacterial pellet was completely resuspended in 250|j,l o f  
the cell suspension solution (50mM Tris-HCl, pH 7.5, lOmM EDTA and 100(ug/ml 
Rnase A). The resuspended pellet was then transferred to a sterile 1.5ml 
microcentrifuge tube. Cell lysis solution (0.2M  NaOH and 1% (w/v) SDS) (250|il) 
was added and mixed gently by inverting the tube four times. The suspension was 
then incubated at room temperature for approximately 1-5 min, until the cell 
suspension cleared to ensure complete cell lysis. Alkaline protease solution (10(4,1) 
was then added and mixed by inverting the tube four times. This was then incubated 
at room temperature for 5 min. Neutralisation solution (4.09M  guanidine-HCl, 
0.759M  potassium acetate and 2.12M  glacial acetic acid, pH 4.2) (350|il) was added 
and mixed by inverting the tube four times. The bacterial lysate was then centrifuged 
at 14,000rpm for 10 min at room temperature. The cleared bacterial lysate was 
transferred to a spin column by decanting and cent fuged at 14,000rpm for 1 minute 
at room temperature. The spin column was removed, the flow through discarded and 
the spin column re-inserted. Column wash solution (60% (v/v) ehanol, 60mM  
potassium acetate, 8.3mM Tris-HCl and 0.04mM EDTA) (750|j.l), previously diluted 
with 95% (v/v) ethanol, was added to the spin column. The column was then 
centi Euged at 14,000rpm for 1 min at room temperature and the flow through 
discarded. Column wash solution (250(4.1) was added to the column, which was then
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centrifuged at 14,000rpm for 2 min at room temperature. The spin column was then 
transferred to a sterile 1.5ml microcentrifuge tube and the plasmid D N A  was eluted 
from the column by adding 100|il o f  autoclaved upH20. The column was centrifuged 
at 14,00rpm for 1 min at room temperature. The eluted plasmid D N A  was then stored 
at -20°C.
2.2.3 Sfil restriction enzyme digest
An Sfil restriction enzyme digest was set up as follows:
Plasmid DNA lOjal
Sfil Buffer (10X) 2|il
Sfil (20U/fil) 2|il
BSA (10mg/ml) 0.5(il
upH20 5.5(il
The restriction digest reaction was incubated at 50°C overnight.
2.2.4 Agarose gel electrophoresis for DNA characterisation
D NA was analysed by running on agarose gels in an Atto horizontal gel apparatus. 
Gels were prepared by dissolving agarose in lxTAE (40mM Tris-acetate, ImM  
EDTA, pH 8.0) containing 400[ig/ml o f  ethidium bromide, to the required 
concentration (typically 0.7 -  1.2% (w/v)) and boiling until the solution went clear. 
The lxTAE, containing 400jig/ml o f  ethidium bromide, was also used as the running 
buffer. A  tracker dye was incorporated into the D NA  samples (lfj.1 o f  dye to 5|_il o f  
sample) to facilitate loading o f  samples. Mini- and maxi-gels were run at 100V for 1 
hour or until the tracking dye reached the base o f  the gel. Gels were then visualised on 
a U V  transilluminator and photographed using a UV image analyser.
2.2.5 DNA agarose gel purification
DNA samples were gel-purified using a Wizard PCR-prep purification kit. DNA was 
electrophoresed on a 1% (w/v) low melt agarose gel at 70V for approximately 1 - 2  
hours. The gel was then visualised under ultra violet (UV) light and the bands o f  
interest excised from the gel using a sterile scalpel and placed in a sterile 1.5ml 
microcentrifuge tube. The gel bands were then incubated in a 70°C water bath until
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the gel was completely melted. Immediately after the gel melted 1ml o f  resin was 
added. The gel resin-mix was then flushed through the wizard mini-column using 5ml 
syringe barrel. The mini-column was then washed with 2ml o f  80% (v/v) propanol. 
The syringe barrel was then removed and the mini-column placed in a fresh 1.5ml 
eppendorf tube. The column and eppendorf were then centrifuged at 14,000 rpm for 2 
min, to remove the propanol. The column was once again transferred to a fresh 1.5ml 
microcentrifuge tube and then 50|il o f  upF^O added to the column. This was incubated 
at room temperature 1 min and the column was then centrifuged at 14,000 rpm for 20 
sec. The eluted D N A  was collected in a sterile microcentrifuge tube and stored at - 
20°C.
2.2.6 Ligation of scFv insert and pAK plasmid DNA
Gel-purified D N A  encoding pAK plasmid and scFv were ligated as follows:
pAK plasmid 3.0^1
scFv insert 2.6fil
Ligation buffer (10X) 1.0(0.1
Water 2A\i\
T 4 D N A lig a se (lU /fil) l.Oul
The ligation reaction was incubated at 15°C overnight.
2.2.7 Preparation of competent E.coli cells
A  single E. coli colony was inoculated in 5ml o f  2x TY, containing the appropriate 
antibiotics, and grown overnight at 37°C shaking. The overnight culture was used to 
inoculate 100ml o f  2x TY and the culture incubated, shaking at 37°C, until the optical 
density at 550nm (OD 550) was between 0.3 and 0.4. The cells were then left on ice for 
15 min and centr uged at 4000rpm for 20 min at 4°C. The supernatant was decanted 
and the pellet was resuspended in 20ml o f  cold lOOmM MgCk. The cells were 
cent: Euged at 4000rpm for 20 min at 4°C and the pellet was resuspended in 20ml o f  
cold 50mM CaCh. The cells were incubated on ice for 30 min and collected by 
centi hjgation at 4000rpm for 20 min at 4°C. The supernatant was decanted and the 
cells were resuspended in 2ml o f  CaCh. The CaCh-competent E. coli were flash 
frozen in 200jul aliquots and stored at -80°C.
6 3
2.2.8 Transformation of JM 83 E.coli with pAK vectors containing the scFv insert
Ligated DNA (50ng) was added to a 200(j.l aliquot o f  CaCl2 -competent JM83 E. coli. 
The transformation was incubated on ice for 60 min. The cells were then heat-shocked 
in a 42°C water bath for 45 sec and then immediately placed back on ice. SOC media 
(700|il) was then added to the heat-shocked cells, which were then incubated shaking 
at 37°C for one hour. The heat-shocked transformation (150|j.l) was plated out onto 2x 
TY agar plates containing 1% (v/v) glucose, 25|j.g/ml chloramphenicol and 50(ig/ml 
streptomycin sulphate. The plates were then incubated, inverted, overnight at 37°C. 
2x TY (1.5ml) was added to each plate and the cells were scraped o ff and collected. 
The collected cells were suspended in 15% (v/v) glycerol, flash frozen and stored at - 
80°C.
2.2.9 Soluble scFv production
An overnight culture o f  JM83 E. coli, harbouring the pAK vector containing the scFv 
gene o f  interest, was used to inoculate 200ml o f  2x  TY containing 25ng/ml 
chloramphenicol. The culture was incubated at 37°C, with vigorous shaking, until the 
OD550nm reached 0.5 -  0.6. The culture was then induced using ImM  
isopropylthiogalactopyranoside (IPTG) and incubated for a further 4 hours, for 
pAK.400 (or 16 hours for pAK500 and pAK600), at 26°C, with vigorous shaking, and 
then centrifuged at 4000rpm for 20 min.
2.2.10 Isolation of scFvs from the periplasm
Following scFv expression the bacterial pellet was resuspended in 10ml o f  TES 
(lOOmM Tris-HCl, pH 8, 0.5M  sucrose, 0.5mM EDTA) and incubated on ice for 1 
hour. Cellular debris was then removed following cent fugat an at 4000rpm for 20 
min and the supernatant (crude periplasmic lysate) dialysed against phosphate- 
buffered saline (PBS: 0.15M NaCl, pH 7.3) overnight at 4°C.
2.2.11 Sequence analysis on the gene encoding the AFBi-specific scFv
Plasmid DNA  for sequencing was purified from overnight cultures using the Promega 
Wizard Plasmid D NA  Purification Kit (See Section 2.2.2). The plasmid D NA was 
quantified using an ultra-violet (UV) spectrophotometer at 260nm and 20p,g o f  D NA  
was transferred to a fresh 1.5ml microcent fuge tube and vacuum dried. The linear
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nucleotide sequence was determined by MWG-Biotech and analysed using a variety 
o f web-based bioinformatic tools (Table 2.6).
Table 2.6: Web-based bioinformatic tools, and their source location, used during the 
sequence analysis of cloned inserts.
Tool Source
Translate tool www.expasv.oru
BLAST www.expasv.oru
Swiss-model httD://swissmodel.expasv.oi'
Deep View http://ca.expasv.ora/spdbv
ClustalW www.ch.embnet.ore/software/CluslalW.html
ESPript http://prodes.toulouse.inra. (r/ESPriptfcei-bin/ESIYipt.cui
Kabat rules http://acrmwww.biochem.ucl.ac uk/abs
2.2.12 Sodium dodecyl sulphate -  polyacrylamide gel electrophoresis (SDS- 
PAGE)
SDS-PAGE analysis was used to assess protein purity and determine the apparent 
molecular mass o f  proteins. Protein electrophoresis was performed using an Atto dual 
minislab AE-6450 gel under reducing conditions, by the method previously described 
by Laemmli (1970). Table 2 .7 details the composition o f  the gels, running buffer and 
sample loading buffer. Samples for analysis (approx. 1 mg/ml) were diluted with the 
sample loading dye (4:1, sample: buffer) and boiled for 10 min. The sample (20^1) 
was added to the gel and electrophoresed alongside appropriate molecular weight 
markers. Prestained molecular weight markers were also electrophoresed when the 
gels were being prepared for western blot analysis (See Section 2.2.13). Initially the 
gels were electrophoresed at 15mA per plate until the samples migrated through the 
stacking gel and then they were electrophoresed at 20mA per plate until the sample 
had migrated to the end o f  the gel (approximately 90 min).
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Table  2. 7: C om position o /S D S -P A G E  g e ls  a n d  buffer.
Stacking gel
Separating gel
Sample loading buffer
Electrophoresis buffer
5% (w/v) acrylamide 
0.13% (w/v) bis acrylamide 
125mM Tris 
0.1% (w/v) SDS
0.15% (w/v) ammonium persulphate 
0.25% (v/v) TEMED
10% (w/v) acrylamide 
0.27% (w/v) bis acrylamide 
375mM Tris 
0.1% (w/v) SDS
0.08% (w/v) ammonium persulphate 
0.08% (v/v) TEMED
60mM Tris 
25% (v/v) glycerol 
2% (v/v) SDS
14.4 mM 2-mercaptoethanol 
0.1% (w/v) bromophenol blue
25mM Tris 
192mM glycine 
0.1% (w/v) SDS
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2.2.13 Coomassie blue staining
SDS-PAGE gels were stained for 4 hours using Coomassie blue staining solution 
(Table 2.8) and then destained overnight in destaining solution (Table 2.8).
Table  2. 8: C om position o f  C oom assie blue s ta in ing  a n d  desta in ing  solutions.
Coomassie blue staining solution 0.1% (w/v) Coomassie Brilliant Blue R-250
25% (v/v) methanol 
10% (v/v) acetic acid
Destaining solution 14% (v/v) methanol
10% (v/v) acetic acid
2.2.14 Western blot analysis
Proteins were transferred from SDS-PAGE gels (Section 2.2.11) to nitrocellulose 
membrane by electophoretic means using a BioRad wet blotter in electrophoresis 
buffer containing 20% (v/v) methanol, for 90 min at 72V. The membrane was blocked 
using PBS-5% (w/v) milk marvel overnight at 4°C. The blocked membrane was then 
washed using 3 x 1 0  min PBS washes. The membrane was probed with the primary 
antibody, to the appropriate dilution with PBS-1% (w/v) milk marvel, for 1.5 hours at 
room temperature and washed as before. An alkaline phosphatase (AP)-labelled 
secondary antibody diluted to 1/2000 with PBS-1% (w/v) milk marvel was added and 
the blot incubated and washed as before. Colour development was then observed 
following addition o f  the substrate, BCIP-NBT, and the reaction stopped by addition 
o f  50mM EDTA.
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2 . 2 . 1 5  E L I S A  a n a l y s i s  o f  s o l u b l e  a n t i - A F B i  s c F v  a n t i b o d i e s
2.2.15.1 Checkerboard ELISA for the determination of conjugate coating 
concentration and optimal scFv antibody dilution for use in a competitive ELISA
A 96-well microtitre plate (Nunc Immunoplate Maxisorp, Gibco Ltd., Paisley, UK) 
was coated with different concentration o f  the AFBi-BSA conjugate ranging from 0 to 
50|ig/ml, at 100(4l/well. The plate was incubated for 1 hour at 37°C and the contents 
emptied. The plate was then washed three times with PBS - 0.05% (v/v) Tween and 
three times with PBS. The plate was blocked using 150(41 o f  PBS - 4% (w/v) milk 
marvel and incubated at 4°C overnight. Serial scFv dilutions ranging from undiluted 
to 1/128 were then prepared in PBS -  1% (w/v) milk marvel and 100(4,1 o f  each 
dilution added per well. The plate was incubated at 37°C for 1 hour and washed as 
before. 100|4l o f  anti-FLAG antibody, diluted to 1/400 in PBS - 1% (w/v) milk 
marvel, was added to each well and the plate incubated at 37°C for 1 hour. After 
washing, 100(4.1 o f  horseradish peroxidase (HRP)-conjugated anti-mouse antibody, 
diluted to 1/2000 in PBS - 1% (w/v) milk marvel, was added to each well. The plate 
was once again incubated at 37°C for 1 hour and washed as before. The substrate 
(100(41), o-phenylenediamine (o-PD), was added to each well and incubated for 30 
min at 37°C. Absorbance values at 405nm were then read using a Titertek plate 
reader.
2.2.15.2 Indirect competitive enzyme-linked immunosorbent assay (ELISA) for 
the detection of AFBi
Microtitre plates were coated with 100(41 o f  AFBi-BSA conjugate prepared in PBS at 
25(4g/ml and 12.5|4g/ml for the monomeric and dimeric scFv, respectively, and 
incubated for 1 hour at 37°C. The plates were then emptied and washed 3 times with 
PBS - 0.05% (v/v) Tween and three times with PBS. The plates were then blocked by 
adding 150(il/well o f  PBS - 4% (w/v) milk marvel and incubated at 4°C overnight. 
Free AFBi standards were prepared in PBS - 5% (v/v) methanol in concentrations 
ranging from 1.5 -  12500ng/ml. The plates were washed as before and 50(il o f  the 
anti-AFBi scFv was added to each well along with 50(11 o f  the AFBi standard. After 
washing 100(j,I o f  anti-FLAG antibody, diluted to 1/400 in PBS - 1% (w/v) milk
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marvel, was added to each well and the plate incubated at 37°C for 1 hour. After 
washing, 100|xl o f  horseradish peroxidase (HRP)-conjugated anti-mouse antibody, 
diluted to 1/2000 in PBS - 1% (w/v) milk marvel, was added to each well. The plate 
was once again incubated at 37°C for 1 hour and washed as before. The substrate 
(100(il), o-phenylenediamine (o-PD), was added to each well and incubated for 30 
min at 37°C. Absorbance values at 405nm were then read using a Titertek plate 
reader
2.2.15.3 Direct competitive ELISA for the detection of AFBi using the pAK600 
alkaline phosphatase-labelled scFv
Microtitre plates were coated with 100|il o f  AFBi-BSA conjugate dissolved in PBS 
6.25(ig/ml and incubated for 1 hour at 37°C. The plates were then emptied and 
washed 3 times with PBS - 0.05% (v/v) Tween and three times with PBS. The plates 
were then blocked by adding 150^1/well o f  PBS - 4% (w/v) milk marvel and 
incubated at 4°C overnight. Free AFBi standards were prepared in PBS - 5% (v/v) 
methanol in concentrations ranging from 1.5 -  12500ng/ml. The plates were washed 
as before and 50|al o f  the alkaline phosphatase-labelled scFv was added to each well 
along with 50pil o f  the AFBi standard. The plates were incubated at 37°C for 1 hour 
and washed as before. The substrate (100(0,1), /rara-nitrophenyl phosphate (pNPP), 
was added to each well and incubated for 30 min at 37°C. Absorbance values at 
405nm were then read using a Titertek plate reader.
2.2.15.4 M easurement of cross-reactions
The monomeric, dimeric and bifunctional scFv antibodies were assayed against a 
range o f  standards o f  aflatoxins B i, B2, M i, M2, Gi and G2. Stock solutions o f  the 
aflatoxins were prepared in methanol and diluted using PBS - 5% (v/v) methanol. The 
assays were carried out as for the competitive ELISAs (Sections 2.2.14.2 and 
2.2.14.3) except the aflatoxin standards were added to the immunoplate with the anti- 
AFBi scFvs.
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Buffers used during the development o f  a lateral flow immunoassay are detailed in 
Table 2.9.
2 . 2 . 1 6  D e v e l o p m e n t  o f  a  l a t e r a l  f l o w  i m m u n o a s s a y  ( L F I A )  f o r  t h e  d e t e c t i o n  o f
A F B i
Table 2.9: Buffers used during the development of a lateral flow immunoassay.
Buffer Composition
Colloidal carbon suspension 1% (w/v) in demineralised water
Carbon conjugate wash solution 5mM borate buffer, pH 8.5 
1% (w/v) BSA  
0.02% (v/v) NaN3
Carbon conjugate storage solution lOOmM borate buffer, pH 8.5 
1% (w/v) BSA  
0.02% (v/v) NaN3
LFIA Running buffer lOOmM borate buffer, pH 8.5 
0.1% (w/v) BSA  
0.05% (v/v) Tween 20 
0.01% (v/v) Triton-X-100 
0.02% (v/v) NaN3
2.2.16.1 Physical adsorption of protein onto colloidal carbon particles
The 1% (w/v) colloidal carbon stock solution was diluted to a final concentration o f  
0.2% (w/v) using 5mM borate buffer pH 8.5. A 1ml suspension was sonicated for 5 -  
10 min and the pH adjusted to 0.5 -  1 pH unit above the pi o f  the protein. The protein 
was dissolved in 5mM borate buffer and the pH also adjusted to 0.5 -  1 pH unit above 
the pi o f  the protein. The protein (350|ig in as small a volume as possible) was added 
to the 1ml colloidal carbon suspension and allowed to mix, gently stirring, overnight 
at 4°C. The protein-sol suspension was then centrifuged at 13,000rpm for 15 min and 
the pellet washed four times using 1.5ml o f  carbon conjugate wash solution. After the
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final wash step the pellet was resuspended in 1ml o f  carbon conjugate storage solution 
and stored in a glass vial at 4°C in the dark.
2.2.16.2 Spraying and production of nitrocellulose strips
Lateral flow strips (10) were prepared using a piece o f  nitrocellulose with plastic 
backing cut 10cm wide and 4.5cm long. Samples were sprayed onto the nitrocellulose 
using a Linomat 5 (Fig. 2.1), with the control and test lines sprayed 3 and 2.7cm, 
respectively, from the bottom o f  the nitrocellulose. A  70mm band was sprayed for the 
test and control lines at a rate o f  400nl/sec. The nitrocellulose strips were dried for at 
least one hour at 37°C and stored in closed laminated foil pouches with a 0.25g silica 
minipax at room temperature.
2.2.16.3 Running test strips
The nitrocellulose strips were stuck to a perspex bridge (Figure 2.2) using double 
sided sticky tape across the bridge. A  small piece o f  filter paper was stuck to the top 
o f each strip and a piece o f  parafilm placed beneath the strips to allow for sample 
application (Figure 2.3). Carbon conjugates were sonicated for 20 sec before use. 
Samples consisting o f  100|j.l o f  running buffer containing 1^1 o f the carbon conjugate 
and any additional solutions were placed on the parafilm and allowed to run up the 
nitrocellulose strip for 1 0 -1 5  min. The strips were then washed by adding lOOpil o f  
running buffer and signal observed.
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Spray head assembly 
with nozzle
Syringe
Nitrocellulose membrane
Plate stage
Linomat 5
Figure 2.1: Photograph of the Linomat 5 sprayer showing a piece of nitrocellulose in 
place for spraying.
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2 0 c m
5 . 5 c m
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18cm 2.5crr
M--------►
lc m
5cm
Figure 2.2: Dimensions of the perspex bridge used during the development of a 
lateral flow immunoassay.
Sample droplet Parafilm
Figure 2.3: Schematic representation of running nitrocellulose strips for the 
development of a lateralflow immunoassay.
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Biacore inhibition assay development was carried out using a Biacore 3000™  
supplied by Biacore International AB (Uppsala, Sweden). Hepes buffered saline 
(HBS) buffer, pH7.4 (lOmM HEPES, 150mM NaCl, 3.4mM EDTA, 0.05% (v/v) 
Tween 20) was used for all Biacore experiments. All solutions were filtered suing 
0.22jim syringe filters and the running buffer degassed using a Millipore sintered 
glass filtration system.
2.2.17.1 AFBi Sensor Chip
A Biacore CM5 chip immobilised with an AFBi derivative was kindly donated by 
XenoSense Ltd., do  Qubis, North Lanyon, Queen’s University Belfast, University 
Rd., Belfast, BT7 INN.
2.2.17.2 Sample Preparation for use in Inhibitive Assay
A 1 mg/ml o f  free AFBi was prepared in 100% methanol. Standards, ranging in 
concentrations from 190 -  24000pg/ml, were prepared in PBS containing 5% (v/v) 
methanol. Each AFBi standard was then pre-incubated with an equal volume o f  a 1/4 
dilution for the monomeric scFv and a dilution o f  1/35 for the dimeric scFv for 30 min 
at 37°C. Each concentration was then passed over the sensor surface three times. 
Regeneration o f  the sensor surface was carried out as described in Section 2.2.17.3.
2.2.17.3 Surface Regeneration
Regeneration o f  the AFBi sensor surface was carried out using lOmM NaOH, for the 
monomeric scFv and 25mM NaOH, for the dimeric scFv.
2.2.17.4 Measurement of Cross-Reactivity
Both the monomeric and dimeric scFv were assayed with a range o f  structurally 
related aflatoxin molecules, which included aflatoxin B 2 , Mi, M2 , Gi and G2 , in order 
to determine potential cross-reactivity in a Biacore inhibition assay format. Stock 
solutions o f  each aflatoxin were prepared in methanol and diluted in PBS - 5% (v/v) 
methanol to a range o f  concentrations ranging from 780 -  6250 pg/ml.
2 . 2 . 1 7  D e v e l o p m e n t  o f  a  B i a c o r e  i n h i b i t i o n  i m m u n o a s s a y  f o r  t h e  d e t e c t i o n  o f
AFBi
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2 . 3  C l o n i n g  a n d  e x p r e s s i o n  o f  B ru ce lla - s p e c i f i c  p r o t e i n s
Heat-killed Brucella abortus 45/20 cells were kindly donated by the Blood Testing 
Laboratory, Department o f  Agriculture and Food (DAFF), Model Farm Rd., Cork.
2.3.1 Isolation of Brucella abortus genomic DNA
The heat-killed B. abortus cells (5ml) were washed three times in PBS and 
resuspended in PBS to a final volume o f  5ml. The resuspended cells (1.5ml) were 
transferred to a sterile 1.5ml microcenl fuge tube and centrifuged at 13,000rpm for 5 
min. The bacterial pellet was resuspended in 1.5ml o f  TES (lOmM Tris, ImM EDTA, 
50mM NaCl, pH8.0) and centrifuged at 13,000rpm for 5 min. The pellet was then 
resuspended in 700|ul o f  TE (lOmM Tris, ImM E D T A  pH8.0). Lysozyme (50jj.1 o f  2 
mg/ml prepared in TE), made up freshly, was added. The culture was incubated at 30° 
for 20 min. Sarkosyl/proteinase (50^1 o f  10% (v/v) sarkosyl in TE, with 5mg/ml 
proteinase) was added. The culture was then incubated at 37° for 60 min. 3M sodium 
acetate (70|jl) was added and mixed by flicking. Kirby mix (49% (v/v) phenol, 49% 
(v/v) chloroform, 1.9% (v/v) isoamyl alcohol, 0.39% (w/v) 8-hydroxy quinolone) 
(600|J) was added and the mix was then centrifuged at 13,000rpm for approximately 
4 min. The aqueous phase was removed to a fresh microcentrifuge tube and a further 
600|il o f  Kirby mix was added. The solution was mixed and then centrifuged at 
13,000rpm for 4 min. The aqueous phase was removed to a fresh microcentrifuge tube 
and 700(11 o f  chloroform: isoamylalcohol (24:1) was added. The mixture was then 
centrifuged at 13,000rpm for 4 min. The aqueous phase was removed and added to an 
equal volume o f  isopropanol. The mixture was centrifuged at 13,000rpm for 5 min (or 
until a pellet formed). The supernatant was discarded and the pellet was washed twice 
with 70% (v/v) ethanol. The pellet was centrifuged at 13,000rpm for 5 min and any 
excess liquid removed. The pellet was then left to air dry for approximately 5 min. 
The dried pellet was then resuspended in 100 - 200|il o f  TE buffer and stored at 4°C.
2.3.2 Prim er design
Forward and reverse D N A  primers were designed for the genes encoding the p i8 and 
bp26 proteins based on D N A  sequences previously submitted to GenBank. The p i8 
primers were based on the sequence o f  the recombinant p i 8 protein cloned and
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expressed by Hemmen and associates (1995) from B. abortus (Accession number 
Z46864). The bp26 specific primers were also based on a recombinant form o f  the 
protein, which was cloned and expressed by Cloeckaert and associates (1996) from B. 
melitemis (Accession number U45996). N co l and BamHI restriction enzyme sites 
were incorporated into the forward and reverse primers, respectively, for subsequent 
directional cloning into the high-level expression vector pQE-60. The DNA  sequences 
o f  the forward and reverse primers for the p l8  and bp26 genes are detailed in Table 
2 .1 0 .
Table 2.10: The nucleotide sequences of the p l8  and bp26-specific forward and 
reverse primers.
Prim er DNA sequence
Ncol
p l8  forward 5' CC ATG G^A AAC CAA AGC TGT CCG AAC AAGAC 3'
Start codon
BamHI
p l8  reverse 5' GGA TCC GAC AAG CGC GGC GAT GCG G 3'
Ncol
bp26 forward 5' c c  ATG GGA AAC ACT CGT GCT AGC AAT 3'
Start codon
BamHI
bp26 reverse 5' GGA TCC CTT GAT TTC AAA AAC GAC ATT G 3'
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2.3.3 PCR amplification of genes encoding the Brucella-specific proteins
Standard polymerase chain reactions (PCRs) were used to amplify the genes encoding 
p i8 and bp26 (Table 2.11) using the PCR cycle detailed in Table 2.12.
Table 2.11: The components for a standard PCR reaction.
Component PCR reaction
dNTP mix (lOmM) ljil
Thermo buffer, containing Mg2+ (10X) 5|j.l
Forward primers (0.5nM/|il) 1 1^
Forward primers (0.5nM/[il) in i
Template DNA l(il
Sterile upF^O 38.5|il
Taq polymerase (lU /fil) 2.5nl
Table 2.12: The stages and steps for a standard PCR reaction.
Stage Step Number of cycles
1 Step 1: 95°C for 10 min
2 Step 1: 95°C for 1 min 
Step 2: 55°C for 30 sec 
Step 3: 72°C for 1 min
30
3 Step 1: 72°C for 10 min
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2.3.4 Ligation of PCR products and pCR2.1 plasmid
The ligation o f  the Taq D NA  polymerase amplified PCR products and the pCR2.1 
vector reaction was set up as follows:
Sterile upF^O 5jxl
Ligation buffer (10X) ljxl
pCR2.1 vector (25ng/|il) 2(0,1
Fresh PCR product lp.1
T4 DNA  ligase (4U/^1) lfil
The ligation reaction was incubated at 14°C for at least 4 hours, but preferably 
overnight. The ligation was then centrifuged briefly and stored at -20°C.
2.3.5 Transformation of IN V aF' with pCR2.1, containing the cloned insert
Vials containing the ligation reaction were centr uged briefly and then placed on ice. 
The overnight ligation reaction (2|ol) was added to 50|_il o f  ‘One Shot’ competent 
INV aF’ E.coli cells and mixed gently. The vials were then incubated on ice for 30 
min. The transformation reaction was then treated with a heat shock, by placing the 
vials in a 42°C water bath for 30 sec and then directly back on ice. SOC media 
(250|il) was then added to each transformation reaction. The transformation reaction 
was then incubated at 37°C for 1 hour, while shaking at 225rpm. Each transformation 
reaction (150^1) was then spread onto LB agar plates containing X-Gal and 50|j.g/ml 
o f  kanamycin. The plates were then incubated, inverted, at 37°C for at least 18 hours. 
The plates were then shifted to 4°C for 2 - 3 hours to allow further colour 
development.
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2.3.6 BamHl and Ncol restriction analysis on pCR2.1, containing the cloned 
insert
Overnight cultures o f  the clones for analysis were inoculated in 5ml o f  2x TY 
containing 50ng/ml o f  kanamycin and grown shaking at 37°C overnight. The plasmid 
DNA was purified from each clone using the Wizard Plus SV Minipreps D NA  
Purification System as described in Section 2.2.2. B am H l/N col restriction enzyme 
digests were set up as follows:
NE buffer 2 (10X) 2\xl
BSA (10mg/ml) 0.5\i\
Plasmid D NA 10nl
UpH20  (Sterile) 30.5^1
BamHl (10U/|il) 2\û
N col (lOU/jil) 2\xl
The restriction digest was incubated at 37°C for two hours.
2.3.7 Sub-cloning of cloned insert from pCR2.1 into pQE-60
A single D H 5a E. coli colony harbouring pQE-60 was grown overnight in 5ml o f  LB 
broth containing 100p.g/ml ampicillin shaking at 37°C. The pQE-60 plasmid DNA  
purified using the Promega Wizard Plus Miniprep D N A  Purification System (See 
section 2.2.2). The pQE-60 plasmid D NA  was then linearised using a BamHl /  N co l 
restriction digest as described in Section 2.3.6 and the linearised plasmid was gel 
purified, following agarose gel electrophoresis, using the Wizard PCR-prep 
purification kit (See Section 2.2.6). A  B am H l/N col restriction digest was also 
carried out on the pCR2.1 plasmid D N A  containing the cloned gene o f  interest (See 
Section 2.3.6). The restriction digest was electrophoresed on a 1% (w/v) low melt 
agarose gel and the bands corresponding to the gene o f  interest was gel purified using 
the Promega Wizard PCR Preps D N A  Purification System (See Section 2.2.5). The 
DNA encoding the gene o f  interest was then directionally cloned into the linearised 
pQE-60 using T4 D N A  ligase.
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T h e  l i g a t i o n  r e a c t i o n  w a s  s e t  u p  a s  f o l l o w s :
T4 DNA ligase (lU /ftl) 
Ligation buffer (10X)
pQE-60 DNA
Gene o f  insert
4{il 
4|il 
1 (j.1 
l |i l
The ligation reaction was incubated at 14° overnight.
2.3.8 Transformation of competent XL-10 Gold E.coli cells with pQE-60 
containing the cloned inserts
CaCl2 -competent XL-10 Gold E coli were prepared as described in Section 2.2.7. The 
competent XL-10 Gold E coli were then transformed with the pQE-60, containing the 
gene o f  interest, as described in Section 2.2.8.
2.3.9 Bam Hl/Ncol restriction analysis on XL-10 Gold E coli transformed with 
pQE-60
B am H l/N col restriction enzyme analysis was carried out on the pQE-60 plasmid 
DNA isolated from the transformed XL-10 Gold E coli as described in Section 2.3.6.
2.3.10 Sequencing of cloned inserts
Plasmid D N A  for sequencing was purified from overnight cultures using the Promega 
Wizard Plasmid D N A  Purification Kit (See Section 2.2.2). The plasmid D N A  was 
quantified using a UV spectrophotometer at 260nm and 20|j,g o f  D N A  was aliquoted 
into a fresh 1.5ml microcentrifuge tube and vacuum dried. Sequence analysis was 
then conducted as detailed in Section 2.2.11.
2.3.11 Small-scale expression culture
Overnight cultures o f  the XL-10 Gold E. coli harbouring the pQE-60 plasmid were 
innoculated in 2x  TY (5ml) containing 100p.g/ml ampicillin, 10|jg/ml tetracycline and 
25(ig/ml chloramphenicol. The culture were grown shaking at 37°C overnight. The 
overnight culture was then used to inoculate 20ml o f  2x TY containing lOOpg/ml 
ampicillin, 10pg/ml tetracycline and 25(ig/ml chloramphenicol. The culture was
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incubated shaking at 37°C until the optical density at 550nm (OD550) reached 0.5. 
Protein expression was then induced following addition o f  ImM IPTG. The culture 
was incubated shaking at 37°C for 4 hours and then centrifuged at 4000rpm for 20 
min. The supernatant was discarded and the pellet resuspended in 1ml o f  denaturing 
buffer (8M Urea, lOOmMNaEbPO^ lOmM Tris, pH8.0) and sonicated for 30 sec with 
6 sec pulses at 220W. The lysed cells were then centrifuged at 13,000rpm for 15 min 
and the supernatant analysed using SDS-PAGE (Section 2.2.11) for protein 
expression.
2.3.12 Optimisation of IPTG concentration
Several small-scale expression cultures were carried out as described in Section
2.3.11, except various IPTG concentrations, ranging from 0 -  ImM, were used for 
induction o f  protein expression.
2.3.13 Optimisation of sonication conditions
Several small-scale expression cultures were carried out as described in Section
2.3.11, except a range o f  sonication times, from 0 - 6 0  seconds, were analysed for 
optimal protein isolation.
2.3.14 Time course expression cultures
Small-scale expression cultures were carried out as described in Section 2.3.11, 
except following IPTG induction 1ml samples were taken at hourly intervals for up to 
five hours and then following overnight induction. A  non-induced sample was also 
taken before IPTG addition.
2.3.15 Large-scale expression culture
Overnight cultures o f  the X L-10 Gold E. coli harbouring the pQE-60 plasmid were 
innoculated in 2x TY (10ml) containing 100|ng/ml ampicillin, 10(j.g/ml tetracycline 
and 25|ig/m l chloramphenicol. The culture were grown shaking at 37°C overnight. 
The overnight culture was then used to inoculate 500ml o f  2x TY containing 
100(o,g/ml ampicillin, 1 O^g/ml tetracycline and 25|ig/m l chloramphenicol. The culture 
was incubated shaking at 37°C until the optical density at 550nm (OD550) reached 0.5. 
Protein expression was then induced following addition o f  0.5mM IPTG. The culture
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was incubated shaking at 37°C for 4 hours and then centrifuged at 4000rpm for 20 
min. The supernatant was discarded and the pellet resuspended in 25ml o f  denaturing 
buffer and sonicated for 30 sec followed by a 30 sec interval and this was repeated 
three times. The lysed cells were then cent fuged at 4000rpm for 15 min and the 
supernatant analysed using SDS-PAGE (See Section 2.2.11) for protein expression 
and the his-tagged recombinant proteins purified using IMAC (See Section 2.3.16).
2.3.16 IMAC purification of the 6x His-tagged recombinant proteins
IMAC running buffer (10ml) (Table 2.13) was added to 1ml o f  Ni-NTA resin. The 
resin mix was centrifuged at 4000rpm for 1 min. The cell lysate (4ml) was added to 
the equilibrated resin and incubated on an over-end rotor for 90 min at room 
temperature. The resin mix was then centr uged for at 4000rpm for 1 min and the 
supernatant removed. Wash buffer (10ml) (Table 2.13) was added to the resin and 
mixed. Following centrifugation at 4000rpm for 1 min the supernatant was removed. 
This wash step was then repeated twice more and followed by three elutions steps, 
which involved addition o f  1ml o f  elution buffer (Table 2.13) followed by 
centrifugation at 4000rpm for 1 min. The eluted fractions were then pooled and 
dialysed in PBS overnight at 4°C. The concentration o f  the purified protein was then 
determined using a BCA assay (See Section 2.3.17) and stored in 1ml fractions at - 
20°C.
2.3.17 Bicinchoninic acid (BCA) assay
Bovine serum albumin (BSA) protein standards ranging in concentration from 0.75 -  
2mg/ml were prepared in PBS. Each standard (10(4,1) was added to a 96-well 
immunoplate along with 200|il o f  the BCA reagent, in triplicate. The plate was 
allowed develop at 37°C for 30 min and the absorbance values obtained at 560nm 
using a Titertek Plate reader. A  standard curve was constructed and used to calculate 
the protein concentration o f  samples.
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Table 2.13: Composition of buffers used during the IMAC purification of his-tagged 
proteins.
Solution Composition
Running buffer 8M Urea
100mM NaH2P04
lOmMTris
pH 8.0
Wash buffer 8M Urea
100mM NaH2P04
lOmMTris
pH 6.3
Elution buffer 8M Urea
100mMNaH2P 0 4
lOmMTris
pH 4.5
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2 . 4  A n t i b o d y  p r o d u c t i o n
2.4.1 Antigen preparation
2.4.1.1 Isolation of the crude cytoplasmic fraction from Brucella abortus 45/20 
The crude cytoplasmic lysate was isolated from Brucella abortus 45/20 cells using a 
method previously described by Goldbaum et al. (1995). Washed B. abortus 45/20 
cells were centrifuged at 16,000g for 10 min. The cells were then washed three times, 
which involved resuspension o f  the bacterial pellet in 1ml o f  Tris buffer (lOmM Tris- 
HC1, pH8.0) followed by centrifugation at 16,000g for 5 min. The cells were then 
resuspended in 1ml o f  Tris buffer (per O.lg dry weight) and sonicated with three 2 
min pulses. The cells were then digested with 10f!g/ml o f  RNase and 10^ig/ml o f  
DNase and incubated for one hour at room temperature. Unbroken cells were 
separated by centrifugation at 16,000g for 5min. The supernatant was then centrifuged 
at 360,000g for 2 hours. The resulting supernatant /  cytoplasmic fraction was dialysed 
in PBS at 4°C overnight and stored in 1ml aliquots at -20°C.
2.4.1.2 Brucella abortus 45/20 cells
Heat-killed B. abortus 45/20 cells were washed three times in PBS and resuspended to 
a final concentration o f 1.6x10* cells/ml in PBS.
2.4.2 Licensing
All animal procedures were approved and licensed by the Department o f  Health and 
Children, with steps taken to minimise levels o f  distress caused to the animals.
2.4.3 Rabbit immunisation protocol
New-Zealand white rabbits were immunised by subcutaneous injection with an 
emulsion (1ml) consisting o f  a 1 mg/ml solution o f  antigen mixed 1:1 with Freund’s 
complete adjuvant. 21 days following the initial immunisation the rabbits were re­
immunised with 1ml o f  the same concentration o f  antigen mixed 1:1 with Freund’s 
incomplete adjuvant. A  blood sample was taken from the marginal ear vein 14 days 
after the second immunisation and an antibody titre determined (See section 2.4.7). 
The cycle o f  boosts and test bleeds were continued until an antibody titre in excess o f
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1/100,000 was obtained. The rabbit was then exsanguinated and serum recovered as 
described in Section 2.4.5.1
2.4.4 Preparation of rabbit serum
Blood samples were allowed to clot at room temperature for two hours. They were 
then stored overnight at 4°C to allow the clot tighten and centrifuged at 4000rpm for 
20 min. The supernatant (serum) was gently removed and stored at -20°C.
2.4.5 Polyclonal antibody purification
Polyclonal antibodies were initially purified from rabbit serum using saturated 
ammonium sulphate precipitation followed by protein G affinity chromatography.
2.4.5.1 Saturated ammonium sulphate (SAS) precipitation
SAS (3.6ml) was added drop wise to 3.6ml o f  the rabbit serum, on ice. The mixture 
was then left stirring on ice for one hour. The precipitated mixture was then 
centrifuged at 3000rpm for 20 min at 4°C. The supernatant was discarded and the 
pellet was resuspended in 3.6ml o f  45% (w/v) SAS. The resuspended pellet was then 
centrifuged at 3000rpm for 20 min at 4°C. The supernatant was, once again, discarded 
and the pellet resuspended in 3.6ml o f  45% (w/v) SAS. The resuspended pellet was 
then centrifuged at 3000rpm for 20 min at 4°C. The pellet was finally resuspended in 
1.8ml o f  PBS and the solution was dialysed overnight at 4°C in PBS.
2.4.5.2 Protein G afTinity-chromatography
A pre-poured protein G column was washed with 25ml o f  running buffer (Table 2.14) 
containing 0.05% (v/v) azide. The column was then equilibrated with 20ml o f  running 
buffer, with the flow rate set at 1.5ml/min. The column was stoppered when the 
running buffer reached the top o f  the column. The sample (1.5ml) was added to the 
column and the flow rate was set at 0.5ml/min. The effluent was monitored at 280 nm 
and fractions containing protein (i.e. OD280mn ^ 0.05) were collected. Running buffer 
was continually added to prevent the column running dry. After all the protein was 
collected the fractions were passed over the column two more times. The gel was 
washed with 20ml o f  wash buffer (Table 2.14), with the flow rate set at 1.5ml/min. 
(any protein collected at this stage was collected and stored in 0.01% (v/v) azide). The
8 5
column was then equilibrated using running buffer, which was allowed to pass 
through the column for five min at 1.5ml/min. The running buffer was allowed reach 
the top o f the column and then 1.5ml o f  elution buffer (Table 2.14) was added. The 
elution buffer was allowed to run into the column. Then the column was stoppered 
and the elution buffer was left within the column for five min. The flow rate was set at 
0.5ml/min and 500^1 fractions o f  protein were collected into tubes containing 50 jil o f  
neutralising buffer (Table 2.14), once protein was detected. Fractions were collected 
until no further protein was detected (i.e. OD28o < 0.05). The fract ms were then 
analysed at 280nm in quartz cuvettes and fractions containing the majority o f  protein 
were pooled and stored in 0.01% (w/v) azide. The protein G column was then washed 
using running buffer and stored in 20% (v/v) methanol.
Table 2.14: Composition of buffers used during the protein G purification of rabbit 
IgG polyclonal antibodies.
Running buffer PBS -  0.05% (v/v) Tween, 0.15M NaCl
Wash buffer PBS -  0.05% (v/v) Tween, 0.35M NaCl
Elution buffer 0. IM Glycine/HCl, pH 2.7
Neutralising buffer 2M Tris/HCl, pH 8.6
2.4.6 Determination of polyclonal antibody titre
A 96-well microtitre plate was coated with 100(xl/well o f  the appropriate antigen 
(approximately 1x10s cells/ml or lOpg/ml o f  protein) and incubated at 37°C for 1 
hour. The plates were washed 3 times with PBS and 3 times with PBS - 0.05%(v/v) 
Tween and then blocked with 150|j,l/well o f  PBS - 4% (w/v) milk marvel. Following 
overnight incubation at 4°C the plate was washed as before. Dilutions o f the 
appropriate antibody, ranging from 1/1000 -  1/5000000, were prepared in PBS - 1% 
(w/v) milk marvel and 100fj.l o f  each added to the immunoplate (in duplicate). The 
plates were then incubated for 1 hour at 37°C and washed as before. A  goat anti-rabbit 
horseradish peroxidase-labelled antibody, previously diluted to 1/5000 with PBS-1%  
(w/v) milk marvel, was added to the plate (100|xl/well) and the plate incubated at 
37°C for 1 hour. Following the wash step lOO^l/well o f  o-PD substrate was added
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and, after 30 min incubation at 37°C, absorbances at 405nm were determined using a 
Titertek plate reader. The results obtained were then graphed using Excel and the 
antibody titre was defined as the highest antibody dilution with an absorbance value 
that was greater than 2 standard deviations (SD) above the mean absorbance value for 
the zero control.
2.4.7 Checkerboard ELISA for the determination of optimal cell-coating 
concentrations and optimal antibody dilution for use in a competitive ELISA
A  96-well microtitre plate was coated with different cell concentrations, ranging from 
0 to 1.6xl09 cells/ml, by adding lOOp.1 o f  each concentration per well. The plate was 
incubated for 1 hour at 37°C and the contents emptied. The plate was then washed 
three times with PBS - 0.05% (v/v) Tween and three times with PBS. The plate was 
blocked using 150|j,l o f  PBS - 4%(w/v) milk marvel and incubated at 4°C overnight. 
Serial antibody dilutions ranging from 1/10 -  1/1000000 were then prepared in PBS -  
1% (w/v) milk marvel and 100|xl o f  each dilution added per well. The plate was 
incubated at 37°C for 1 hour and washed as before. Goat anti-rabbit-horseradish 
peroxidase-labelled antibody, previously diluted to 1/5000 with PBS - 1% (w/v) milk 
marvel, was added to the plate (100|il/well) and the plate incubated at 37°C for 1 
hour. Following the wash step, 100|j.l/well o f  o-PD substrate was added and, after 30 
min incubation at 37°C, absorbances at 405nm were determined using a Titertek plate 
reader.
2.4.8 Indirect competitive enzyme-linked immunosorbent assay (ELISA) for the 
detection of B. abortus
Microtitre plates were coated with lOOpl o f  the appropriate B. abortus cell 
concentration and incubated for 1 hour at 37°C. The plates were then emptied and 
washed 3 times with PBS - 0.05% (v/v) Tween and three times with PBS. The plate 
were then blocked by adding 150[ol/well o f  PBS - 4% (w/v) milk marvel and 
incubated at 4°C overnight. Free B. abortus cell concentrations, ranging from
1.95xl06 and lxlO 9 cells/ml, were prepared in PBS. The plate was washed as before 
and 50(j,l o f  each cell concentration was added to each well along with 50fj.l o f  the 
Brucella-specific polyclonal antibody previously diluted to 1/5000 with PBS - 2% 
(w/v) milk marvel. The plate was incubated at 37°C for 1 hour and washed as before.
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Goat anti-rabbit-horseradish peroxidase-labelled antibody, previously diluted to 
1/5000 with PBS -1%  (w/v) milk marvel, was added to the plate (100|il/well) and the 
plate incubated at 37°C for 1 hour. Following the wash step 100|il/well o f  o-PD 
substrate was added and, after 30 min incubation at 37°C, absorbances at 405nm were 
determined using a Titertek plate reader.
2.4.9 Measurement of cross-reactions
The Brucella-specific polyclonal antibodies were assayed against a variety o f gram­
negative and positive bacterial strains. The assays were carried out as for the 
competitive ELISAs (Section 2.4.9) except the bacterial strains were added to the 
immunoplate with the Brucella-specific polyclonal antibodies.
2.5 Screening for scFv phage display antibodies from a naive phage display 
library
2.5.1 Selection of antigen binders by panning in immunotubes
An immunotube was coated with 0.5ml o f  the appropriate antigen at 10|og/ml 
overnight at 4°C. Following incubation the immunotube was washed three times with 
PBS and then blocked with 3% (w/v) milk marvel, for 2 hours at room temperature. 
Meanwhile, a 500p.l sample o f  phage, at a concentration o f  approximately lx lO 12 
cfu/ml, was pre-blocked with 3% (w/v) milk marvel. The blocking solution was 
removed from the immunotube, which was washed three times with PBS. The pre­
blocked phage were then added to the immunotube and incubated for 90 min at 37°C. 
The immunotube was then rinsed 10 times with PBS - 0.05% (v/v) Tween and 10 
times with PBS. Bound phage were then eluted using 0.5ml o f freshly prepared 
lOOmM glycine-HCl, pH 2.2. The eluted phage was neutralised upon addition o f  
100p.I o f  Tris-HCl, pH 8.0. XL-1 Blue cells were then infected with the eluted phage 
and the output titre determined (Section 2.5.2).
2.5.2 Re-infection of XL-1 B lu e £  coli cells with eluted phage
A 20ml culture o f  2x TY was inoculated with a single colony o f  XL-1 Blue E. coli 
and incubated shaking for 4 hours at 37°C, until OD550 was approximately 0.5. 
Exponentially growing XL-1 Blue (5ml) were placed in a Falcon tube and 300fil o f
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the eluted phage were allowed infect the E. coli at 37°C for 30 min, while stationary, 
and for 30 min while shaking at 200rpm. Four ten-fold dilutions o f  the infected E. coli 
were prepared in 2x TY and lOOpl o f  each dilution plated on 2x TY agar plates 
containing lOOfig/ml ampicillin, lO^g/ml tetracycline and 2% (w/v) glucose. The 
remaining cells were centrifuged at 3500rpm for 10 min and then resuspended in 
500pl o f  2x TY and spread on 2x TY agar plates containing 100(ig/ml ampicillin, 
10(ig/ml tetracycline and 2% (w/v) glucose. The agar plates were then incubated at 
37°C overnight, while inverted.
2.5.3 Storage and rescue of phagemid antibodies after selection
Colonies were scraped from the stock plates into 10ml o f  2x TY in a 50ml Falcon 
tube. Sterile 50% (v/v) glycerol (5ml) was added to the cell suspension and 1ml 
aliquots were flash frozen using liquid nitrogen and stored at -70°C. 25ml o f  2x TY  
containing 100(ig/ml ampicillin, lO^g/ml tetracycline and 2% (w/v) glucose was 
inoculated with 100|il o f  the plate scrape and grown at 37°C to mid-log phase (OD550 
= 0.5). M 13K 07 helper phage (200p.l) were then added and allowed to infect the cells 
at 37°C for 30 min stationary and 30 min at 200rpm. The infected cells were then 
centrifuged at 3500rpm for 10 min and the bacterial pellet resuspended in 25ml o f  2x  
TY containing 100(j.g/ml ampicillin, lOpg/ml tetracycline and 25(j.g/ml kanamycin. 
The resuspended pellet was then transferred to a sterile 250ml flask and grown for 
either 3.5 hours at 30°C or overnight at 25°C at 300rpm. For each selection, 1ml o f  
culture was centrifuged for 5 min at 13000rpm. The phage-containing supernatant 
(1 Ofj.1) was then used to infect mid-log phase XL-1 Blue E. coli, in order to determine 
the input phage titre.
2.5.4 Rescue of phagemid clones in microtitre trays for phage ELISA
Colonies (95) were selected from the selection output agar plates and inoculated into 
100p.l o f  2x TY containing 100(ig/ml ampicillin, 10(4g/ml tetracycline and 2% (w/v) 
glucose in a 96-well immunoplate plate and grown at 37°C with shaking at 120rpm. 
This was the master plate. A  replica plate was then prepared by inoculating lOOfil o f  
2x TY containing 100|j.g/ml ampicillin, 10|ig/ml tetracycline and 2% (w/v) glucose 
with 20jul o f  the overnight cultures from the master plate. The replica plate was grown
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at 37°C for 5 - 6 hours at 120rpm and 50(.il o f  50% (v/v) glycerol was added to each 
well o f  the master plate, which was stored at -20°C. M 13K 07 helper phage (10(4.1) 
was then added to each well o f  the replica plate and allowed to infect the cells at 37°C 
for 60 min at 125rpm. The replica plate was centrifuged at 2000rpm for 10 min and 
the pellets resuspended in 100(41 o f  2x TY containing 100|4g/ml ampicillin, lOpg/ml 
tetracycline and 25|4g/ml kanamycin. The plate was then grown at 37°C overnight at 
120rpm to produce phage particles.
2.5.5 Phage ELISA
A 96-well plate was coated with the appropriate antigen at 10(4g/ml, with 100nl/well 
and incubated overnight at 4°C. The coated immunoplate was then washed three times 
with PBS and blocked with 4% (w/v) milk marvel (150|4l/well). The phage was then 
pre-blocked by centrifuging the replica plate at 2000 rpm for 10 min and transferring 
the supernatant to a fresh immunoplate containing 50(41 o f  9% (w/v) milk marvel in 
each well. The phage were pre-blocked for 30 min at room temperature and then 
added to the coated and blocked immunoplates and incubated at 37°C for 1 hour. The 
plate was washed three times with PBS - 0.05% (v/v) Tween and three times with 
PBS. The anti-fd bacteriophage, previously diluted to 1/5000 with PBS, was added 
(100(4l/well) and the plate incubated at 37°C for 1 hour. The plate was washed as 
before and 100(41 o f  a 1/5000 dilution o f  the HRP-labelled anti-rabbit Ig antibody 
added and the plate incubated at 37°C for 1 hour. The plate was re-washed, 100(41 o f  
o-PD substrate added to each well and then incubated for 30 min at 37°C. Absorbance 
values were then recorded at 405nm.
2.5.6 Soluble ELISA
Colonies (95) were chosen from the selection output agar plates and inoculated into 
100|4l o f  2x TY containing 100(4g/ml ampicillin, 10|4g/ml tetracycline and 2% (w/v) 
glucose in a 96-well immunoplate plate and grown at 37°C with shaking at 120rpm. 
This was the master plate. A  replica plate was then prepared by inoculating 100(41 o f  
2x TY containing 100|4g/ml ampicillin, 10(4g/ml tetracycline and 2% (w/v) glucose 
with 20(41 o f  the overnights cultures from the master plate. The replica plate was 
grown at 37°C for 5 - 6 hours at 120rpm and 50(41 o f  50% (v/v) glycerol was added to
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each well o f  the master plate, which was stored at -20°C. The replica plate was 
centrifuged at 2000rpm for 10 min and the pellets resuspended in 100(il o f  2x TY  
containing 100|4g/ml ampicillin, 10ng/ml tetracycline and ImM BPTG. The plate was 
then grown at 30°C overnight at 120rpm to induce antibody expression.
A 96-well plate was coated with the appropriate antigen (lOOp.1 o f  a 10|ig/ml 
concentration) and incubated overnight at 4°C. The coated immunoplate was then 
washed three times with PBS and blocked with 150^1/well o f  4% (w/v) milk marvel. 
The soluble scFvs were then pre-blocked by centrifuging the replica plate at 2000 rpm 
for 10 min and transferring the supernatant to a fresh immunoplate containing 50p,l o f  
9% (w/v) milk marvel in each well. This was incubated for 30 min at room 
temperature. The pre-blocked scFvs were then added to the previously coated and 
blocked immunoplate and incubated at 37°C for 1 hour. The plate was washed three 
times with PBS - 0.05% (v/v) Tween and then three times with PBS. An anti-c-myc- 
HRP antibody, previously diluted to 1/1000 in PBS was added (100(il/well) and the 
plate incubated at 37°C for 1 hour. Once again the plate was washed and 100|_il o f  o- 
PD substrate added to each well and incubated for 30 min at 37°C. Absorbance values 
were then recorded at 405nm.
2.5.7 Sequence analysis on the gene encoding the bp26-specific scFvs 
Nucleotide and amino acid sequence comparisons were carried out on the bp26- 
specific scFvs as previously described in Section 2.2.11.
2.5.8 Checkerboard ELISA for the determination of optimal bp26 coating 
concentration and optimal scFv dilution for use in a competitive ELISA
A 96-well microtitre plate was coated with different bp26 concentrations, ranging 
from 0 to 50|og/ml, by addition o f  100[il o f  each concentration per well. The plate was 
incubated for 1 hour at 37°C and the contents emptied. The plate was then washed 
three times with PBS - 0.05% (v/v) Tween and three times with PBS. The plate was 
blocked using 150(j.l o f  PBS - 4% (w/v) milk marvel and incubated at 4°C overnight. 
Serial scFv dilutions ranging from undiluted to 1/1000 were then prepared in PBS -  
1% (w/v) milk marvel and 100(j.l o f  each dilution added per well. The plate was
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incubated at 37°C for 1 hour and washed as before. Anti-c-myc-horseradish 
peroxidase-labelled antibody, previously diluted to 1/1000 with PBS - 1% (w/v) milk 
marvel, was added to the plate (100|j.l/well) and the plate incubated at 37°C for 1 
hour. The plate was washed, as before, and o-PD substrate added (lOO^l/well). After 
30 min incubation at 37°C absorbances at 405nm were determined using a Titertek 
Plate reader.
2.5.9 Indirect competitive enzyme-linked immunosorbent assay (ELISA) for the 
detection of bp26
Microtitre plates were coated with 100p.l o f  the bp26 at 12.5jj.g/ml and incubated for 1 
hour at 37°C. The plates were then emptied and washed 3 times with PBS - 0.05% 
(v/v) Tween and three times with PBS. The plate were then blocked by adding 
150pl/well o f  PBS - 4% (w/v) milk marvel and incubated at 4°C overnight. Free bp26 
concentrations, ranging from 24 -  25000ng/ml, were prepared in PBS. The plate was 
washed as before and 50^1 o f  each bp26 concentration was added to each well along 
with 50p.l o f  the bp26-specific scFv previously diluted to 1/8 with PBS - 2% (w/v) 
milk marvel. The plate was incubated at 37°C for 1 hour and washed as before. Anti- 
c-myc-horseradish peroxidase-labelled antibody, previously diluted to 1/1000 with 
PBS-1% (w/v) milk marvel, was added to the plate (100(jl/well) and the plate 
incubated at 37°C for 1 hour. The plate was washed, as before, and o-PD substrate 
added (100|j.l/well). After 30 min incubation at 37°C absorbances at 405nm were 
determined using a Titertek plate reader.
2.6 Development of diagnostic assays for the detection of bovine brucellosis
All serum samples used in the development o f  the diagnostic assays for the detection 
o f  bovine brucellosis were kindly donated by Blood Testing Laboratory, Department 
o f Agriculture and Food (DAFF), Model Farm Rd., Cork. A  set o f  three standard 
serum samples were provided, which included the two Brucella-positive standards, 
which displayed significantly high antibody titres against Brucella abortus, the 
DeVeere Hunt Serum and the National Standard Serum (NSS), and the standard 
Brucella-negative serum. A  panel o f  Brucella-positive and negative serum samples 
were also obtained, which consisted o f  18 positive serum samples, which were 
previously identified as positive for a Brucella infection using the conventional LPS-
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indirect ELISA, and 50 serum samples, which were previously identified as negative 
for a Brucella infection.
2.6.1 Indirect enzyme-linked immunosorbent assay for the detection of bovine 
brucellosis in serum samples
Wells o f  a 96-well immunoplate were coated with the appropriate antigen diluted in 
PBS. The immunoplate was then incubated at 37°C for 1 hour. The plate was washed 
three times with PBS - 0.05% Tween and three times with PBS. Milk marvel (4% 
(v/v)) in PBS was added to each well (150[xl /  well) and the plates were incubated at 
4°C overnight. The Brucella-positive and negative bovine serum samples diluted to 
1/50 in PBS - 0.05% (v/v) Tween containing 4% (w/v) milk marvel were pre­
incubated at 37°C for 1 hour. The immunoplate was washed as before and 100|il o f  
each serum dilution was added to each well, in duplicate. The plate was incubated at 
37°C for one hour and washed as before. The anti-bovine horseradish peroxidase­
labelled antibody (lOOpl), previously diluted to 1/2000 and pre-incubated in PBS- 
0.05% (v/v) Tween containing 4% (w/v) milk marvel, was added to each well. The 
plate was then incubated at 37°C for one hour. The plate was washed, as before, and 
o-PD substrate added (lOOpl/well). After 30 min incubation at 37°C absorbances at 
405nm were determined using a Titertek plate reader.
2.6.2 Sandwich enzyme-linked immunosorbent assay for the detection of bovine 
brucellosis in serum samples
A  1/500 dilution o f  the purified polyclonal antibody was prepared in carbonate buffer, 
pH 9.6, and lOOp.1 added to a 96-well immunoplate. The plate was incubated at 37°C 
for one hour and washed three times with PBS - 0.05% (v/v) Tween and three with 
PBS. 150pl o f  4% (w/v) milk marvel in PBS was added to each well and the plates 
were incubated at 4°C overnight. The plates were washed as before and lOOp.1 o f  the 
appropriate antigen, diluted in PBS, added to each well. The plate was then incubated 
at 37°C for 1 hour. The Brucella-positive and negative bovine serum samples, diluted 
to 1/50 in PBS - 0.05% (v/v) Tween containing 4% (w/v) milk marvel, were pre­
incubated at 37°C for 1 hour. The immunoplate were washed as before 100|il o f  each 
serum dilution was added to each well, in duplicate. The plate was incubated at 37°C 
for one hour and washed as before. The anti-bovine horseradish peroxidase-labelled
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antibody (IOOjj.1), previously diluted to 1/2000 and pre-incubated in PBS - 0.05% 
(v/v) Tween containing 4% (w/v) milk marvel was added to each well. The plate was 
then incubated at 37°C for one hour. The plate was washed, as before, and o-PD 
substrate added (lOO^l/well). After 30 min incubation at 37°C absorbances at 405nm 
were determined using a Titertek plate reader.
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CHAPTER 3
T h e  p r o d u c t i o n  a n d  c h a r a c t e r i s a t i o n  o f  g e n e t i c a l l y  
d e r i v e d  s c F v  a n t i b o d y  f r a g m e n t s  d i r e c t e d  a g a i n s t  
a f l a t o x i n  B i  ( A F B i )
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3 . 1  I n t r o d u c t i o n
The discovery o f  aflatoxins stems from 1960 following the death o f  several thousand- 
turkey poults in East Anglia (Hartley et al, 1963). Aflatoxins consist o f  a group o f 
approximately 20 related fungal metabolites that occur in Aspergillus species 
(O’Kennedy and Thornes, 1997). High humidity, in tropical and sub-tropical climates 
favours fungal growth and the production o f  aflatoxins. Contamination is widespread 
in agricultural commodities including maize, cottonseed, peanuts and tree nuts and 
occurs during growth and, to greater extent, storage. They can also occur in a wide 
range o f  important raw food produce including spices, figs and dried fruit. Aflatoxins 
are members o f  the coumarin family and are the most widely spread group o f toxins 
from naturally occurring moulds that results in contamination o f  food products. 
Aflatoxins B i, B 2, Gi and G2 are normally found in food, with additional metabolites, 
aflatoxins Mi and M2, found in milk. Aflatoxin B] (AFBi), which is produced by A. 
flavus and A. parasiticus, is the most predominant and toxic. AFBi is considered to be 
one o f  the most potent naturally occurring carcinogens, is linked to human 
hepatocellular carcinoma and is regarded as a human carcinogen by the International 
Agency for Research on Cancer (Ward et al., 1990).
3.1.1 Chemical and physical properties of aflatoxins
Aflatoxins are crystalline structures that fluoresce under UV radiation. Aflatoxins are 
hydrophobic in nature and soluble in solvents such as chloroform, methanol and 
dimethyl sulfoxide (DMSO), and in water to the extent o f  10 -  20mg/l. They are 
extremely stable in the absence o f  light and UV  radiation, even at temperatures in 
excess o f  100°C. The presence o f  the lactone moiety makes them susceptible to 
alkaline hydrolysis. However, this hydrolysis appears to be reversible following 
acidification. Aflatoxins are broken down in the presence o f  oxidising agents, such as 
sodium hypochlorite, potassium permanganate and hydrogen peroxide, resulting in the 
loss o f  fluorescence. In acid solutions aflatoxins B] and Gi are converted to aflatoxins 
B2a and G2a due to the acid-catalysed addition o f  water across the double bond o f  the 
furan ring. Figure 3.1 illustrates the structure o f  AFBi and its structural analogues.
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Figure 3.1: Chemical structure of aflatoxin Bj (AFBi) and its structural analogues: 
aflatoxinB2 (AFB2), aflatoxin Gi (AFGi), aflatoxin G2 (AFGz), aflatoxin (AFMj), 
aflatoxin M2 (AFM2), aflatoxin B2a (AFB2a) and aflatoxin G2a (AFG2a)-
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3.1.2 Aflatoxin production and biosynthesis
A. flavus, A. parasiticus and A. nomius are widely distributed moulds that share the 
ability to produce aflatoxins (Gourama and Bullerman, 1995). Aflatoxins are 
secondary metabolites o f  these fungal species and are not essential for growth. Several 
factors, including fungal species, substrate and environment contribute to aflatoxin 
production. The optimal growth temperature for A. flavus is 25°C and 25 -35°C for A. 
parasiticus and the optimum temperature for aflatoxin production is generally 
accepted to be 25 - 28°C. Maximum levels o f  aflatoxin production are linked to the 
exhaustion o f  sugars in the medium and the onset o f  mycelial autolysis. Relative 
humidity levels o f  at least 83 -  88% are required for aflatoxin production. Aflatoxin 
yields increase as the relative humidity increases, up to 99%. Since fungal growth and 
aflatoxin production are aerobic, CO2 concentrations from 20 -  100% gradually 
inhibit aflatoxin production. Zinc and magnesium are essential for aflatoxin 
biosynthesis and a mix o f  cadmium and iron was found to stimulate production. 
However, iron has been found to inhibit fungal growth and, therefore, aflatoxin 
production. Other substances such as nitrate, ethylene, sorbic acid and competing 
mycoflora, such as A. niger and Rhizopus oligosporus, also inhibit aflatoxin 
production.
The majority o f  genes involved in the biosynthesis o f  aflatoxins are contained within a 
single cluster on a chromosome, which in A. flavus and A. parasiticus is estimated to 
be 75kb (Woloshuk and Prieto, 1998). The main precursors o f  aflatoxins are acetate 
polyketides. Aflatoxins are produced from the acetate building blocks, which are 
produced during the idiophase o f  the fungal life-cycle. Aflatoxin B i biosynthesis is 
complex and involves numerous intermediate compounds, including norsolorinic acid, 
averantin, averufin, versiconal hemiacetal acetate, versicolerin A  and sterigmatocystin 
(Fig. 3.2).
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Acetate "1 — ► 1 Norsolorinic acid - > Averatin — ► Averufanin — ► Averufin
pksA norl fasi fas2 aflR aflJ adhA norA verlA  aflS avnA verB ord2 omtA ord ì vbs aflB
Figure 3.2: Biosynthetic pathway of aflatoxin Bj, detailing the major intermediates and the genetic organisation of the aflatoxin gene cluster 
(after Woloshuk and Prieto, 1998).
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3.1.3 Mode of action of aflatoxins
The most toxic and carcinogenic effects associated with aflatoxin Bi are as a result o f  
metabolic activation. Several cytochrome P450 enzymes including 1A2, 2A, 3 A  and 
2A5, are involved in the biotransformation o f  aflatoxin Bi (Pelkonen et al., 1997). 
Cytochrome P450 can metabolise AFBi to both an exo- and endo-AFBj-8,9-epoxide. 
In an attempt to rid the body o f  aflatoxin the cytochrome P450 enzymes add a highly 
reactive epoxide group, making it highly mutagenic (Goodsell, 2001). The resulting 
exo-epoxide reacts covalently with D N A  to form adducts that ultimately result in 
heritable genetic change (Smela et a l, 2001). The activated epoxide forms covalent 
attachments with the N 7 o f guanine resulting in the formation o f  a number o f  adducts 
(Hussein and Brasel, 2001). 8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B i 
(AFBi-N7-Gua) is the most abundant, both in vivo and in vitro (Smela et al., 2001). 
Other adducts formed include an apurinic (AP) site, resulting following depurination 
by the positively charged imidizole ring o f  the principal adduct, and a more 
chemically and biologically stable AFBi formanidopyrimidine (AFBi-FAPY), which 
is produced when the imidizole ring on the AFBi-N7-Gua opens (Smela et al., 2001). 
All three adducts represent the chemical precursors that account for the genetic effects 
o f AFBi, which are dominated by G-T tranversions. The epoxide has been liked to G- 
T tranversions at codon 249 o f the p53 tumour suppressor gene, which is associated 
with many human cancers (Smela et al., 2001). Hydroxylation o f  the epoxide results 
in the formation o f  AFBi-8-9-dihydrodiol, which inhibits in vivo and in vitro protein 
synthesis presumably explaining the cause o f  liver necrosis and resulting death 
(Gourama and Bullerman, 1995). Figure 3.3 details the metabolic pathway o f  AFBi 
leading to covalent adduct formation.
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Aflatoxin Bt
Cytochrome P450
AFBr 8,9-cxo-epoxide AFB!-8,9-endo-epoxide
Figure 3.3: Pathway detailing the metabolic activation of qflatoxin B} leading to the 
formation ofDNA adducts.
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3.1.4 Toxicity of aflatoxins
Aflatoxins are potent, carcinogenic, mutagenic, immunosuppressive agents that can be 
both acutely and chronically toxic. AFBi is considered to be one o f  the most potent 
naturally occurring carcinogens, is linked to human hepatocellular carcinoma and is 
regarded as a human carcinogen by the International Agency for Research on Cancer 
(Ward et al., 1990). Acute aflatoxin poisoning in man is extremely unlikely and in 
animals is rare in temperate developed areas. However, the outbreak o f  Turkey X  
disease, in the 1960s highlighted the potential devastating effects o f  mycotoxin 
contamination, in particular the aflatoxins.
The susceptibility o f  animals to acute mycotoxin poisoning is determined from the 
LD50 (mg/kg o f  body weight), which in turn is dependent on several factors including 
species, age, sex and nutrition. In general LD 50 for animals range between 0.5 -  
lOmg/kg o f  body weight. Clinical signs o f  aflatoxosis in animals include 
gastrointestinal dysfunction, reduced reproducibility, reduced feed utilisation and 
efficiency, anaemia and jaundice. The effects o f  aflatoxin poisoning varies from 
species to species with calves, chicks, ducklings, guinea pigs and pigs being 
susceptible to aflatoxin Bi and goats, rats, mice and sheep being relatively resistant 
(Gourama and Bullerman, 1995).
Cases o f  acute aflatoxin poisoning in humans have been reported sporadically, mainly 
in Africa and Asia. In the majority o f  reported cases the humans become exposed to 
aflatoxins by consuming contaminated food such as maize, rice or cereal products. A  
broad range o f  symptoms can be found, including vomiting, abdominal pain, 
pulmonary edema, acute liver damage, loss o f  function o f  the digestive tract, 
convulsions, cerebral edema and death, depending on dose consumed. The onset o f  
symptoms is relatively slow (i.e. > 8  hours post exposure). In general our 
understanding on the affects o f  aflatoxin poisoning on humans is limited to case 
studies on sporadic outbreaks o f  aflatoxosis. Studies on human outbreaks suggest a 
minimum dose o f  50|ig/kg/day is required for clinically significant effects. A  woman 
who attempted suicide by ingesting 5.5mg over 2 days and 35mg over two weeks ( 6  
months later) o f  aflatoxin B i recovered completely with no significant signs o f liver 
damage (Hussein and Brasel, 2001). This suggests that extended subacute doses, as
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seen in dietary exposure in certain countries, are necessary for inducing lethal acute 
effects.
One o f  the most significant accounts o f  aflatoxin poisoning occurred in India in 1974. 
397 people were affected following consumption o f  contaminated corn. The com  was 
contaminated with aflatoxin at levels ranging from 0.25 -  15mg/kg. It is estimated 
that the daily aflatoxin Bi intake was at least 55|ig/kg o f  body weight, for an 
undetermined number o f  days. Patients experienced several symptoms including high 
fever, jaundice, vomiting, pain and swollen livers and out o f  the infected people 108 
died. In Malaysia in 1990 approximately 40 people were affected and 13 children died 
following the consumption o f  noodles highly contaminated with aflatoxin and boric 
acid. In this case autopsy results later revealed high levels o f  aflatoxin in the liver, 
lung, kidney heart, brain and spleen.
Aflatoxins have also been found in tissue specimens taken from children suffering 
from Kwashiorkor and R eye’s syndrome suggesting that aflatoxins may be a 
contributing factor to these diseases (Hussein and Brasel, 2001). Studies, carried out 
in Asia and Africa, have demonstrated the positive association between dietary 
aflatoxin exposure and liver cell cancer. In 1987 the International Agency for 
Research on Cancer (IARC) classified aflatoxin B i as a class I human carcinogen 
(Ward et al., 1990). Although less studies have been conducted on aflatoxins Gi and 
Mi they appear to be toxicologically similar to aflatoxin Bi. However, they are 
slightly less potent liver carcinogens and slightly more potent kidney carcinogens.
3.1.5 Aflatoxin sampling and analysis
As previously discussed aflatoxin contamination can occur in a wide range o f  
agricultural commodities including com, peanuts and maize. The aflatoxin 
concentration in grains or nuts can vary from less than lppb to more than 12ppb with 
the aflatoxin highly concentrated in individual kernels (Gourama and Bullerman, 
1995). Therefore, it is essential to select an analytical sample that is truly 
representative o f  the consignment. Polar solvents such as methanol, chloroform and 
acetonitrile are used extract the aflatoxins from food and animal feed. Sample clean­
up using solid phase extraction techniques and immunoaffinity columns may also be
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required for the traditional methods o f  detection for AFBi, which include thin-layer 
chromatography (TLC), high-pressure liquid chromatography (HPLC), gas-liquid 
chromatography (GLC) and mass spectrometry (Nawaz et al., 1995). These 
conventional analytical techniques have offered good resolution, a high degree o f  
precision, reproducibility and sensitivity in the detection o f  aflatoxins. Hunt et al. 
(1978) describes a HPLC system combined with the use o f  a fluorescence detection 
system for the detection o f  aflatoxins and ochratoxin in food. This system offered 
detection limits o f  2.5(og/ml for AFBi. A  gas chromatography /  mass spectrometry / 
selected ion monitoring system has also been described for the confirmation o f  
aflatoxin B i and B 2 with limits o f  detection for aflatoxin B i and B2 at 0. lppb (Rosen 
et al., 1984). Although these techniques may offer good sensitivity extensive sample 
clean up is required making them time-consuming and costly. Therefore, attention has 
focused on immunoanalytical techniques incorporating AFB] -specific antibodies, 
which offer increased sensitivity and specificity for AFBi detection. AFBi has a 
relatively small molecular mass o f  approximately 312 Daltons and in order to elicit an 
immune response it must be covalently attached to a large carrier molecule such as 
bovine serum albumin (BSA), for immunisation. The protein conjugate is required 
during the production, screening and characterisation o f  antibodies. A variety o f  
immunoassay formats have been described for aflatoxin detection with varying 
degrees o f  sensitivity and specificity. The more conventional immunoassays 
incorporate either polyclonal or monoclonal antibodies and, more recently, 
developments in recombinant antibody techniques have provided novel antibody 
fragments, with desirable affinities and specificities.
One o f  the first immunoassays described for the detection o f  AFBi was a 
radioimmunoassay incorporating an AFBi-specific polyclonal antibody (Langone and 
Van Vunakis, 1976). This immunoassay was capable o f  detecting AFBi in crude 
extracts o f  com  and peanut butter, supplemented with AFBi, at levels as low as 
lpg/kg. Recently, a more sensitive radioimmunoassay was described for the detection 
o f  AFBi, in a variety o f  agricultural commodities, using a polyclonal antibody (Korde 
et al., 2003). Separation systems, incorporating PEG (liquid phase) or antibody-coated 
beads (solid phase), resulted in increased sensitivity levels, over the
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radioimmunoassay described by Langone and Van Vunakis (1976), with limits o f  
detection for AFBi at 0.2ng/ml.
However, there are several drawbacks to the use o f  radioimmunoassay, the 
radioisotopes used are hazardous, labile and expensive. Therefore, the majority o f  
immunoassays developed for aflatoxin detection incorporate enzymes. Several 
enzyme-linked immunosorbent assays (ELISAs) have been developed for the 
detection o f  aflatoxin. Candlish et al. (1985) describes the development o f  a 
competitive ELISA for AFBi detection using a monoclonal antibody. This was one o f  
the first reported cases on the development and use o f  monoclonal antibodies against 
AFBi. This competitive ELISA offered limits o f  detection for AFBi at 0.2ng/ml. 
Ward et al. (1990) has described the development o f  competitive ELISAs for AFBi 
using both polyclonal and monoclonal antibodies, raised against an aflatoxin Bi 
oxime-BSA conjugate. The polyclonal antibodies offered the lowest sensitivity levels 
with limits o f  detection for AFBi at O.lpg/well. The monoclonal antibodies developed 
offered limits o f  detection for AFBi as low as 1 pg/well. Polyclonal antibodies have 
also been applied to the development o f  competitive ELISAs for the detection o f  
AFBi in peanut at levels as low  as 0.25ppb (Aldao et al., 1995). Polyclonal antibodies 
have also been applied to the development o f  Biacore inhibition assays for the 
detection o f  AFBi with limits o f  detection for AFBi at 3 ng/ml (Daly et al., 2000). 
More recently, scFv antibody fragments directed against AFBi have been isolated 
from a phage display library (Daly et al., 2002). The library was constructed using a 
method previously described by Krebber et al. (1997) and the specific scFvs applied 
to the development o f  competitive ELISAs and Biacore inhibition assays. The 
competitive ELISA offered limited sensitivity with a limit o f  detection for AFBi at 
98ng/ml. Increased levels o f  sensitivity were observed with the Biacore inhibition 
assay format with limits o f  detection for AFBi at 3 and 0.75ng/ml in PBS and spiked 
grain, respectively. A Biacore-based inhibition assay, incorporating a commercial 
monoclonal antibody, has also been described for AFBi detection with limits o f  
detection o f  0.2ppb (ng/ml) (Van Der Gaag et al, 1998). Other immunoanalytical 
techniques described for aflatoxin detection include a dipstick enzyme immunoassay 
for the simultaneous detection o f  5 mycotoxins with a lower limit o f  detection for 
AFBi at 2ng/ml (Schneider et al., 1995) and an immunoaffinity fluorometric 
biosensor with a lower limit o f  detection at O.lppb (Carlson et al., 2000). A  sol-
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particle lateral flow immunoassay (LFIA) with limits o f  detection o f for AFBi O.lppb 
in buffer and lOppb in grain samples has also been developed (Niessen et ah, 1998). 
Research has also focused on the development o f  on-site immunoassays for the 
detection o f  aflatoxins. Pal and Dhar (2004) have developed a nitrocellulose-based 
immunoassay using an improved catalysed reporter deposition method o f signal 
amplification involving biotinylated tyramine and advin-horseradish peroxidase 
conjugates. This system is capable o f  analysing 12 extracted samples in a single test 
within 12 minutes and offers detection limits o f  O.Olng/ml.
3.1.6 Methods of control and management of aflatoxins
Aflatoxins are considered unavoidable contaminants o f  food for both human and 
animal consumption, irrespective o f  good manufacturing practice. Therefore, several 
international agencies have established specific guidelines on acceptable levels o f  
aflatoxins in food and feed. In the US the Federal Food Drug and Cosmetic Act Sec. 
402 (a) and the FDA have established specific action levels set at 20ppb total 
aflatoxins in food and 0.5ppb for aflatoxin Mi in milk (Hussein and Brasel, 2001). 
The EU has also established guidelines on maximum residue limits for aflatoxins in a 
range o f  commodities (Table 3.1). However, several countries within the EU have 
proposed their own maximum residue limits with some degree o f  variation observed 
from country to country. Table 3.2 details the maximum limits for aflatoxin Bi in 
various European countries. The FAO in conjunction with the WHO Joint Expert 
Committee on Food Additives and Contaminants have established programs to ensure 
proper sampling and analysis for mycotoxins in developing countries (Hussein and 
Brasel, 2001).
Numerous detoxification strategies for aflatoxins, including chemical and physical 
treatments, have also been investigated. Physical treatments including blending, heat, 
microwaves, gamma waves, X-rays, UV light and adsorption have all been used to 
reduce aflatoxins levels in animal feed in an attempt to reduce aflatoxin Mi yields in 
milk. Ammoniation appears to be the most successful chemical method for degrading 
aflatoxins and appears to result in 95 -  98% decomposition o f  AFBi (Creppy, 2002). 
This procedure is used in various countries for the detoxification o f  animal feed. 
However, detoxification o f  aflatoxin-contaminated food for human consumption may
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result in undesirable alterations in the nutritional and organoleptic qualities o f  the 
food (Das and Mishra, 2000).
Table 3.1: Maximum levels for aflatoxins in a variety of food types established as 
guidelines by the EU set out in Commission Regulation (EC) No 466/2001.
Products B!
(PPb)
Bi + B2 + Gì + G2 
(PPb)
Mi
(PPb)
Groundnuts, nuts and dried fruit, for direct 
human consumption
2 4
Groundnuts, nuts and dried fruit, subject to 
sorting or physical treatment
8 15
Cereals for direct human consumption 2 4 -
Milk - - 0.05
Table 3.2: Maximum limits for aflatoxin Bj in foods established by various countries 
within the European Union (Creppy, 2002).
Country Maximum limit of AFBi (ppb) Foods
Finland 2 All
Germany 2 All
The Netherlands 5 All
Belgium 5 All
Portugal 25 Peanuts
5 Children’s food
20 Others
Austria 1 Alls
2 Cereals, nuts
Switzerland 1 All
2 Maize, cereals
Spain 5 All
Luxemburg 5 All
Ireland 5 All
Denmark 5 All
Greece 5 All
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3.1.7 Chapter outline
This chapter focuses on the production and characterisation o f  three genetically 
derived scFv antibody fragments, a monomeric, dimeric and alkaline phosphatase­
labelled scFv, directed against aflatoxin B i (AFBi). The scFvs were applied to the 
development o f  several immunoassay formats, including competitive ELISAs and 
Biacore inhibition assays, for the detection o f  AFBi. A  lateral flow immunoassay was 
also developed for the detection o f  AFBi, which incorporated an anti-AFBi rat 
monoclonal antibody.
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3 . 2  R e s u l t s
3.2.1 Production of genetically derived scFv antibodies to aflatoxin Bi
3.2.1.1 Construction of a pre-immunised phage display library for the isolation of 
functional scFvs against aflatoxin Bi
An aflatoxin Bi recombinant antibody library was constructed by Dr. Stephen Daly, 
DCU (Daly et al., 2002). The pre-immunised scFv phage display library was 
developed using a method previously described by Krebber et al (1997). Basically, 
Balb/C mice were immunised with a commercially available AFBi-BSA conjugate 
and when sufficient titres were obtained the splenomic RNA was isolated and reverse 
transcribed into cDNA. The mouse heavy and light chain genes were then amplified 
by multiplex PCR and annealed together using a splice by overlap extension PCR 
(SOE-PCR). The 800bp SOE-PCR product was then ligated into the phage display 
vector, pAKlOO, and the ligated vector transformed into supercompetent XL-1 Blue 
E. coli. The resulting phage display library consisted o f  5 x  103 clones and following 
three rounds o f  panning six clones recognising free AFB] were isolated.
3.2.1.2 Isolation and nucleotide and amino acid sequence analysis on an AFBi- 
specific scFv
Following three rounds o f  panning on the pre-immunised phage-display library a 
positive clone (D l)  was selected and used for the production o f soluble scFvs specific 
to AFBi. Plasmid DNA, encoding the AFBi-specific scFv, was purified from XL-1 
Blue E. coli, as described in Section 2.2.2. The plasmid DNA  was quantified and sent 
to MWG-Biotech (Germany) for sequencing. Comfort reads were obtained in both 
directions on the scFv insert, using primers specific to the multiple cloning site o f  the 
pAKlOO vector. The nucleotide sequence o f  the scFv gene was determined and used 
to deduce the amino sequence (Fig. 3.4). The deduced amino acid sequence was 
compared with variable regions o f  immunoglobulins found in the SwissProt database 
and used along with the Kabat rules to identuy the loops corresponding to the CDRs 
within the variable heavy and variable light domains. The 3-D structure o f  the scFv 
was also predicated, using SwissModel, based on structurally related proteins (Fig.
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Figure 3.4: The nucleotide and deduced amino acid sequences of the gene encoding 
the AFBj specific scFv. The amino acid sequences representing the CDRs are 
underlined and in bold and were defined according to Kabat et al. (1991). The four 
conserved cystine residues are indicated with an asterisk.
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Figure 3.5: The 3-D structure of the monomeric scFv, which was predicted using 
SwissModel. The complementary determining regions (CDIis) are shown in red on the 
light chain and in green on the hea\>y chain.
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3.2.1.3 Sfll restriction digest on pAK100/400/500/600
In order to produce soluble scFvs the gene encoding the scFv was sub-cloned from 
pAKlOO into a variety o f  soluble expression vectors, pAK400, 500 and 600. This 
involved purifying the D1 plasmid DNA from XL-1 Blue E. coli as described in 
Section 2.2.2. The plasmid D N A  was then restricted using Sfil and electrophoresed on 
an agarose gel. The soluble expression vectors, pAK400, 500 and 600 were also 
digested using Sfil and electrophoresed alongside the pAKlOO (Fig. 3.6). A  band at 
approximately 800bp, representing the scFv insert, was isolated following restriction 
o f the pAKlOO and bands representing the excised tetracycline stuffer gene were 
visible at 2101bp following digestion o f  the pAK400, 500 and 600. The bands 
representing the scFv insert and the restricted pAK400, 500 and 600 plasmid D NA  
were then gel purified as described in Section 2.2.5.
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Figure 3.6: Restriction enzyme digest on pAKlOO, 400, 500 and 600 using Sfil. Lanes 
1 and 10: 1Kb PLUS DNA ladder (Gibco-BRL); Lane 2: Purified pAKlOO plasmid 
DNA containing the scFv insert; Lane 3: Sfil restriction digest on pAKlOO plasmid 
DNA with scFv insert at 800bp; Lane 4: PurifiedpAK400 plasmid DNA; Lane 5: Sfil 
restricted pAK400 with 2101bp tetracycline insert; Lane 6: Purified pAK500 plasmid 
DNA; Lane 7: Sfil restricted pAK500 with 2101bp tetracycline insert; Lane 8: 
Purified pAK600 plasmid DNA; Lane 9: Sfil restricted pAK600 with 2101bp 
tetracycline insert.
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3.2.1.4 Ligation and transformation of pAK400/500/600 into JM83 E. coli
The gene encoding the AFBj-specific scFv was ligated into pAK400, 500 and 600, as 
described in Section 2.2.6. Following ligation, the vectors encoding the scFv gene 
were transformed into calcium-competent JM83 E. coli.
3.2.1.5 Soluble expression of the monomeric, dimeric and alkaline phosphatase­
labelled scFvs
Following selection o f  JM83 E. coli positively transformed with the appropriate 
vector (pAK400/500/600), single colonies were isolated, grown in 2x TY and soluble 
scFv expression induced upon addition o f  BPTG, as described in Section 2.2.9. 
Optimum induction periods were determined for each scFv, with 4 hours post 
induction proving sufficient for the monomeric scFv, and a 16 hour induction period 
required for the dimeric and alkaline phosphatase-labelled scFvs (Data not shown). 
The alkaline phosphatase-labelled scFv is referred to as the bifunctional scFv, 
throughout this chapter, due to its ability to bind aflatoxin and act as a reporter 
antibody with the enzyme label. Following IPTG induction the cellular distribution o f  
each scFv was determined. Figure 3.7 shows the ELISA analysis on the culture 
supernatant and periplasmic lysate following expression o f  the monomeric and 
dimeric scFvs. High-levels o f  soluble expression into the periplasm were observed 
with the monomeric and dimeric scFvs. Figure 3.8 shows the ELISA analysis o f  the 
culture supernatant and periplasmic lysate following expression o f  the bifunctional 
scFv. Minimal expression levels were observed in the culture supernatant and high- 
levels o f  expression were observed in the periplasm. For subsequent characterisation 
the soluble scFvs were isolated from the periplasm.
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Figure 3.7: ELISA analysis on the culture supernatant and periplasmic lysate 
following soluble expression of the monomeric and dimeric scFvs. Results indicated 
that high-levels of the monomeric and dimeric scFvs were expressed into the 
periplasm.
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Figure 3.8: ELISA analysis of the culture supernatant and periplasmic lysate 
following soluble expression of the bifunctional scFv. The bifunctional scFv was 
isolated into the periplasm.
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3.2.1.6 Western blot analysis on the monomeric, dimeric and bifunctional scFvs 
Western blot analysis was carried out on the scFvs in order to demonstrate that the 
secondary (anti-FLAG) and tertiary (anti-mouse) antibodies could specifically detect 
the scFvs from the crude periplasmic lysate. The crude lysates containing the 
expressed scFvs were electrophoresed using SDS-PAGE and then transferred onto 
nitrocellulose, which was probed using anti-FLAG followed by an alkaline 
phosphatase-labelled anti-mouse antibody. Figure 3.9 indicates that the secondary and 
tertiary antibodies enabled specific detection o f  the scFvs. A single band at 
approximately 32kDa was visible following expression from pAK400, which 
represented the monomeric scFv. A single band was also visible following expression 
using the pAKSOO. However, this band appeared at approximately 35kDa representing 
the cleaved dimeric scFv, consisting o f  a monomeric scFv attached to a portion o f the 
double helix. Following expression from the pAK600 vector two bands were visible at 
approximately 85kDa and 32kDa, representing the alkaline phosphatase-scFv fusion, 
and the monomeric scFv, respectively.
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Figure 3.9: Western blot analysis on the monomeric, dimeric and bifunctional scFvs. 
The membrane containing the transferred scFvs was probed using the anti-FLAG 
monoclonal M l antibody followed by an alkaline phosphatase-labelled anti-mouse 
antibody and visualised upon addition of BCIP/NBT substrate. Lanes 1 and 5: 
BlueRanger prestained protein molecular weight markers (Pierce); Lane 2: 
Monomeric scFv expressed from pAK400; Lane 3: Dimeric scFv expressed from 
pAKSOO; Lane 4: Bifunctional scFv expressedfrom pAK600.
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3.2.2 The use of genetically derived scFvs in the development of immunoassays 
for the detection of AFBi
Following the successful expression and initial characterisation o f the three 
genetically derived scFvs several immunoassay formats, incorporating the scFvs, were 
investigated for the detection o f  AFBi.
3.2.2.1 Development of Competitive ELISAs for the detection of aflatoxin Bi
3.2.2.1.1 Optimisation of assay param eters for competitive ELISA for AFBi
Initial checkerboard ELISA was carried out in order to determine the optimal 
conjugate coating concentrations and scFv antibody dilutions for use in competitive 
ELISAs. Varying AFBi-BSA coating concentrations ranging from 0 -  50|ig/ml and 
scFv antibody dilutions ranging from undiluted -  1/64 were assayed for the 
monomeric, dimeric and bifunctional scFvs. The optimal conjugate coating 
concentration for the monomeric scFv was found to be 25jj.g/ml o f  the AFBi-BSA and 
the optimum scFv dilution determined to be 1/4 (Fig. 3.10). For the dimeric scFv the 
optimal coating concentration was 12.5 |og/ml o f  the AFBi-BSA with a 1/8 dilution o f  
the scFv (Fig. 3.11), and for the bifunctional scFv 6.25|ig/ml o f  the AFBi-BS A and a 
1/4 dilution o f  the scFv were determined to be optimal (Fig. 3.12).
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Figure 3.10: Checkerboard ELISA for determination of optimal conjugate coating 
concentration and monomeric scFv antibody dilution for use in a competitive ELISA. 
Varying AFBi-BSA coating concentrations ranging from 0 -  50fig/ml and scFv 
antibody dilutions from undiluted to 1/64 dilution were assayed. A 2 5fug/ml conjugate 
concentration and a 1/4 scFv antibody dilution was chosen for use in the competitive 
ELISA.
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Figure 3.11: Checkerboard ELISA for determination of optimal conjugate coating 
concentration and dimeric scFv antibody dilution for use in a competitive ELISA. 
Varying AFBj-BSA coating concentrations ranging from 0 -  50/ug/ml and scFv 
antibody dilutions from undiluted to 1/64 dilution were assayed. A 12.5fig/ml 
conjugate concentration and a 1/8 scFv antibody dilution were chosen for use in the 
competitive ELISA.
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Figure 3.12: Checkerboard ELISA for determination of optimal conjugate coating 
concentration and bifunctional scFv antibody dilution for use in a competitive ELISA. 
Varying AFBi-BSA coating concentrations ranging from 0 -  50/ug/ml and scFv 
antibody dilutions from undiluted to 1/64 dilution were assayed A 6.25fig/ml 
conjugate concentration and a 1/4 scFv antibody dilution was chosen for use in the 
competitive ELISA.
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3.2.2.1.2 Optimisation of methanol concentration for the preparation of free 
A F B i
Due to its strong hydrophobic nature it is necessary to prepare free AFBi standards in 
methanol. However, methanol can have an inhibitory effect on an assay’s sensitivity. 
In order to determine the optimal methanol concentration competitive ELISAs were 
carried out with each scFv using varying methanol concentrations to prepare the free 
AFBj standards. A series o f  AFBi standards ranging in concentration from 6 -  
6250ng/ml were prepared in PBS containing varying methanol concentrations from
2.5 to 40% (v/v). 50(j.l o f  each o f  these standards were then added to an AFBi-BSA- 
coated plate along with 50|xl o f  the appropriate scFv dilution. Fig. 3.13, 3.14 and 3.15 
show the graphs obtained for the methanol concentration optimisation with the 
monomeric, dimeric and bifunctional scFvs, respectively. In each case 5% (v/v) 
methanol appeared optimal for the preparation o f  the free AFBj standards.
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Figure 3.13: Competition ELISA using the monomeric scFv, to determine optimum 
methanol concentration for preparation offree AFBi. AFBj standards ranging from 6 
to 6250ng/ml were prepared in PBS containing varying methanol concentrations 
ranging from 2.5 to 40% (v/v). 5% (v/v) methanol appeared to cause the least 
inhibitory effect on the assay and was therefore chosen to be the optimum methanol 
concentration for the preparation of free AFBi.
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Figure 3.14: Competition ELISA using the dimeric scFv, to determine optimum 
methanol concentration fo r  preparation o f free  AFBj. AFB} standards ranging from  6 
to 6250ng/ml were prepared in  PBS containing varying methanol concentrations 
ranging from  2.5 to 40% (v/v). 5% (v/vj methanol appeared to cause the least 
inh ib itory effect on the assay and was therefore chosen to be the optimum methanol 
concentration fo r  the preparation offree AFBh
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Figure 3.15: Competition ELISA using the bifunctional scFv, to determine optimum 
methanol concentration fo r  preparation o ffree  AFBj. AFB] standards ranging from  6 
to 6250ng/ml were prepared in PBS containing varying methanol concentrations 
ranging from  2.5 to 40% (v/v). 5%(v/v) methanol appeared to cause the least 
inh ib itory effect on the assay and was therefore chosen to be the optimum methanol 
concentration fo r  the preparation offree AFBj.
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3.2.2.1.3 Development o f competitive ELISAs for A FBi
Following optimisation o f  the various assay parameters, competitive ELISAs were 
developed for the detection o f AFBi using the monomeric, dimeric and bifunctional 
scFvs. Immunoplates coated with 25|ig/ml, 12.5|og/ml and 6.25|ig/ml o f  AFBi-BSA  
for the monomeric, dimeric and bifunctional scFvs, respectively, were used to 
determine the range o f  detection o f  free AFBi for each scFv. AFBi standards ranging 
in concentration from 3 -  781ng/ml were prepared in PBS-5% (v/v) methanol and 
added to an equal volume o f  the optimal scFv dilution. Intra and inter-day variability 
studies were carried out the monomeric, dimeric and bifunctional scFvs, in order to 
estimate assay reproducibility.
In order to determine intra-day assay variation, each AFBi concentration was assayed 
five times on one day and the mean absorbance o f  bound antibody at each AFBi 
concentration was plotted against the free AFBi concentration. Intra-day studies 
showed the monomeric scFv had a range o f  detection between 12 and 781ng/ml and 
the coefficients o f  variation (C.V.’s) obtained ranged from 1.22 to 11.5%. The dimeric 
scFv had a range o f  detection between 3 and 781ng/ml and CVs remained below
11.98%. The bifunctional scFv yielded a range o f  detection between 3 and 390ng/ml 
with CVs between 0.20 and 8.28%.
Inter-day assay variability studies were also carried out on the each scFv by 
performing the assays over five separate days. The coefficients o f  variation (CVs) 
were determined for each assay by expressing the standard deviation as a percentage 
function o f  the mean. The inter-day assay on the monomeric scFv displayed a range o f  
detection between 12 and 781ng/ml (Fig. 3.16) and as can be seen in Table 3.3 the 
coefficients o f  variation ranged from 2.72 to 11.35%. The inter-day assay on the 
dimeric scFv had a range o f  detection between 3 and 781ng/ml (Fig. 3.17) and the 
coefficients o f  variation for the inter-day assay ranged from 1.25 to 6.99% (Table 
3.4). The inter-day assay on the bifunctional scFv displayed a range o f  detection 
between 3 and 390ng/ml (Fig. 3.18) and as can be seen in Table 3.5 the coefficients o f  
variation ranged from 3.01 to 5.25%, indicating that the three assays were 
reproducible over the five days.
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Table 3.3: Inter-day assay coefficients o f variation fo r  the detection o f free AFBi 
using the monomeric scFv. Five sets o f seven standards were assayed on five  different 
days and the C. V. ’s were calculated as the standard deviation (S.D.) expressed as a 
percentage o f the mean values fo r  each standard.
AFBi concentration  
(ng/ml)
Calculated mean ± S.D., A/A0 Coefficient o f variation
(%)
781.2 0.27 ±  0.02 6.25
390.6 0.32 ± 0.02 6.05
195.3 0.44 ± 0 .05 11.35
97.7 0.61 ± 0 .05 8.97
48.8 0.79 ± 0 .0 5 5.83
24.4 0.90 ±  0.04 4.26
12.2 0.96 ± 0.03 2.72
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Figure 3.16: Inter-day competitive ELISA fo r  the determination o f the range o f 
detection fo r  free AFB i using the monomeric scFv. A 25ng/m l AFB¡-BSA conjugate 
coating concentration was used w ith a 1/4 d ilu tion o f the monomeric scFv. The range 
o f detection was found to be between 12 and 781ng/ml.
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Table 3.4: Inter-day assay coefficients o f variation fo r  the detection o f free AFBi 
using the dimeric scFv. Five sets o f nine standards were assayed on five  different days 
and the C. V. ’s were calculated as the standard deviation (S.D.) expressed as a 
percentage o f the mean values fo r  each standard.
AFBj concentration  
(ng/ml)
Calculated mean ± S.D., A/AO Coefficient o f variation
(%)
781.2 0.61 ±  0.043 6.99
390.6 0.60 ±  0.008 1.36
195.3 0.68 ±  0.028 4.18
97.7 0.70 ± 0 .026 3.69
48.8 0.74 ± 0.009 1.25
24.4 0.84 ± 0 .035 4.14
12.2 0.89 ± 0 .004 0.49
6.1 0.92 ±  0.027 2.99
3.0 0.93 ±  0.035 3.72
Free AFB1 concentration (ng/ml)
Figure 3.17: Inter-day competitive ELISA fo r  the determination o f the range o f 
detection fo r  free AFB j using the dimeric scFv. A 12.5/ng/ml AFBi-BSA conjugate 
coating concentration was used w ith a 1/8 d ilu tion o f the dimeric scFv. The range o f 
detection was found to be between 3 and 781ng/ml.
124
Table 3.5: Inter-day assay coefficients o f variation fo r  the detection o f free AFBj 
using the bifunctional scFv. Five sets o f eight standards were assayed on five  different 
days and the C. V ’s were calculated as the standard deviation (S.D.) expressed as a 
percentage o f the mean values fo r  each standard.
A FBi concentration  
(ng/ml)
Calculated mean ± S.D., 
A/A0
Coefficient o f variation
(%)
390 0.17±0.008 4.52
195 0.23±0.009 4.00
97 0.31±0.010 3.32
48 0.47±0.024 5.11
24 0.67±0.023 3.45
12 0.81±0.042 5.25
6 0.90±0.031 3.44
3 0.98±0.029 3.01
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F igure 3.18: Inter-day competitive ELISA fo r  the determination o f the range o f 
detection fo r  free AFB j using the bifunctional scFv. A 6.25/ng/ml AFBj-BSA conjugate 
coating concentration was used w ith a 1/4 d ilution o f the bifunctional scFv. The range 
o f detection was found  to be between 3 and 390ng/ml.
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3.2.2.1.4 Cross-reactivity studies
Cross reactivity studies were then carried out on the monomeric, dimeric and 
bifunctional scFvs in relation to various structurally related aflatoxins. The least 
detectable dose (LDD) and IC50 values were determined for each aflatoxin as 90% 
A/AO and 50% A/AO, respectively. The percentage cross reactivities were then 
estimated at the LDD (CR90) and at the IC50 (CR50) by expressing 100-fold the ratio o f  
the aflatoxin Bi and o f  the cross-reacting aflatoxin.
Table 3.6 summarizes the specificity and cross reactivity studies on the monomeric 
scFv with the structurally related aflatoxins B 2, Gi, G2, Mi and M2. The monomeric 
scFv displayed some degree o f  cross-reactivity with aflatoxins B 2, Gi and G2 (i.e. < 
12.5%) and low-levels o f  cross-reactivity against aflatoxins Mi and M2 (i.e. < 3%) at 
the LDD. Whereas slightly higher levels o f  cross-reactivity (19%) were obtained at 
the IC50 values with aflatoxins B 2, Gi and G2 and low-levels o f  cross-reactivity was 
observed against aflatoxins Mi and M2 (i.e. < 3%). The dimeric scFv offered greater 
specificity towards aflatoxin B i, in comparison with the monomeric scFv, with the 
percentage cross reactivity against the various aflatoxins remaining below 3% at the 
LDD and 8% at the IC50 (Table 3.7). The 1 fund >nal scFv displayed high levels o f  
cross-reactivity towards aflatoxins B 2 Gi and G2 (i.e. > 30%) and low-levels o f  cross­
reactivity towards aflatoxins M i and M2 (i.e. < 3%) at the LDD (Table 3.8). The 
b unctional scFv also cross-reacted with the aflatoxins B 2, Gi and G2 and to a lesser 
extent with aflatoxins Mi and M2 (i.e. < 6%), at the IC50.
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Table 3.6: Cross reactivity and specificity studies on the monomeric scFv against 
various aflatoxins. The cross-reactivity potentia l was approximated a t the least 
detectable dose (LDD), which was estimated at 90% A/AO, and at the IC 50 value, 
which was estimated at 50% A/AO. The CR90 and CR50 were then expressed as 100-
fo ld  the ra tio  o f the antigen and o f the cross-reactant.
Aflatoxin LDDa (ng/ml) IC50" (ng/ml) CR9«c(%) CRsod (%)
B, 6 150 100 100
b 2 48 781 12.5 19
Gl 120 781 5 19
g 2 48 781 12.5 19
M i 195 6250 3 2.4
m 2 50000 50000 <0.1 0.3
a Least detectable dose calculated at 90% A/AO 
b 50% inhibition concentration (50% A/AO) 
c Percentage cross-reactivity determined at IC50 
d Percentage cross-reactivity determined at LDD
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Table 3.7: Cross reactivity and specificity studies on the dimeric scFv against various 
aflatoxins. The cross-reactivity potential was approximated a t the least detectable 
dose (LDD), which was estimated a t 90% A/AO, and at the ICso value, which was 
estimated a t 50% A/AO. The CR90 and CR50 were then expressed as 100-fold the ratio  
o f the antigen and o f the cross-reactant.
Aflatoxin LDDa (ng/ml) IC50b (ng/ml) CR9«c(%) CRso" (%)
Bi 3 97 100 100
b 2 97 12500 3 0.8
G i 97 1200 3 8
g 2 390 12500 0.8 0.8
M i 390 50000 0.8 0.2
m 2 50000 50000 <0.1 0.2
a Least detectable dose calculated at 90% A/AO 
b 50% inhibition concentration (50% A/AO) 
c Percentage cross-reactivity determined at IC50 
d Percentage cross-reactivity determined at LDD
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Table 3.8: Cross reactivity and specificity studies on the bifunctional scFv against 
various aflatoxins. The cross-reactivity potential was approximated at the least 
detectable dose (LDD), which was estimated at 90% A/AO, and at the IC 50 value, 
which was estimated at 50% A/AO. The CR90 and CR50 were then expressed as 100­
fo ld  the ra tio  o f the antigen and o f the cross-reactant.
Aflatoxin LDDa (ng/ml) IC50b (ng/ml) CR90C(%) CR50d (%)
Bi 6 45 100 100
b 2 20 97 30 46
Gj 6 97 100 46
g 2 20 195 30 23
M i 195 781 3 6
m 2 3125 >3125 0.2 <1.5
a Least detectable dose calculated at 90% A/AO 
b 50% inhibition concentration (50% A/AO) 
c Percentage cross-reactivity determined at IC50 
d Percentage cross-reactivity determined at LDD
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3.2.2.2 Development o f Biacore inhibition assays for the detection o f aflatoxin Bi
This section focuses on the development o f  a Biacore inhibition assay for AFBi using 
a Biacore CM5 chip immobilised with an AFBi derivative, which was kindly donated 
by Andrew Baxter, XenoSense Ltd., Queen’s University Belfast. Both the monomeric 
and dimeric scFv were applied for the development o f inhibition assays. For the 
successful development o f  an inhibition assay for the detection o f  AFBl5 the 
optimisation o f  a number o f  parameters was required. These included optimal 
antibody dilution, removal o f  non-specific interactions and surface regeneration 
conditions.
3.2.2.2.1 Assessm ent o f non-specific binding
The degree o f  non-specific binding o f  the monomeric and dimeric scFvs to the CM5 
dextran layer was assessed. This was achieved by passing the monomeric and dimeric 
scFvs over an unactivated CM dextran surface, diluted to 1/8 and 1/70, respectively. 
Figure 3.19 and 3.20 show the overlay plots obtained following injection o f the 
monomeric and dimeric scFvs, respectively, over the AFBi surface and an unactivated 
CM dextran layer. Negligible binding to the dextran (i.e. < 10 RU) was observed with 
each scFv and as a result there was no need to incorporate dextran into the diluent 
buffer.
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F igure 3.19: Overlay p lo t demonstrating binding o f the monomeric scFv to the 
immobilised AFB j surface (A) and an unactivated dextran surface (B). Negligible 
binding o f the monomeric scFv was observed to the unactivated dextran. However, 
approximately 350 response units (RU) o f the monomeric scFv bound to the directly 
immobilised AFB i surface. This indicates the specificity o f the monomeric scFv 
towards AFBj.
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Figure 3.20: Overlay p lo t demonstrating binding o f the dimeric scFv to the 
immobilised AFBi surface (A) and an unactivated dextran surface (B). Negligible 
binding o f the dimeric scFv was observed to the unactivated dextran. However, 
approximately 250 response units (RU) o f the dimeric scFv bound to the directly 
immobilised AFB i surface, 'fhis indicates the specificity o f the dimeric scFv towards
3.2.2.2.2 Regeneration studies
Optimisation o f  scFv antibody dilution and effective regeneration conditions was also 
required. The monomeric scFv was diluted to 1/8 and the dimeric to 1/70 with HBS 
running buffer and 20|j,l was injected over the immobilised AFBi surface at a flow- 
rate o f  lO^il/min. Initial studies showed little dissociation o f the scFv from the 
immobilised surface. A  regeneration solution consisting o f  lOmM NaOH enabled 
complete removal o f  the bound monomeric scFv and 25mM NaOH was sufficient for 
removing the dimeric scFv (Fig. 3.21). In each case a 0.5-min pulse at a flow-rate o f  
10|J/min was sufficient to regenerate the AFBi surface.
The efficiency o f  the regeneration process was then evaluated by performing multiple 
(i.e. 75) binding-regeneration cycles on the AFBi surface. Figure 3.22 shows the 
regeneration studies using the monomeric scFv. The monomeric scFv diluted to 1/8 
was passed over the surface using a 2-minute pulse at lOpI/min. The bound scFv was 
completely removed using a 0.5-min pulse o f  lOmM NaOH at lOfil/min. Over the 75 
binding-regeneration cycles the antibody binding capacity varied slightly but it did not 
significantly affect the assay performance. Figure 3 .23 shows the regeneration studies 
on the dimeric scFv, which was diluted to 1/70 and passed over the surface using a 2- 
min pulse at 10(il/min. The bound scFv was completely removed using a 0.5-min 
pulse o f  25mM NaOH at 10|xl/min. Once again, over the 75 binding-regeneration 
cycles, the antibody binding capacity slightly oscillated without significantly affecting 
the performance o f  the assay. In each case binding o f  the scFv to the AFBi surface 
was highly reproducible, with approximately 400RU o f the monomeric scFv and 280 
RU o f  the dimeric scFv binding to the surface each time. This indicates that the 
regeneration solutions, lOmM NaOH for the monomeric scFv and 25mM NaOH for 
the dimeric scFv, did not affect antibody binding throughout the regeneration study.
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Figure 3.21: Typical sensor gram showing the binding and regeneration o f the 
monomeric scFv (1) and the dimeric scFv (2) on the AFB j surface. A 1/8 and a 1/35 
dilution o f the monomeric and dimeric scFvs, respectively, was passed over the sensor 
surface a t lOjul/m in fo r  4 min w ith approximately 400 and 350 response units o f the 
monomeric and dimeric scFv binding, respectively (A). The surface was then 
completely regenerated using a 0.5 min pulse o f 10 and 25mM NaOH fo r  the 
monomeric and dimeric scFvs, respectively (B).
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Figure 3.22: Graph showing the regeneration studies on the immobilised AFBi 
sensor surface. Seventy-five consecutive regeneration cycles were carried out w ith the 
monomeric anti-AFBj scFv. A 2-min pulse o f the monomeric scFv was fo llow ed by a 
0.5-min injection o f lOmM NaOH, as the regeneration solution. This regeneration 
solution enabled the complete removal o f a ll bound scFv after each binding cycle. 
Resulting in highly reproducible binding cycles, as can be seen w ith no significant 
decrease in the binding response measured over the course o f the regeneration 
studies.
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F igure 3.23: Graph showing the regeneration studies on the d irectly immobilised 
AFB j sensor chip. Seventy-five consecutive regeneration cycles were carried out w ith 
the dim eric anti-AFBi scFv. A 2-min pulse o f the dimeric scFv was fo llow ed by a 0.5- 
min injection o f 25mM NaOH, as the regeneration solution. This regeneration 
solution enabled the complete removal o f a ll bound scFv after each binding cycle. 
Resulting in  highly reproducible binding cycles, as can be seen with no significant 
decrease in  the binding response measured over the course o f the regeneration 
studies.
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3.2.2.2.3 Development of a Biacore inhibition assays for the detection o f AFBi
Following optimisation o f  the various assay parameters, inhibition assays, 
incorporating the monomeric and dimeric scFvs, were developed for the detection o f  
AFBi using the Biacore CM5 chip immobilised with an AFB] derivative. Free AFBi 
standards, ranging in concentration from 375 - 12,000pg/ml for the monomeric scFv 
and 190 -  24,000pg/ml for the dimeric scFv, were prepared in PBS containing 
5%(v/v) methanol. Each free AFBi concentration was incubated with an equal volume 
o f  the monomeric scFv diluted to 1/4 (to ensure a final dilution o f  1/8) and a 1/35 
dilution (to ensure a final dilution o f  1/70) o f  the dimeric scFv and allowed to 
equilibrate for 30 min at 37°C. The equilibrated samples were then passed over the 
sensor surface, in random order, and followed by regeneration o f  the AFBi sensor 
surface using the appropriate regeneration solution. Figs. 3.24 and 3.25 show a typical 
overlay sensorgram showing the antibody binding responses o f  the monomeric and 
dimeric scFvs, respectively, in the presence o f  a range o f  free AFBi standards.
Intra and inter-day variability studies were carried out on the inhibition assays with 
monomeric and dimeric scFvs, in order to estimate the reproducibility o f  the assays. 
In order to determine intra-day assay variation, each concentration was assayed three 
times on one day and the mean response units o f  bound antibody for each AFBi 
concentration was plotted against the free AFBi concentration. Intra-day variability 
studies showed the monomeric scFv had a range o f  detection for free AFBi from 375
-  12,000pg/ml with coefficients o f  variation (CVs) remaining below 0.61% and the 
dimeric scFv had a range o f  detection between 190 and 24,000pg/ml with CVs below  
3.37%. The inter-day assay variation was then estimated by performing the assay over 
three separate days, and a separate calibration curve plotted for each normalised 
response unit (response units /  response units 0 (R/R0)) value versus the respective 
AFBi concentration for each assay carried out on each day. Fig. 3.26 and 3.27 show  
the inter-day assay curves for the monomeric and dimeric scFvs, respectively, where 
the range o f  detection o f  free AFBi was 375 -  12,000pg/ml for the monomeric and 
190 and 24,000pg/ml for the dimeric scFv. The CVs obtained for the inter-day 
variability studies on the monomeric scFv ranged between 1.9 and 4.18% (Table 3.9) 
and between 3 and 11.53% for the dimeric scFv (Table 3.10), indicating that both 
assays were reproducible over the 3 days.
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F igure 3.24: Typical overlay sensorgram showing the antibody binding responses o f 
the monomeric scFv in  the presence o f a range o f free  AFB i standards. Free AFB] 
concentration, ranging in concentration from  0 -  J2000pg/ml, were pre-incubated 
with an equal volume o f the monomeric scFv and passed over the sensor surface. The 
sensor surface was regenerated using lOmM NaOH.
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Figure 3.25: Typical overlay sensorgram showing the antibody binding responses o f 
the dimeric scFv in the presence o f a range o f free  AFBi standards. The AFBi 
standards, ranging in concentration 0 -  24000pg/ml, were pre-incubated with an 
equal volume o f the dimeric scFv and passed over the sensor surface. The sensor 
surface was regenerated using 25mM NaOH.
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Table 3.9: Inter-day assay co-efficients o f variation fo r  the Biacore inhibition assay 
fo r  the detection o f AFB j using the monomeric scFv. Three sets o f six standards were 
assayed on three different days and the C. V. ’s were calculated as the standard 
deviation (S.D.) expressed as a percentage o f the mean values fo r  each standard.
AFBi concentration  
(pg/ml)
Calculated mean ± S.D. Coefficient o f variation
(%)
12000 0.11 ± 0 .0 0 4 3.75
6000 0.19 ± 0 .006 3.16
3000 0.35 ± 0 .015 4.18
1500 0.59 ±  0.020 3.40
750 0.77 ± 0 .0 1 2 1.58
375 0.88 ± 0 .017 1.90
1,  
0.9 
0.8 
0.7 
0.8 
g 0.5 . 
0.4 . 
0.3 
0.2 
0.1 .
0
1 10 
Free AFB1 concentration (ng/ml)
F igure 3.26: Inter-day Biacore inhibition assay fo r  the determination o f the range o f 
detection offree AFB i using the monomeric scFv. The range o f detection was found to 
be between 375 and 12000 pg/ml.
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Table 3.10: Inter-day assay co-efficients o f variation fo r  the Biacore inhibition assay 
fo r  the detection o fA F B i using the dimeric scFv. Three sets o f eight standards were 
assayed on three different days and the C. V ’s were calculated as the standard 
deviation (S.D.) expressed as a percentage o f the mean values fo r  each standard.
AFBj concentration 
(pg/ml)
Calculated mean ± S.D. Coefficient o f  variation
(%)
24000 0 .1 6 ±  0.013 7.95
12000 0.19 ± 0 .017 8.89
6000 0.26 ± 0 .030 11.53
3000 0.39 ±  0.020 5.27
1500 0.58 ±  0.048 8.28
750 0.72 ± 0 .055 7.66
375 0.85 ± 0 .0 5 4 6.36
190 0.98 ±  0.029 3.00
1.2 
1­
0.8 
0.6
o
0.4
0.2
0-1--------------------------------- - ' .----------------------------------------------------------------------------------
0.1 1 10 100
Free AFB1 concentration (nq/mi)
F igure 3.27: Inter-day Biacore inhib ition assay fo r  the determination o f the range o f 
detection o f free AFB j using the dimeric scFv. The range o f detection was found to be 
between 190 and 24000pg/ml.
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3.2.2.2.4 Cross-Reactivity Studies
Cross-reactivity potential o f  the scFvs were determined against five structurally 
related aflatoxins, B 2, Gi, G2, Mi and M2, in a Biacore inhibition assay format. 
Comparisons o f  the LDD and IC50 values were used to accurately estimate levels o f  
cross-reactivity, with the IC50 value defined as the analyte concentration that results in 
50% inhibition and the least detectable dose (LDD) as the analyte concentration that 
results in 90% inhibition or as the smallest concentration o f analyte that produces a 
response that can be significantly distinguished from zero. Levels o f  cross-reactivity 
were estimated at the LDD (CR90) and at the IC50 (CR50) as 100-fold the ratio between 
the LDD and IC50 values o f  the antigen and o f  the cross reactant, respectively. Table 
3.11 shows the results obtained with the monomeric scFv, which displayed highest 
level o f  cross-reactivity with aflatoxin Mi and Gi at the LDD (12.5%) and aflatoxin 
Gi at the CR50 (13%). Low-levels o f  cross-reactivity was observed with the 
monomeric scFv against aflatoxins B2, G2, M i and M2 at the IC50 (i.e. < 5%) and 
against aflatoxins B2, G2, and M2 at and LDD (i.e. < 3%). The dimeric scFv displayed 
low-levels o f  cross-reactivity with aflatoxins B2, G2, Mi and M2 at the IC50 and LDD  
(i.e. ^ 5%) (Table 3 .12). Slightly higher-levels o f  cross-reactivity were observed with 
aflatoxin Gi at the IC50 (10%) and LDD (20%). This suggests that both the 
monomeric and dimeric scFvs appear to specifically bind to AFBi with relatively low- 
levels o f  cross-reactivity (i.e. < 20%) observed at the IC50 and LDD.
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Table 3.11: Cross reactivity studies on the monomeric scFv in  a Biacore inhibition  
assay form at. The cross reactivity potential was approximated at the least detectable 
dose (LDD), which is estimated at 90% A/AO, and a t the IC 50 value, which is 
estimated at 50% A/AO. The CR90 and CR50 were then expressed as 100-fold the ratio  
o f the antigen and o f the cross-reactant.
Aflatoxin LDDa (ng/ml) IC50b (ng/ml) CR9«C(%) CRso11 (%)
Bi 375 2000 100 100
b 2 12500 200000 1 3
M i 3000 40000 5 12.5
m 2 31250 > 250000 < 1 1.2
G i 3000 15000 13 12.5
g 2 12500 200000 1 3
a Least detectable dose calculated at 90% A/AO 
b 50% inhibition concentration (50% A/AO) 
c Percentage cross-reactivity determined at IC50 
d Percentage cross-reactivity determined at LDD
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Table 3.12: Cross reactivity studies on the dim eric scFv in a Biacore inhibition assay 
form at. The cross reactivity potential was approximated a t the least detectable dose 
(LDD), which is estimated at 90% A/AO, and a t the IC 50 value, which is estimated at 
50% A/AO. The CR90 and CR50 were then expressed as 100-fold the ratio o f the 
antigen and o f the cross-reactant.
Aflatoxin LDD“ (ng/ml) ICsob (ng/ml) CR9oc(%) CR50d (%)
Bi 300 2000 100 100
b 2 25000 300000 <1 1.2
M i 20000 200000 1 1.5
m 2 125000 > 250000 <1 <1
G i 1500 20000 10 20
g 2 25000 250000 <1 1.2
a Least detectable dose calculated at 90% A/AO 
b 50% inhibition concentration (50% AJAO) 
c Percentage cross-reactivity determined at IC50 
d Percentage cross-reactivity determined at LDD
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This section focuses on the development o f  a lateral flow immunoassay (LFIA) for the 
detection o f  AFBi, which incorporates colloidal carbon labels to generate the signals 
in the assay.
3.2.2.3.1 Indirect competitive LFIA
A lateral flow immunoassay (LFIA) is a one-step sol particle immunoassay (See 
Section 1.8.2). Carbon particles are physically adsorbed onto an antibody or hapten­
protein conjugate, which are then used as the detection ligand. This section describes 
the development o f  an indirect competitive LFIA, which incorporates an anti-AFBi 
rat monoclonal antibody, for the detection o f  AFBi. Colloidal carbon was absorbed 
onto an AFBi-BSA conjugate and used to generate the test signal.
Mouse anti-rat antibodies were sprayed onto a nitrocellulose membrane as the test 
line, 3mm below the control line, which consisted o f  anti-horse antibodies sprayed 
onto the nitrocellulose. A  droplet o f  running buffer containing free AFBi, the AFBi- 
BSA-carbon-conjugate, the anti-AFBi rat monoclonal antibody and a carbon- 
conjugated horse antibody was mixed and allowed to flow along the nitrocellulose. 
The free AFBi and the AFBi-BSA-carbon conjugate compete for binding to the anti- 
AFBi rat monoclonal antibody, as the sample droplet travels along the membrane. 
The intensity o f  the generated signal increases, as the concentration o f  free AFBi in 
the sample droplet deceases, because the numbers o f  antibodies available for binding 
the AFBl-BSA-carbon conjugate increases. Figure 3.28 shows a schematic 
representation o f  the indirect competitive LFIA developed using the anti-AFBi rat 
monoclonal antibody, for the detection o f  AFBi.
3.2.2.3 Development o f a lateral flow immunoassay (LFIA) for the detection o f
AFBi
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Figure 3.28: Schematic representation o f an indirect competitive LFIA fo r  the 
detection o f AFBj. Test lines and control lines consisting o f an anti-ra t antibody and 
anti-horse antibody, respectively, were sprayed onto nitrocellulose. A sample droplet 
consisting o f free AFBj, an AFBj-BSA-carbon conjugate, the anti-AFBi ra t 
monoclonal antibody and the carbon-conjugated horse antibody in running buffer 
was allowed travel along the nitrocellulose. Free AFB j and the AFB¡-BSA-carboon 
conjugate compete fo r  binding to the anti-AFBj ra t monoclonal antibody as the 
sample travels along the nitrocellulose. Signals are generated as the carbon 
conjugates bind to the captured antibodies immobilised on the nitrocellulose. The 
intensity o f the generated signal decreases as the concentration o f free  AFBi
increases.
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3.2.2.3.2 Optimisation o f flow-rate
From a safety point o f  view it was necessary to develop the LFIA assay format that 
involved spraying either anti-AFBi antibodies or species-specific antibodies, designed 
to capture the anti-AFBi antibodies, directly onto the nitrocellulose. Significant safety 
concerns were envisaged spraying the AFBi-BSA conjugate directly onto the 
nitrocellulose. The antibodies in question were sprayed onto the nitrocellulose 
membrane using a Linomat 5 sample application device. The flow-rate used to deposit 
the antibodies onto the nitrocellulose membrane was initially optimised. Various 
flow-rates, ranging from 100 -  500nl/sec, were tested by spraying 500|_ig/ml o f  anti­
horse antibody. Signals were developed using a carbon-conjugated horse antibody in 
running buffer, which was allowed run up the nitrocellulose strip. A  flow-rate o f  
400nl/sec was chosen for use in subsequent assays, as it produced a definite line with 
minimal dispersion (Fig. 3.29).
3.2.2.3.3 Optimisation o f control line
The incorporation o f  an appropriate control line is essential for the development o f  a 
LFIA. The control line is sprayed approximately 3 mm above the test line and signals 
are only generated when the sample has travelled along the nitrocellulose over the test 
line and then over the control line, confirming that the sample droplet has passed over 
the test line. It is essential, when selecting an appropriate control line, to ensure that 
the carbon-labelled antigen used to generate the signals for the control line does not 
interact non-specifically with the capture antibodies sprayed onto the nitrocellulose 
for the test line. This would result in false-positive results. Colloidal carbon was 
adsorbed onto a mouse antibody, a horse antibody and a rabbit antibody. The three 
carbon-conjugates were investigated for use in the generation o f  the signal for the 
control line. Nitrocellulose strips were sprayed with a several capture antibodies, 
including the anti-AFBi monomeric and dimeric scFvs, the anti-AFBi rat monoclonal 
antibody, a mouse anti-FLAG antibody and a mouse anti-rat antibody. Each o f  the 
three carbon-conjugated antibodies was passed over the capture antibodies in order to 
ensure they did not interact non-specifically. The carbon-conjugated horse antibody 
was selected for use in subsequent assays, as negligible non-specific interactions were 
observed between it and the capture antibodies. Therefore, control lines consisting o f
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goat anti-horse antibodies, sprayed onto the nitrocellulose, and a carbon-conjugated 
horse antibody were incorporated into subsequent assays.
The concentration o f the goat anti-horse antibody for use in the development o f  the 
control line was then optimised. Various concentrations o f  the goat anti-horse 
antibody, ranging from 0 -  750|xg/ml, were sprayed onto nitrocellulose. Signals were 
generated using 100(j.l o f  running buffer containing the carbon-conjugated horse 
antibody (Fig. 3.30). It was found that 500pg/ml o f  the goat anti-horse antibody 
sprayed onto the nitrocellulose was sufficient for the development o f  an acceptable 
control line.
Figure 3.29: Optimisation o f flow -rate used to spray the nitrocellulose strips. The 
goat anti-horse antibody (500jug/ml) was sprayed onto the nitrocellulose w ith various 
flow-rates. Signals were generated using the carbon-conjugated horse antibody. 
Strips 1, 2, 3, 4 and 5 represent flow -rates o f 500, 400, 300, 200 and lOOnl/sec, 
respectively. 400nl/sec was chosen fo r  subsequent assay development.
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Figure 3.30: Optimisation o f the concentration o f goat anti-horse antibody sprayed 
on the nitrocellulose fo r  development o f the control line. Strips I, 2, 3, 4, 5 and 6 were 
sprayed with 750, 500, 250, 125, 62.5 and Opg/ml o f the anti-horse antibody, 
respectively. 500jug/m lof the goat anti-horse antibody was found to be optimal.
3.2.2.3A  Development and optimisation o f test line
Initially attempts were made to develop a competitive LFIA incorporating the AFBi- 
specific monomeric and dimeric scFvs. Test lines, consisting o f  the monomeric or 
dimeric scFvs sprayed onto the nitrocellulose, were investigated for use in the 
development o f  a direct competitive LFIA for AFBi. However, following addition o f  
the sample droplet, which consisted o f  running buffer, free AFBi and the AFBi-BSA  
carbon conjugate, no test line developed. Attempts were then made to develop an 
indirect competitive LFIA were strips were sprayed with a mouse anti-FLAG 
antibody, to capture the FLAG-tagged scFvs. However, once again no signals were 
generated for the test line, following addition o f  the sample droplet, containing the 
monomeric or dimeric scFv, free AFBi and the AFBi-BSA carbon conjugate.
Due to the difficulties encountered trying to develop a LFIA incorporating the 
monomeric and dimeric scFvs, an indirect LFIA was developed using an anti-AFBi 
rat monoclonal antibody, which was kindly donated by the Institute o f  Food Research 
(Norwich, U  K). This assay format consisted o f  spraying nitrocellulose strips with a 
mouse anti-rat capture antibody and allowing the sample droplet, containing the rat 
anti-AFBi monoclonal antibody, free AFBi and the AFBi-BSA carbon conjugate, run
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up the strip (Fig. 3.28). A control line consisting o f  immobilised goat anti-horse 
antibody and the carbon-conjugated horse antibody was incorporated. The 
optimisation o f several assay parameters was also required for the development o f  the 
test line.
Initially four AFBi-BSA carbon conjugates were developed for use with the LFIA. 
They four carbon conjugates were produced using different quantities o f  the AFBi- 
BSA, 50, 150, 250 and 350^g, absorbed onto the colloidal carbon. The optimum 
conjugate for use in the development o f  the indirect LFIA was determined. Strips 
were sprayed with 500(j.g/ml o f  the goat anti-horse antibody as the control line and 
with 500|ig/ml o f  the mouse anti-rat antibody as the test line. Allowing the sample 
droplet, containing the carbon-conjugated horse antibody and the various AFBi-BSA  
carbon-conjugates, travel along the strips enabled the generation o f the signals. 
Minimal difference was observed between the four AFBi-BSA carbon conjugates 
(Fig. 3 .31). Therefore, subsequent assay development was carried out using the 350[ig 
AFBi-BSA conjugate.
Optimisation o f  the concentration o f  the mouse anti-rat antibody for use in the 
development o f  the test line was also carried out. Various concentrations o f  the mouse 
anti-rat antibody, ranging from 0 -  750[ig/ml, were sprayed onto nitrocellulose along 
with the anti-horse antibody as the control line, at 500ng/ml. Signals were then 
generated using a sample droplet containing the AFBi-BSA-carbon conjugate (test 
line) and a carbon-conjugated horse antibody (control line) (Fig. 3.32). It was found 
that 500p.g/ml o f  the mouse anti-rat antibody sprayed onto the nitrocellulose was 
sufficient for the development o f  an acceptable test line.
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Figure 3.31: Optimisation o f the amount o f AFBi-BSA absorbed to the colloidal 
carbon fo r  the development o f the test line. Strips 1, 2, 3 and 4 were sprayed 
500/j.g/ml o f the mouse anti-ra t antibody and developed using the carbon-conjugates 
produced using 350, 250, 150 and 50/ig/m l o f the AFBj-BSA conjugate. A control line 
consisting o f and goat anti-horse antibody sprayed at 500pg/ml, developed using a 
carbon-conjugated horse antibody, was also incorporated
Control line 
Test line
F igure 3.32: Optimisation o f the concentration o f mouse anti-ra t antibody sprayed 
onto the nitrocellulose fo r  the development o f the test line. Strips 1, 2, 3, 4, 5 and 6 
were sprayed with 750, 500, 250, 125, 62.5 and 0jug/ml o f the mouse anti-rat 
antibody, respectively. 500/ug/ml o f the mouse anti-ra t antibody was found to be 
optimal. A control line consisting o f a goat anti-horse antibody sprayed at 500jug/ml, 
developed using a carbon-conjugated horse antibody, was also incorporated.
3.2.2.3.5 Development o f indirect com petitive LFIA for the detection o f AFBi
Following optimisation o f  the various parameters required for the control and test 
lines an indirect competitive LFIA for the detection o f AFBi was developed using the 
anti-AFBi rat monoclonal antibody. Nitrocellulose stripes were sprayed with 
500|ig/ml o f  the mouse anti-rat antibody (test line) and 500|j,g/ml o f  the goat anti­
horse antibody (control line). Standards o f  free AFBi, ranging in concentration from 
390 -  25000pg/ml, were prepared in running buffer. 50(j.l o f  each AFBi standard was 
then mixed with 50fil o f  running buffer containing the anti-AFBi rat monoclonal 
antibody, the AFBi-BSA-carbon conjugate and carbon-conjugated horse antibody. 
The mixed samples were allowed travel along the nitrocellulose membrane followed 
by 100p.l o f  running buffer to wash the strips. The limit o f  detection o f  the assay was 
found to be 1.5ng/ml (Fig. 3.33).
Control line 
Test line
Figure 3.33: Competitive LFIA  fo r  the detection o f AFBi, using an anti-AFBi ra t 
monoclonal antibody. The numbers below the strips represent the concentration o f 
free A FB i added to the sample in ng/ml. The lower lim it o f detection fo r  the assay was 
1.5ng/ml. A control line consisting o f an anti-horse antibody sprayed at 500pig/ml, 
developed using a carbon-conjugated horse antibody, was also incorporated.
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3.2.2.4 Summary o f results
Table 3.13 summarises the limits o f  detection obtained with each immunoassay 
format developed in this chapter.
Table 3.13: Summary o f the lim its o f detection, fo r  free AFBi, using a variety o f 
immunoassay form ats incorporating AFB ¡-specific, scFv and monoclonal, antibodies.
Anti-AFBi
antibody
Competitive
ELISA
Biacore inhibition 
assay
Competitive LFIA
Monomeric scFv 12ng/ml 0.39ng/ml N/A
Dimeric scFv 3ng/ml 0 .19ng/ml N/A
Bifunctional scFv 3ng/ml N/A N/A
Rat monoclonal N/A N/A 1.5ng/ml
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3.3 Discussion
The main focus o f  this chapter was the production and characterisation o f genetically 
derived scFv antibody fragments specific for AFBi. The gene encoding an AFBi- 
specific scFv was isolated from a phage display library. The nucleotide sequence was 
determined and used to deduce the amino acid sequence (Fig. 3.4). The 
complementary determining regions (CDRs) regions were then identified on the 
heavy and light chains according to Kabat et al. (1991) and the 3-D structure o f  the 
scFv predicted using SwissModel (Fig. 3.5).
The scFv gene was sub-cloned into pAK400 for the soluble expression o f  a 
monomeric scFv, pAK500 for the soluble expression o f  a dimeric scFv and into 
pAK600 for the soluble expression o f  an alkaline phosphatase-labelled bifunctional 
scFv. Sfil restriction digestion was used to directionally clone the scFv insert the 
restricted plasmid (Fig. 3.6). Soluble expression o f each scFv was induced using ImM  
IPTG. Sufficient levels o f  expression o f  the monomeric scFv were observed following 
a 4 hour induction period and 16 hours was required for the dimeric and bifunctional 
scFvs. The cellular distribution o f  the expressed scFvs was then determined following 
ELISA analysis on the culture supernatant and periplasmic lysate. High-levels o f  
soluble expression, o f  the monomeric, dimeric and bifunctional scFvs, were observed 
into the periplasm (Fig. 3.7 and 3.8).
Following expression from pAK400 and 500 a C-terminal his-tag was incorporated in 
the monomeric and dimeric scFvs, respectively. Immobilised metal affinity 
chromatography was employed for the purification o f  the his-tagged scFvs. However, 
following purification SDS-PAGE analysis showed the presence o f  several 
contaminating E. co li proteins. Western blot analysis was carried out on the scFvs in 
order to demonstrate the specificity o f  the secondary and tertiary antibodies and to 
confirm the contaminating protein within the periplasmic lysates did not result in non­
specific binding. Western blot analysis was also used to confirm the monomeric or 
dimeric nature o f  the expressed scFvs (Fig. 3 .9). Following expression from pAK400 
a band at approximately 32kDa represented the monomeric scFv. Expression from 
pAK500 yielded a band at approximately 35kDa representing the reduced monomeric 
fusion, confirming the dimeric nature o f  the scFv expressed from pAK500. Two 
bands were visible, at 85kDa and 32kDa, following scFv expression from pAK600,
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representing the alkaline-phosphatase-labelled scFv, and the monomeric scFv, 
respectively. Brennan et al. (2002) also reported similar finding using the pAK vector 
series for the expression o f  scFvs against M3G.
Following the successful expression and initial characterisation o f  the three 
genetically derived scFvs several immunoassay formats were investigated for the 
detection o f AFBi. Competitive ELISAs and Biacore inhibition assays, incorporating 
the genetically derived scFvs, were developed and a lateral flow immunoassay (LFIA) 
was developed using an anti-AFBi rat monoclonal antibody.
Initially, attention focused on the development o f  three competitive ELISAs for the 
detection o f  AFBi. Two indirect competitive ELISAs were developed, with the 
monomeric and dimeric scFvs, and a direct competitive ELISA was developed using 
the alkaline phosphatase-labelled (t functional) scFv. In order to develop a sensitive 
competitive ELISA for AFBi several parameters were optimised. The limit o f  
detection o f  a competitive ELISA can be affected by an antibodies affinity and the 
equilibrium between free and immobilised hapten. I f  the concentration o f  the 
immobilised hapten-conjugate were too high than there would be an unfair binding 
bias towards the immobilised conjugate. For similar reasons the optimal scFv dilution 
used must be the limiting factor because excess would result in binding to both free 
and immobilised AFBi to a higher degree affecting the assay limit o f  detection. 
Checkerboard ELISAs were carried out with each scFv to determine the optimal 
conjugate coating concentration and scFv dilution for use in a competitive ELISA 
(Fig. 3.10, 3.11 and 3.12). AFBi-BSA coating concentrations o f  25, 12.5 and 
6.25|ig/ml were found to be optimal for the monomeric, dimeric and bifunctional 
scFvs, respectively. The optimal scFv dilutions, which displayed between 50 -70%  o f  
maximum binding, were found to be 1/4, 1/8 and 1/4 for the monomeric, dimeric and 
bifunctional scFvs, respectively. Due to its strong hydrophobic nature it was necessary 
to prepare standards o f  AFBi in methanol. However, methanol can have an inhibitory 
effect on the limit o f  detection o f  an assay. Therefore, the optimal methanol 
concentration for use with each scFv was also optimised by carrying out competitive 
ELISA on each scFv using varying concentrations o f  methanol ranging from 2.5 -
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40% (v/v). 5% (v/v) methanol appeared optimal for each scFv (Figs. 3.13, 3.14 and 
3.15).
Optimisation o f the various assay parameters was then followed by the development 
o f  three competitive ELIS As. The range o f  detection for the monomeric, dimeric and 
bifunctional scFvs were determined and ranged between 12 and 781ng/ml, 3 and 
781ng/mland 3 and 390ng/ml, respectively (Fig. 3.16, 3.17, 3.18). Intra- and inter-day 
variability studies were conducted to determine the reproducibility o f  the assays. The 
coefficients o f  variation (CVs) for intra-day assay with the monomeric, dimeric and 
bifunctional scFvs remained below 11.5, 11.98 and 8.28%, respectively. Inter-day 
CVs for the monomeric, dimeric and bifunctional scFvs were less than 11.35, 6.99 
and 5.25%, respectively (Tables 3.3, 3.4 and 3.5). The results discussed above 
suggest that the monomeric, dimeric and bifunctional scFvs offer excellent sensitivity 
and reproducibility for a model assay system for AFBi.
Cross-reactivity studies were then carried out on each scFv, in a competitive ELISA 
format; in order to determine the cross-reactivity potential o f  the scFvs against five 
structurally related aflatoxins, B 2, Gi, G 2, Mi and M2 (Tables 3.6, 3.7 and 3.8). 
Hennion et al. (1998) recommends the comparison o f  two sets o f  values, the LDD and 
IC50, in order to accurately estimate cross reactivity over the measurement range. The 
least detectable dose (LDD) is defined as the smallest concentration o f  analyte that 
produces a response that can be significantly distinguished from zero (Hennion et al., 
1998) and the IC50 is defined as the analyte concentration that results in 50% 
inhibition. The cross-reactivity is then estimated at the LDD (CR90) and at the IC50 
(CR50) as 100-fold the ratio between the LDD and IC50 values o f  the antigen and o f  
the cross reactant, respectively. The dimeric scFv displayed low-levels o f  cross­
reactivity with each o f  the structurally related aflatoxins at both the LDD (i.e. < 3%) 
and CR50 (i.e. < 8%). In comparison with the dimeric scFv the monomeric scFv 
displayed slightly higher levels o f  cross-reactivity at the LDD (i.e. < 12.5%) and IC50 
(i.e. < 19%). The bifunctional scFv appeared to cross-react with the aflatoxins to a 
greater extent with levels as high as 100% and 46% observed at the LDD and IC50, 
respectively. However, it must be noted that each scFv displayed minimal cross­
reactivity with aflatoxins Mi and M2, suggesting that both the monomeric and dimeric
156
scFvs appear to specifically bind to AFBi with low-levels o f  cross-reactivity (i.e. < 
20%). Non-specific interactions, with high-levels o f  cross-reactivity, were observed 
with the bifunctional scFv against aflatoxins B2, Gi and G2.
Attempts made to develop a sandwich ELISA for AFBi incorporating the dimeric 
scFv, as the capture antibody, and the alkaline-phosphatase labelled antibody, for 
detection, were unsuccessful (Data not shown). Brennan et al. (2002) also carried out 
a similar study that was unsuccessful. The difficulties encountered are probably due to 
the size o f  AFBi (312Da), whereby once an antibody binds the AFBi molecule the 
other epitopes are inaccessible.
The development o f  a Biacore inhibition assay was then investigated for the detection 
o f AFBi. In the past several difficulties have been encountered during the 
development o f  Biacore assays for AFBi. Problems have been encountered when 
trying to immobilise anti-AFBi antibodies to a sensor surface, either directly or 
indirectly (Keating 1998). When directly immobilising the antibodies to the sensor 
surface the coupling chemistry affected the antibodies binding capacity and indirectly 
immobilising the antibodies, using either protein A or species specific antibodies, 
resulted in no binding between the captured antibody and the protein conjugate. Daly 
et al. (2000) also encountered difficulties developing a Biacore assay for the detection 
o f AFBi using polyclonal antibodies. In this case a sensor surface immobilised with 
an AFBi-BSA conjugate was used in the development o f  an inhibition assay format 
but difficulties were encountered when trying to regenerate the sensor surface. 
Therefore, this study focused on the use o f  a CM5 chip immobilised with an AFBi 
derivative for the development o f  assays for the detection o f  AFBi. The monomeric 
and dimeric scFvs were applied to the development o f  Biacore inhibition assays for 
the detection o f AFBi.
For the successful development o f  an inhibition assay for the detection o f  AFBi, the 
optimisation o f  a number o f  parameters was required. These included optimal 
antibody dilution, removal o f  non-specific interactions and surface regeneration 
conditions. Several scFv dilutions were passed over the AFBi surface and the dilution 
resulting in the binding o f  approximately 300 -  400RU was selected as optimal. A 1/8
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dilution o f  the monomeric and a 1/70 dilution o f the dimeric scFv were found to 
produce binding responses o f  approximately 380 and 280RU, respectively. Non­
specific binding analysis was carried out on the monomeric (Fig. 3.19) and dimeric 
scFvs (Fig. 3.20) to ensure any observed binding was due specifically to the 
interaction between the scFv and immobilised AFBi. Negligible binding was observed 
with each scFv to the dextran and, as a result, there was no need to incorporate 
dextran into the diluent buffer.
The regeneration o f  the sensor surface is a major factor affecting the development o f  
Biacore assays. The regeneration conditions for the removal o f  the monomeric and 
dimeric scFv from the AFBi sensor surface were optimised. A  0.5 min pulse o f  lOmM 
NaOH and 25mM NaOH enabled complete removal o f  the monomeric and dimeric 
scFvs, respectively. Figure 3.21 show a typical sensogram for the binding and 
regeneration o f  the monomeric and dimeric scFvs, respectively, on the AFB] sensor 
surface. Previous studies have encountered problems regenerating the sensor surface 
immobilised with hapten -  protein conjugates following injection o f  specific 
polyclonal antibodies. The need for stringent regeneration conditions were required, 
including 1M ethanolamine, pH 13.6 for the regeneration o f  an M3G-OVA surface 
(Dillon8 et a l 2003) and 1M ethanolamine with 20% (v/v) acetronitrile, pH 12.0 for 
the regeneration o f  an AFBi-BSA surface (Daly et al. 2000). In the case o f  this study 
the use o f  10 and 25mM NaOH for the monomeric and dimeric scFvs, respectively, 
enabled the complete regeneration o f  the AFBi surface. The need for a higher NaOH  
concentration with the dimeric scFv suggests that the two binding sites increase the 
avidity o f  the scFvs for AFBi. Recent publications on the development o f  Biacore 
assays with monomeric scFvs have also reported the need for less stringent 
regeneration conditions in comparison with the use o f  polyclonal antibodies (Brennan 
et al., 2002; Daly et al., 2002 and Dillonb et al., 2003). Multiple regenerations o f  the 
sensor surface is essential in the development o f  an assay in order to enable the 
analysis o f  multiple samples, making the biosensor a more cost effective method o f  
detection. Multiple binding -  regeneration cycles were carried out on the sensor 
surface to determine the binding capacities o f  the monomeric and dimeric scFvs. Over 
the course o f  the binding-regeneration cycles the binding capacity o f  the scFv to AFBi 
should not decrease by more than 20% (Wong et al., 1997). Following optimisation o f  
the regeneration solution for use with the monomeric and dimeric scFv regeneration
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studies were conducted. This involved repeatedly injecting the scFv over the AFBi 
sensor surface and regenerating it with the appropriate regeneration solution. It was 
possible to regenerate the sensor surface at least 75 times using the monomeric scFv, 
before a decrease o f  12% in the ligand binding capacity was observed (Fig. 3.22). The 
sensor surface could also be regenerated at least 75 times using the dimeric scFv, with 
a decrease in the ligand binding capacity o f  10% being observed (Fig. 3.23). These 
results suggest excellent reproducibility o f  the AFBi sensor surface and the decrease 
in ligand binding capacity remains well below the limits suggested by Wong et al. 
(1997). It should also be noted at this point that the majority o f  the Biacore work 
carried out in this chapter was done using only one flow-cell, making it possible to 
carry out at least 530 regenerations on one CM5 surface immobilised with the AFBi 
derivative.
Following optimisation o f  the various assay parameters, inhibition assays, 
incorporating the monomeric or dimeric scFvs, were developed for the detection o f  
AFBi using the CM5 chip immobilised with an AFBi derivative. Intra- and inter-day 
studies were conducted for each assay to give an indication on the assay’s 
reproducibility. Studies on the intra-day variability showed that the monomeric scFv 
had a range o f  detection for free AFBi from 375 -  12,000pg/ml (Fig. 3.24) with 
coefficients o f  variation (CVs) remaining below 0.61%. The intra-day variability 
assay with the dimeric scFv had a range o f  detection between 190 and 24,000pg/ml 
(Fig. 3.25) and the CVs remained below 3.37%. Inter-day variability studies were also 
carried out in order to determine the reproducibility o f  the assay over three days. 
Figures 3.26 and 3.27 show the inter-day assay curves for the monomeric and dimeric 
scFvs, respectively, where the range o f  detection for free AFBi was 375 -  
12,000pg/ml for the monomeric and 190 and 24,000pg/ml for the dimeric scFv. The 
CVs obtained for the inter-day variability studies on the monomeric scFv ranged 
between 1.9 and 4.18% (Table 3.9) and between 3 and 11.53% for the dimeric scFv 
(Table 3.10), indicating that both assays were reproducible over the 3 days. The 
results show that both the monomeric and dimeric scFvs offer excellent specificity 
and reproducibility for a model Biacore inhibition assay system for AFBi.
Cross-reactivity studies were then carried out on each scFv in an inhibition assay 
format on the Biacore. Cross-reactivity potential o f  the scFvs were determined against
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five structurally related aflatoxins, B 2, Gi, G2, Mi and M2 at the LDD and IC50. The 
monomeric scFv displayed highest level o f  cross-reactivity against aflatoxin Mi and 
Gi at the LDD (12.5%) and aflatoxin Gi at the CR50 (13%) (Table 3.11). The 
monomeric scFv displayed low-levels o f  cross-reactivity against aflatoxins B2, G2, Mi 
and M2 at the IC50 (i.e. < 5%) and against aflatoxins B2, G2, and M2 at and LDD (i.e. < 
3%). The dimeric scFv displayed low-levels o f  cross-reactivity against aflatoxins B2, 
G2, Mi and M2 at the IC50 and LDD (i.e. < 5%) (Table 3.12). Slightly higher-levels o f  
cross-reactivity were observed against aflatoxin Gi at the ICso (10%) and the LDD 
(20%). This suggests that both the monomeric and dimeric scFvs appear to 
specifically bind to AFBi with low-levels o f  cross-reactivity (i.e. < 20%) observed at 
the IC50 and LDD.
The development o f  a lateral flow  immunoassay (LFIA) was also investigated as a 
rapid assay for the detection o f  AFBi. Direct and indirect assay configurations, 
incorporating the monomeric and dimeric scFvs, were investigated. The direct assay 
format involved spraying the anti-AFBi scFvs directly onto nitrocellulose and the 
indirect format involved immobilising a capture antibody onto the nitrocellulose. 
Usually it is possible to spray hapten-protein conjugates directly onto nitrocellulose. 
However, from a safety point it was envisaged that spraying the AFBi-protein 
conjugate might result in the release o f  hazardous vapours. The optimisation o f  
numerous parameters was required. Initially the flow-rate at which strips was sprayed 
was optimised to give a definite line with minimal dispersal. Flow-rates ranging from 
100 -  500nl/sec were used to spray strips with 500^g/ml o f  an anti-horse antibody. 
Upon development o f  the lines using a sample droplet consisting o f  running buffer 
and a carbon-conjugated horse antibody it was apparent that 400nl/sec was optimal 
(Fig. 3.29). This flow-rate enabled a quick spraying time and resulted in minimal 
dispersion o f  the line. The development o f  a specific control line is an essential part in 
the development o f  a LFIA. The use o f  three carbon-labelled antibodies, a mouse 
antibody, a horse antibody and a rabbit antibody, was investigated. The carbon- 
conjugated horse antibody was selected for subsequent assay development because it 
did not non-speciflcally interact with immobilised antibodies used with the test lines, 
The concentration o f  the anti-horse antibody sprayed onto the nitrocellulose, for use in 
the control line, was then optimised. Various concentrations o f  the anti-horse
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antibody, ranging from 0 -  750|ig/ml, were investigated. 500(ig/ml was sufficient for 
the development o f  a sufficient control line (Fig. 3.30).
Initially attempts were made to develop a competitive LFIA incorporating the AFBi- 
specific monomeric and dimeric scFvs. Test lines, consisting o f  the monomeric and 
dimeric scFvs sprayed directly onto the nitrocellulose, were investigated for the 
development o f  a direct competitive LFIA for AFBi. However, upon development no 
test line appeared. Attempts were also made to develop an indirect competitive LFIA 
were strips were sprayed with an anti-FLAG antibody, to capture the FLAG-tagged 
scFvs. However, once again no test line developed. Observations on the optimisation 
o f  the control line suggested the need for spraying lines at relatively high 
concentrations (500jig/ml). Therefore, the scFvs were concentrated 10-fold, using an 
Amicon filter, and re-applied to each assay format. Once again no test line developed. 
Difficulties were previously encountered trying to purify the his-tagged scFvs. SDS- 
PAGE analysis on the IMAC purification confirmed the presence o f  a large number o f  
contaminating E. co li proteins. Therefore, attempts made to concentrate the scFvs 
would also have resulted in the concentration o f the contaminating proteins, which 
may have resulted in an inhibitory effect on the development o f  the test line. The 
porosity o f  the nitrocellulose can affect the sensitivity o f  a LFIA. Highly 
concentrated solutes may result in clogging o f  the nitrocellulose, preventing the 
sample running up over the test line and control line. The concentrated scFv, 
containing the concentrated contaminating proteins, may have clogged the 
nitrocellulose preventing the sample passing over the control and test lines. 
Suggesting the need for nitrocellulose with a larger pore size or the need for a 
relatively pure antibody stock for the development o f  the LFIA for the detection o f  
AFBi.
Therefore, the use o f  a purified rat monoclonal antibody, specific for AFBi was 
employed for the development o f  an indirect competitive LFIA for the detection o f  
AFBi. This assay format consisted o f  spraying nitrocellulose strips with a anti-rat 
capture antibody and allowing the sample droplet, consisting o f  running buffer, the rat 
anti-AFBi antibody, free aflatoxin and the AFBi-BSA carbon conjugate, run up the 
strip (Fig. 3.28). The quantity o f  the AFBi-BSA conjugate absorbed onto the colloidal
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carbon was initially optimised. Carbon conjugates containing 50, 150, 250 and 350p,g 
o f AFBi-BS A absorbed onto the colloidal carbon were developed. Minimal difference 
between the four conjugates was observed (Fig. 3.31). Therefore the conjugate 
containing 350|ig o f  the AFBi-BSA conjugate was selected for subsequent assays. 
The concentration o f  anti-rat sprayed onto the nitrocellulose for the development o f  
the test line was also optimised. Various concentrations o f  the anti-rat, ranging from 0
-  750pg/ml, were investigated. 500(.ig/ml was sufficient for the development o f  a 
sufficient test line (Fig. 3.32).
Following optimisation o f  the various parameters required for the control and test 
lines an indirect competitive LFIA for the detection o f AFBi was developed using the 
rat anti-AFBi monoclonal antibody. Nitrocellulose stripes were sprayed with the anti­
rat (test line) and the anti-horse (control line). Standards o f  free AFBi, ranging in 
concentration from 0.39 -  25ng/ml, were prepared and mixed with an equal quantity 
o f  running buffer containing the AFBi-BSA and horse carbon conjugates. The mixed 
samples were allowed travel along the nitrocellulose membrane followed by lOOpl o f  
running buffer to wash the strips. The signal intensity o f  the test line increased as the 
concentration o f  free hapten decreased (Fig. 3.33). The control line remained constant 
on each strip. The limit o f  detection was then selected as the highest concentration 
that produced a test line and in this case was found to be 1 5ng/ml.
This chapter focused on the development o f  several immunoassay formats, 
incorporating the genetically derived scFvs, for the detection o f  AFBi. Table 3.13 
summarises the limits o f  detection obtained with each immunoassay format. The 
limits o f  detection obtained using the competitive ELISAs compare favourably with 
published literature. Daly et al. has described competitive ELISAs for the detection o f  
AFBi incorporating both polyclonal antibodies (2000) and monomeric scFvs (2002) 
with limits o f  detection o f  3ng/ml and 98ng/ml, respectively. However, more sensitive 
ELISAs have been described by Candlish et al. (1985), Aldao et al. (1995) and 
Abouzied et al. (1998) with limits o f  detection at 0.2ng/ml, 0.25(ig/kg (ppb), and 
0.5ng/ml, respectively. Limits o f  detection described with the Biacore inhibition 
assays also compare positively with published literature on Biacore-based inhibition 
assays for the detection o f  AFBi. Van der Gaag et al. (1999) developed an assay in
162
spiked grain samples using a monoclonal antibody with similar detection limits o f  0.2 
ppb. Daly and collaborators developed an assay using a polyclonal antibody in PBS 
with a limit o f  detection o f  3ng/ml (Daly et al., 2000) and an scFv-based assay with a 
limit o f  detection o f 3ng/ml in PBS and 0.75ng/ml in spiked grain (Daly et a l, 2002). 
The limits o f  detection described in this chapter also compare favourably with several 
other immunoassay formats including a fluorescence polarization assay for aflatoxins 
with a range o f  detection between 5 and 200ppb (Korde et a l, 2003) and a dipstick 
assay with a limit o f  detection o f  2ng/ml (Schneider et al., 1995). However, analytical 
techniques, including a HPLC detection system described by Kussak et al. (1995) 
with limits o f  detection for aflatoxins B i, B2, Gi and G2 at 6.8pg/ml in urine and an 
immunoaffinity fluorometric biosensor with a lower limit o f  detection at 0.1 ppb 
(Carlson et al., 2000) have offered greater levels o f  sensitivity. In the case o f  the 
lateral flow immunoassay, a sol-particle lateral flow immunoassay with limits o f  
detection for AFBi at O.lppb in buffer and lOppb in grain samples (Niessen et al., 
1998), has offered improved sensitivity, for the detection o f  AFBi in buffer, over the 
lateral flow developed using the AFBi-specific monoclonal antibody.
Although some assay formats described in the literature may offer lower limits o f  
detection it must be noted that the assays described in this chapter are highly 
reproducible, with acceptable levels o f  sensitivity and specificity. The competitive 
ELISAs described are relatively cheap and cost effective, with the bifunctional scFv 
eliminating the need for secondary and tertiary detection antibodies, further reducing 
the cost and time o f  the assay. The ELISAs developed using the dimeric and 
bifunctional scFvs are also capable o f  detecting AFBi levels below the EU maximum 
residue level, which is set at 8ppb (ng/ml) in nuts and dried fr t subjected to sorting, 
or other physical treatment, for human consumption. The development o f  the Biacore 
inhibition assays enabled results to be viewed in real-time and offered in excess o f  a 
10-fold increase in sensitivity over the competitive ELISAs. The Biacore inhibition 
assays also enabled detection o f  AFBi below the EU maximum residue level, which is 
set at 2ppb (ng/ml) in nuts, dried fruit and cereals for direct human consumption or as 
ingredients in foodstuffs. The lateral flow  immunoassay described in this chapter is 
also relatively cheap and results are obtained within 5 - 1 0  min. The LFIA is also 
capable o f  detecting AFBi at levels below the EU maximum residue limits o f  2ppb, in
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nuts, dried fruit and cereals for direct human consumption or as ingredients in 
foodstuffs.
This chapter focused on the development o f  several immunoassays for the detection 
o f AFBi using recombinant scFv antibodies and throughout the course o f  this study 
several advantages o f  recombinant antibody technology have been highlighted. 
Recombinant antibody techniques have provided an alternative unlimited source o f  
antibodies with desirable affinity and specificity. Initially, a monomeric scFv was 
expressed using an antibody phage display library and used in the development o f a 
competitive ELISA for AFBi. Although this scFv was specific for AFBi it was unable 
to detect levels as low as the EU maximum residue level, which is set at 8ppb (ng/ml) 
in nuts and dried fruit subjected to sorting, or other physical treatment, for human 
consumption. Using recombinant antibody technology the scFv was expressed as a 
dimeric fusion, altering the scFvs affinity and specificity for AFBi. In the competitive 
ELISA format the dimeric scFv offered increased affinity and specificity with a 
decrease in the limit o f  detection, enabling detection for AFBi below the EU  
maximum residue level, and a decrease in cross-reactivity levels with structurally 
related aflatoxins. The AFBi-specific scFv was also expressed as a dimerised form 
fused to an alkaline phosphatase enzyme and used in the development o f  a direct 
competitive ELISA. This also resulted in a lower limit o f  detection, enabling detection 
below the EU maximum residue level. The presence o f  the alkaline phosphatase label 
on the scFv eliminated the need for secondary and tertiary detection antibodies, 
reducing the cost and time o f  the assay. Similar results were noted following 
comparisons on the Biacore inhibition assays incorporating the monomeric and 
dimeric scFvs, with the dimeric scFv assay offering increased sensitivity over the 
monomeric assay.
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C H A P T E R  4
The cloning and expression of an 18kDa cytoplasmic and 
a 26kDa periplasmic Brucella-specific protein
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4.1 Introduction
The cloning and subsequent expression o f  recombinant B. abortus proteins offers 
several advantages over the isolation o f  native proteins from whole B. abortus cells. 
Cloning eliminates the need for growing large-scale cultures o f  this class III pathogen 
and provides an unlimited supply o f  the recombinant proteins that may have 
incorporated affinity tags enabling one-step purification.
4.1.1 TA cloning
The Original TA Original TA cloning kit provides a one step cloning strategy that 
allows the direct insertion o f  a Taq-polymerase-amplified PCR product into the 
pCR2.1 plasmid (Figure 4.1).
Following PCR with Taq-polymerase a non-template-dependent terminal transferase 
activity adds a single deoxyadenosine (A) to the 3' ends o f  the amplified PCR 
product. The PCR product can then be efficiently ligated into the linearised pCR2.1 
plasmid because it has been engineered to contain 3' deoxythymidine (T) overhanging 
residues.
3'
Figure 4.1: Schematic representation o f the concept behind the TA cloning kit. The 
PCR product w ith its 3 ' single deoxyadenosine (A) overhang can be efficiently ligated  
into the linearisedpCR2.1 vector w ith its 3 ' deoxythymidine (T) overhang.
166
4.1.2 QIAexpress cloning
The QIAexpress system (Qiagen) provides a complete system for the cloning, 
expression, purification and detection o f  heterologous proteins. High-level expression 
o f  6x-His-tagged proteins in E. co li is achieved using the QIAexpress pQE vectors, 
which in turn can be purified using nickel-nitrilotriacetic acid (Ni-NTA).
The pQE plasmids were derived from the plasmids pDS56/RBSII and pDS781/RBSII- 
DHFRS (Stuber et al., 1990) and belong to the pDS plasmid family (Bujard et a l, 
1987). Depending on the intended use o f  the expressed protein pQE vectors 
incorporating C- or N-terminal 6xHis tags can be used. When incorporating C- 
terminal His tags the cloned insert must be in-frame with the ATG start codon and the 
6xHis tag. The use o f  a C-terminal His tag ensures only full-length proteins are 
purified.
pQE-60 results in the incorporation o f  a C-terminal 6xHis tag. A  number o f  features 
present on this low-copy plasmid contribute to the efficient high-level expression o f  
recombinant proteins (Fig. 4.2). The plasmid has a phage T5 promoter, which is 
recognised by the RNA polymerase from E. co li and two lac operator sequences, 
which cause an increase in lac repressor binding allowing for efficient repression o f  
the T5 promoter. The plasmid also harbours a synthetic ribosomal binding site, RBSII, 
that increases the rate o f  translation and a sequence coding a 6xHis-tag 3' to the 
cloning region. pQE-60 also has a multiple cloning site (Fig. 4.3) and translational 
stop codons in all reading frames for convenient preparation o f  the expression 
construct. Two robust transcriptional terminators, to from phage lambda and T1 from 
the rraB operon o f  E. co li are also encoded on the plasmid, which prevent read- 
through transcription and increase construct stability. The P-lactamase gene (bla), 
which confers ampicillin resistance at lOOpig/ml, and the colE l origin o f  replication 
are also important features encoded for on the pQE-60 plasmid.
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Figure 4.2: pQE-60 vector used fo r C-term inal 6xIIis tag constructs. PT5: T5 
promoter, lacO: lac operator, UBS: ribosome binding site, A TG: start codon, 6xHis: 
6xHis tag sequence, MCS: multiple cloning site with Nco I, Bam H> and Bgl I I I  
restriction sites, stop codons: Stop codons in  a ll three reading frames, Col E l: Col E l 
orig in o f replication.
EcoRl / RBS
Ncol BamHI___ Bglll
CCATGGGAGGATCCAGATCT
1------ T T
Hind III
AAGCTTAATTAGCTGAG
Figure 4.3: M ultip le cloning site o f pQE-60 vector containing Ncol, BamHI and 
BglHI restriction sites.
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4.1.3 Protein expression
High-level recombinant protein expression using pQE-60 is induced upon addition o f  
isopropyl-P-D-thiogalactoside (IPTG). IPTG binds to the lac repressor protein 
resulting in its inactivation. This allows the host strains RNA polymerase to transcribe 
the sequence downstream o f  the promoter sequence with the resultant transcript being 
translated into the recombinant protein.
4.1.3.1 Protein solubility
Heterologous protein expression in E. co li can result in the formation o f  insoluble 
inclusion bodies. Although the QIAexpress system enables purification o f  inclusion 
bodies, following solubilisation with denaturing buffer, several approaches for the 
isolation o f  functional proteins have been described.
Several factors, including growth temperature, the promoter, plasmid copy number 
and inducer concentration, affect protein expression levels. Increased levels o f  protein 
expression can result in the formation o f  insoluble inclusion body. Therefore, 
reducing the rate o f  protein synthesis can lead to increased levels o f  soluble protein 
production. The ratio o f  soluble to insoluble protein can also be increased using non- 
metabolisable sugars such as sucrose, that have been shown to directly effect the 
folding o f  the protein (Bowden and Georgiou, 1990). Periplasmic expression can also 
increase the levels o f  soluble protein obtained. The periplasm offers an oxidising 
environment, which allows formation o f  disulphide bonds, exhibits reduced 
proteolysis, allows accumulation o f  toxic proteins and it contains two foldases 
(disulfide oxidoreductase (DsbA) and disulfide isomerase (DsbC)). These factors all 
play a role in protein solubility. Levels o f  soluble protein expression can also be 
increased with the co-expression o f  chaperones (Georgiou and Valax, 1996), which 
aid in protein folding, and the use o f  gene fusions, which consist o f  the target protein 
fused to a carrier protein such as E. co li thioredoxin (TRX) (LaVallie et a l, 1993) and 
glutathione S-transferase (GST) (Ghosh et ah, 1995 and Smith and Johnson, 1988).
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4.1.3.2 Expression hosts
Recombinant protein expression can be produced in a variety o f  expression hosts 
including E. coli, mammalian cells, insect cells using baculovirus, vectors, yeast and 
plants. The selection o f  the expression host depends on the intended use o f the 
protein, with E. coli incapable o f  performing post-translational modifications.
4.1.2.2.1 E. co li
Up until the mid-90’s E. co li was the preferred host strain due to its ease o f  handling 
and detailed working knowledge available on its capacity and performance. E. coli 
was the first host strain for recombinant protein expression when used for the 
expression o f  human insulin (Swartz, 2001).
The QIAexpress system recommends the use o f  th e£ . coli strain M l 5 [pREP4], when 
using pQE-60 for high-level protein expression. M l 5 [pREP4] contain a low copy 
number o f  the pREP4 plasmid, which encodes a gene, lacl, for the constitutive 
expression o f  the lac repressor protein. High levels o f  the lac repressor protein are 
required to control the exceptionally high transcription rate, which is initiated by the 
T5 promoter. E. co li host strains, such as XL1 Blue, TGI and X L-10 Gold, harbouring 
the lacP  mutation also produce enough lac repressor to efficiently regulate and 
repress protein expression.
When using E. co li for the expression o f  recombinant proteins it is important to take 
into account the fact that the tRNAs that recognise certain codons are rarely found. 
For example the tRNAs that recognise the codons AGG and AGA, which encode 
arginine, are among the least abundant in E. coli. I f  the recombinant protein being 
expressed contains several o f  this rare codons a truncated version o f  the protein is 
likely to be produced. For this reason it is necessary to establish the number o f  rare 
codons within the protein sequence. I f  several rare codons are located within the 
sequence it maybe necessary to express the protein in a host strain, which contains an 
extra plasmid that encodes these rare tRNAs. The bacterial host strains Rosetta and 
RosettaBlue have been engineered to contain a chloramphenicol resistant plasmid, 
pRARE that encodes tRNAs for the codons A U A  AGG, A G A  C U A  CCC, and GGA 
(Fig. 4.4), therefore, allowing the universal expression o f proteins, which would 
otherwise be limited by the codon usage o f  E. coli.
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XL 10-Gold cells are derivatives o f  Stratagene’s highest-efficiency competent cell 
line XL2-Blue MRF’ and contain the Hte phenotype, which increases transformation 
efficiency o f  ligated D N A  molecules. XL 10-Gold cells also grow faster than XL1 
and XL2-Blue cells, resulting in larger colonies. XL 10-Gold cells are endonuclease- 
deficient (endA l), which greatly improves the quality o f  plasmid miniprep DNA, and 
recombination-deficient (recA), which ensures insert stability. The mcrA, mcrCB and 
m rr mutations prevent cleavage o f  the cloned DNA that carries cytosine and/or 
adenine methylation, which is often present in eukaryotic D N A  and cDNA. The hsdR 
mutation prevents the cleavage o f  the cloned DNA by the EcoK endonuclease system.
Figure 4.4: M ap o f the pRARE plasm id fam ily. A chloramphenicol resistance gene 
(Cam), a replicon (P15A ori) and tRNA genes, w ith the rare E. co li codons in blue, 
are encoded on the pRARE plasmid.
4.1.2.2.2 Yeast
Eukaryotic protein expression in yeast offers the distinct advantage o f  providing most 
eukaryotic post-translational modifications with the protein folding pathways and 
codon usage mimicking that o f  mammalian cells (Cho et al., 1998). The ease o f
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handling also makes the use o f  yeast as expression hosts appealing. The two most 
commonly used yeast expression systems involve Saccharomyces cerevisiae and 
Pichia pastoris. P. pastoris has been successfully applied to the expression o f human 
chitinase (Goodrick et al., 2001), insulin precursors (Wang et al., 2001) and 
recombinant scFv antibody fragments (d’Anjou and Daugulis, 2001 and Hellwig et 
al., 2001). E  co li /  yeast shuttle plasmids are the most commonly used expression 
vectors (Baldarini and Cesareni, 1985 and Clare et a i, 1991). The expression vectors 
are easily introduced into the yeast cells using either electroporation or transformation 
into competent cells. Protein expression is induced using either the galactosidase- 
inducible system in S. cerevisiae or the methanol-driven induction in the 
methylotropic, P. pastoris.
4.1.2.2.3 Baculovirus
The baculovirus is capable o f  infecting and multiplying within cultured insect cells 
making it possible to express heterologous proteins within insect cells. Insect cells 
offer comparative advantages to mammalian cells, which include ease o f  culture, 
higher expression-levels and higher osmolality and by-product concentration 
tolerance (Ikonomou et a l,  2003). Insect cells are also capable o f  performing post- 
translational modification such as glycosylation, phosphorylation, precursor 
processing and targeting. Autographa califom ica  nuclear polyhedrosis virus 
(AcMNPV), a lytic virus that infects lepidopterans, is the most widely used virus. The 
most frequently used insect cell lines are Sf9 and S f2 l. Following cloning o f  the gene 
into a plasmid transfer vector, the D N A  is co-transferred into the insect cell along 
with a double stranded baculovirus DNA. The gene o f  interest is incorporated into the 
viral genome following homologous recombination o f  the plasmid and insert DNA  
with the viral DNA.
4.1.2.2.4 M ammalian cells
Although expression levels from mammalian cells are generally low they provide the 
same post-translational modifications and recognise the same synthesis, processing 
and secretion signals for recombinant vertebrate proteins. Several mammalian systems 
have been developed for the high-level expression o f  recombinant proteins with 
Chinese hamster ovary (CHO), human embryonic kidney (HEK) and baby hamster 
kidney dominating the field (Wurm and Bernard, 1999). The expression vectors
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contain a strong promoter such as the cytomegalovirus (CMV) for transcription 
initiation, mRNA processing signals such as mRNA cleavage and polyadenylation 
sequences and markers for the selection o f  cells containing the stably integrated DNA. 
Mammalian expression vectors can also contain sequences for the controlled 
induction o f expression using an external stimulus such as P-interferon, heavy metal 
ions, glucocorticoids and heat shock. A  number o f  plasmid D NA  delivery systems for 
mammalian cells have been described, which include calcium phosphate DNA co­
expression (Graham and Van der Eb, 1973), polyethyleneimine (PEI) DNA  
complexes (Boussif et ah, 1995) and electroporation (Chu et al., 1987).
4.1.3.3 The 6xHis tag
The 6xHis tag is relatively small (0.84kDa) in comparison to other affinity tags such 
as glutathione-S-transferase (26kDa) and maltose-binding protein (40kDa). Its small 
size, low immunogenicity and absence o f  charge at pH8.0 means it does not usually 
interfere with protein secretion, compartmentalisation or folding within the host 
strain. The 6xHis tag also allows the linkage o f  the tagged protein to a metal chelating 
surface enabling immobilised metal affinity chromatography (IMAC) (See Section 
4.1.3.1). Detection o f  the expressed protein is easily achieved using anti-His 
antibodies.
4.1.4 Immobilised metal affinity chromatography (IM AC)
Porath and associates (1975) were first to introduce the use o f  immobilised metal 
affinity chromatography (IMAC), while working on the fractionation o f  proteins from 
human serum. Since then hundreds o f  papers have been published detailing the use o f  
IMAC for group purification and the highly selective purification o f  target proteins 
from complex biological samples. Hochuli and co-workers (1987 and 1988) were first 
to apply IMAC for the purification o f  recombinant proteins containing engineered N ­
or C-terminus histidine tags.
The principle o f  IMAC is based on the affinity o f  proteins for immobilised metal ions. 
The interaction between the immobilised metal ions and the side chains o f  amino 
acids is reversible under mild conditions. IMAC offers a number o f  advantages over 
conventional biospecific chromatographic techniques, including low cost, ligand
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stability, mild elution conditions, simple regeneration and high protein loading 
(Arnold, 1991). IMAC also offers the distinct advantage o f  its applicability to protein 
purification under both native and denaturing conditions since the interaction between 
the Ni-NTA and the 6xHis tagged recombinant protein does not depend on the tertiary 
structure.
Protein adsorption during IMAC is based on the coordination between an immobilised 
metal ion and electron donor groups on the protein surface. Transition metal ions 
including Zn (II), Cu (II), Co (II) N i (II) and Fe (HI), which act as electron-pair 
acceptors, are most commonly used. The metal ions are attached to the 
chromatographic support via electron donor atoms (N, S, O) in the chelating 
compounds forming metal chelates, which may be bidentate, tridentate etc., 
depending on the number o f  occupied coordination bonds (Gaberc-Porekar and 
Menart, 2001). The remaining coordination sites, generally occupied by water 
molecules, can then be exchanged with suitable electron-donor groups from the target 
protein. Several amino acids such as Glu, Asp, Tyr, Cys, His, Arg, Lys and Met can 
participate in metal adsorption, with IMAC primarily focusing on the availability 
histidine residues. In neutral or slightly basic solutions the nonprotonated imidazole 
nitrogens in the histidine residues absorb the IMAC support, with the reduction in 
non-specific electrostatic interactions observed using relatively high-ionic strength 
buffers (0.1 -  1M NaCl). Elution o f  the immobilised protein can be achieved by 
means o f  protonation using a pH shock, ligand exchange using imidazole or metal ion 
chelation using a strong chelator such as EDTA. The affinity o f  a protein for metal 
chelates depends strongly on the metal ion involved, with Cu (II) > Ni (II) > Zn (II) > 
Co (H) showing increasing affinities. The are several commercially available 
chelating ligands, which include iminodiacetic acid (IDA) (Amersham Pharmacia 
Biotech, TosoHaas, Sterogene), nitrilotriacetic acid (NTA) (Qiagen), 
carboxymethylated aspartic acid (CM-Asp) (Clontech) and tris-carboxymethyl 
ethylene diamine (TED) (Inovata), with the IDA offering tri-dentate, the NTA and 
CM-Asp offering tetra-dentate and the TED adsorbent offering penta-dentate 
complexes with the corresponding metal ion (Fig. 4.5). The tetra-dentate chelators 
offer higher affinities for metal ions than the tri-dentate ligands but may exhibit 
decreased protein binding due to the loss o f  one coordination site. The lower binding
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capacity is even more evident with the penta-dentate ligands with only one protein 
binding coordination site remaining. However, the use o f  the tri-dentate IDA chelator 
results in weak binding to the metal ions, which leads to the leaching o f  strongly 
chelating peptides and proteins. This results in low protein yields, impurities and 
metal ion contamination following purification. The QIAexpress system recommends 
the use o f  the nitrilotriacetic acid (NTA) containing the four metal-chelating sites 
because it binds to the metal ions more stably and retains them under stringent 
washing and eluting conditions.
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Figure 4.5: Structures o f commercially available immobilised metal affin ity  
chromatography (IMAC) chelators complexed w ith metal ions. Me (II) represents Cu 
(II), N i (II), Zn (II) or Co (II). A : Im inodiacetic acid (IDA) (Amersham Pharmacia 
Biotech, TosoHaas, Sterogene); B : N itrilo triacetic acid (NTA) (Qiagen); C:
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Carboxymethylated aspartic acid (CM-Asp) (Clontech); D : Tris-carboxymethyl 
ethylene diamine (TED) (Inovata).
4.1.5 Chapter outline
This chapter focuses on the cloning and expression o f  two recombinant B. abortus 
proteins, p l8  and bp26. A  two step cloning strategy incorporating TA cloning and 
subsequent QIAexpress cloning enabled the successful cloning and expression o f  the 
two recombinant proteins (Fig. 4.6).
Total genomic D NA was isolated from heat-killed B. abortus 45/20 cells and used as 
template DNA  for the PCR amplification o f  the p i 8 and bp26 specific genes. The Taq 
DNA polymerase amplified PCR products containing the deoxyadenosine (A) 
overhangs was then ligated into the linearised pCR2.1 plasmid containing the 
deoxythymidine (T) overhanging residues. The pCR2.1 plasmid D N A  encoding the 
gene o f  interest was purified (following the identification o f  a successfully 
transformed INVaF' E. co li). The cloned insert gene was isolated from the pCR2.1 
plasmid following a B am H l/N col restriction digest and then directionally ligated into 
the high-level expression vector pQE-60, that was previously linearised following a 
B am H l/N col restriction digest. The ligated pQE-60 and cloned insert were then 
transformed into competent XL-10 Gold E. co li for subsequent protein expression.
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F igure 4.6: Schematic representation o f the two-step cloning strategy. Follow ing 
PCR am plification o f the DNA sequence encoding the recombinant protein, the DNA 
insert is ligated into the vector pCR2.1. From there the insert is sub-cloned into the 
high-level expression vector pQE-60. 7he recombinant protein is then expressed in  
XL 10 Gold E. co li cells, w ith a 6xHis tag attached to the C-terminus to a id  in 
purifica tion  and detection.
I l l
4.2 Results
4.2.1 FC R  amplification o f the genes encoding p l8  and bp26
Total genomic D N A  was extracted from heat-killed Brucella abortus 45/20 cells as 
described in Section 2.3.1 and electrophoresed on an agarose gel (Fig. 4.7). The 
genomic D N A  was used as a template for the amplification o f  the p l8  and bp26 
genes. Forward and reverse primers were engineered for each gene with N col and 
BamHI restriction sites incorporated for the subsequent directional cloning into the 
high-level expression vector pQE-60. The optimum annealing temperature for use 
with each gene was determined using a temperature gradient PCR. This involved 
carrying out several standard PCR reactions with varying annealing temperatures, 
ranging from 58 - 65°C. The optimum annealing temperature for the amplification o f  
each gene was found to be 65°C (Fig. 4.8). Following optimisation o f  the conditions 
for PCR the p i8 and bp26 genes were amplified for ligation onto the pCR2.1 plasmid. 
Figure 4.9 shows the optimised PCR amplification o f  the genes encoding p l8  (Lane 
2) and bp26 (Lane 4) with bands visible at approximately 485 and 785bp, 
respectively.
1 2
Figure 4.7: Total genomic DNA isolated from  Brucella abortus 45/20. Lane 1: IK p  
DNA p lus Ladder. Lane 2: Total genomic DNA from B. abortus 45/20.
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Figure 4.8: Optimisation o f annealing temperature fo r  use in the PCR am plification  
o f the genes encoding p l8  and bp26. A : Temperature gradient PCR fo r  p l8 . Lane l: 
lOObp DNA ladder; Lane 2: Annealing temperature (AT) o f 58X1; Lcme 3: A T  o f 
60 °C; Lane 4: A T  o f 62 °C; Lane 5: A T  o f 65 °C. B : Temperature gradient PCR fo r  
bp26. L a ne l: 1Kb plus DNA ladder; Lane 2: Annealing temperature (AT) o f 58 °C; 
Lane 3: A T  o f 60 °C; Lane 4: A T  o f 62 °C; Lane 5: A T  o f 65 °C.
1 2  3 4
Figure 4.9: Optimised PCR on the genes encoding p l8  and bp26. The PCR products 
were am plified using an optimised annealing temperature o f 65 °C. Lane 1: lOObp 
DNA ladder; Lane 2: PCR am plification o f the gene encoding p i  8; Lane 3 :1Kb plus 
DNA ladder Lane 4: PCR am plification o f the gene encoding bp26.
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4.2.2 TA cloning
The Original TA cloning kit provides a one step cloning strategy that allows the direct 
insertion o f  a Taq-polymerase-amplified PCR product into the pCR2.1 plasmid (as 
described in Section 4.1.1). The PCR amplified genes encoding p l8  and bp26 were 
ligated into the pCR2.1 and the ligation transformed into competent INVaF' E. coli, 
which were provided with the Original TA Cloning Kit. The presence o f  the multiple 
cloning sites within the LacZ gene o f  the pCR2.1 vector enables blue/white colony 
selection. The LacZ gene encodes the enzyme beta-galactosidase, which metabolises 
X-gal resulting in the formation o f  blue colonies. However, positive transformants 
containing the cloned insert disrupt the LacZ gene and colonies appear colourless, 
when screened on X-gal plates following transformation. Five positive transformants 
(white colonies) were selected for each gene and grown up individually. The pCR2.1 
plasmid D NA  was isolated from each clone and analysed using a BamHl /  N co l 
restriction digest for the presence o f  the 485bp or 793bp insert. Figure 4.10 shows the 
agarose gel analysis for the restriction analysis on the p i 8 clone bp26 clones, with 
bands clearly visible at 485 and 793bp, respectively.
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Figure 4.10: BcanHI and N co l restriction digest on the p l8  and bp26pCR2.1 clones. 
Lane 1: 1Kb plus DNA ladder; Lane 2: BamHI/NcoI restriction digest on the pCR2.1 
vector containing the gene encoding p l8 ; Lane 3: BamHI/NcoI restriction digest on 
the p C R l.l vector containing the gene encoding bp26.
181
4.2.3 Sub-cloning from pCR2.1 into pQE-60 and subsequent transformation into 
competent XL-10 Gold E .coli
The next stage o f  the cloning strategy involved sub-cloning the p l8  and bp26 genes 
from the pCR2.1 vector into the high-level expression vector pQE-60. Protein 
expression from pQE-60 results in the incorporation o f  a C-terminal 6xHis tag for 
ease in purification and analysis. Initially, a BamHl /  N co l restriction digest was 
carried out on the pCR2.1 vector containing the genes encoding p i 8 and bp26 (See 
Section 2.3.6). The 485 and 793bp fragments encoding the p l8  and bp26, 
respectively, were then gel-purified as described in section 2.2.5. A  BamHl /  N co l 
restriction digest was used to linearise the pQE-60, which was also gel purified (See 
Section 2.3.6). The p i 8 and bp26 genes were directionally cloned into the pQE-60 
vector using T4 DNA  ligase and the ligated pQE-60 transformed into CaCk 
competent XL-10 Gold E. co li cells. Screening for positive transformants was 
performed on LB agar plates containing ampicillin and kanamycin. Figure 4.11 shows 
the B am H l/N col restriction digests on the pQE-60 plasmid DNA. pQE-60 plasmid 
DNA containing no cloned insert was restricted (Lanes 2&3) along with pQE-60 
plasmid D N A  containing the cloned p l8  (Lanes 4&5) and bp26 (Lanes 6&7) genes. 
Bands clearly visible at 485 and 793bp represent the cloned p i8 and bp26 genes, 
respectively.
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Figure 4.11: Bam H l and N co l restriction analysis on the pQE-60 clones fo llow ing  
transformation into XL-10 Gold E. coli. Lane 1 :1Kb plus DNA ladder; Lane 2 &  3: 
B am H l/N co l digested on pQE-60 plasm id DNA containing no cloned insert; 
B am H l/N co l digested on pQE-60 plasm id DNA containing the p l8  cloned insert; 
Lanes 6 &  7: B am H l/N co l digested on pQE-60 plasm id DNA containing the bp26 
cloned insert.
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4.2.4 Initial small-scale protein expression
Following the successful transformation o f  the competent X L-10 Gold E. co li with the 
pQE-60 vectors containing the appropriate genes, small-scale expression cultures 
were carried out on a number o f clones, to determine host strain suitability as 
described in Section 2.3.11.
Single colonies were picked from a freshly streaked plate and used to inoculate 5ml o f  
2x TY containing the appropriate antibiotics. The culture was grown overnight at 
37°C overnight and used to inoculate a 20ml culture o f  2x TY containing the 
appropriate antibiotics. The culture was incubated at 37°C, while shaking, until OD550 
reached approximately 0.5. Protein expression was then induced upon addition o f  
ImM IPTG. The induced culture was then further incubated for 4 hours at 37°C, 
while shaking. The bacterial cells were then pelleted following centrifugation, at 
4000rpm for 20 min, and the supernatant discarded. The bacterial pellet was then 
resuspended in 1ml o f  denaturing buffer and sonicated for 30 secs at 220W. Cell 
debris was then removed following centrifugation, at 13,000rpm for 15 min, and the 
supernatant analysed by SDS-PAGE in order to confirm protein expression.
SDS-PAGE analysis on the p i8 and bp26 initial expression cultures yielded the 
appropriate bands at 18kDa and 26kDa. The SDS-PAGE analysis on the initial small- 
scale expression cultures o f  p i 8 can be seen in Figure 4.12. A band at 18kDa is 
clearly visible in 4 out 5 clones analysed, which represents the expressed p l8 protein. 
Figure 4.13 shows the SDS-PAGE obtained following the initial expression cultures 
on the bp26 protein in X L-10 Gold. A band at 26kDa is clearly visible in each o f  the 5 
clones analysed, which represents the expressed bp26 protein. Indicating that the two 
recombinant proteins, p l8 and bp26, were successfully expressed in X L -10 Gold from 
the high-level expression vector pQE-60.
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Figure 4.12: SDS-PAGE analysis on the small-scale expression cultures o f p i8. 
Follow ing the transformation o f X L-10 G oldE. coli. with the ligated pQE-60 and p !8  
gene, 5 clones were analysed post IPTG induction. Lane M : Sigma wide-range 
molecular weight markers; Lane 1: Small-scale expression cultures on p l8  clone 1; 
Lane 2: Small-scale expression cultures on p l8  clone 2; Lane 3: Small-scale 
expression cultures on p l8  clone 3; Lane 4: Small-scale expression cultures on p l8  
clone 4; Lane 5: Small-scale expression cultures on p l8  clone 5. A band at 18kDa is 
clearly visible fo llow ing  induction o f protein expression in clones 2-5.
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Figure 4.13: SDS-PAGE analysis on the small-scale expression cultures o f bp26. 
Follow ing the transformation o f XL-10 Gold E. coli. w ith the ligated pQE-60 and 
bp26 gene, 5 clones were analysed post IPTG induction. Lane M : Sigma wide-range 
molecular weight markers; Lane 1: Small-scale expression cultures on bp26 clone 1; 
Lane 2: Small-scale expression cultures on bp26 clone 2; Lane 3: Small-scale 
expression cultures on bp26 clone 3; Lane 4: Small-scale expression cultures on bp26 
clone 4; Lane 5: Small-scale expression cultures on bp26 clone 5. A band a t 26kDa is 
clearly visible fo llow ing  induction o f protein expression in  each o f the 5 clones.
4.2.5 Protein solubility determination
The high-level expression o f  recombinant proteins in E. co li may result in the 
formation o f  insoluble inclusion bodies, consisting o f  aggregates o f  the expressed 
protein (See section 4.1.3.1). Protein solubility determination enables high-level 
recombinant protein recovery, following optimisation o f  the buffer required for 
protein isolation.
Single colonies o f  XL-10 Gold E. coli, harbouring pQE-60 encoding the p i8 or bp26 
proteins, were picked from a freshly streaked plate and used to inoculate 5ml o f  2x 
TY containing the appropriate antibiotics. The culture was grown at 37°C overnight 
and used to inoculate a 10ml culture o f  2x TY containing the appropriate antibiotics. 
The culture was incubated at 37°C, while shaking, until the OD550 reached 
approximately 0.5. Protein expression was then induced upon addition o f  ImM IPTG. 
The induced culture was then further incubated for 4 hours at 37°C, while shaking. 
The bacterial cells were then pelleted by centrifugation, at 4000rpm for 20 mins, and 
the supernatant discarded. The bacterial pellet was resuspended in 1ml o f  dEhO and 
sonicated for 30sec. at 220W. Following centrifugation, at 13,000rpm for 15 mins, the 
supernatant (soluble protein) was analysed by SDS-PAGE. The pellet was 
resuspended in 1ml o f  denaturing buffer and sonicated for 30sec 220W. Following 
centrifugation, at 13,000rpm for 15 mins, the supernatant (insoluble protein) was 
analysed using SDS-PAGE.
The protein solubility determination for p l8 and bp26 can be seen in Figure 4.14. 
Although, some soluble expression o f  p l8 and bp26 was observed (Lanes 2 and 4, 
respectively), the majority o f  the expressed p i 8 and bp26 forms insoluble inclusion 
bodies, which were solubilised using 8M  urea (Lanes 2 and 4, respectively). This 
suggests the need for denaturing buffer (containing 8M  urea) for the subsequent 
isolation o f  recombinant p l8 and bp26, following high-level expression in XL-10 
Gold E. coli. A web-based bioinformatics program was also used to determine the 
solubility o f  the recombinant proteins (Harrison, 2000). Based on the amino acid 
sequence o f  the protein this model uses the approximate charge average, which 
accounts for the differences in the numbers o f  Asp plus Glu verses Lys plus Arg 
residues, and the turn-forming residue content, which accounts for the total number o f
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Asn, Gly, Pro, and Ser residues, to determine the protein solubility. This program 
estimated that the p i8 protein had a 62% chance o f  solubility and that the bp26 
protein had an 80% chance o f  insolubility, therefore, confirming the need for 
denaturing buffer, containing 8M  urea, for the solubilisation and isolation o f  the 
recombinant p i8 and bp26 proteins, following expression in XL-10 Gold E. coli.
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Figure 4.14: SDS-PAGE analysis on the so lub ility determination fo llow ing  p l8  and 
bp26 expression in X L-10 Gold. Lane M : Sigma wide-range molecular weight 
markers; Lane 1: Isolation o f soluble p l8  under native conditions; Lam  2: Isolation 
o f insoluble p l8  under denaturing conditions; Lam  3: Isolation o f soluble bp26 under 
native conditions; Lane 4: Isolation o f insoluble bp26 under denaturing conditions.
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4.2.6 Optimisation of IPTG concentration for induction of protein expression
Expression o f  p l 8 and bp26, from pQE-60, is rapidly induced upon addition o f  
isopropyl-P-D-thiogalactoside (IPTG). The IPTG binds to the lac repressor protein 
and inactivates it. Once the lac repressor is inactivated, the host cell’s RNA  
polymerase can transcribe the sequence downstream from the promoter. The transcript 
produced can then be translated into the recombinant protein either for p l8 or bp26. 
However, the concentration o f  IPTG required for induction must be optimised, so that 
the highest level o f  protein expression is achieved without the level o f  protein 
expression and IPTG concentration becoming toxic to the cell. IPTG concentrations 
ranging from 0.01 -  ImM were used in order to determine the optimal concentration 
required for the high-level protein expression in XL 10-Gold.
Expression cultures o f  the X L -10 Gold E. coli, harbouring pQE-60 encoding the p i 8 
or bp26 proteins, were prepared, as described in Section 4.2.5, except that individual 
cultures were induced using varying IPTG concentrations ranging from 0 -  ImM. 
Following induction, the cultures were incubated for 4 hours at 37°C and then the 
bacteria were pelleted by centrifugation, at 4000rpm for 20 mins. The resulting pellets 
were resuspended in 2ml o f  denaturing buffer and sonicated for 30 secs at 220W. The 
lysed cells were centrifuged, at 13,000rpm for 15 mins, and the supernatants analysed 
by SDS-PAGE.
Figures 4.15 and 4.16 show the gel pictures obtained for the expression o f  p i 8 and 
bp26, respectively, in XL 10-Gold E. coli, following induction with the various IPTG 
concentrations. In each case 0.5mM IPTG appeared to be the optimal concentration 
for the expression o f  p l8 and bp26. The levels o f  p i8 and bp26 expression were 
estimated, at each IPTG concentration, using ImageJ software, which monitors the 
band intensities on an SDS-PAGE. Tables 4.1 and 4.2 display the expression levels o f  
pi 8 and bp26, respectively, as a percentage o f  the total protein content. The levels o f  
p i 8 and bp26 expressed at each IPTG concentration suggested that 0.5mM IPTG was 
optimal for the induction o f  p l8 and bp26, with the highest levels o f  recombinant 
protein expression observed. Basal level expression o f  the p i8 and bp26 was visible 
following induction with zero concentration o f  IPTG.
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Figure 4.15: IPTG concentration optim isation fo r  induction o f p  18 expression in  XL- 
10 Gold E. coli. Lane M : Sigma wide-range molecular weight markers; Lane 1: p l8  
induction using Im M  IPTG; Lane 2: p i8 induction using 0.5mM IPTG; Lane 3: p I8  
induction using 0. Im M  IPTG ; Lane 4: p l8  induction using 0.05mM IPTG; Lane 5: 
p l8  induction using 0. O lmM IPTG; Lane 6; p l8  induction using OmM IPTG. A band 
at 18kDa is clearly visible fo llow ing  induction w ith each o f the IPTG concentrations.
Table 4.1: IPTG concentration optim isation fo r  use w ith the expression o f p  18. The 
levels o f p i8 expression, expressed as a percentage o f the total protein concentration, 
are shown a t each IPTG concentration.
IPTG  concentration 
(mM)
1 0.5 0.1 0.05 0.01 0
p l8  expression 
(%  of total protein)
6 17 13 13 14 10
1 9 0
Figure 4.16: IPTG concentration optim isation fo r  induction o f bp26 expression in 
X L-10 Gold E. co li. Lane M : Sigma wide-range molecular weight markers; Lane 1: 
bp26 induction using Im M IP T G ; Lane 2: bp26 induction using 0.5m M IPTG; Lane 
3: bp26 induction using O .lm M IPTG ; Lane 4: bp26 induction using 0.05mMIPTG; 
Lane 5: bp26 induction using 0.0Im M  IPTG; Lane 6; bp26 induction using OmM 
IPTG. A band at 26 kDa is clearly visible fo llo w ing  induction w ith each o f the IPTG  
concentrations.
Table 4.2: IPTG concentration optim isation fo r  use w ith the expression o f bp26. The 
levels o f bp26 expression, expressed as a percentage o f the total protein 
concentration, are shown a t each IPTG concentration.
IPTG concentration 
(mM)
1 0.5 0.1 0.05 0.01 0
bp26 expression 
(%  of total protein)
24 32 29 18 19 18
1 9 1
4.2.7 Optimisation of sonication conditions
Following intracellular protein expression the bacterial cells must be lysed to isolate 
the recombinant protein. For the isolation o f  inclusion bodies the pelleted bacteria 
were resuspended in denaturing buffer, containing 8M urea, and then sonicated. 
Sonication involves pulsing the cells with a high voltage current, which perforates the 
cell membrane and allows the cell contents to be released. However, the bacterial cells 
should only be sonicated for the minimum time necessary because prolonged 
sonication may destroy the protein and cleave the 6xHis tag. Therefore, the optimum 
sonication time for the isolation o f  the p i8 and bp26 proteins from XL 10-Gold E. 
coli was determined.
Expression cultures o f  the X L-10 Gold E. coli, harbouring pQE-60 encoding the p i8 
or bp26 proteins, were prepared, as described in Section 4.2.6, except the cultures 
were induced upon addition o f  0.5mM IPTG and incubated at 37°C for four hours, 
lm l samples were taken and following centr iigation, at 13,000rpm for 15 mins, the 
pelleted bacteria were resuspended in 200p.l o f  denaturing buffer. The resuspended 
bacteria were then sonicated with at 220W, for between 0 - 6 0  secs and the 
supernatants (following centrifugation at 13,000rpm for 15 mins) were analysed by 
SDS-PAGE.
Fig. 4.17 shows the optimisation o f  sonication conditions for the isolation o f  p l8 from 
XL 10-Gold E. coli. The intensity o f  the 18kDa band gradually increased as the 
sonication time increased up until 30 seconds, after which time the band intensities 
levelled off. Suggesting that a 30 second sonication pulse was optimal for the 
isolation o f  p i8 . Determining the levels o f  p i8 expression for each sonication time, 
using ImageJ, also confirmed 30 secs was optimal (Table 4.3).
Fig. 4.18 shows the optimisation o f  sonication conditions for the isolation o f  bp26 
from XL 10-Gold E. coli. The intensity o f  the 26kDa band also gradually increased as 
the sonication time increased, with a 20  second sonication appearing optimum. 
ImageJ analysis on the levels o f  protein expression at each sonication time also 
confirmed that a 20 second sonication was optimal for the isolation o f  bp26 (Table
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Figure 4.17: Optimisation o f sonication conditions fo r  the isolation o f p  18 from XL- 
10 Gold. iMne M : Sigma wide-range molecular weight markers; Lane I :  Isolation o f 
p l8  using 0 sec sonication; Lane 2: Isolation o f p 18 using 10 secs sonication; Lane 3: 
Isolation o f p l8  using 20 secs sonication; Lane 4: Isolation o f p I8  using 30 secs 
sonication; Lane 5: Isolation o f p !8  using 40 secs sonication; Lane 6: Isolation o f 
p !8  using 50 secs sonication; Lane 7: Isolation o f p !8  using 60 secs sonication. A 
band representing the p I8  is clearly visible at 18kDa.
Table 4.3: Optimisation o f sonication conditions fo r  the isolation o f p  18 from  X L-10 
Gold E. coli. The levels o f p  18 expression, expressed as a percentage o f the tota l 
protein concentration, are shown a t varying sonication times ranging from  0 - 6 0  
seconds.
Sonication time 
(seconds)
0 10 20 30 40 50 60
p l8  expression 
(%  of total protein)
10 13 14 17 17 17 15
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Figure 4.18: Optimisation o f sonication conditions fo r  the isolation o f bp26 from  XL - 
10 Gold E. coli. Lane M : Sigma wide-range molecular weight markers; Lane 1: 
Isolation o f bp26 using 0 sec sonication; Lane 2: Isolation o f bp26 using 10 secs 
sonication; Lane 3: Isolation o f bp26 using 20 secs sonication; Lane 4: Isolation o f 
bp26 using 30 secs sonication; Lane 5: Isolation o f bp26 using 40 secs sonication; 
Lane 6; Isolation o f bp26 using 50 secs sonication; Lane 7: Isolation ofbp26 using 60 
secs sonication. A band representing the bp26 is  clearly visible a t 26kDa.
Table 4.4: Optimisation o f sonication conditions fo r  the isolation o f bp26 from  X L-10 
Gold E. co li. The levels o f bp26 expression, expressed as a percentage o f the total 
protein concentration, are shown a t varying sonication times ranging from  0 - 6 0  
seconds.
Sonication time 
(seconds)
0 10 20 30 40 50 60
bp26 expression 
(%  of total protein)
10 15 20 16 16 16 19
1 9 4
4.2.8 Time-course analysis on the expression of p l8  and bp26
Following optimisation o f  the various parameters for protein expression a time-course 
analysis on the level o f  protein expression was carried out in order to determine the 
optimal induction time for protein expression This is important in order to get a 
balance between the amount o f  soluble protein in the cells, the formation o f  inclusion 
bodies, and protein degradation. By checking the recombinant protein present at 
various times after IPTG induction, the optimal induction period can be established. 
This section describes the time-course analysis on p l8 and bp26 expression in XL 10- 
Gold E. coli.
Expression cultures o f  the X L-10 Gold E. coli, harbouring pQE-60 encoding the p i 8 
or bp26 proteins, were prepared, as described in Section 4.2.7, except that following 
IPTG induction, 1ml samples were taken every hour, for up to five hours, and then 
following overnight (20 hours) induction. A 1ml non-induced control sample was also 
taken prior to IPTG addition. Each o f the 1ml samples was centrifuged, at 13,000rpm 
for 15 mins and the pelleted bacteria resuspended in 200j.il o f  denaturing buffer. The 
resuspended bacteria were then sonicated for 30 secs for p i8 or for 20  secs for bp26, 
at 220W, and the supernatants analysed by SDS-PAGE.
SDS-PAGE analysis on the time course analysis for p i 8 and bp26 suggested the 
optimal induction period for protein expression was 4 hours, after which no major 
difference in the levels o f  protein expression were observed (Figs. 4.19 and 4.20). 
ImageJ analysis on the band intensities o f  the SDS-PAGE was used to determine the 
level o f  p i 8 and bp26 expression, as a percentage o f  the total protein content (Tables 
4.5 and 4.6). The ImageJ analysis confirmed that a 4-hour induction period was 
sufficient with levels o f  p l8 and bp26 expression at 25% and 19%, respectively, o f  
the total protein content. Although slightly higher levels o f  p l8 (28%) and bp26 
(21%) expression were observed following a 5-hour induction period, 4 hours was 
selected to minimise proteoltytic degradation o f  the proteins and 6xHis tag cleavage.
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Figure 4.19: Time course expression analysis on p i8 in  X L -10 Gold E. co li. Lane M : 
Sigma wide-range molecular weight marker; Lane 1: Non- induced control; Lane 2: 
p l8  expression I  hour post IPTG induction; Lane 3: p l8  expression 2 hours IPTG  
post induction; Lane 4: p l8  expression 3 hours post IPTG induction; Lane 5: p l8  
expression 4 hours post IPTG induction; Lcme 6: p l8  expression 5 hours post IPTG  
induction; Lane 7: p l8  expression fo llow ing  overnight induction using IPTG. A band 
representing the p l8  is clearly visible a t 18kDa.
Table 4.5: Time course expression to determine optimum induction period fo r  the 
expression o fp l8 fro m  XL-10 Gold E. co li. The levels o f p !8  expression, expressed as 
a percentage o f the to ta l protein concentration, are shown a t varying time intervals 
fo llow ing  IPTG induction.
Induction time 
(hours)
0 1 2 3 4 5 20
p i 8 expression 
(%  of total protein)
10 14 18 22 25 28 16
1 9 6
F igure 4.20: Time course expression analysis on bp26 in XL-10 G o ldE. co li. Lane 
M : Sigma wide-range molecular weight marker; Lane 1: Non- induced control; Lane 
2: bp26 expression I  hour post IPTG induction; Lane 3: bp26 expression 2 hours post 
IPTG induction; Lane 4; bp26 expression 3 hours post IPTG induction; Lane 5: bp26 
expression 4 hours post IPTG induction; Lane 6; bp26 expression 5 hours post IPTG  
induction; Lane 7: bp26 expression fo llow ing  overnight induction using IPTG. A band 
representing the bp26 is clearly visible a t 26kDa.
Table 4.6: Time course expression to determine optimum induction period fo r  the 
expression ofbp26 from  XL-10 G oldE. coli. The levels ofbp26 expression, expressed 
as a percentage o f the to ta l protein concentration, are shown a t varying time intervals 
fo llo w ing  IPTG induction.
Induction time 
(hours)
0 1 2 3 4 5 20
bp26 expression 
(%  of total protein)
10 11 14 19 19 21 22
1 9 7
4.2.9 Immobilised metal affinity chrom atography (IMAC) purification of p l8  
and bp26
Following expression o f  the p i 8 and bp26 from pQE-60 a C-terminal 6xHis-tag was 
incorporated into the recombinant proteins (See section 4.1). This enables the use o f  
immobilised metal chelating affinity chromatography for the purification o f  the His- 
tagged recombinant proteins. This section describes the use o f  N i-NTA (nickel- 
nitrilotriacetic acid) resin (QIAgen) for the purification o f  the 6xHis-tagged p i 8 and 
bp26, from X L-10 Gold E. co li lysates under denaturing conditions.
A batch purification method was chosen for the purification o f  the recombinant p i 8 
and bp26 proteins as described in section 2.3.16. 5ml o f  the N i-NTA resin was 
incubated with 20ml o f  the cytoplasmic lysate from the X L-10 Gold cells for 90 min 
at room temperature on an over-end rotor. The resin was then washed three times with 
20ml denaturing buffer, pH 6.3, and the immobilised recombinant proteins eluted in 3 
x 3ml fractions using denaturing buffer, pH 4.5. The purified fractions were pooled 
and then dialysed into PBS, overnight at 4°C.
Fractions from each stage o f  the purification process, including the wash steps, were 
analysed using SDS-PAGE. Figure 4.21 shows the IMAC purification o f  p l8 with the 
eluted fragments pooled and analysed in Lane 9. The gel picture clearly shows that the 
purity o f  the p i8 greatly increased following the IMAC purification with one main 
band visible at 18kDa. Figure 4.22 represents the SDS-PAGE analysis on the IMAC 
purification o f  bp26, with the eluted fragments pooled and analysed in Lane 9. The 
purity o f  the bp26 is greatly improved following the IMAC purification when 
compared with the cell lysate (Lane 1). However, the pooled eluted fractions 
contained some contaminating E. co li proteins.
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Figure 4.21: SDS-PAGE analysis on the IM AC  purifica tion  o fp l8  using a p H  shock 
elution. Lane M : Sigma wide-range molecular weight markers; Lane 1: Crude
cytoplasmic lysate from  X L-10 Gold fo llow ing  p i  8 expression; Lane 2: Flow-through 
from  IM AC  column fo llow ing  application o f crude lysate; Lane 3, 4 and 5: Wash 
fractions 1, 2 and 3, respectively; Lane 6, 7 and 8: Elutions 1, 2 and 3, respectively; 
Lane 9: P urified  p l8 , consisting o f elutions 1, 2 and 3 pooled. A band at 18kDa is 
clearly visible in  each o f the 3 elutions and in  the purified  sample.
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Figure 4.22: SDS-PAGE analysis on the IM A C purifica tion  o f bp26 using a p H  shock 
elution. Lane M : Sigma wide-range molecular weight markers; Lane 1: Crude
cytoplasmic lysate from  XL-10 Gold fo llow ing  bp26 expression; Lane 2: Flow­
through from  IM AC  column fo llow ing  application o f crude lysate; Lane 3, 4 and 5: 
Wash fractions 1, 2 and 3, respectively; Lane 6, 7 and 8: Elutions 1, 2 and 3, 
respectively; Lane 9: P urified bp26, consisting o f elutions 1, 2 and 3 pooled A band 
at 26kDa is clearly visible in  each o f the 3 elutions and in the pu rified  sample.
4.2.10 Nucleotide and amino acid sequence analysis on the recombinant p l8  and 
bp26 proteins cloned in pQE-60
The nucleotide sequence o f  the cloned p l8  and bp26 genes were obtained as described 
in section 2.3.10. The pQE-60 plasmid D NA  containing the p l8  and bp26 inserts was 
purified from the X L-10 Gold E. coli. A  Comfort read (in both directions) was then 
obtained from MWG-Biotech on each plasmid and the nucleotide sequence returned. 
The amino acid sequences were then deduced from the nucleotide sequences using a 
web-based translate tool (See section 2.2.11).
Nucleotide sequence comparisons between the cloned p i 8 and the previously 
sequenced p l8  genes revealed that the cloned p i 8, the B. melitensis p i8 and the B. 
abortus p i8 were identical with only a two base pair difference with the B. suis p i8 
(Fig. 4.23) suggesting 99.6% homology between the 4 analysed nucleotide sequences. 
However, amino acid sequence analysis revealed that the four proteins were identical 
(Fig. 4.24) suggesting 100% homology between the four aligned amino acid 
sequences.
Nucleotide sequence comparisons between the recombinant bp26 and the previously 
sequenced bp26 genes revealed a 3 base pair difference between the cloned bp26 and 
two B. melitensis sequences (U30815 and U45996), a 4 bp difference with the B. suis 
sequence and a 6 bp difference with B. melitensis 16M gene (Fig. 4.25) suggesting 
99.1% homology with the 5 aligned sequences. Whereas, amino acid sequence 
analysis suggested that the cloned bp26 displayed 99.6% homology with the 
previously sequenced genes (Fig. 4.26).
2 0 1
p i  B _ n l a n e d  
Q d  4  6  6  0 J J _ m e  1  i t  e n  a  i  h  
Z 4  6 B 6 4  _ P _ a b o r t T ] B  
Q i  4  C C B _ B _ a u i _ B
20 Jo
AAl ■ AftAr-.CTOTCCiSAAXAAlJA.^ATOCTTTAAAATeiiCATTCATTCAGijCCCu-.CTiiOe AOSC.Cii ACA-Tl. 
HJkCi. AAAG--TGT'? -aAA'-AA-JACATCCTTTAAAAT'CiiCAT5! * AT TCAGOCCCG'CTftGi' ACGCCGA.: ATCC 
A ACr AAA'SCTGTC *-G A AC AAG AC ATCCTTT AAAAT C^CAT TC Al TCAOOCCCGCTGGC ACuCCliAC ATC 
AACCAAJ.CSC TGTCCOI'.ACAAGACATC.CTTTAAAATCGi'.ATTCA’ TC AOQCC^O CTOGC ACGO CilAC ITC
Z 4  6 B 6 4 _ J J _ a b a r t u a  
Q d 4 f i f i B _ B _ « u i a
• O 90 100 110 12 0 1 »0 140
p L B _ c l o n e d
Q i 4 6 6 B _ £ _ j n j e l i t e i i e i e  Q
TGACGAAGCGCGCAAAAGCTTTGTCGCCGAACTGGCCGC A A AG ACgGGTGGCAGCGTCGAGGTAGAGAT 
TGACGAAGCGCGCAAAAGCTTTGTCGCCGAACTGGCCGCAAAGAC^GGTGGCAGCGTCGAGGTAGAGAT 
TGACGAAGCGCGCAAAAGCTTTGTCGCOGAACTGGCCGCAAAGAcgGGTGGCAGCGTCGAGGTAGAGAT 
t g a c g a a g c g c g c a a a a g c t t t g t c g c c g a a c t g g c c g c a a a g a c 3g g t g g c a g c g t c g a g g t a g a g a t
i s o 1 4 0 I T © 1 9 0 1*0 2 0 0 210
p i  8 _ c l o n e d  
Q 4  4 G  f i  B _ B _ m e l i t « T i a i a  
2 4  6  B  6 4  _ f l i w r t u u  
Q I 4 6 f i B _ B _ a u i a
TTCGACGTGCCGGGTGCATATGAAATTCCCCTTCACGCCAAGACATTGGCCACAACCGGGCGCTATGC 
kTTC GACGTGCCG GOTGCATA T  GAAATTCCCCTTCACGCC A AG AC ATTGGCCAGAACCGGGC GCTATGC A 
lTTC GACG TGCCG GGTGC AT AT OAAATTCCC CTT*. ACtiCC A AG AC AT TGGCCAGA AC £ GGGCGCT AT GC A 
TTC 6ACGTGCCG GGTGCA7AT GAAATTCCC C TTC ACGCC AAGACATTC GCCA'i AACC G G G C G C T AT GC,‘
p L  B _ c l o n e d  
Q 4 4 f i G 8 _ £ _ _ p L e I i t e n a i a  
2 4  6  B  6 4  _ B _ a b o r t u a  
Qd 4  6  G B _ B _ a u i a
2 9 0
CCATCGT ;GGTGCGGCCTTCCiTG AT CGACGGCGuC ATC T ATCGT CAT GATTTCGTOGCG AC iyflCCGTT 
CC AT :GTC<3GTGCGGCOTTCG'TGAT!CGACG;X3CGgCATCTATCGTCATG ATTTCGTGGCGACGGCCGTT 
CC ATCGTCGGTG CGGCCTTCO T A T  CGACGGCil JJc ATCT ATCGTCATGATTTCGTGGCGACGGCCGTT 
CCATCGTCGGTGCGGOCTTCGTGATOGACGGCGlCATCTATCG'TCATGATTTCGTGGCGACGGCCGTT
2  9 0 3 0 0 3 1 0 3 2  0 3 3  0 3 AO
p i  B _  c l o n e d .
Q d 4 C f i B _ J B _ m f f l i . ' f c e n a i B  
Zd 6 B  B 4 _ B _ a b o r t u a  
Q d  4  6 6 B _ B _ a u i a
c a a c g g c a t g a t g c a g g t g c a ;g c t t g a a a c g g a a g t g c c :<j g t g c t g a g c g t c c t g c t g a c g c c g c a c c  
rCAAi. GGC ATGATGC AGGTGC AGCTTGAAAC GGAAGTGCCGGTGCTGAGCGTCGTGCT GACGCCGCACC 
rcAACGGCATGATGCAGGTGCAGCTTGAAACGGAAGTGCCGGTGCTGAGCGTCGTGCTGACGCCGCACC 
CAACCGC.ATGATGCAGGTGCAGCTTGAAACGGAAGTGCCGGTGCTGAGCGTC6TGCTGACGCCGCACC
p i B _ c l a n e d
Z 4  6 B C 4 _ f l _ J a b a r f c u a
Q d  C  f i f i B _ J l _ B u i «
3  4 0 3 * » 0 )IO 3 9 0 40 0 4  1 0 * 3 0
TTCICATGAAAGC AAGG AGC ATC ACGJkCTTCTTCCATGCTCATTTCAAuGTGAAGGGCGTGGAAGCGGC , 
TTCCATGAAAGC AAGG AGC AT C ACG ACTTCTTCC ATGCT C ATT TC AAG GTGA AGGGCGTG<*AAGCGGCC 
TTCCATGAAAGC AAGG AGC AT CACGACTTC TTCC ATGCT CATT TC AAGGTGA AGGGCGTGG AAGCGGCC 
TTCCATGAAAGC AAGGAGC ATiCACiV ACTTC TTCC ATGCTC ATT TCAAGGTG AAGGGC GTGfl AAGCGGCC1
p L B _ c l a n e d  
Q i  4  6  6  B  _ & _ j n e  1  i t «  ■  i  ■  
Z 4 G B G 4  _ B _ f l b o r t u o  
Q 4 4  6 6 B _ B _ a u i n
ATGCCGC CTTGCAGAT CGTGAGCGAGCGCAGCCGCATCGCCGCGCTTGTC 
IATGCCGCCTTGC AGATCGTGAGCGA^GCGCAGCCGCATCGxrCGCGCTTGTC 
:ATG,CCGCCTTGC AGATCGTGAGCGAGCGCAGCCGCATCG-CCGCGCTTGTC 
ATGCCGCCTTGCAGATCGTGAGCGAGCGCAGCCGCATCGCCGCGCTTGTC
Figure 4.23: Nucleotide sequence alignment on the cloned p i8. The p i8 nucleotide 
sequence was aligned w ith 3 previously sequenced p i8 genes from  B. melitensis 
(Q44668), B. abortus (Z46864) and B. suis (Q44668).
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Figure 4.24: Amino acid sequence alignment on the cloned p i 8. The p i  8 amino acid 
sequence was aligned w ith 3 previously sequenced p l8  proteins from  B. melitensis 
(Q44668), B. abortus (Z46864) and B. suis (Q44668).
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Figure 4.25: Nucleotide sequence alignment on the cloned bp26. The bp26 nucleotide 
sequence was aligned w ith 4 previously sequenced bp26 genes from  B. melitensis 
(U30815, U45996andB.mel_16M), andB. suis (B suis genome).
203
1 0 2 0 3 □ «0 t o € 0 70
b p {2 6  c l o n « d
T J 3 D 0 1 5 _ j a _ m e l
U 4 5 9 9 6 _ f t _ j i L e l
8 i _ C h x o o L Q  a o m e  
B _ p u i  B _ g e n o n i e _ p e q
a  I I F L A  A S F  S T  I M » . V  , A F  S L  P  J i F A O E  M O K T T  3P  A  f t  I S V T O  EF1KNT A  S  P  D M A  I  L I I L S  V L R ^ A h T A *  E
3 i l F L A  A S F  S T  t H L ' . ' G A F  s  L  F  A  F  A 1 j  E I I  i ; K T  T  v P  A  P  I  A  V  T  G  E 0 M N T  A  S I C i K A  I L I I 1. S  V  L t t Q A K T  A  R*K 
3 I I F  L A  A  *3 F  , - T  I H L V  3 A  F  S  L  P  A F  A O E  H - ' ( I t T  v P  A F  I A V T G E ^ r t M T A S  i  D M A  [  L I U .5 V L R ( J  A K T A U  E  
II F  L A  A  3 F  S T  I M L V . 3A F  3 L P  A F  A v m i Q t - i T T O F  A F  I A V T G e M h M T J  - - P D N A I  L H L S  V  U R O  A K T A U  B  
3 H  F  L  A  A  3 F  3 T  I  H  L  V  C  A  F  S  L  p  A  F  A  ■_■!! H O K T  T O P  A R T A V T  .3 b S h M T  A  S  F  D N  A I  U I  L S  V  L f t C A K T  A R  E
b p 2 6 _ c l o n e c i
U 3 0 B 1 5 _ f t _ m * l  
U45996_Bjm1 
B j n e l _ l  a C j C h r c m o  b o :  
B _ b  u i  a _ g e n o m e _ i  e q
1)0
TAWHEAKT KVLDANK KAGT EDR D I.QT GG I HI QP IY V Y P DIi*KHHIrKEFT I TGY S VST SL’TVRVRE LAW Vi 
TAHH’EAMT K V LDANKKACI E D RDLQT GG I If I QP t YVYFDD KWH LKEPT I TG Y S:VST 5 LTVRVRELAH VS 
TAMH E ANT KVLDANKK AG I E DR.I* LQTGG I H I OP t Y VYPI.D KHH LK.EPT I TGTfS VSTS L T V R V R BLAH VG 
TA1I1IEAKT KVLDA_MKK*Gr E&RtiLjTGGIHI QJ>r Y VYPDDKHHLKEPTtTGYSVSTSLTVftYRELAHVG 
TAllll EAMT KVLDA M.KKAO lEDftlf LOT GG III F  y P  I YVYPDDKHHLK8FT I TGY S V3T S  LT VRYRE LA11.V
b p 2  6 _ _ c l o n t d
U 3 D B 1 5 _ B _ j n e l  
D d 5996_ a _ j n « s l  
B _ j a e  1 _ 1  f f i ( _ C h r o m o  b o  
B _ ^ u i a _ g e n a i n e  _ p c q
n o
sI J L U E  S V T L G V W Q G G D L H  L V H L  H P  S  A V  1 1 1 E  A R  K R A V  A i l  A  I  A K A  R T  L A D  A A G V G I i G R  V V E  I S E L S R P P K P  
I  L [ < E  S V T L G V H Q G G D L H  LVN& tl I *  S  A V  I  H E  A R : K R  A  V A M  A  I  A  K A * t  L A L A A G V G  L G R V V E  I S E L S R P P K P  
i l L O E S V T  L G  V j I Q G G b L H  L V H L  U P S  A V  I  H E  A P . K R  A  v ' a H A  I  A J l A K T  L A G  A A - G Y G L G P V V f i  I  S  E L S R F P K P M  
i r i . b g  S V T L ' G V H Q G G & L H  L V H L H P 5  A Y  I  H E  A R K  R  A  Y * A H  A I A K A K T  L A l i  A A G V G L G  R  V Y S  r  S E L S R P P M P t f  
t  L B B  S V T L G V H 0 G G I 1  L H  L V W D H P S A V  I  H E A R K R A Y A h  A  I  A K A K T  L\b A  A G  V G L G  R V V . B  I  S E L 5 R P P H P I
II T P .  A  
H T R A  
HTRA 
H T R A  
H T R A
! b p 2  f i _ d a a e d  
U 3 O 0 1 5 _ B _ j n e l  
T M 5996_ B _ n i e l  
B _ j m e l _ l  S L C h r a a o  b o  m e  
B j  u i  s _ g e n o m e j e q
P  .3 *5P R T M L A  A  A  P
I  A
R G >  
R <3 > 
P  G
2F
,'F
j F
P
R
P
T
T
T
{(
M
( (
L  A  A  A  i  
L A A A P  
L A  A  A  P
I  A R G } F R T H L  A  A  A  t
2  3  0
5 V P  r A A G E  
¿IVTF jZHHaH £ 
S  V P  I  A  A  E
sVpIaage3 V P  I A  A  ■ j  E
v s v v v f  E  r
V  G V V V F  E  I
V  i  v V V F  E  r
W F  £  I
V  E  V V V F  E  I
22 0
Figure 4.26: Amino acid sequence alignment on the cloned bp26. The bp26 amino 
acid sequence was aligned w ith 4 previously sequenced bp26 proteins from  R  
melitensis (U30815, U45996 andB.mel_16M), andB. suis (B suisgenome).
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4.2.11 Immunogenicity studies on the recombinant p l8  and bp26 expressed in 
XL-10 Gold E. co li
Western blot analysis was then carried out on the two recombinant proteins, p i 8 and 
bp26, to establish the antibody binding activity and immunogenicity o f  the 
recombinant proteins.
The recombinant proteins were electrophoresed alongside a prestained molecular 
weight marker using SDS-PAGE as described in Section 2.2.11. Figure 4.27 A  shows 
the Coomassie stained gel with bands representing the p l8  (Lane 2) and bp26 (Lane 
3) clearly visible at 18 and 26kDa, respectively. The electrophoresed proteins were 
transferred to nitrocellulose for western blot analysis as described in Section 2.2.13. 
The nitrocellulose blots were then probed with an anti-His antibody and three 
standard serum samples, the DeVeere Hunt serum, the National Standard Serum 
(NSS) and a standard negative serum. Initially, a Western blot was carried out using 
an anti-His antibody to ensure the 6xHis tag remained in place following IMAC 
purification and to confirm that the recombinant proteins were expressed in the 
correct reading-frame. Figure 4.21 B represents the blot probed with the anti-His 
antibody with bands are clearly visible at 18kDa and 26kDa representing the p l8  and 
bp26, respectively. The usefulness o f  the recombinant proteins as diagnostic markers 
for a bovine brucellosis infection was also initially investigated using Western 
blotting. The nitrocellulose containing the transferred recombinant proteins was 
probed using two Brucella-positive serum standards, the DeVeere Hunt Serum and 
the National Standard Serum (NSS) and one standard negative serum. Bands at 18kDa 
and 26kDa are clearly visible following Western blot analysis with the two positive 
sera, the DeVeere Hunt Serum (Figure 4.21 C) and the NSS (Figure 4.21 C). 
However, no bands were visible on the Western blot using the standard negative 
serum (Figure 4.21 E), thus, indicating the discriminatory capabilities o f the 
recombinant proteins between Brucella-positive and negative serum samples.
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Figure 4.27: SDS-PAGE and Western blot analysis on the high-level expression o f 
p l8  (Lane 2) and bp26 (Lane 3) in XL10 Gold E. co li (with prestained molecular 
weight markers in Lane 1). (A) SDS-PAGE analysis on the expression o f p I8  and 
bp26, w ith bands clearly visible 18kDa and 26kDa, respectively. (B) Western blot 
analysis on the expression o f p  18 and bp26 using an anti-H is antibody to probe the 
nitrocellulose, with bands clearly visible a t 18kDa and 26kDa, respectively. (C) 
Western blot analysis on the expression o f p i8 and bp26 using the De Veere Hunt 
Serum, a Brucella-positive standard sera, to the probe the nitrocellulose, w ith bands 
clearly visible a t 18kDa and 26kDa, respectively. (D) Western blot analysis on the 
expression o f p  18 and bp26 using the N ational Standard Serum, a Brucella-positive 
standard sera, to the probe the nitrocellulose, w ith bands clearly visible at 18kDa and 
26kDa, respectively. (D) Western blot analysis on the expression o f p l8  and bp26 
using the Brucella-negative standard sera, to the probe the nitrocellulose, with no 
bands visible a t either 18kDa or 26kDa.
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4.3 Discussion
The main focus o f  this chapter was the cloning and expression o f  two Brucella- 
specific proteins, p i8, an 18kDa cytoplasmic protein, and bp26, a 26kDa periplasmic 
protein. The recombinant proteins were then investigated for use as diagnostic 
markers o f  bovine brucellosis. Their subsequent use in the development o f  an 
immunoassay for the detection o f  bovine brucellosis w ill also be investigated (See 
Chapter 6).
Total genomic D N A  was isolated from heat-killed B. abortus 45/20 cells and used as 
the template D N A  for PCR amplification o f  the specific genes. Studies using pulse- 
field gel electrophoresis (PFGE) have revealed that the Brucella  genomes consist o f  
two circular chromosomes o f  2.1Mb and 1.15Mb (Jumas-Bilak et a l, 1998 and 
Michauex et al., 1993). The quality o f  the isolated genomic D N A  was assessed by 
agarose gel electrophoresis (Figure 4.7) with only one distinct band visible. The 
extremely large size o f  the two chromosomes makes it impossible to separate them 
using conventional gel electrophoresis. However, the presence o f  only one band 
confirmed that the D NA  was o f  good quality and that no shearing o f  the DNA  
occurred during the isolation process.
The genes encoding the p i8 and bp26 Brucella-specific proteins were then PCR 
amplified using the total genomic D N A  as the template. Forward and reverse primers 
were engineered for each gene based on nucleotide sequences previously submitted to 
GenBank. The p 18-specific primers were based on the nucleotide sequence 
(Accession number Q4468) o f  an 18kDa Brucella-specific lumazine synthase 
previously submitted to GenBank by Goldbaum and associates (1999). The bp26- 
specific primers were based on the nucleotide sequence o f  a 26kDa periplasmic 
protein from B. melitensis (Accession number U45996) previously submitted to 
GenBank by Cloeckaert and associates (1996). An N co l restriction site was 
engineered into the forward primers and a Bam H l site into the reverse to enable the 
directional cloning into pQE-60. Since proteins expressed from pQE-60 contain a C- 
terminal 6xHis tag the genes were cloned in frame with the 3' sequence encoding the 
6xHis tag. The authentic ATG start codons within the protein sequences were used to 
initiate protein expression using the optimised Shine Dalgarno region o f  the pQE-60.
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The sequence o f  the forward and reverse primers are given in Table 2.10 with the 
BamHl / N co l restriction sites and the authentic start codons highlighted.
A  standard PCR reaction was then used to amplify the genes encoding the pi 8 and 
bp26 proteins. Initially, a temperature gradient PCR was carried out in order to 
determine the optimum annealing temperature for use with the specific primers. 
Standard PCR reactions were carried out with varying annealing temperatures ranging 
from 58 -  65°C. An annealing temperature o f  65°C was found to be optimum for the 
specific amplification o f  the genes encoding p l8  and bp26 (Figure 4.8). Failure to 
optimise the annealing temperature would result in non-specific amplifications, which 
would interfere in the later stages o f  cloning. Following PCR optimisation the genes 
encoding the p i8 and bp26 genes were amplified using D N A  Taq polymerase as 
described in Section 2.3.3 (Fig. 4.9). The PCR amplified genes were then cloned 
using the TA cloning kit, which provides a one step cloning strategy that allows the 
direct insertion o f  a Taq-polymerase-amplified PCR product into the pCR2.1 plasmid. 
The fresh PCR products, containing the deoxyadenosine (A) overhangs, were ligated 
into the linearised pCR2.1 vector containing the 3' deoxythymidine (T) overhanging 
residues and transformed into competent INVaF' E. coli. The presence o f  the multiple 
cloning sites within the LacZ gene o f  the pCR2.1 vector enables blue/white colony 
selection. The LacZ gene encodes the enzyme beta-galactosidase, which metabolises 
X-gal resulting in the formation o f  blue colonies. However, positive transformants 
containing the cloned insert disrupt the LacZ gene and when grown in the presence o f  
X-gal appear colourless. Following the selection o f  positive transformants the 
presence o f  the 485bp and 793bp cloned inserts (encoding p i 8 and bp26, respectively) 
within the pCR2.1 vector were confirmed following a B am H l/N col restriction digest 
(Figure 4.10). The B am H l/N col restricted genes encoding the p i8 and bp26 were 
then gel-purified and directionally cloned into the high-level expression vector pQE- 
60, which was previously linearised using a BamHl /  N co l restriction digest. The 
pQE-60 plasmids containing the cloned inserts were then transformed into CaCh- 
competent XL-10 Gold E. coli, which are fast growing E. co li that allow a sufficiently 
high transformation rate. Once again the presence o f  the 485bp and 793bp cloned 
insert were confirmed following a B am H l/N col restriction digest o f  the pQE-60 
plasmid (Fig. 4.11).
208
Following the successful cloning o f  the p i8 and bp26 genes into the high-level 
expression vector pQE-60 the suitability o f  the XL-10 Gold E. co li host strain was 
determined. Initial small-scale expression cultures were carried out on the p i8 and 
bp26 XL-10 Gold E. co li clones as described in Section 2.3.11. Following protein 
expression the cell lysates were analysed using SDS-PAGE. Figures 4.12 and 4.13 
show the small-scale expression cultures on the p l8  and bp26, respectively. A strong 
band at 18kDa is visible in 4 out o f  the 5 p i 8 clones and a band at 26kDa is clearly 
visible in each o f  the 5 bp26 clones analysed, confirming the suitability o f  the XL-10 
Gold E. co li as a host strain for the expression o f  p i8 and bp26 from the high-level 
expression vector pQE-60.
High-level protein expression within E. co li host strains may result in the formation o f  
insoluble aggregated folding intermediates. These inclusion bodies must be 
solubilised using strong dénaturants such as 8M urea or 6M guanidine hydrochloride, 
resulting in an inactive protein. Active proteins can be isolated from inclusion bodies 
but following isolation under denaturing conditions the dénaturant must be removed 
under optimal conditions for protein re-folding. However, following the refolding 
process the yield o f  renatured protein can be relatively low. Other approaches for the 
expression o f  soluble proteins include the co-exprerssion o f  chaperones (Georgiou 
and Valax, 1996 and Hannig and Makrides, 1998), which aid in protein folding and 
the use o f  gene fusions, which consist o f  the target protein fused to a carrier protein 
such as E. co li thioredoxin (TRX); (LaVallie et a l, 1993) and glutathione S- 
transferase (GST); (Ghosh et al., 1995 and Smith and Johnson, 1988). However, 
protein re-folding, co-expression with chaperones and gene fusions can be time­
consuming, ineffective and in some cases, depending on the desired use, unnecessary. 
Solubility determination studies on the recombinant p i8 and bp26 proteins (Fig. 4.14) 
indicated that the high-level expression o f  p i 8 and bp26 resulted in the formation 
insoluble exclusion bodies, which could be solubilised using 8M urea (Lanes 3 and 5, 
respectively). A web-based bioinformatics program, to determine the solubility o f  the 
recombinant proteins (Harrison, 2000), predicted that the p i8 protein had a 62% 
chance o f  solubility and that the bp26 protein had an 80% chance o f  insolubility, 
confirming the need for denaturing buffer, containing 8M urea, to ensure high-level 
recovery o f  p i 8 and bp26 following expression in XL-10 Gold E. coli.
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Following confirmation on the suitability o f  the X L-10 Gold as an expression host 
and the need for denaturing buffer for the isolation o f  each recombinant protein 
factors affecting the expression and recovery levels o f  the recombinant proteins were 
optimised individually for the p i8 and the bp26. Theses parameters included IPTG 
concentrations, sonication conditions and incubation time post induction.
Expression o f  recombinant proteins from pQE-60 is under the control o f  an optimised 
promoter-operator element consisting o f  the phage T5 promoter, which is recognised 
by E. co li RNA polymerase, and two lac operator sequences, which increase lac 
repressor binding. The extremely high transcription rate initiated at the T5 promoter 
can be effectively regulated and repressed by the presence o f  high levels o f  the lac 
repressor. The lacP  gene contained on the F' episome o f  X L -10 Gold E. co li ensures 
the production o f  high levels o f  the lac repressor protein and tightly regulates 
recombinant protein expression. High-level protein expression from pQE-60 is rapidly 
induced upon addition o f  isopropyl-P-D-thiogalactoside (IPTG), which binds to the 
lac repressor protein and inactivates it. However, previous studies have demonstrated 
the need to optimise the concentration o f  IPTG so that the levels o f  protein expression 
and IPTG concentration are not toxic to the host cell (Liu et al., 1999). Therefore, the 
optimal IPTG concentration for the induction o f  p l8  and bp26 expression in XL-10 
Gold E. co li was determined. Varying IPTG concentrations ranging from 0.01 -  ImM 
were investigated for the high-level expression o f  p i8 and bp26. Figures 4.15 and 
4.16 show the SDS-PAGE analysis on p i8 and bp26 expression, respectively, with 
the highest-levels o f  expression observed following induction with 0.5mM IPTG. The 
band intensities on an SDS-PAGE were monitored, using ImageJ software, and used 
to estimate the concentration (as a percentage o f  the total protein content) o f  p i 8 and 
bp26 expressed at each IPTG concentration. Tables 4.1 and 4.2 indicate p i8 and bp26 
expression levels, respectively, which confirmed 0.5mM IPTG was optimal for the 
induction o f  p i 8 and bp26 production. Basal level expression o f  the p i 8 and bp26 was 
visible with zero concentration o f  IPTG.
High-level expression o f the recombinant p i 8 and bp26 proteins in X L -10 Gold E. 
co li resulted in the formation o f  insoluble intracellular inclusion bodies. Recovery o f  
the intracellular proteins involved resuspending the pelleted bacteria in denaturing
210
buffer and pulsing the resuspension with an electrical current using a sonicator. 
Sonication results in the perforation o f the cell membrane and allows the cell contents 
to be released. However, Ausubel and co-workers (1996) have reported that prolonged 
sonication can lead to co-purification o f  E  co li host proteins and breakdown o f fusion 
proteins. SDS-PAGE (Figs. 4.17 and 4.18) and Image J (Tables 4.3 and 4.4) analysis 
on the optimisation o f  sonication time suggested that a 30 and 20 sec sonication pulse 
was optimal for the isolation o f  p i 8 and bp26, respectively, from X L-10 Gold E. coli.
Time-course expression cultures were also carried out to determine the optimal 
induction period, post IPTG addition, for p i 8 and bp26 expression. Intracellular 
protein content is a balance between the amount o f  soluble protein in the cells, the 
formation o f  inclusion bodies and protein degradation. Analysis on the levels o f  
protein expression at hourly intervals post IPTG induction was used to determine the 
optimal induction period. SDS-PAGE (Figs. 4.19 and 4.20) and ImageJ (Tables 4.5 
and 4.4) analysis on the time-course expression cultures for p i 8 and bp26 suggested 
that a 4-hour induction period enabled sufficient levels o f  protein production. Slightly 
higher levels o f  p i 8 and bp26 expression were observed following a 5-hour induction 
period. However, the 4-hour induction period appeared satisfactory and minimised the 
risk o f  potential proteoltytic degradation and 6xHis tag cleavage.
The optimised parameters, as discussed above, were then applied for the large-scale 
production o f  the p i8 and bp26 recombinant proteins. Immobilised metal affinity 
chromatography (IMAC) was then used for the purification o f  the recombinant 
proteins, which contained C-terminal 6xHis tags. Figures 4.21 and 4.22 show the 
IMAC purification o f  the p l8  and bp26, respectively, were the use o f  a pH shock 
elution enabled the one-step purification o f  the recombinant proteins. The highest 
levels o f  purity were obtained for the p l8  protein with some contaminating proteins 
remaining following the purification o f  bp26. Certain E. co li proteins have been 
identified that may bind to IMAC columns under certain conditions. These proteins 
include superoxide dismutase, chloramphenicol acetyl-transferase, camp receptor 
protein, heat shock protein, host factor-1 protein and wondrous histidines-rich protein 
which contain 8, 12, 6, 14, 5 and 18 native histidines residues, respectively (Muller et 
al., 1998) and may account for the impurities obtained following the IMAC 
purification o f  the bp26. However, the IMAC purification did provide a suitable one-
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step purification strategy for the p i 8 and bp26 proteins with the purity o f  the proteins 
greatly increasing following pH elution (Lanes 9) in comparison to the denatured cell 
lysate (Lanes 1). The concentration o f  the purified proteins was then estimated using a 
BCA assay. A  standard curve was constructed using B SA  and concentration values 
for the purified protein obtained from it. The final concentration o f  the purified p i8 
and bp26 was 62.5pg/ml and 500pig/ml, respectively.
The genes encoding the p i8 and bp26 recombinant proteins were then sequenced and 
used to deduce the amino acid sequence. The 18kDa cytoplasmic protein p i8 was 
previously identified as lumazine synthase and a possible diagnostic marker for 
brucellosis (Hemmen et al., 1995 and Goldbaum et al., 1999) (See section 4.1). 
Nucleotide and amino acid sequences o f  the p i 8 have been submitted to GenBank and 
NCBI, from different Brucella  species. Hemmen and associates cloned and expressed 
the p i8 gene from B. abortus and submitted the sequence to NCBI (Accession  
number Z46864). Nucleotide and amino acid sequences o f  the p l8  were also 
submitted to GenBank following completion o f  the genomic sequence o f  B. melitensis 
(Accession number AE009695 /  Q44668) and B suis (Accession number AE014565 /  
Q44668). A  26kDa outer membrane protein Omp26 was initially identified as a useful 
diagnostic marker for brucellosis (Lindler et al., 1996). Linder and associates cloned 
and expressed this 26kDa and submitted the sequence to GenBank (Accession number 
U30815). The protein was later cloned and expressed and then re-identified as 26kDa 
cytoplasmic protein (Cloeckaert et a l, 1996) (Accession number U45996). Nucleotide 
and amino acid sequences o f  the bp26 were also submitted to GenBank following 
completion o f  the genomic sequence o f  B. melitensis (Accession number AE009496) 
and B. suis (Accession number AE014442). Nucleotide and amino acid sequence 
alignments were then used to compare the cloned p l8  and bp26 described in this 
chapter with the sequences previously submitted to GenBank and the NCBI database. 
Nucleotide (Figure 4.23) and amino acid (Figure 4.24) sequence analysis on the p l8  
showed 100% homology between the cloned p l8  and the recombinant 17kDa protein 
previously identified by Hemmen et al., 1995 (Accession no. Z46864) and the B. 
melitensis sequence, submitted to GenBank following genome sequencing (Accession  
number AE009695 / Q44668), with the B. suis sequence, submitted to GenBank 
following genome sequencing (Accession number AEO14565 /  Q44668) showing a
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2bp difference. Suggesting 99.6% homology between the 4 nucleotide sequences and 
100% between the corresponding amino acid sequences. Nucleotide (Fig. 4.25) and 
amino acid (Fig. 4.26) sequence alignments on the bp26 suggest 99.1% and 99.6% 
homology, respectively. With a 3 base pair difference between the cloned bp26 and 
two o f  the B. melitensis sequences (U30815 and U45996), a 4 bp difference with the 
B. suis sequence and a 6 bp difference with B. melitensis 16M gene.
The bioreactivity and immunogenicity o f  the two recombinant proteins were then 
determined using Western blotting. The two recombinant proteins were 
electrophoresed-using SDS-PAGE (Fig. 4.27 A) and the bands representing the 
expressed p i 8 and bp26 were clearly visible at 18 and 26kDa, respectively. The 
proteins were then transferred to nitrocellulose for Western blotting. Initially the 
nitrocellulose was probed with an anti-His antibody to ensure the recombinant 
proteins were expressed in frame. The presence o f  the bands at 18kDa (Lane 2) and 
26kDa (Lane 3) confirm the proteins were fully expressed in frame with a 6xHis tag 
(Fig. 4.27 B). The ability o f  the recombinant proteins to discriminate between 
standard positive sera, the DeVeere Hunt Serum and the NSS, and the standard 
negative serum, was also investigated using Western blotting. Nitrocellulose 
containing the transferred proteins was probed with the two standard positive sera and 
the standard negative serum. The presence o f  the bands at 18kDa (Lane 2) and 26kDa 
(Lane 3) on the nitrocellulose probed with the DeVeere Hunt Serum (Fig. 4.27 C) and 
the National Standard Serum (Fig. 4.27 D ) and their absence on the nitrocellulose 
probed using the standard negative serum suggests the recombinant proteins are 
capable o f  distinguishing between Brucella-positive and negative serum samples.
This chapter focused on the cloning and subsequent high-level expression o f  two 
Brucella-specific proteins, p l8  an 18kDa cytoplasmic protein and bp26 a 26kDa 
periplasmic protein, from B. abortus cells. Following optimisation o f  the various 
parameters required for high-level protein expression the recombinant proteins were 
purified using IMAC. The ability o f  the proteins to discriminate between Brucella­
positive and negative serum samples was then confirmed using Western blotting. The 
recombinant proteins were then applied to the development o f  an indirect ELISA for 
the diagnosis o f  bovine brucellosis in serum samples (See Chapter 6).
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CHAPTER 5
The production and characterisation of Brucella-specific 
polyclonal antibodies and scFv antibody fragments
2 1 4
5.1 Introduction to Brucella
The genus Brucella consists o f  a group o f gram-negative facultative intracellular 
pathogenic bacteria. These non-motile bacteria may be rods or coccobacilli with an 
approximate size o f  0.5-0.7pm x 0.6-1.5pm and they may become pleomorphic. 
These non-sporing bacteria are strictly aerobic, they may produce urease and they are 
oxidase-positive and catalase-positive. Brucellae grow best on trypticase, soy-based 
or other enriched media and have a doubling time o f  2 hours (Hoover and Friedlander, 
2004). They are the causative agent o f  Brucellosis, which is an infectious disease 
affecting several animal species that can be transmitted to man (See Chapter 6). 
Brucella  spp. are classified as class III pathogens and are regarded as a potential 
bioterrorist agent (Kortepeter and Parker, 1999; Robinson-Dunn, 2002 and Rotz et al., 
2 0 0 2 ) .
5.1.1 Taxonomy and classification o f the genus Brucella
Brucellae belong to the alpha-Proteobacteria and are phylogenetically related to plant 
pathogens and symbionts such as Rhizobium  and Agrobacterium, intracellular animal 
parasites including Bartonella  and Rickettsia and to the opportunistic and free-living 
bacteria Ochrobacterum and Caulobacter (Moreno et a l, 2002).
The genus Brucella  is subdivided into six species, B. abortus, B. canis, B. melitensis, 
B. neotomae, B. ovis and B. suis based mainly on pathogenicity and host preference 
(Table 5.1). B. abortus is mainly responsible for bovine brucellosis, B. canis for 
canine brucellosis, B. ovis causes ram epididymitis, B suis is responsible for swine 
brucellosis, B. melitensis causes ovine and caprine brucellosis and B. neotomae has 
been isolated from desert rats. Three o f  the six Brucella  species include several 
biovars. B. abortus includes biovars 1, 2, 3, 4, 5, 6, and 9, biovars 1, 2 and 3, are 
defined for B. melitensis and B. suis includes biovars 1, 2, 3, 4 and 5. Distinction 
between the Brucella  species and their biovars are based on metabolic and antigenic 
properties, phage typing, CO2 requirement, H2S production, and dye sensitivity (Alton 
et a l, 1988). Brucella  species can also be further classified according to their colony 
morphology. Brucellae can present themselves wither either a smooth or rough 
colonial morphology. Smooth species have lipopolysaccaride (LPS) molecules 
containing a polysaccharide O-chain, while rough organisms lack this chain on their
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LPS molecule. In some strains the O-chain plays an important role in virulence, with 
rough species o f  B. abortus being non-virulent.
DNA polymorphisms have enabled molecular typing o f the Brucella species and their 
biovars. In particular the omp2 locus encoding the 36kDa major porin OMP has 
enabled distinction between all Brucella  species and some o f  their biovars (Cloeckaert 
et al., 1995).
DNA-DNA hybridisation studies have revealed that the Brucella  genus comprises a 
highly homogeneous group o f  bacteria with greater than 90% DNA homology 
between all six species (Cloeckaert et ah, 1996). During the mid-1980s it was 
suggested that the genus should represent only one genomic species, B. melitensis, 
and that the classical species should be considered as biovars. However, to date, no 
agreement has been made by the Subcommittee on the Taxonomy o f  Brucella  o f  the 
International Committee on Systematic Bacteriology and thus the six species 
classification is still used (Cloeckaert et ah, 2000).
More recently, several Brucella  strains that do not fit into the classical species have 
been isolated from several marine mammals such as seals, porpoises and dolphins 
(Ross et ah, 1994 and Foster et ah, 1996). It was suggested that these new isolates 
should comprise a new nomen species to be called B. maris (Jahans et al., 1997). 
DNA polymorphism studies at the omp2 locus o f  33 Brucella strains isolated from 
marine mammals suggest that grouping the isolates from marine mammals into one 
species, B. maris, would be inappropriate (Cloeckaert et ah, 2001). Based on the 
current classification system, Cloeckaert et a l (2001), has proposed that marine 
mammal Brucella  isolates should in fact comprise at least two new Brucella  species, 
B. pinnipediae (for seal isolates) and P. cetaceae (for cetacean isolates). However, 
this is yet to be confirmed by the Subcommittee on the Taxonomy o f  Brucella  o f  the 
International Committee on Systematic Bacteriology.
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Table 5.1: Overview of the taxonomy of the Brucella genus.
Species Biovars H ost preference Human
pathogenicity
B. abortus 1, 2, 3, 4, 5, 6, 9 Cattle Intermediate
B. melitensis 1 ,2 ,3 Goats and sheep High
B. suis 1, 2, 3, 4, 5 Swine High
B. neotomae N /A Desert rats None
B. ovis N /A Rams None
B. canis N /A Dogs Intermediate
5.1.2 Brucella  pathogenesis
Brucellae gain entry in mammalian hosts via skin abrasions and cuts, the conjunctiva, 
the gastrointestinal tract and the respiratory tract. Once within in the host the 
Brucellae survive and replicate within macrophages and non-professional phagocytes. 
Brucellae have also been shown to survive and replicate within non-phagocytic cells 
(Detilleux et al., 1990). The ability to survive and replicate within macrophages 
enables the bacteria to evade the extracellular mechanisms o f the host defense 
systems, which is a key aspect o f  Brucella  virulence (Liautard el al., 1996 and Sangari 
and Aguero, 1996). Brucellae create a novel intracellular environment in which to 
multiple by modifying the process o f  phagosome maturation. Porte et al. (1999) have 
demonstrated that following uptake o f  the Brucella  the phagosome is rapidly acidified 
to a pH o f  4.0, which inhibits fusion o f  the early phagosome and lysosome. 
Phagosome acidification has been shown as the major signal that induces expression 
o f Brucella virulence factors (Boschiroli et al., 2002). A type IV secretion system has 
been identified as critical for the intracellular survival and multiplication o f  Brucella. 
The proteins encoded by the virB  operon, which consists o f  12 genes, are essential for 
Brucella  virulence in mice and culture cells (Boschiroli e ta l., 1999). Transcription o f  
the virB  operon is induced specifically within macrophages, with phagosome 
acidification being the key intracellular signal (Boschiroli et al., 2002). Virulence 
factors are responsible for the interaction and fusion that occurs between the 
phagosome and the endoplasmic reticulum (ER), where a sub-compartment within the 
ER is the final destination for Brucella. Currently the genes involved in transporting 
the bacteria from the phagosome to the ER are unknown.
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Studies carried out by Riley and associates suggest that the intracellular survival o f  
Brucella  in human and bovine polymorphonuclear leukocytes is aided by the ability 
o f  Brucella  to resist intraleukocytic killing systems (1984). In contrast to the non­
virulent B. abortus 45/20 rough strain the B. abortus 45/0 smooth strain does not 
stimulate an effective level o f  degranulation following bacterial ingestion.
Rafie-Kolpin and associates (1996) have identified 42 Brucella proteins that are 
upregulated and over 100 that are down regulated in bovine macrophages. Many o f  
the genes involved in the protein regulation are metabolic and probably involved in 
the adaptation to the intracellular environment. Two interesting genes manB/ppm, 
which is involved in LPS biosynthesis and essential for virulence, and mtgA, which is 
involved in peptidoglycan metabolism, are upregulated suggesting that restructuring 
o f  the bacterial envelope occurs (Boschiroli et a l, 2001). These molecules play a 
critical role in remodelling the phagosome and bacterial envelope creating a unique 
intracellular compartment in which the Brucella  replicates. Ultimately the bacteria 
destroy the host cell and infect additional cells.
The completion o f  the B. melitensis (DelVecchio et al., 2002), B. suis (Paulsen et a l, 
2002) and B. abortus (Sanchez et a l, 2001) genome projects will give further insight 
into the intracellular behaviour and pathogenicity o f  Brucella.
5.1.3 Immunity and protection against Brucella
Immunity and protection against Brucella  involves the entire repertoire o f  the immune 
system. In the early stages o f  infection, non-specific, innate immunity is involved. 
The classical complement pathway, neutrophils, natural killer cells and macrophages 
all play a role in reducing the number o f  bacteria and providing the environment for 
generating a Thl immune response (Fig. 5.1). Adaptive immunity then provides 
protection against Brucella  and is critical for providing memory function, which plays 
an important role in vaccination. Antigen specific T-cell activation, CD4+ and CD8+ 
T-cells and humoral responses are all involved (Oliveira et al., 2002). Protection 
against Brucella  is primarily mediated by a Thl type immune response (Zhan et a l, 
1993). Brucella  trigger release o f  interleukin 12 (11-12) by antigen presenting cells, 
which results in differentiation o f  ThO cells into Thl cells. INF-y has been shown to
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play an important role in mediating resistance to primary and secondary Brucella 
infection (Zhan and Cheers, 1993). Up-regulation o f  macrophage killing is then 
initiated following secretion o f  gamma interferon (INF-y) from Thl cells. In addition, 
Brucella infected macrophages are killed by the INF-y secreting CD8+ cytotoxic T 
cells, which is critical in the fight against a Brucella  infection.
5.1.4 Brucella abortus 45/20
The need for a successful vaccine against B. abortus has been extensively investigated 
since the early 1920’s (See chapter 6). The use o f  a live, attenuated rough strain would 
offer protective immunity and due to the lack o f  the smooth LPS would not result in 
virulence. The smooth strain B. abortus 45/0 was isolated from a cow in 1922 and a 
rough derivative was obtained following 20 passages in guinea pigs (Schurig et al., 
2002). This phenotypically rough strain was named B. abortus 45/20. This strain 
enabled protective immunity in guinea pigs and cattle but when used as a live vaccine 
it was unstable and tended to revert back to the virulent smooth strain.
Current immunoassays for the detection o f  B. abortus focus on the immunodominant 
lipopolysaccaride (LPS) antigen. However, several bacterial species share the 
immunologically distinguishing 0.9 epitope on the O-chain. In particular, Yersiniae 
strains have cross-reacted with anti -Brucella  sera (Caroff et a l, 1984). Distinction 
between Brucella  and Yersinia cells is critical since double infections can be common 
(Kittelberger et a l, 1995) and because Yersiniae are also considered biological 
warfare agents. Throughout the course o f  this chapter B. abortus 45/20 cells are used. 
These cells were chosen for use because o f  their rough morphology and, therefore, 
lack the LPS O-chain. This rules out the cross-reactivity potential with structurally 
related bacterial cells containing the LPS O-chain.
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Figure 5.1: An overview o f  protection and immunity against Brucella. Brucella 
trigger antigen presenting cells (APCs) to release IL-12, which recruits natural killer 
cells (NK) to kill infected targets. It causes ThO cells to differentiate into Thl cells, 
resulting in a Thl immune response, which involves the cytotoxic T-cell (CTL) 
killing o f  infected cells.
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5.2 Results
This chapter focuses on the production and characterisation o f  Brucella-specific 
antibodies for use in the development o f  immunoassays for the detection o f Brucella  
abortus. The antibodies described in this chapter will also be investigated for use in 
the development o f  a diagnostic immunoassay for bovine brucellosis (See Chapter 6). 
Polyclonal antibodies were raised against the crude cytoplasmic lysate from B. 
abortus 45/20 and whole B. abortus 45/20 cells. Brucella-specific scFv antibody 
fragments were also isolated from a naïve scFv phage display library, which was 
panned using the recombinant Brucella-specific proteins, p i8 and bp26 (See Chapter
4).
5.2.1 Production and purification of polyclonal anti -Brucella  antibodies
Polyclonal antibodies were raised against Brucella abortus 45/20 cells in two rabbits, 
rabbit 1 and rabbit 2. Antibodies were raised against the crude cytoplasmic lysate 
from the B. abortus 45/20 cells in rabbit 1 and against whole B. abortus 45/20 cells in 
rabbit 2. The polyclonal antibodies were purified from the rabbit serum by saturated 
ammonium sulphate precipitation followed by protein G affinity chromatography. The 
purification process was investigated using SDS-PAGE and Western Blots. The two 
polyclonal antibodies were then investigated for use in the development o f  
competitive ELIS As for the detection o f  B. abortus.
5.2.1.1 Estimation of antibody titres in rabbit serum
N ew  Zealand white female rabbits were immunised with the appropriate immunogen 
by sub-cutaneous injection as described in Section 2.4.3. Rabbit 1 was immunised 
with the crude cytoplasmic lysate from Brucella abortus 45/20 cells and rabbit 2 was 
immunised with whole Brucella abortus 45/20 cells. Each rabbit was sacrificed 72 
days after the initial immunisation and the serums recovered. Antibody titres against 
the crude cytoplasmic lysate and whole Brucella abortus 45/20 cells were determined 
for each rabbit, as detailed in Section 2.4.6. The antibody titre was defined as the 
highest antibody dilution with an absorbance value that was greater than 2 standard 
deviations (SD) above the mean absorbance value for the zero control. The resulting 
titres were greater than 1/327,6800 and are shown in Figures 5.2 and 5.3 for rabbit 1 
and 2, respectively.
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Figure 5.2: Graphical representation o f the fin a l serum titres obtained from  rabbit 1 
against the crude cytoplasmic lysate from  B. abortus 45/20 and whole B. abortus 
45/20 cells. Serial dilutions o f the serum ranging from  1/800 -  1/327,6800 were 
prepared in PBS and added to wells o f a m icrotitre plate coated w ith the crude 
cytoplasmic o r whole B. abortus cells. The fin a l serum titre obtained was 1/327,6800 
against the crude cytoplasmic lysate and 1/163,8400 against B. abortus 45/20 cells.
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Figure 5.3: Graphical representation o f the fin a l serum titres obtained from  rabbit 2 
against the crude cytoplasmic lysate from  B. abortus 45/20 and whole B. abortus 
45/20 cells. Serial dilutions o f the serum ranging from  1/800 -  1/327,6800 were 
prepared in PBS and added to wells o f a m icrotitre plate coated with the crude 
cytoplasmic o r whole B. abortus cells. The fin a l serum titre obtained was 1/327,6800 
against the crude cytoplasmic lysate and 1/163,8400 against B. abortus 45/20 cells.
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5.2.1.2 Purification o f polyclonal anti-sera
The purification o f  polyclonal anti-Brucella antibodies from the rabbit serum was 
achieved using a saturated sulphate ammonium sulphate (SAS) precipitation followed 
by protein G affinity chromatography, as described in Section 2.4.5. The partially 
purified antibodies from the SAS precipitation were affinity purified using a protein G 
column. The rabbit IgG antibodies were eluted from the protein G, following 
extensive washing, using glycine buffer at pH 2.2. The absorbances o f  the eluted 
fractions were analysed at 280nm to monitor the protein content. Figure 5.4 shows 
the typical elution profile o f  the IgG antibodies from the protein G column, for rabbit 
1 and rabbit 2. Results suggest that the majority o f  antibody was eluted in the first 
three fractions, which were pooled and dialysed in PBS. Titres o f  the affinity-purified 
antibodies were then determined for rabbit 1 (pA B l) and rabbit 2 (pAB2). Titres in 
excess o f  1/400,000 were obtained for pAB l and pAB2 against the crude cytoplasmic 
lysate and whole B. abortus cells.
Elution volum e (ml)
Figure 5.4: Typical elution p ro file  fo r  polyclonal antibodies from  rabbit 1 and rabbit 
2 from  a lm l protein G a ffin ity chromatography column. The pu rified  IgG  antibodies 
were eluted from  the protein G column using 0.2 M  glycine, p H  2.2. lm l fractions  
were collected and the protein content estimated by measuring absorbance a t 280nm. 
In  the case o f rabbits 1 and 2 fractions 1-3 contained the m ajority o f the eluted IgG  
antibodies and were collected and pooled.
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5.2.1.3 Characterisation of purified antibodies by SDS-PAGE
The purification process was investigated by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) as described in Section 2.2.22. The antibodies, at 
each stage o f  the purification process, were electrophoresed under reducing 
conditions, which separated the proteins and their components on the basis o f  
molecular weights. The level o f  purity obtained was assessed by comparisons between 
the serum, SAS precipitated and the protein G-purified antibodies. Figures 5.5 and 5.6 
show the acrylamide gels obtained for rabbit 1 and rabbit 2, respectively. In each case, 
two bands were clearly visible following the protein G affinity chromatography. One 
band with a molecular weight o f  50kDa corresponds to the heavy chain and the 
second band with a molecular weight o f  25kDa indicates the presence o f  the light 
chain.
5.2.1.4 Western blot analysis of purified antibodies
A s previously discussed in Section 5.2.1.3, the purification process was assessed 
using SDS-PAGE, which separates the proteins according to the molecular weights. 
However, the SDS-PAGE cannot be probed with antibodies to confirm the presence 
o f  rabbit IgG antibody molecules. Therefore, the proteins were transferred from the 
polyacrylamide gels to nitrocellulose by electophoretic means. The nitrocellulose was 
probed using an alkaline phosphatase labelled anti-rabbit IgG secondary antibody. 
The presence o f  rabbit IgG antibodies was then confirmed upon addition o f  a 
chromogenic substrate. Figures 5.7 and 5.8 show the Western blots for rabbits 1 and 
2, respectively. Two bands are visible on each blot for the protein G-purified 
antibody. A  band at 50kDa represents he heavy chain and one at 25kDa represents the 
light chain.
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Figure 5.5: SDS-PAGE analysis on the purification o f the anti-Brucella antibodies 
from  serum isolated from  rabbit 1. Lane M l:  Sigma wide-range molecular weight 
marker; Lane M 2: Sigma prestained molecular weight markers; Lane 1: Unpurified 
anti-Brucella antibodies from  rabbit serum, which was diluted 1 in  5 w ith PBS; Lane 
2: P artia lly  pu rifie d  rabbit antibodies fo llow ing  sodium sulphate precipitation, which 
was diluted 1 in  2 w ith PBS; Lane 3: P urified  rabbit antibodies obtained fo llow ing  
protein G a ffin ity chromatography. The protein G -purified sample in lane 3 has two 
distinct bands, at approximately 25 and 50kDa, which are consistent w ith the 
presence o f antibody heavy and lig h t chains, respectively.
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Figure 5.6: SDS-PAGE analysis on the purifica tion  o f the anti-Brucella antibodies 
from  serum isolated from  rabbit 2. Lane M l:  Sigma wide-range molecular weight 
marker; Lane M 2: Sigma prestained molecular weight markers; Lane 1: Unpurified 
cmti-Brucella antibodies from  rabbit serum, which was diluted 1 in  5 w ith PBS; Lane 
2: P artia lly  p u rifie d  rabbit antibodies fo llow ing  sodium sulphate precipitation, which 
was diluted 1 in  2 w ith PBS; Lane 3: P urified  rabbit antibodies obtained fo llow ing  
protein G a ffin ity chromatography. The protein G -purified sample in lane 3 has two 
distinct bands, a t approximately 25 and 50kDa, which are consistent w ith the 
presence o f antibody heavy and ligh t chains, respectively.
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Figure 5.7: Western blot analysis on the purifica tion  o f the anti-Brucella antibodies 
from  serum isolated from  rabbit 1. The proteins were electrophoresed using SDS- 
PAGE and then transferred to nitrocellulose membrane, which was probed using an 
alkaline phosphatase-labelled anti-rabbit antibody to confirm the presence o f rabbit 
antibodies. Lane M : Pierce Blue Ranger prestained molecular weight markers; Lane 
1: Unpurified anti-Brucella antibodies from  rabbit serum, which was diluted 1 in  5 
with PBS; Lane 2: P artia lly  pu rified  rabbit antibodies fo llow ing  sodium sulphate 
precipitation, which was d ilu ted 1 in 2 w ith PBS; Lane 3: P urified  rabbit antibodies 
obtained fo llow ing  prote in G a ffin ity chromatography. The protein G -purified 
antibody sample in  lane 3 has two distinct bands, a t approximately 25 and 50kDa, 
which are consistent w ith the presence o f antibody heavy and ligh t chains, 
respectively.
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Figure 5.8: Western blot analysis on the purifica tion o f the anti-Brucella antibodies 
from  serum isolated from  rabbit 2. The proteins were electrophoresed using SDS- 
PAGE and then transferred to nitrocellulose membrane, which was probed using an 
alkaline phosphatase-labelled anti-rabbit antibody to confirm the presence o f rabbit 
antibodies. Lane M : Sigma prestained molecular weight markers; Lane 1: Unpurified 
anti-Brucella antibodies from  rabbit serum, which was diluted 1 in 5 w ith PBS; Lane 
2: P artia lly  pu rified  rabbit antibodies fo llow ing  sodium sulphate precipitation, which 
was diluted 1 in 2 w ith PBS; Lane 3; P urified  rabbit antibodies obtained fo llow ing  
protein G a ffin ity  chromatography. The protein G -purified antibody sample in lane 3 
has two distinct bands, at approximately 25 and SOkDa, which are consistent w ith the 
presence o f antibody heavy and ligh t chains, respectively.
5.2.1.5 Development o f competitive ELISAs for the detection o f B. abortus
Competitive ELISAs were then developed for the detection o f  B. abortus using the 
affinity purified polyclonal antibodies from rabbit 1 and 2, which were designated 
pABl and pAB2, respectively.
5.2.1.5.1 Optimisation o f com petitive ELISA for the detection o f B. abortus 
Initial checkerboard ELISAs was carried on the pAB l and pAB2 to determine the 
optimal antibody dilution and cell-coating concentration for use in a competitive 
ELISA. Several B. abortus 45/20 cell coating concentrations, ranging from 0 to 
1 .6x l010 cells/ml and antibody dilutions between 1/100 and 1/1000000, o f  pA B l and 
pAB2, were assayed. The optimal cell-coating concentration for pAbl was found to 
be 1 .6x l08 cells/ml and the optimum antibody dilution determined to be 1/5000 (Fig. 
5.9). The optimal cell-coating concentration for pAB2 was also found to be 1 .6xl08 
cells/ml, with a 1/5000 antibody dilution (Fig. 5.10).
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Figure 5.9: Checkerboard ELISA on pA B l, fo r  determination o f the optimal cell- 
coating concentration and antibody dilution, fo r  use in a competitive ELISA fo r  the 
detection o f B. abortus. The optim al ce ll coating concentration chosen was 1.6xl08 
cells/m l and the optim al antibody dilution, which gave 70% o f the maximum 
absorbance, was 1/5000.
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Figure 5.10: Checkerboard ELISA on pAB2, fo r  determination o f the optimal cell- 
coating concentration and antibody d ilu tion fo r  use in a competitive ELISA fo r  the 
detection o f B. abortus. The optim al ce ll coating concentration chosen was 1.6xl08 
cells/m l and the optim al antibody dilution, which gave 70% o f the maximum 
absorbance, was 1/5000.
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5.2.1.5.2 Development of competitive ELISAs for the detection of B. abortus 
Following optimisation o f  the various assay parameters, competitive ELISAs were 
developed for the detection o f  B. abortus. The range o f  detection for each antibody 
was determined using immunoplates coated with 1 .6xl08 cells/ml o f  B. abortus. B. 
abortus standards ranging from 9.77x10s to l.OOxlO9 cells/ml were added to the 
immunoplate with an equal volume o f  the pA B l or pAB2 antibody diluted to 1/5000. 
Intra- and inter-day variability studies were then carried out on the polyclonal 
antibodies in order to estimate assay reproducibility.
In order to determine the intra-day assay variation each B. abortus cell concentration 
was assayed five times on one day and the mean absorbance o f  bound antibody at 
each cell concentration plotted against the cell concentration. Using Biaevaluation 3.1 
software the calibration curve was plotted using the four-parameter equation with the 
range o f  detection for free B. abortus 45/20 cells found to be between 1.95xl06 and 
l.OOxlO9 cells/ml for pABl and 9 .77x l05 to l.OOxlO9 cells/ml for pAb2 (Data not 
shown). The coefficients o f  variation (CVs) between the five replicates at each cell 
concentration were determined by expressing the standard deviation as a percentage 
function o f  the mean. The intra-day coefficients o f variation (CVs) ranged from 1.32 
to 8.96% and 0.32 and 8.97% for pA B l and pAB2, respectively.
The inter-day assay variations were then calculated for each o f  the antibodies by 
performing the same assay over five separate days. The normalised mean values, 
which were calculated as the mean absorbance at each antigen concentration / 
absorbance in the presence o f  zero antigen concentration (A/Ao), over the five days 
were used to construct a separate calibration curve for the inter-day assay. The inter­
day assay on pA B l had a range o f  detection for B. abortus cells between 1.95xl06 and 
l.OOxlO9 cells/ml (Fig. 5.11). The C.V.’s for this inter-day assay were determined and 
ranged between 0.73 and 5.85% (Table 5.2). The inter-day assay obtained for pAB2 
had a range o f  detection for B. abortus cells between 9 .77x l05 and l.OOxlO9 cells/ml 
(Fig. 5.12) and CVs between 1.14 and 6.40% (Table 5.3), indicating that the two 
competitive ELISAs were reproducible over five days.
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Table 5.2: Inter-day assay coefficients o f variation fo r  the detection o f B. abortus 
45/20 cells using pA B l. Five sets o f ten standards were assayed on five  different days 
and the coefficients o f variation calculated.
B. abortus 45/20 
cells/ml
Calculated mean ± S.D.
(A/Ao)
Coefficient of variation
(%)
1.00x10s 0.219 ± 0 .005 2.33
5 .00xl08 0.250 ± 0.007 3.11
2 .50x l08 0.306 ± 0 .014 4.70
1.25xl08 0.380 ± 0 .022 5.85
6.25x107 0.520 ±  0.020 3.85
3 .13xl07 0.594 ± 0 .004 0.73
1.56xl07 0.700 ±  0.023 3.31
7.81xl06 0.769 ±0 .013 1.68
3.90x106 0.894 ± 0 .018 2.05
1.95xl06 0.946 ± 0 .013 1.40
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Figure 5.11: Inler-day assay curve fo r  the detection o f B. abortus 45/20 cells using 
p A B l in  a competitive ELISA form at. The range o f detection o f the antibody fo r  b  
abortus was between 1.95x106 and Ix lO 9 cells/ml. The calibration curve was plotted  
using Biaevaluation software 3.1 and represents the average normalised (A/Ao) 
results obtained over five  individual days.
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Table 5.3: Inter-day assay coefficients o f variation fo r  the detection o f B. abortus 
45/20 cells using pAB2. Five sets o f eleven standards were assayed on five  different 
days and the coefficients o f variation calculated
B. abortus 45/20 
cells/ml
Calculated mean ± S.D.
(A/Ao)
Coefficient of variation
(%)
l.OOxlO9 0.232 ± 0 .015 6.40
5.00x108 0.276 ± 0 .012 4.33
2.50x10s 0.324 ± 0 .018 5.65
1.25xl08 0.393 ± 0 .010 2.36
6 .25xl07 0.501 ± 0 .006 1.14
3 .13xl07 0.575 ±  0.025 4.26
1.56xl07 0.664 ± 0 .016 2.42
7 .81xl06 0.715 ± 0 .019 2.68
3 .90xl06 0.809 ±0.021 2.64
1.95xl06 0.841 ±  0.025 2.97
9.77x105 0.911 ± 0 .014 1.49
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Figure 5.12: Inter-day assay curve fo r the detection o f B. abortus 45/20 cells using 
pAB2 in  a competitive ELISA format. The range o f detection o f the antibody fo r B. 
abortus was between 5.77x10s and 1x109 cells/ml. The calibration curve was plotted  
using Biaevaluation software 3.1 and represents the average normalised (A/Ao) 
results obtained over five  individual days.
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5.2.1.5.3 Cross-reactivity studies
Cross reactivity studies were then carried out on the polyclonal antibodies to 
determine the antibody specificity towards B. abortus in relation to ubiquitous gram­
positive and gram-negative bacteria (as described in Section 2.4.9). The assays were 
carried out as for the competitive ELIS As except the cross-reactants were added to the 
immunoplate with the Brucella-specific polyclonal antibodies. Separate calibration 
curves were plotted for each bacterial strain and the least detectable dose (LDD) and 
IC50 values were determined for each as 90% A/Ao and 50% A/Ao, respectively. The 
percentage cross reactivities were then estimated at the LDD (CR90) and at the IC50 
(CR50) by expressing 100-fold the ratio o f  B. abortus and the cross-reacting bacterial 
strain.
Table 5.4 summarises the specificity and cross reactivity studies on the pAbl against 
5 gram-negative and 5 gram-positive bacterial strains. pABl did not display any 
specificity towards the gram-positive bacteria B. subtilus, L. invanovii, L. welshimeri, 
L. innocua and L  sw ligeri at either the LDD or IC50 values with minimal levels o f  
cross-reactivity observed (i.e. < 0.2%). Minimal levels o f cross-reactivity (i.e. < 1%) 
were also observed between the gram-negative bacteria E. coli, S. marcescens, E. 
aerogenes, Ps. aeruginosa and P. vulgaris and pABl at both the LDD and IC50 
values. Minimal cross-reactivity was also seen with pAb2 against the gram-positive 
and negative bacterial strains (Table 5.5). The gram-positive bacteria displayed < 
0.01% cross-reactivity with pAB2 at the LDD and IC50 and < 0.02% cross-reactivity 
was observed between pAB2 and the gram-negative bacteria at the LDD and IC50-
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Table 5.4: Cross-reactivity and specificity studies on p A B l against various ubiquitous 
bacterial strains. The cross-reactivity potentia l was approximated a t the least 
detectable dose (LDD) and a t the IC 50 value.
Bacterial strain Gram stain LDDa
(cells/ml)
i c 50b
(cells/ml)
CR90C
(%)
CR50d
(%)
B. abortus Negative 1.9 x 10° 3.1 x 107 100 100
B. subtilus Positive >2.5 x 1010 >2.5 x 1010 <0.01 < 0 .2
E. coli Negative > 5.0 x 109 > 5.0 x 109 < 0 .04 < 1
L. invanovii Positive 4.0 x 10n > 8.0 x 1011 0.01 <0.01
L. welshimeri Positive 2.7 x 1010 > 5.5 x 1010 <0.01 <0.1
L. innocua Positive >1.0 x 1011 >1.0 x 10u <0.01 <0.1
L swligeri Positive 5.0 x  1010 > 1.0 x l O 11 <0.01 <0.1
S. marcescens Negative >1 x 1011 > l x  1011 <0.01 <0.01
E. aerogenes Negative > 1 x 1010 > 1 x 1010 <0.01 <0.01
Ps. aeruginosa Negative > 1 x 1010 > 1 x 1010 <0.01 <0.01
P. vulgaris Negative > 1 x 1010 > 1 x 1010 <0.01 <0.01
a Least detectable dose calculated at 90% A/Ao 
b 50% inhibition concentration (50% A/Ao)
c Percentage cross-reactivity determined at IC50 
d Percentage cross-reactivity determined at LDD
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Table 5.5: Cross-reactivity and specificity studies on pAB2 against various ubiquitous 
bacterial strains. The cross-reactivity potential was approximated at the least 
detectable dose (LDD) and at the IC 50 value.
Bacterial strain Gram stain LDDa
(cells/ml)
ic 50b
(cells/ml)
CR90C
(%)
CRS0d
(%)
B. abortus Negative 9.7 x 105 6.3 x lO7^ 100 100
B. subtilus Positive >2.5 x 1010 >2.5 x 1010 <0.01 <0.01
E. coli Negative > 5.0 x 109 >5.0 x 109 <0.02 <0.01
L. invanovii Positive 2.0 x 1011 > 8.0 x 1011 <0.01 <0.01
L. welshimeri Positive 6.9 x 109 > 5.5 x 1010 <0 .02 <0.01
L. innocua Positive 2.5 x  1010 > 1.0 x 1011 <0.01 <0.01
L swligeri Positive 2.5 x 1011 >1.0 x 1011 <0.01 <0.01
S. marcescens Negative >1 x 1011 > l x  1011 <0.01 <0.01
E. aerogenes Negative > 1 x 1010 > 1 x 1010 <0.01 <0.01
Ps. aeruginosa Negative > 1 x 1010 > 1 x 1010 <0.01 <0.01
P. vulgaris Negative > 1 x  1010 > 1 x 1010 <0.01 <0.01
a Least detectable dose calculated at 90% A/Ao 
b 50% inhibition concentration (50% A/Ao)
c Percentage cross-reactivity determined at IC50 
d Percentage cross-reactivity determined at LDD
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5.2.1.6 Antibody binding reactivity analysis on pABl and pAB2
The antibody binding reactivity o f  pABl and pAB2 was determined against the crude 
cell lysate from B. abortus 45/20 cells and against the Brucella-specific recombinant 
proteins, p l8  and bp26, using Western blot analysis as described in Section 2.2.23.
B. abortus 45/20 cells were disrupted by sonication and the crude cell lysate 
electrophoresed using SDS-PAGE. The electrophoresed proteins were then transferred 
to nitrocellulose, which was probed using pABl and pAB2 followed by an alkaline 
phosphatase-labelled anti-rabbit antibody. Figure 5.12 shows the Western blots 
obtained for the crude cell lysate, which was probed using pABl (A) and pAB2 (B). 
pA B1 recognised two main proteins from the crude cell lysate with molecular weights 
o f  approximately 18 and 45kDa (Fig. 5.13 A). The pAB2 antibody, which was raised 
against whole B. abortus 45/20 cells, recognised four main proteins, with apparent 
molecular weights o f  15, 18, 38 and 45kDa (Fig. 5.13 B).
The specificity o f  pABl and pAB2 towards p i 8 and bp26 was established using 
Western blot analysis. The recombinant proteins were electrophoresed alongside a 
prestained molecular weight marker using SDS-PAGE and then transferred to 
nitrocellulose for Western blot analysis. The transferred proteins were probed using 
pA B l and pAB2 followed by an alkaline phosphatase-labelled anti-rabbit antibody. 
Figure 5.14 represents the Western blots obtained using pABl (A) and pAB2 (B). 
Both polyclonal antibodies were capable o f  detecting p i 8 (Lane 1) with a band clearly 
visible at 18kDa. However, the polyclonal antibodies failed to detect the 26kDa 
periplasmic protein, bp26 (Lane 2).
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Figure 5.13: Antibody binding reactivity analysis on p A B l and pAB2 against the 
crude ce ll lysate from  B. abortus 45/20. The crude ce ll lysate was electrophoresed 
using SDS-PAGE and transferred to nitrocellulose, which was then probed using 
p A B l andpAb2. (A) Represents Western blot analysis on the crude ce ll lysate probed 
using pA B l. Lane M : Pierce Blue Ranger prestained molecular weight markers; Lane 
1: Crude ce ll lysate from  B. abortus 45/20 cells. (B) Represents the Western blot 
analysis on the crude ce ll lysate probed using pAB2. Lane M : Pierce Blue Ranger 
prestained molecular weight markers; Lane 1: Crude ce ll lysate from  B. abortus 
45/20 cells. Specific-proteins detected w ith p A B l andpAB2 denoted with an asterisks.
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Figure 5.14: Antibody binding reactivity analysis on p A B l and pAB2 against the two 
recombinant proteins p l8  and bp26. The recombinant proteins were electrophoresed 
using SDS-PAGE and transferred to nitrocellulose, which was then probed using 
p A B l and pAb2. (A) Represents Western b lo t analysis on the recombinant proteins 
probed using pA B l. Lane M : Pierce Blue Ranger prestained molecular weight 
markers; Lane 1: p i8; Lane 2: bp26. (B) Represents the Western blot analysis on the 
recombinant proteins probed using pAB2. Lane M : Pierce Blue Ranger prestained 
molecular weight markers; Lane 1: p i8; Lane 2: bp26. p A B l andpAB2 are capable 
o f detecting p l8  w ith bands clearly visible a t 18kDa (Lanes 1). However, the 
polyclonal antibodies are unable to detect the bp26 w ith no corresponding bands at 
26kDa visible in  Lanes 2.
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5.2.2 The isolation of Brucella-specific scFv antibody fragments from a naive 
phage display library
The BM V library is a large non-immunised scFv phage display library that was 
developed by Vaughan et al. (1996) and kindly donated by Cambridge Antibody 
Technology (CAT) (Cambridge, England). Functional V-gene segments were isolated 
from 43 non-immunised human donors and used to construct a repertoire o f  1.4 x 1010 
single-chain Fv (scFv) displayed on the surface o f  phage. The scFv fragments were 
cloned into a phagemid vector, pCANTAB6, which enables the production o f  phage- 
displayed scFv in the presence o f  a helper phage ( M l3 K07) or soluble scFv in the 
presence o f  IPTG in the growth media. scFvs expressed from the pCANTAB vector 
contain a stretch o f  six histidines (6xHis) for immobilised metal affinity 
chromatography (IMAC) purification and a sequence derived from c-myc for 
detection.
BMV library stocks were panned against the p l8  and bp26 recombinant proteins, for 
the selection o f  specific-phage clones, displaying scFvs directed against the 
recombinant proteins. Generally, 4-6 rounds o f  panning are required for the successful 
selection o f  positive clones from a non-immunised library (Vaughan et a l, 1996). 
This section details six rounds o f  panning carried out on the BMV library against the 
p i 8 and bp26 recombinant proteins and the subsequent isolation and characterisation 
o f  soluble scFvs.
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5.2.2.1 Panning procedure for the detection of scFv phage display antibodies 
directed against p l8
Six rounds o f  panning were carried out on the BMV library stocks against the 
recombinant p i 8. Table 5.6 gives a summary o f  the phage titres obtained and the 
number o f positive clones isolated that recognised p i 8.
The BMV library stocks received consisted o f  1.4 x 1010 cfu/ml o f  scFv-displaying 
phage particles. These were initially used for the first round o f  panning against p i 8. 
Panning was carried out in immunotubes coated with 10|.ig/ml o f  p i 8 (as described in 
Section 2). Following the first round o f  selection panned library stocks were prepared 
and the output phage titre obtained (as described in Section 2.5.1). 5.6 x 104 cfu/ml o f  
phage were produced following the first round o f panning. These were then used for 
the second round o f panning, where a phage titre o f  2 x 102 cfu/ml was obtained. 95 
random clones were selected from the second round o f  panning and the scFv- 
displaying-phage produced from each were analysed, using a phage ELISA, for 
recognition o f  pl8. N o positive phage recognising p l8  were isolated. A third round o f  
panning was then carried out and a phage titre o f  1.6 x 106 cfu/ml obtained. 95 
random clones screened did not recognise p i 8. Following the fourth round o f  
panning, which yielded a phage titre o f  5.6 x 105 cfu/ml, 5 positive phage recognising 
p l8  were isolated. However, attempts made to express soluble pl8-specific scFvs 
were unsuccessful. Therefore, a fifth and sixth round o f panning was carried out with 
phage titres o f  3.7 x 104 and 3.7 x 103 cfu/ml obtained, respectively. Phage ELIS As 
were carried out on 95 random clones from each round o f panning and 8 positives 
clones recognising p i8 were selected following the fifth round o f  panning and 10 
were selected following the sixth round (Fig. 5.15). However, once again attempts 
made to isolate soluble p l8-specific scFvs were unsuccessful. Figure 5.16 shows the 
results obtained for the soluble ELISA on the supernatant and periplasmic lysate, 
following the sixth round o f  panning, with no soluble scFvs directed against the p i 8 
isolated.
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Table 5.6: Data obtainedfollowing six rounds o f panning on the naïve BMV library
against pl8.
Pan In p u t T itre 
(cfu/ml)
O u tpu t T itre 
(cfu/ml)
# Clones 
assayed
# Positive 
phage clones
# Clones 
recognising free 
protein
1 1 x lO1^ 5.6 x 104 - - -
2 7.2 x IO10 2 x  102 95 0 0
3 2.4 x 108 1.6 x 106 95 0 0
4 4.9 x 109 5.6 x 105 95 5 0
5 1.9 x 108 3.7 x 104 95 8 0
6 8.1 x 107 3.7 x 103 95 10 0
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Figure 5.15: Bar graph represents the phage ELISA analysis on the 95 clones 
randomly selected follow ing the sixth round o f  panning on the BM V library against 
p l8 . The flagged bars represent the positive phage clones that recognised 
immobilised p!8 .
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Figure 5.16: Bar graphs representing the soluble ELISA analysis on the 95 clones 
randomly selected follow ing the sixth round o f  panning on the BM V library against 
p l8 . Following soluble scFv expression, upon addition o f  IPTG, the culture 
supernatants (A) and the periplasmic lysates (B) were analysed fo r  the expression o f  
pl8-specific scFvs. However, no soluble scFvs directed againstp!8  were isolated.
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5.2.2.2 Panning procedure for the detection of scFv phage display antibodies 
directed against bp26
Six rounds of panning were also carried out on the BMV library stocks against the 
recombinant bp26. Table 5.7 gives a summary o f the phage titres obtained and the 
number o f positive clones isolated that recognised bp26.
The BMV library stocks consisting of 1.4 x 1010 cfu/ml o f phage were used for the 
first round o f panning against bp26. Phage particles produced from the first round 
stocks were then used for the second round o f panning. A phage titre o f 1.5 x 10 
cfu/ml was obtained following the second round o f panning and the 95 random clones 
analysed did not recognise bp26. A third round o f panning was then carried out, as 
before, and a phage titre o f 1.2 x 104 cfu/ml was obtained. 95 random clones were 
screened and no phage recognising bp26 were isolated. A fourth round of panning 
yielded a phage titre o f 4.4 x 105 cfu/ml o f  phage and following analysis, o f  95 
random clones, 12 positive phage recognising bp26 were isolated. However, attempts 
made to isolate soluble bp26-specific scFvs were unsuccessful. Therefore, a fifth and 
sixth round o f panning was carried out with phage titres o f 1.3 x 104 and 2.7 x 105 
cfu/ml obtained, respectively. Phage ELISAs were carried out on 95 random clones 
from each round o f panning and 2 positives clones recognising bp26 were isolated 
following the fifth round o f panning and 9 were isolated following the sixth round 
(Fig. 5,17). Attempts made to isolate soluble bp26-specific scFvs were unsuccessful 
following the fifth round of panning. However, following the sixth round o f panning 
soluble scFvs were isolated from the culture supernatant o f 5 clones and from the 
periplasm o f 5 clones (Fig. 5.18). The 5 positive clones B7, B ll ,  B12, C12 and D9 
expressed anti-bp26 scFvs into the supernatant and clones B7, B9, B l l ,  B12 and D9 
expressed soluble scFvs into the periplasm.
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Table 5.6: Data obtained following six rounds o f panning on the naive BMV library
against bp26.
Pan In p u t T itre 
(cfu/ml)
O u tpu t Titre 
(cfu/ml)
# Clones 
assayed
# Positive 
phage clones
# Clones 
recognising free 
protein
1 1 x 10* 5.1 x 104 - - -
2 6.3 x 1010 1.5 x 102 95 0 0
3 2.7 x 108 1.2 x 104 95 0 0
4 3.5 x 108 4.4 x 10s 95 12 0
5 2.2 x 108 1.3 x 104 95 2 0
6 9.5 x 107 2.7 x 10s 95 9 6
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Figure 5.17: Bar graph representing the phage ELISA analysis on the 95 clones 
randomly selected follow ing the sixth round o f  panning on the BM V library against 
bp26. The flagged bars represent the positive phage clones that recognised 
immobilised bp26.
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Figure 5.18: Bar graphs representing the soluble ELISA analysis on the 95 clones 
randomly selected follow ing the sixth round o f  panning on the BM V library against 
bp26. Following soluble scFv expression, upon addition o f  IPTG, the culture 
supernatants (A) and the periplasmic lysates (B) were analysed fo r  the expression o f  
bp26-specific scFvs. The flagged  bars represent the soluble scFvs that recognised 
bp26.
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S.2.2.3 Analysis on the soluble anti-bp26 scFvs for recognition of free bp26
Competitive ELISAs were then carried out on the soluble scFvs, expressed in the 
periplasm and culture supernatant. Different concentrations o f bp26 were prepared in 
PBS, ranging from 0.39 -  100(j,g/ml and mixed with an equal volume o f the 
periplasmic lysate or culture supernatant containing the expressed scFv. The mixture 
was then added to immunoplates coated with 10ng/ml o f  bp26 and the competitive 
ELISA completed as described in Section 2.5.9 Each o f  the 6 clones analysed were 
capable o f  expressing soluble scFvs into both the supernatant and periplasmic lysate, 
which exhibited affinity for free bp26 (Figs. 5.19 and 5.20).
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Figure 5.19: Competition ELISA on the clones B7, B9, B l l ,  B12, C12 and D9 
following soluble scFv expression into the culture supernatant. Free bp26 standards, 
ranging from  0.39 — lOOjug/ml were assayed. Each o f  the six clones analysed clearly 
show competition fo r  free  bp26.
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Figure 5.20: Competition ELISA on the clones B7, B9, B l l ,  B12, C l2 and D9 
following soluble scFv expression into the periplasm. Free bp26 standards, ranging 
from  0.39 -  100/ug/ml were assayed. Each o f  the six clones analysed clearly show 
competition fo r  free  bp26.
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5.2.2.4 Nucleotide and am ino acid sequence analysis on clones B7, B l l ,  C12 and 
D7
Following confirmation that the soluble scFvs exhibited affinity for free bp26, 4 
positive clones (B7, B l l ,  D7 and C12) were selected for sequence analysis and 
comparisons. Plasmid DNA, encoding the bp26-specific scFvs, was purified from XL- 
1 Blue E. coli, as described in Section 2.2.2. The plasmid DNA was quantified and 
sent to MWG-Biotech (Germany) for sequencing. Comfort reads were obtained in 
both directions on the scFv inserts, using primers specific to the multiple cloning site 
o f the pCANTAB6 vector. Nucleotide sequence alignments o f the four scFv genes 
confirmed that clones B7, B l l  and D9 were identical with clone C12 containing a one 
base pair substitution (Fig. 5.21). In comparison with clones B7, B l l  and D9 clone 
C12 contained a G at base 496 instead o f an A. The amino acid sequence o f each 
scFv was then deduced from the nucleotide sequence. The amino acid sequences 
alignments on the four clones confirmed they were identical (Fig. 5.22).
Therefore, clone B7 was selected for further characterisation and analysis. The 
deduced amino acid sequence o f clone B7 was compared with variable regions o f 
immunoglobulins found in the SwissProt database and used along with the Kabat 
rules to identify the loops corresponding to the CDRs within the variable heavy and 
variable light domains (Fig. 5.23). The 3-D structure o f the scFv was also predicated, 
using SwissModel, based on structurally related proteins (Fig. 5.24).
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Figure 5.21: Nucleotide sequence alignment on the DNA encoding the 4 anti-bp26 scFvs, 
B7, B l l ,  C12 and D9, which were isolated from  the BM Vphage display library. The one 
base-pair difference observed between the nucleotide sequences ofB7, B l l  andD 9 and that 
o f  C l 2 is shown in white. 253
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Figure 5.22: Amino acid sequence alignment on the DNA encoding the 4 anti-bp26 
scFvs, B7, B l l ,  C12 and D9, which were isolated from  the BM V phage display 
library. The amino acid sequences alignments on the four clones proved they were 
identical.
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Figure 5.23: The nucleotide and deduced amino acid sequences o f  the gene encoding 
the bp26 specific scFv from  clone B7. The amino acid sequences representing the 
CDRs were identified using the Kabat rules and are clearly visible underlined and in 
bold. The fo u r  conserved cystine residues are indicated with an asterisk.
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Figure 5.24: The predicted 3-D structure o f  the anti-bp26 scFv from  clone B7, which 
was obtained using SwissMudel. The complementary determining regions (CDRs) are 
shown in red on the light chain and in green on the heavy chain.
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5.2.2.5 W estern blot analysis for the specific detection of bp26 using the B7 scFv 
Following soluble expression o f the scFv antibodies from pCANTAB6 a c-myc tag is 
incorporated at the C-terminus to aid in detection. During the course of the ELISA 
characterisation o f the B7 scFv, the interaction between the bp26 and the B7 scFv will 
be indirectly detected using an anti-c-myc-HRP antibody. In order to confirm that the 
anti-c-myc-HRP antibody specifically binds the B7 scFv Western blot analysis was 
conducted.
Initially the specificity o f the anti-c-myc HRP-labelled antibody for c-myc-tagged 
scFvs was determined. The supernatant containing the B7 scFv was electrophoresed 
along with a c-myc-tagged scFv, previously isolated from the BMV against a Listeria 
monocytogens protein (Positive control) and a FLAG-tagged scFv, with no c-myc tag, 
isolated from a pre-immunised phage display library against AFBi-BSA (Negative 
control) using SDS-PAGE. The scFvs were then transferred to nitrocellulose, which 
was probed using the anti-c-myc-HRP antibody and colour developed following 
addition o f chromogenic substrate (Figure 5.25 (A)). The anti-c-myc-HRP antibody 
was capable o f specifically detecting the B7 scFv (Lane 3) and the L. monocytogenes- 
specific positive control scFv (Lane 2), with bands clearly visible at approximately 
32kDa. However, the anti-c-myc antibody was unable to detect the anti-AFB] scFv 
(Lane 1), which lacked a c-myc tag.
Western blot analysis was also conducted to confirm the B7 scFv specifically 
recognised bp26. The recombinant p i 8 (Negative control) and bp26 proteins were 
electrophoresed using SDS-PAGE and then transferred to nitrocellulose. The 
nitrocellulose was probed using the B7 scFv, followed by the anti-c-myc-HRP 
antibody (Figure 5.25 (B)). The anti-c-myc-HRP antibody specifically detected the 
interaction between the recombinant bp26 and B7 scFv (Lane 2), with one band 
clearly visible at approximately 26kDa representing the bp26. However, the B7 scFv 
failed to detect the p l8  protein (Lane 1) with no bands visible.
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Figure 5.25: Western blot analysis on the specific detection o f  bp26 using the B7  
scFv. (A) Represents Western blot analysis to determine the specificity o f  the anti-c- 
myc antiboify fo r  the detection o f  c-myc-tagged scFvs. Lane M: Pierce Blue Ranger 
prestained molecular weight markers; Lane 1: FLAG-tagged scFv, which was not 
detected using the anti-c-myc antibody; Lane 2; L. monocytogens-specific scFv, which 
was specifically detected using the anti-c-myc antibody with a  band clearly visible at 
32kDa; Lane 3: The B 7 scFv, which was specifically detected using the anti-c-myc 
antibody with a band clearly visible a t 32kDa. (B) Represents the Western blot 
analysis to determine i f  the interaction between the bp26 and B7 scFv can be 
specifically detected using the anti-c-myc antibody. Lane M: Pierce Blue Ranger 
prestained molecular weight marker; Lane 1; Negative control consisting o f  p !8  
probed using the anti-bp26 scFv (B7) fo llow ed by the anti-c-myc antibody with no 
bands observed; Lane 2; The interaction between bp26 and the B 7 scFv was 
indirectly detected using the anti-c-myc-HRP antiboify with a band clearly visible at
26kDa.
5.2.2.6 ELISA analysis of the soluble B7 scFv antibody directed against bp26
Following selection of a soluble scFv that recognised the recombinant bp26 protein, 
both in solution and immobilised, competitive ELISA characterisation was carried out 
in order to give a further insight into the sensitivity, stability and reproducibility o f the 
scFv.
5.2.2.6.1 Checkerboard ELISA for the determ ination of the optimal scFv 
antibody dilution and bp26 concentration for use in a competitive ELISA
A checkerboard ELISA was carried out in order to determine the optimal scFv 
antibody dilution and protein coating concentration for use in a competitive ELISA. 
Rows o f wells on a 96-well microtitre plate were coated with concentrations o f 
recombinant bp26 ranging from 0 to 50(a.g/ml and blocked with 4% (w/v) milk marvel 
powder. Dilutions o f the B7 scFv antibody from undiluted to 1/1000 were prepared in 
PBS and each scFv dilution was added to each protein coating concentration on the 
plate. Figure 5.26 shows titre curves obtained for the B7 scFv antibody. The optimal 
protein coating concentration was found to be 12.5(j.g/ml and the optimal scFv 
dilution determined to be 1/8.
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Figure 5.26: Checkerboard ELISA fo r  determination o f  optimal bp26 protein coating 
concentration and scFv antibody dilution. The optimal bp26 protein coating 
concentration chosen was 12.5fig/ml and the optimal scFv dilution, which gave 70% 
o f  the maximum absorbance, was 1/8.
I 260
S.2.2.6.2 In tra- and inter-day assay variability studies of the B7 scFv antibody 
Following optimisation o f the various parameters for a competitive ELISA, intra- and 
inter-day assays were carried out. Immunoplates coated with 12.5|j,g/ml o f bp26 were 
used to determine the range o f detection for bp26 o f the scFvs. Free bp26 standards, 
ranging in concentration from 24 -  25000ng/ml, were prepared in PBS and added to 
an equal volume o f the optimal dilution o f  B7 scFv. Intra and inter-day variability 
studies were carried out on the scFv in order to estimate the sensitivity and 
reproducibility of the scFvs.
In order to determine intra-day assay variation, each concentration was assayed five 
times on one day and the mean absorbance of bound antibody for each bp26 
concentration was plotted against the free bp26 concentration. The range o f detection 
o f the scFv antibody for free bp26 was 97 -  12500ng/ml and the coefficients o f 
variation (C.V.’s) for the assay ranged from 1.51 -  8.39%.
Inter-day assay variability studies were also carried out on the scFv by performing the 
assays over five separate days. The coefficients of variation (CVs) were determined 
for each assay by expressing the standard deviation as a percentage function o f the 
mean. The inter-day assay for the B7 scFv had a range o f detection for free bp26 from 
97 -  12500ng/ml (Fig. 5.27) and CVs ranged between 3.3 and 10.88% (Table 5.8), 
indicating that the assay were reproducible over five days.
2 6 1
Table 5.8: Inter-day assay coefficients o f  variation fo r  the detection o f  bp26 using the 
B7 scFv antibody fragment. Five sets o f  eight standards were assayed on five  different 
days and the coefficients o f  variation calculated.
bp26
(ng/ml)
C alculated mean ± S.D. Coefficient of variation 
<%)
12500 0.33 ±0.035 10.88
6250 0.42 ± 0.039 9.21
3125 0.53 ±0.050 9.30
1562 0.64 ±0.021 3.30
781 0.71 ±0.045 6.28
390 0.82 ± 0.044 5.37
195 0.89 ±0.059 6.63
97 0.97 ±0.046 4.71
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Figure 5.27: Inter-day assay curve fo r  the detection o f  bp26 using the B7 scFv in a 
competitive F.L1SA format. The range o f  detection o f  the antibody for free  bp26 was 
between 97 and 12500ng/ml. The calibration curve was plotted using Biaevaluation 
software 3.1 and represents the average normalised (A/An) results obtained over five 
individual days.
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5.2.2.6.3 Cross-reactivity studies on the anti-bp26 scFv
Cross-reactivity studies were then carried out on the bp26-specific scFv to determine 
the antibody specificity towards bp26 in relation to a panel o f proteins (as described in 
Section 2.4.9). The assays were carried out as for the competitive ELISAs except the 
cross-reactants were added to the immunoplate with the bp26-specific scFv. Separate 
calibration curves were plotted for each protein and the least detectable dose (LDD) 
and IC50 values were determined for each as 90% A/Ao and 50% A/Ao, respectively. 
The percentage cross reactivities were then estimated at the LDD (CR90) and at the 
IC50 (CR50) by expressing 100-fold the ratio between values obtained for bp26 and 
those o f the cross-reacting proteins.
Table 5.10 summarises the specificity and cross reactivity studies on the anti-bp26 
scFv against the different proteins. Minimal levels o f cross-reactivity (i.e. < 0.39) 
were observed between the anti-bp26 scFv and any o f the 5 proteins tested at the 
LDD. Low levels o f cross reactivity were also observed at the IC50 with % cross­
reactivity remaining below 8.
Table 5.10: Cross-reactivity and specificity studies on the anti-bp26 B7 scFv against 
various proteins. The cross-reactivity potential was approximated at the least 
detectable dose (LDD) and at the 1C50 value.
Protein LDDa
(ng/ml)
K V
(ng/ml)
c r 90c
(% )
CRso“
(% )
bp26 195 4000 100 100
pi 8 >50000 >50000 <0.39 < 8
Bovine serum albumin (BSA) >50000 >50000 <0.39 <8
Thyroglobulin (THY) >50000 >50000 <0.39 < 8
Ovalbumin (OVA) >50000 >50000 <0.39 < 8
Horse IgG >50000 >50000 <0.39 < 8
a Least detectable dose calculated at 90% A/Ao 
b 50% inhibition concentration (50% A/Ao)
c Percentage cross-reactivity determined at IC50 
d Percentage cross-reactivity determined at LDD
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5.2.2.7 Investigations on the use of the anti-bp26 scFv in the development of an 
im munoassay for the detection of Brucella abortus
The initial aim o f this chapter was the production o f Brucella-specific antibodies and 
the subsequent development o f  immunoassay for the detection o f B. abortus. A 
Brucella-specific scFv, directed against bp26, was isolated from a naive phage display 
library. Attempts have been made to incorporate this scFv into an immunoassay for 
the detection of B. abortus.
Attempts have been made to develop a competitive ELISA, which would involve 
immobilised recombinant bp26 and cellular bp26 competing for binding to the scFv. 
The ELISA was carried out using an immunoplate coated with 12.5|ag/ml of the 
recombinant bp26. A range o f B. abortus cell concentrations, ranging from 1.95 x 106 
to 1.6 x 1010 cells/ml, were prepared in PBS and the cells lysed using a lmg/ml 
solution o f lysozyme. The lysed cells were centrifuged and an equal volume o f the 
scFv added to the cellular supernatant. The mixture was added to the immunoplate 
and the ELISA completed. However, no competition was observed.
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5.3 Discussion
The main focus of this chapter was the production and characterisation o f Brucella- 
specific antibodies. Polyclonal and scFv antibodies were produced against Brucella- 
specific antigens and their sensitivity and specificity determined. The antibodies were 
then investigated for use in the development o f an immunoassay for the detection o f 
Brucella abortus. Their subsequent use in the development o f an immunoassay for the 
detection o f bovine brucellosis was also investigated (See Chapter 6).
Polyclonal antibodies were raised against Brucella abortus 45/20 cells in two rabbits, 
rabbit 1 and rabbit 2. Antibodies were raised against the crude cytoplasmic lysate 
from B. abortus 45/20 cells in rabbit 1 and against whole B. abortus 45/20 cells in 
rabbit 2. The rabbits were sacrificed 72 days after the initial immunisation and serum 
titres in excess o f 1/163,8400 were obtained against the crude cytoplasmic lysate and 
whole B. abortus cells (Figs. 5.2 and 5.3). The polyclonal antibodies were purified 
from the rabbit serum by saturated ammonium sulphate precipitation, which involved 
the relatively crude precipitation o f antibodies from the rabbit serum, followed by the 
more refined protein G affinity chromatography step in order to obtain pure IgG 
antibodies. The purification process was investigated using SDS-PAGE (Figs. 5.5 and 
5.6). The level o f  purity obtained greatly increased when going from the serum, to the 
SAS precipitate to the protein G affinity purified antibodies, where ultimately a pure 
solution o f IgG antibodies was obtained. The presence o f the purified IgG antibodies 
in the protein G-purified sample was confirmed following Coomassie staining with 
two bands clearly visible at 25 and 50kDa, which represented the antibodies heavy 
and light chains, respectively. Western blots were then carried out in order to confirm 
that the bands present on the SDS-PAGE were in fact rabbit IgG antibodies, The 
proteins were transferred from the acrylamide gel to nitrocellulose, which was then 
probed with an alkaline phosphatase-labelled anti-rabbit antibody. Bands at 25 and 
50kDa representing the heavy and light chains, respectively, confirmed the presence 
o f the rabbit IgG antibodies in each sample (Figs. 5.7 and 5.8). The band representing 
the light chain appeared less intense, in comparison with the heavy chain, which was 
due to the smaller size and different amino acid composition o f the light chain.
The purified polyclonal antibodies form rabbit 1 (pABl) and rabbit 2 (pAB2) were 
then applied to the development o f competitive ELISAs for the detection o f B.
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abortus. In order to develop a sensitive competitive ELISA for B. abortus several 
parameters were optimised. The limit o f detection of a competitive ELISA can be 
affected by the affinity o f an antibody and the equilibrium between free and 
immobilised antigen. If  the concentration o f the immobilised antigen were too high 
than there would be an unfair binding bias towards the immobilised antigen. For 
similar reasons the optimal antibody dilution used must be the limiting factor because 
excess would result in binding to both free and immobilised B. abortus cells to a 
higher degree affecting the limits o f  detection o f the assays. Checkerboard ELISAs 
were carried on each polyclonal antibody to determine the optimal cell-coating 
concentration and antibody dilution for use in a competitive ELISA (Figs. 5.9 and 
5.10). A cell-coating concentration o f 1.6xl08 cells/ml was found to be optimal for 
pABl and pAB2. The optimal antibody dilution, which displayed 70% of maximum 
binding, was found to be 1/5000 for both pABl and pAB2.
Optimisation o f the various assay parameters was then followed by the development 
o f competitive ELISAs. The range o f detection for free B. abortus 45/20 cells was 
found to be between 1.95xl06 and l.OOxlO9 cells/ml for pABl and 9.77xl05 to 
l.OOxlO9 cells/ml for pAb2 (Figs. 5.11 and 5.12). Intra- and inter-day variability 
studies were conducted to determine the reproducibility o f the assays. The coefficients 
o f variation (CVs) for the intra-day assay using pAbl and pAb2 remained below 8.96 
and 8.97%, respectively. Inter-day CVs for pAbl ranged between 0.73 and 5.85% 
(Table 5.2) and for pAB2 ranged between 1.14 and 6.40% (Table 5.3). The results 
discussed above suggest that the competitive ELISAs are statistically viable and 
reproducible over a period o f five days for the detection o f B. abortus, within the 
defined range.
Cross-reactivity studies were then carried out on the polyclonal antibodies, in a 
competitive ELISA format, in order to determine the cross-reactivity potential o f the 
antibodies against ubiquitous gram-negative and gram-positive bacteria (Tables 5.3 
and 5.4). Hennion et al. (1998) recommends the comparison o f two sets o f values, the 
LDD and IC 50, in order to accurately estimate cross reactivity over the measurement 
range. The least detectable dose (LDD) is defined as the smallest concentration of 
analyte that produces a response that can be significantly distinguished from zero 
(Hennion et al., 1998) and the IC50 is defined as the analyte concentration that results
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in 50% inhibition. The cross-reactivity is then estimated at the LDD (CR90) and at the 
IC50 (CR50) as 100-fold the ratio between the LDD and IC50 values o f the antigen and 
o f the cross reactant, respectively. Minimal cross-reactivity (i.e. < 1%) was observed 
with pAbl and pAb2 against the bacterial strains analysed (Tables 5.4 and 5.5). 
Therefore, confirming the specificity o f pAB 1 and pAB2 for Brucella abortus 45/20 
cells.
The specificity o f pABl and pAB2 towards the recombinant p i 8 and bp26 proteins 
and against the crude cell lysate from B. abortus 45/20 was then determined using 
Western blot analysis. B. abortus 45/20 cells were disrupted by sonication and the 
resulting supernatant electrophoresed using SDS-PAGE. The electrophoresed proteins 
were then transferred to nitrocellulose, which was probed using pABl and pAB2 (Fig. 
5.13). The crude cell lysate probed with pA Bl detected two main bands one at 18kDa 
and the other at 45kDa. Four bands were detected using pAB2, at 16kDa, 18kDa, 
38kDa and 45kDa. The band at 18kDa represents the 18kDa cytoplasmic protein 
(p i8), which was previously discussed in Chapter 4. The antibody binding reactivity 
o f pAbl and pAb2 against the recombinant p i 8 and bp26 was also assessed using 
Western blotting. Purified recombinant p i 8 and bp26 were electrophoresed using 
SDS-PAGE and then transferred to nitrocellulose, which was probed using pABl and 
pAB2. Bound polyclonal antibodies directed against the recombinant proteins were 
then detected using an alkaline phosphatase-labelled anti-rabbit antibody. Figure 5.14 
shows the Western blots obtained using pABl (A) and pAB2 (B). Both polyclonal 
antibodies recognised the p i 8 with band visible at 18kDa. However, they failed to 
detect bp26. These results were expected due to the cellular location o f the native 
proteins, p l8  is an 18kDa cytoplasmic protein and bp26 is a 26kDa periplasmic 
protein. The polyclonal antibodies were raised against whole B. abortus 45/20 cells 
and a crude cytoplasmic lysate. Therefore, reactivity o f the antibodies would have 
been expected against a cytoplasmic protein (p i8) and not against a periplasmic 
protein (bp26).
This chapter also focused on the isolation o f Brwce//«-specific scFv antibody 
fragments from the BMV scFv phage display library. The BMV is a naive human 
library, which was constructed using functional V-gene segments from 43 non­
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immunised donors and consisted o f a repertoire o f 1.4xl010 scFv fragments displayed 
on the surface o f phage. This library has previously proven useful in the isolation of 
highly-specific monoclonal antibodies with high affinities against a variety o f target 
antigens including carcinoembryonic antigen (CEA), doxorubicin, diethylenetriamine- 
pentaacetic acid (DTPA), fluorescein, merozoite surface protein 1 (MSP-1) o f 
Plasmodium falciparum  (malaria), human oestradiol and chicken very low density 
lipoprotein receptor (VDL-R) (Vaughan et al., 1996).
The BMV library was panned against the two recombinant Brucella-specific proteins, 
p i 8 and bp26 (previously described in Chapter 4). In general, between four and six 
rounds o f panning are required for the isolation o f specific scFvs from naïve scFv 
repertoires (Vaughan et al., 1996).
Six rounds o f panning were carried out on the BMV library against p i 8. The first 
three rounds o f panning against the p i 8 did not yield any positive clones. Following 
the sixth round o f panning against p l8  10 positive phage clones were isolated (Fig. 
5.15). These phage clones expressed scFv fragments on their surface that were 
specific for the p i 8 protein. However, several attempts to isolate soluble scFvs failed 
(Fig. 5.16). Attempts made to express the respective soluble scFvs may have failed 
due to poor solubility or in vivo degradation o f the c-myc tag used for the detection o f 
the soluble scFvs. Similar problems were encountered when Hayhurst and associates 
(2003) reported the isolation o f scFv antibody fragments against B. melitensis. Phage 
bound scFvs specific for B. melitensis were isolated from a pre-immunised phage- 
display library. However, attempts made to isolate the respective scFvs in a soluble 
form failed. Although, the expression o f soluble functional specific-antibodies was 
achieved following (i) fusion o f a human kappa light chain constant domain (Ck) 
chain to the scFv to generate a single chain antibody fragment (scAb) antibody 
fragments and (ii) co-expression of the periplasmic chaperone Skp, the phage bound 
scFvs offered greater sensitivity in an ELISA format.
Six rounds o f panning were also carried out on the BMV against the bp26 
recombinant protein. Following the sixth round o f panning 9 positive clones were 
identified in phage that were capable o f  detecting the bp26 protein (Fig. 5.17). 
Following analysis on the sixth pan soluble scFvs were isolated from the culture
269
supernatant and periplasm o f 5 clones (Fig. 5.18). Competitive ELISAs were then 
carried out on the soluble scFvs, directed against bp26, in order to estimate the 
specificity o f  the scFvs towards free recombinant bp26. Each o f the 10 clones tested 
showed specificity towards the free bp26 (Figs. 5.19 and 5.20).
Nucleotide and amino acid sequence analysis were then conducted on four clones, B7, 
B l l ,  D7 and C12. The pCANTAB6 plasmid DNA was purified from each clone and 
comfort reads were obtained on the scFv insert. Nucleotide sequence analysis on the 
four clones showed that the four clones were identical apart from a one base pair 
substitution in clone C l 1 at base 496, were a G was substituted with an A (Fig. 5.21). 
However, comparisons on the deduced amino acid sequences confirmed the four 
clones were identical (Fig. 5.22). Clone B7 was then selected for further 
characterisation. The complementary determining regions (CDRs) regions were 
identified on the heavy and light chains, o f the B7 scFv, according to Kabat et al. 
(1991) (Fig. 5.23) and the 3-D structure o f the B7 scFv was predicated using 
SwissModel (Fig. 5.24).
Western blot analysis was carried out to determine the specificity o f the B7 scFv. The 
scFv-containing supernatant was electrophoresed along with an anti -Listeria and an 
anti-AFBi scFvs using SDS-PAGE and then transferred to nitrocellulose. The anti­
Listeria scFv was previously isolated from the BMV library and following soluble 
expression had a c-myc tag incorporated. It served as a positive control. The anti- 
AFBi scFv was previously isolated from a pre-immunised phage display library and 
following soluble expression from pAK400 had a FLAG tag incorporated. The anti- 
AFBi scFv, lacking a c-myc tag, then served as a negative control. The nitrocellulose 
was probed with an anti-c-myc antibody and developed upon addition o f the 
chromogenic substrate. The anti-c-myc antibody specifically detected the c-myc- 
tagged scFvs with the presence o f a band at approximately 32kDa, representing the 
scFvs clearly visible in the lanes containing the anti-bp26 and anti -Listeria scFvs (Fig. 
5.25 (A)). However, the anti-c-myc antibody failed to detect the FLAG-tagged scFv 
confirming the specificity o f  the anti-c-myc antibody for the c-myc-tagged scFvs. The 
ability o f the anti-c-myc antibody to indirectly detect the interaction between the anti- 
bp26 scFv and bp26 was also confirmed using Western blotting. The bp26 and p i 8 
(Negative control) proteins were electrophoresed using SDS-PAGE and transferred to
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nitrocellulose. The nitrocellulose was probed with the B7 scFv, followed by the anti- 
c-myc antibody. The presence o f a band at 26kDa in the lane cOontaining bp26 
confirmed that the scFv was specifically binding to the recombinant bp26 (Fig. 5.25 
(B)). However, the absence o f a band in the lane containing p l8  confirms that the 
anti-c-myc antibody can be used to specifically detect the interaction between the 
anti-bp26 scFv and bp26.
ELISA characterisation was also carried out on the B7 scFv to give a further insight 
into the sensitivity, stability and reproducibility o f the scFv, prior to application to a 
competitive assay format for the detection o f either B. abortus or a bovine brucellosis 
infection. A checkerboard ELISA was carried out in order to determine the optimal 
scFv antibody dilution and protein coating concentration for use in a competitive 
ELISA. Various bp26 coating concentrations ranging from 0 to 50(j.g/ml and scFv 
dilutions ranging from undiluted to 1/1000 were tested to see which were optimal for 
use in a competitive ELISA for bp26 (Fig. 5.26). 12.5[ig/ml was selected as the 
optimal coating concentration o f the bp26 as it provided the highest absorbance values 
without depleting protein stocks and a 1/8 dilution o f the bp26 was chosen because it 
displayed 70% of the total binding to the bp26. Following optimisation o f the 
competitive ELISA parameters, intra/inter-day variability studies were carried out in 
order to determine the range o f detection o f the scFv and to establish the assay’s 
reproducibility. The intra-day coefficients o f  variation for the detection o f bp26 using 
the B7 scFv ranged between 1.51 -  8.39% and the range o f detection for bp26 was 
between 97 -  12500ng/ml. Table 5.8 shows the inter-day coefficients o f variation, 
which ranged between 3.30- 10.88%. Figure 5.27 shows the inter-day competitive 
ELISA where the range o f detection for bp26 was also between 97 -  12500ng/ml. 
These results suggest that the ELIS As are reproducible over a period of five days, 
within the defined range.
A selection o f proteins including bovine serum albumin (BSA), ovalbumin (OVA), 
thyroglobulin (THY), horse IgG and the recombinant p i 8 were used to determine the 
cross reactivity potential o f  the anti-bp26 scFv. The percentage cross reactivity was 
estimated for each protein at the LDD (CR90) and at the IC50 (CR50). Minimal cross­
reactivity (i.e. < 0.39%) was observed between the anti-bp26 scFv and the panel of
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proteins analysed at the LDD with low levels o f cross-reactivity (i.e. < 8%) also 
observed at the IC50 (Table 5.10).
Attempts were then made to incorporate the anti-bp26 scFv in a competitive ELISA 
format for the detection o f B. abortus cells. This assay format involved the 
immobilised recombinant bp26 and cellular bp26, from the periplasmic lysate o f B. 
abortus 45/20 cells, competing for binding to the anti-bp26 scFv. Immunoplates were 
coated with the recombinant bp26 at 12^g/ml and the periplasmic lysate was isolated 
from various cell concentrations, ranging from 1.95xl06 and 1.6xl010 cells/ml, using 
lysozyme. However, no competition was observed between the cellular and 
recombinant bp26, which may have been due to a number o f reasons, (i) The anti- 
bp26 scFv may have exhibited an unfair binding bias towards the recombinant protein 
inhibiting competition between the recombinant and cellular bp26. (ii) The anti-bp26 
scFv was isolated from a naive phage display library following six rounds o f panning 
against the recombinant bp26, which was isolated from XL-Gold E. coli under 
denaturing conditions, indicating that only linear epitopes on the recombinant bp26 
would have been exposed during the scFv selection process. This implies that the anti- 
bp26 scFv only recognised a linear epitope. However, during the competitive ELISA 
described above, the competing cellular bp26, in its native 3-D conformation, may 
have masked the anti-bp26 specific-linear epitope, therefore, ruling out any chance o f 
competition between the recombinant and cellular bp26 for binding with the anti-bp26 
scFv. (iii) Although the bp26 protein has been described as highly immunogenic the 
levels o f  expression o f the cellular bp26 have yet to be determined. Therefore, if the 
levels o f  expression were relatively low the cellular concentration o f bp26 would not 
be sufficient to compete with the recombinant bp26. (iv) Although bp26 has been 
identified as an immunodominant antigen in Brucella infections in sheep, goats, cattle 
and humans (Lindler et al., 1996; Rossetti el ah, 1996 and Debbarh el ah, 1996) its 
function has yet to be defined. The fact that bp26 is immunodominant during an 
infection may suggest it might play a role in Brucella virulence and may be 
upregulated in virulent strains o f  Brucella while being down regulated in non-virulent 
strains such as the B. abortus 45/20 rough strain, therefore, ruling out competition 
between the recombinant bp26 and cellular bp26 from the non-virulent B. abortus 
45/20. However, until the function and intracellular behaviour o f bp26 has been
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identified no definite conclusion on the lack o f  competition between the recombinant 
and cellular bp26 for binding with the anti-bp26 can be reached.
Conventional methods for the detection o f pathogenic bacteria include a 
morphological evaluation o f the micro-organism and growth determination in various 
media under a variety o f conditions. Traditional detection methods are laborious and 
time-consuming involving numerous steps such as pre-enrichment, selective 
enrichment, biochemical screening and serological confirmation (Invintski et al.,
1999). Polymerase chain reaction (PCR) has also been applied to amplify small 
quantities o f  species/strain-specific genetic material. Although PCR is a relatively 
quick procedure extensive sample clean up and processing maybe required.
More recently the use o f immunoanalytical techniques have provided systems for the 
rapid sensitive detection o f pathogenic bacteria. Immunoassays, incorporating both 
polyclonal and monoclonal antibodies, have been described for numerous highly toxic 
and infectious pathogenic bacteria. A fluorescence immunoassay (FIA), incorporating 
both monoclonal and polyclonal antibodies, has been developed for the detection of 
Yersiniapestis, which is the causative agent o f the bubonic plague (Coo et al., 1995). 
Immunoassays have also been developed for the detection o f Bacillus anthracis 
(Wijesuriya et al., 1994) and E. coli 0157:H7 (Pyle et al., 1995).
Recombinant antibody technology has provided an alternative source o f antibodies 
with desirable affinity and specificity. Large repertoire recombinant antibody libraries 
have been developed allowing the isolation o f  antibody fragments such as the antigen 
binding (Fab) and single chain variable fragments (scFv) displayed on the surface o f 
phage particles. scFv antibody fragments have been isolated against numerous 
pathogenic bacteria and their spores. Immunised, non-immunised and semi-synthetic 
phage display libraries have been used for the isolation o f specific-scFvs against 
several human and animal pathogens. A naive human library was used for the 
isolation o f scFvs against antigens associated with Chlamydia trachomatis, which 
causes trachoma (resulting in blindness) and sexually transmitted diseases (Lindquist 
et al., 2002). scFvs specific for microcystin-LR a cyanobacterial hepatotoxins 
(McElhiney et al., 2000), Bacillus subtilus spores (Zhou et a l, 2002) and Candida 
albicans (Haidaris et al., 2001) has also been isolated from large human naive
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libraries. The Griffin 1 library, a semi-synthetic phage display library, has been used 
for the successful isolation o f scFvs against Streptococcus suis, which causes severe 
infections in young pigs resulting in meningitis, septicemia and arthritis (de Greeff et 
al., 2000). B. melitensis-specific scFv antibody fragments, capable o f  distinguishing 
between Brucella melitensis and several Yersiniae, were isolated from a pre­
immunised phage display library (Hayhurst et al., 2003).
Recent developments in biological warfare have highlighted the requirements for 
sensitive and specific detection systems for hazardous bacterial strains such as 
Brucella. To date, the majority o f detection methods for B. abortus involve laborious 
and time-consuming cell-culture and biochemical techniques. Isolation o f B. abortus 
involves taking multiple blood cultures, which are incubated under 10% CO2, at 35°C 
for up to six weeks. Special rich media is required, including blood, serum and 
haemin. Since Brucella is a class III pathogen strong biosafety measures need to be 
addressed, including at least level 3 containment facilities. Ideally, a sensitive and 
specific immunoanalytical technique would rule out the need for the laborious cell 
culture techniques and possibly reduce the dangers associated with growing up the 
bacterial cultures. However, immunoassays for the detection o f B. abortus generally 
yield high levels o f  cross-reactivity with structurally related bacteria, such as Yersinia, 
that contain a similar 0.9 LPS epitope. Although, Hayhurst and associates (2003) have 
described the isolation o f B. melitensis-specific phage-displayed scFv antibody 
fragments capable o f distinguishing between Brucella melitensis and several Yersiniae 
difficulties were encountered when trying to isolate soluble scFvs. Therefore, 
Brucella-specific antibodies are generally applied to the development of 
immunoassays for the detection o f a bovine brucellosis infection in serum samples. 
Brucella-specific antibodies have been successfully used in sandwich assay format as 
the capture antibody (Gomell et al., 1984 and Al-Shamaly and Wright, 1998) or as a 
competing antibody in a competitive assay format (Gall and Nielsen, 1994, Uzal et 
al., 1996, Stack et al., 1999 and McGiven et al., 2003) and this will be further 
addressed in Chapter 6.
This chapter, while focusing on the production o f  antibodies for the development of 
an immunoassay for the detection o f a bovine brucellosis infection (See Chapter 6),
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addresses the need for an immunoassay for the detection o f  B. abortus cells. 
Although, difficulties were encountered when trying to develop a competitive ELISA 
for the detection of B. abortus incorporating the anti-bp26 scFv the development of a 
competitive ELISA incorporating the anti-Brucella polyclonal antibodies was 
successful. Both polyclonal antibodies produced had a limit o f detection for B. 
abortus cells at 1.95 x 106 cells/ml. pABl was raised against the crude cytoplasmic 
lysate from B. abortus 45/20 cells and pAB2 was raised against whole B. abortus 
45/20 cells, as previously discussed. Due to the rough morphology o f the B. abortus 
45/20 cells the polyclonal serum obtained will contain no antibodies against the 0.9 
side chain. This rules out the cross-reactivity potential between the polyclonal 
antibodies and Yersinia cells.
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CHAPTER 6
The development and validation of immunoassays for the 
detection of bovine brucellosis in serum samples
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6 .1  I n tr o d u c t io n
6.1.1 Brucellosis
Brucellosis is an infection caused by a gram-negative intracellular pathogen from the 
genus Brucella, which affects humans and domestic animals (Hemmen et a l ,  1995). 
The disease is regarded as a major zoonosis in some parts o f the world (Shamelian,
2000). In animals the infection is characterised by foetal abortions, lowered fertility 
and in some cases by reduced milk production (Toth et al., 1995). In humans 
symptoms include undulant fever, arthritis and osteomyelitis (Rossetti et al. 1996). 
The disease usually presents as acute, sub-acute or localized, but in some cases 
chronic and sub-clinical infections are also common (Shamelian, 2000). B. abortus 
and B. melitensis are the most prevalent and economically significant because they 
cause infection in humans and ruminants (cows, sheep and goats) (Hemmen et al., 
1995). Brucellosis results in economic losses worldwide, having major impacts on 
underdeveloped and developing countries (Rossetti et al., 1996) and it can also 
introduce limitations in the trade o f animals and animal products internationally 
(Jacques et al., 1998). Programs o f control o f brucellosis typically involve vaccination 
followed by diagnosis and elimination o f reactors. However, some countries opt out 
o f vaccination programs and are more in favour o f regular routine testing programs 
followed by the slaughter o f positive animals.
6.1.2 Brucellosis in Ireland
Ireland is considered to be free o f Brucella melitensis and is recognised as such under 
the EU Commission Decision 93/52/EC. However, Brucella abortus poses problems 
with reported cases o f bovine brucellosis. In 1965 a milk ring test survey carried out 
on 105,000 dairy herds indicated that at least 12% o f herds were infected with 
brucellosis. This survey also concluded that higher levels o f infection were observed 
in the intensive dairying areas in the south o f Ireland. This study promoted the 
initiation o f a national program for bovine brucellosis eradication. This program 
involved a combination o f vaccination using the 45/20 vaccine, serological testing and 
slaughter o f positive reactors. By the mid 1980s the number positive reactor herds 
identified had been reduced to between 300 and 500 annually. Vaccination was then 
ceased in 1984, in 1986 annual serological testing o f the National herd was suspended 
and the pre-movement test was then withdrawn in 1988. During this period the
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number o f positive reactors identified stayed between 300 and 400 per annum. 
However, the introduction o f the suckler cow quota scheme lead to a unusually high 
volumes o f movement o f  older dairy cows, which is believed to have lead to an 
increase dissemination o f brucellosis infections throughout Ireland as the levels of 
brucellosis increased from 434 new reactors in 1994 to 1081 in 1998. The re­
introduction o f serological testing in 1998 (along with a range o f measures discussed 
below) led to a significant decrease in the number o f positive reactors identified. This 
national bovine brucellosis eradication program is in accordance with the 
requirements o f Directive 64/52/EC. Numerous enhanced program measures have 
been introduced, which have collectively resulted in a marked improvement. These 
improvements include: (1) A 30-day compulsory pre-movement test is required for all 
eligible animals; (2) A full round o f serological testing o f all eligible animals (all 
females and males over 12 months o f age); (3) Rapid depopulation o f infected herds 
to prevent contiguous spread; (4) Slurry treatment, with hydrated lime in liquid form, 
in all brucellosis depopulated herds; (5) Diagnostic improvements have seen the 
introduction o f newer blood tests including indirect ELISA and competitive ELISAs, 
the fluorescence polarization assay (FPA) and the brucellin skin test; (6) Improved 
milk testing has resulted in the milk ring test being replaced by the more specific and 
sensitive whey ELISA test; (7) District Veterinary Offices now have the option of 
extending the rest period following depopulation; (8) The Special Investigation Unit 
o f the Department o f Agriculture Food and Rural Development has focused 
considerable attention on tackling fraud and irregularities in relation to brucellosis; 
and (9) A cull cow-monitoring program has focused on blood sampling from cows in 
all slaughter plants for brucellosis testing.
Although vaccination can be a highly effective tool in relation to brucellosis 
eradication there are some significant drawbacks to the use o f  brucellosis vaccination 
in Ireland. Under current EU legislation any vaccinated herd would lose its Official 
Brucellosis Free (OBF) status for a three-year period and any herd containing animals 
from a previously vaccinated herd would also lose its OBF status. This would result in 
significant restrictions on live animal exports from such herds. However, the fact that 
some infected animals will not show positive in blood tests, particularly at certain 
stages o f pregnancy, supports the need to develop new diagnostic assays that may
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Ihelp to overcome this diagnostic defect that hinders brucellosis eradication both in 
Ireland and worldwide
6.1.3 Conventional methods for the detection of Brucellosis
The diagnosis and control o f brucellosis is generally based on the serological testing. 
Numerous serological assays have been described for the detection of brucellosis. 
With the more conventional methods including the Rose Bengal Plate Test (RBPT) 
(Davies, 1971), the Complement Fixation Test (CFT) (Alton et al., 1988), the 
Buffered Brucella Plate Agglutination Test (BBAT), the Rapid Slide Agglutination 
Test (RSAT) and the Serum Agglutination Test (SAT), with the CFT and RBPT being 
the most accepted worldwide. These serological assays are generally used to detect 
antibodies directed against the rough lipopolysaccharide o f Brucella.
6.1.3.1 Rose Bengal Plate Test (RBPT)
The Rose Bengal Plate test is a rapid agglutination used to detect acute Brucella- 
specific agglutins associated with previous exposure to Brucella organisms. An equal 
volume o f serum and antigen is mixed on a white tile or enamel plate and rocked 
gently for 4 minutes and then observed for agglutination (Morgan et al., 1969). This 
test is considered a valuable screening test (Farina 1985) and is very sensitive, 
especially in vaccinated animals. However, it is less effective than the CFT at 
detecting brucellosis in sheep (Joint F AO/WHO Expert Committee on Brucellosis, 
Technical report 740, 1986). Positive samples are usually retested using a 
confirmatory test such as the ELISA of CFT. However, false-negative reactions can 
occur. Cell concentration and standardisation procedure o f the antigen can influence 
the efficiency o f the test (Blasco et al., 1994).
6.1.3.2 Com plem ent Fixation Test (CFT)
The complement fixation test is a widely used and accepted confirmatory test and it is 
considered the most effective test for diagnosing brucellosis (Joint FAO/WHO Expert 
Committee on Brucellosis, Technical report 740, 1986). Numerous variations of the 
test are available and each is conventionally carried out using microtitre plates. The 
degree o f haemolysis that has occurred in each well is compared with a set o f known 
standards. The results are expressed in international CFT units (icftu). Although this 
test is highly sensitive and specific, false positive reactions have been reported in
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animals vaccinated with the S19 vaccine. This complex technique requires good 
laboratory facilities and adequately trained staff to accurately titre and maintain the 
reagents. However, it has no particular advantage over the SAT performed in a 
hypertonic environment o f 5 -  20% NaCl.
6.1.3.3 Buffered Brucella P late agglutination Test (BBAT)
The Buffered Brucella plate agglutination test is a rapid agglutination test. The serum 
sample is mixed with the appropriate antigen, which is prepared from B. abortus strain 
1119-3, and, following incubation, any visible signs o f agglutination represent a 
positive result. This test has proven to be very sensitive especially in vaccinated 
animals. However, positive test results must be confirmed by ELISA or CFT.
6.1.3.4 R apid Slide Agglutination Test (RSAT)
The rapid slide agglutination test is also a rapid agglutination test that is carried out on 
slides. A serum sample is mixed with a Brucella bacterial suspension in a circular spot 
on a slide. After approximately one minute a visible agglutination will appear if  the 
serum contains specific anti -Brucella antibodies.
6.1.3.5 Serum Agglutination Test (SAT)
The serum agglutination test is use for the detection o f acute Brucella infections and 
is based on the detection o f IgM antibodies. The test can be performed in the presence 
o f 2-mercaptoethanol (2-ME test) or dithiothreitol (SAT-DTT). This test can only be 
performed by skilled laboratory personnel and is not satisfactory for the detection o f 
bovine brucellosis. The test can also fail to agglutinate in the presence o f sheep sera 
and can result in a marked prozone phenomenon, whereby the specific antigen and 
antibody do not agglutinate or precipitate visibly because o f an excess o f either 
antibody or antigen.
6.1.4 Im m unoassays for the diagnosis of brucellosis
6.1.4.2 ELISAs for the diagnosis of brucellosis
ELISAs are also commonly used as screening tests for the diagnosis o f brucellosis. 
The performance o f ELISAs is comparable with that o f the CF test, and since they are 
technically simpler to perform and more robust, their use may be preferred in many
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laboratories as screening and confirmatory tests. Numerous indirect (Uzal et a l, 1996; 
Jacques et a l, 1998 and Vanzini et al., 1998), sandwich (Al-Shamaly and Wright, 
1998) and competitive (Gall and Nielsen, 1994, Stack et al., 1999 and McGiven et al., 
2003) ELISAs have been described with the majority based on the detection o f 
antibodies directed against the smooth lipopolysaccharide (LPS).
More recently, ELISAs incorporating cytosoluble proteins (Goldbaum et al., 1992 and 
Debbarh et al., 1995) and outer membrane proteins (OMPs) (Dubray and Bezard, 
1980; Verstreate et al., 1982; and Dubray and Charriaut, 1983) have been described 
for the detection o f human (Goldbaum et al., 1992), ovine (Debbarh et al., 1996 and 
Cloeckaert et al., 2001), canine (Baldi et al., 1997) and caprine (Kittelberger et al., 
1995, 1998 and Zygmunt etal., 2002) brucellosis.
The use o f several cytosoluble proteins, including an 18kDa cytoplasmic protein (p i8) 
(Goldbaum et al., 1993 and Hemmen et al., 1995) and a 26kDa periplasmic protein 
(bp26) (Debbarh et al., 1996 and Rossetti et al., 1996), were described as markers of 
an active Brucella infection in bovines. However, little research has focused on their 
use in the development o f diagnostic assays for bovine brucellosis.
6.1.4.2 Fluorescent polarisation assay (FPA) for the diagnosis of brucellosis
The fluorescence polarization assay (FPA), described by Nielsen and associates 
(1996), is a homogeneous immunoassay based on the detection o f serum antibodies 
directed against the LPS. The principal o f an FPA is based on the fact that a molecule 
in solution rotates randomly at a rate inversely proportional to its size. The rate of 
rotation can be measured in the horizontal and vertical planes using a fluorescent label 
and polarized light. The rotational rate o f a small-labelled antigen molecule will be 
altered if antibody is attached to it and this change in rotation can be measured. 
Therefore, the FPA assay only requires addition o f labelled antigen to appropriately 
diluted test samples (so that the total time required is approximately 2 minutes). The 
FPA has been described for the diagnosis brucellosis in cattle (Nielsen et al., 1996; 
and Dajer et al., 1999), pigs (Nielsen et al., 1999), bison (Gall et a l, 2000) and 
various species o f deer (Gall et al., 2001). The FPA was initially developed and 
validated in Canada, for the detection o f antibodies to Brucella abortus, where 
brucellosis was eradicated (Nielsen et a l,  1996). The performance o f the FPA was
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then tested in areas o f various incidences o f brucellosis, which included Missouri, 
Texas, Chile, Mexico and Argentina (Nielsen et ah, 1998 and Dajer et ah, 1999).
6.1.5 Proteins as serological diagnostic m arkers of brucellosis
To date, the majority o f serological tests for the detection o f bovine brucellosis have 
targeted membrane-anchored lipopolysaccharides. However, such assays frequently 
yield false positive serological reactions due to cross reactivity with polysaccharide 
antigens o f  other micro-organisms such as Yerisinia enterocolitica 0.9 (Garin-Bastuji 
et al., 1999). Problems have also been encountered with these assays when trying to 
discriminate between actively infected and vaccinated cattle (Goldbaum et ah, 1993). 
Therefore, a greater emphasis is now being placed on the use o f specific-proteins as 
serological diagnostic markers. Individual studies on the isolation of protein markers 
for brucellosis have yielded interesting results.
The major outer membrane proteins (OMPs) o f Brucella species were initially 
identified in the early 1980s and identified as potential immunogenic and protective 
antigens (Dubray and Bezard, 1980; Verstreate et a l, 1982; and Dubray and 
Charriaut, 1983). The were classified as group 2 porin proteins, which consisted of 
proteins with a molecular mass o f 36 -  38kDa, and group 3 proteins, which consisted 
o f 31 -  34kDa and 25 -  27kDa OMPs. However, further studies using recombinant 
protein technology and monoclonal antibodies have shown major OMPs induce only 
low and heterogeneous antibody responses and thus constitute poor immunogens in B. 
abortus-mtectzd cattle (Cloeckaert et ah, 1992) and B. melitemis-infected sheep 
(Zygmunt etal., 1994). However, group 3 OMPs appear to be immunodominant in the 
course o f B. ovis infection in rams suggesting they may be useful for the development 
o f a serological diagnostic test for ram brucellosis (Kittelberger et ah, 1995, 1998).
Attention then focused on the identification o f sero-reactive cytosoluble proteins as 
diagnostic markers for brucellosis. Two interesting proteins, p i 8 (Goldbaum et ah, 
1992) and bp26 (Debbarh et ah, 1995), were identified as possible serological 
diagnostic markers for Brucella infections.
Two research groups, working independently, on the identification of protein markers 
for the detection o f brucellosis isolated the 26kDa periplasmic protein bp26,
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previously identified as CP26 (Debbarh et al., 1996 and Rossetti et ah, 1996). Rossetti 
et ah were working on the isolation o f a specific-protein marker for bovine brucellosis 
and Debbarh et ah were focusing on the identification o f protein markers for 
brucellosis in sheep. Sequence analysis of the cloned B. melitensis bp26 gene later 
revealed that it was nearly identical to the previously sequenced B. abortus bp26 gene 
(Debbarh et ah, 1996). Comparison of the nucleotide and amino acid sequences of the 
bp26 protein also revealed no sequence homology with other bacterial proteins 
(Rossetti et ah, 1996). This 26kDa protein has proven useful in the discrimination 
between vaccinated and naturally infected animals. The bp26 protein was capable o f 
discriminating between an antibody response from B. melitensis Rev. 1 vaccinated and 
B. melitensis-\nfQCtQ& sheep in a competitive ELISA (Debbarh et al., 1996). The 
protein also proved beneficial in discriminating between naturally infected and SI 9- 
vaccinated cattle (Rossetti et ah, 1996). This protein is also likely to elicit a strong 
immune response during early infection. Following experimental infection o f sheep an 
antibody response to the bp26 protein was first recognised at 21 days and a high 
frequency o f reactivity was also observed among naturally infected sheep following 
immunoblotting (Debbarh et ah, 1996).
A group in Argentina have been investigating the 18kDa cytoplasmic protein (pi 8) as 
an alternative diagnostic marker for brucellosis (Goldbaum et ah, 1993; Baldi et ah, 
1996 and Goldbaum et al., 1999). Furthermore, Hemmen et ah (1995) cloned and 
sequenced a Brucella abortus cytoplasmic protein with an apparent molecular weight 
o f 17kDa. It has been speculated that both these proteins are identical (Goldbaum et 
ah, 1999). This 18kDa protein has been successfully cloned and expressed in E. coli 
and the reactivity o f animal and human sera was similar to that o f the native protein 
contained in the cytoplasmic fractions o f  Brucella cells (Goldbaum et ah, 1999). 
Nucleotide and amino acid sequence comparisons have shown that this protein is also 
unique to Brucella spp. The protein is likely to be highly immunogenic due to its 
polymeric arrangement. Therefore, it is likely to elicit a strong immune response 
during early infection. This should greatly increase the pick-up efficiency during 
field-testing, and hence, reduce the numbers o f false negative results. Furthermore, a 
detectable response may be elicited in pregnant cattle that are not identifiable by 
conventional tests. The protein is also capable o f discriminating between SI 9-
283
vaccinated and naturally infected cattle (Goldbaum et ah, 1993). The protein has 
previously proven useful in the diagnosis o f bovine, canine and human brucellosis.
6.1.6 ELISA validation
The ultimate aim o f this research project was the development and validation o f a 
sensitive and specific assay for the detection o f bovine brucellosis in serum samples. 
This chapter focuses on the validation o f indirect and sandwich ELISA assays using a 
process described by Jacobson (1998), who previously defined a validated assay as 
one that “consistently provides test results that identify animals as being positive or 
negative for an analyte or process, and, by inference, accurately predicts the infection 
status o f animals with a predetermined degree o f statistical certainty”.
There are several variables that may affect the performance o f an assay and these 
must be addressed during the assay validation. Factors introducing assay variability 
can be categorised into three groups:
1. The sample: host/organ interaction affecting analyte concentration in the 
serum. Factors that may affect analyte concentration and composition in the 
serum sample include age, sex, breed, nutritional status, pregnancy and 
immunological responsiveness.
2. The assay system: physical, chemical biological and user-related factors, 
affecting assay performance in detecting the specific analyte in the serum 
sample. Interfering factors include instrumentation, operator error, reagent 
choice and calibration, reaction vessels, water quality, pH and ionicity o f 
buffers and reagents, incubation temperatures and duration and cross reactants.
3. The test result: the ability o f the assay results to determine the status o f the 
host in relation to the analyte in question.
Therefore, there are many variables that need to be addressed during the validation o f 
an assay. In order to try and address such issues assay validation was carried using an 
incremental process consisting o f three steps:
Step 1: Feasibility studies
Step 2: Development and standardisation
Step3: Characterisation o f assay performance
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6 .2  R e su lts
This chapter focuses on the development and validation of enzyme-linked 
immunosorbent assays for the diagnosis o f bovine brucellosis in serum samples. Four 
indirect ELISAs and two sandwich ELISA formats were investigated as alternative 
sensitive and specific immunoassays for the detection o f  a B. abortus infection. The 
indirect and sandwich ELISAs were developed and validated using the incremental 
process described by Jacobson (1998) (See Section 6.1.6). Throughout the course o f 
the assay development and validation process the Brucella-positive DeVeere Hunt 
Serum and the National Standard Serum (NSS) and the standard Brucella-negative 
serum were used to assess the discriminatory capabilities o f the ELISAs and their 
selected reagents and protocols. The indirect and sandwich ELISAs were conducted 
as described in Sections 2.6.1 and 2.6.2, respectively.
6.2.1 Feasibility studies
Initially, feasibility studies were carried out in order to determine the discriminatory 
capabilities o f the selected ELISA formats and reagents. These studies were intended 
to give an initial insight into the analytical sensitivity and specificity o f the assay 
formats.
Feasibility studies were carried out on four indirect ELISAs incorporating the two 
recombinant proteins, p i 8 and bp26, the crude cytoplasmic lysate from B. abortus 
45/20 and whole B. abortus 45/20 cells. Figure 6.1 (A) details the initial feasibilities 
studies on the four indirect ELISA formats, which indicates that each antigen and 
assay format offered discriminatory capabilities in distinguishing between the 
Brucella-positive and negative sera.
Feasibility studies were also carried out on two sandwich ELISAs, which incorporated 
the two anti-Brucella polyclonal antibodies, pABl and pABl (Section 5.2.1). The 
feasibility studies were carried out using immunoplates coated with p A B1 and pAB2, 
as the capture antibody to immobilise the crude cytoplasmic lysate and whole B. 
abortus 45/20 cells, respectively. The pABl And pAB2 sandwich ELISAs were both 
capable o f discriminatory between the Brucella-positive and negative sera (Fig. 6.1 
(B)).
285
(A)
120
■IDeVeere
■  NSS 
□  Neg
p18 bp26 CTY whole cells
iB)
120
|  100 
O
2  80 
c3
*  60
<D0)
>O
Q
yp0s
40
20
■  DeVeere
■  NSS 
□  Neg
pAB1 pAB2
Figure 6.1: Initial feasibility studies on the indirect (A) and sandwich (B) ELISAs fo r  
the detection o f  bovine brucellosis. (A) Indirect ELISAs, incorporating p l8 , bp26, the 
crude cytoplasmic lysate and whole B. abortus cells, were investigated as diagnostic 
immunoassays fo r  bovine brucellosis. (B) Sandwich ELISAs incorporating p A B l and 
pAB2 polyclonal antibodies were developed using whole B. abortus and the crude 
cytoplasmic lysate, respectively. The feasibility studies were carried out using the 
standard positive serum samples, the DeVeere Hunt Serum, the National Standard 
Serum (NSS) and the standard negative serum. Each antigen and ELISA form at was 
capable o f  discriminating between the Brucella-positive and negative serum samples.
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6.2.2 Assay developm ent and standardisation
Following the initial feasibility studies on the indirect and sandwich ELISAs assay 
development and standardisation was conducted on each ELISA format. The ultimate 
aim o f the assay development and standardisation was to obtain an optimised assay, 
which repeatedly achieved the same results for a standard serum. Development and 
standardisation o f each ELISA assay involved the optimisation o f the various assay 
parameters including antigen/antibody coating concentration/dilution and the serum 
and secondary antibody dilutions that were determined using checkerboard titrations. 
The optimal blocking reagents and antibody diluent were also determined along with 
preliminary estimates o f the repeatability on the assays.
6.2.2.1 Optim isation of blocking reagents and antibody diluent
Initial stages o f assay development and standardisation involved the optimisation o f 
the blocking solution and antibody diluent. The polyclonal nature of the bovine serum 
samples increases the chances o f  non-specific interactions between the serum 
antibodies and the blocking reagent. Optimisation o f the blocking reagent and serum 
diluent would result in a reduction in levels o f  the non-specific interactions occurring.
The blocking reagent and antibody diluent were optimised for use in the indirect and 
sandwich ELISAs. Milk marvel, chicken egg albumin (ovalbumin) and bovine serum 
albumin (BSA) were investigated as the blocking reagent and antibody diluent. In 
order to establish the optimum blocking reagent and antibody diluent immunoplates 
were coated with 4% (w/v) milk marvel (Plate 1), 4%  (w/v) ovalbumin (Plate 2) and 
4% (w/v) BSA (Plate 3). A 1/50 dilution o f each o f the 3 standard serum samples 
were prepared using each of the following diluents; PBS containing 4%  (w/v) milk 
marvel, PBS containing 4% (w/v) ovalbumin and PBS containing 4%  (w/v) BSA. 
Each o f  the serum dilutions was then pre-incubated at 37°C for 1 hour and then added 
to the three immunoplates, in duplicate. A 1/2000 dilution o f the HRP-labelled anti­
bovine antibody was then prepared using the three different diluents, PBS containing 
4% (w/v) milk marvel, PBS containing 4% (w/v) ovalbumin and PBS containing 4% 
(w/v) BSA. The three anti-bovine dilutions were then incubated for 1 hour at 37°C 
and then added to the three immunoplates. Bound serum antibodies were then
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detected following the addition o f the chromogenic substrate. The absorbance values 
obtained were then plotted on a bar graph.
Figures 6.2, 6.3 and 6.4 represent the results obtained from plate 1, plate 2 and plate3, 
respectively. A high degree o f non-specific interactions was observed between the 
plates coated with the milk marvel, ovalbumin and BSA, and the serum samples 
diluted and pre-incubated in the PBS containing both 4%  (w/v) ovalbumin and 4% 
(w/v) BSA. Whereas, negligible non-specific interactions were observed between the 
plates coated with the milk marvel, ovalbumin and B SA  and the serum samples 
diluted and pre-incubated in the PBS containing 4%  (w/v) milk marvel.
Therefore, in order to rule out any non-specific interactions 4% (w/v) milk marvel 
was selected as the optimal blocking reagent and antibody diluent for the serum 
samples and secondary antibody (following pre-incubation).
Ec
in
&
2 5
2.0
1.5
0)o
J 1.0
0.5
0.0
■  Marvel
■  OVA  
□  BSA
■O
<
DeVeere NSS Neg
Figure 6.2: Optimisation o f  blocking reagent and antibody diluent. Results obtained 
fo r  plate 1, which was coated with 4% (w/v) milk marvel. Each o f  the standard serum 
samples was added to the immunoplate, diluted to 1/50 with the 3 different diluents; 
PBS containing 4% (w/v) milk marvel, PBS containing 4% (w/v) ovalbumin and PBS  
containing 4% (w/v) BSA). A high degree o f  non-specific interactions was observed 
between the milk marvel blocking solution and serum samples diluted in ovalbumin 
and BSA. However, negligible non-specific interactions were observed between the 
milk marvel blocking solution and serum samples diluted in milk marvel.
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Figure 6.3: Optimisation o f blocking reagent and antibody diluent. Results obtained 
fo r  plate 2, which was coated with 4% (w/v) ovalbumin. Each o f  the standard serum 
samples was added to the immunoplate, diluted to 1/50 with the 3 different diluents; 
PBS containing 4% (w/v) milk marvel, PBS containing 4% (w/v) ovalbumin and PBS  
containing 4% (w/v) BSA). A high degree o f  non-specific interactions was observed 
between the ovalbumin blocking solution and serum samples diluted in ovalbumin and 
BSA. However, negligible non-specific interactions were observed between the 
ovalbumin blocking solution and serum samples diluted in milk marvel.
289
2.5
■  M arvel
D eV eere N S S  Neg
Figure 6.4: Optimisation o f  blocking reagent and antibody diluent. Results obtained 
fo r  plate 3, which was coated with 4% (w/v) BSA. Each o f  the standard serum 
samples was added to the immunoplate, diluted to 1/50 with the 3 different diluents; 
PBS containing 4% (w/v) milk marvel, PBS containing 4% (w/v) ovalbumin and PBS  
containing 4% (w/v) BSA). A high degree o f  non-specific interactions was observed 
between the BSA blocking solution and serum samples diluted in ovalbumin and BSA. 
However, negligible non-specific interactions were observed between the BSA 
blocking solution and serum samples diluted in milk marvel.
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6.2.2.2 Optim isation of antigen coating concentrations/dilutions for use in the 
indirect ELISAs
A panel of four coating antigens, the two recombinant proteins, p i 8 and bp26, the 
crude cytoplasmic lysate and whole B. abortus cells, were selected for the 
development of an indirect ELISA for the detection of bovine brucellosis. Following 
optimisation o f the blocking reagent and antibody diluent assay development and 
standardisation focused on optimising the antigen coating concentration/dilution for 
each o f the four antigens.
The indirect ELISAs were carried out as described in Section 2.6.1. Figure 6.5 shows 
the results obtained for the whole cell indirect ELISA. Cell coating concentrations 
ranging from 1 .6x  105 -  1 .6x  109 cells/ml were investigated and 1.6 x 10s cells/ml 
offered the optimal discrimination capabilities when distinguishing between the 
standard Brucella-positive and negative sera (Fig. 6.5). p l8  coating concentrations 
ranging from 0 - 25(ig/ml were investigated for use with the p l8  indirect ELISAs. A 
coating concentration o f 25(j,g/ml enabled the optimal discrimination between the 
standard Brucella-positive sera, the DeVeere Hunt Serum and the NSS, and the 
standard negative serum (Data not shown). Varying bp26 coating concentrations, 
ranging from 0 - 25fjg/ml, were investigated for use in the bp26 indirect ELISA. A 
bp26 coating concentration o f 6.25|ig/ml offered the optimal discrimination between 
the standard Brucella-positive and negative sera (Data not shown). CTY coating 
dilutions ranging from 1/2 -  1/64 were investigated for use in the CTY indirect 
ELISA  where a 1/4 dilution o f the CTY enabled the optimal discrimination between 
the standard Brucella-positive and negative sera (Data not shown).
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Figure 6.5: Optimisation o f  the whole B. abortus coating concentration fo r  use in the 
whole cell indirect ELISA. Coating concentrations, ranging from  1.6x10s - 1.6 x  109 
cells/ml, were tested in order to determine which concentration enabled optimal 
discrimination between the Brucella-positive and negative serum samples. A 1/500 
dilution o f  pAB2 was selected as optimal. 1.6 x  108 cells/ml was selected as the 
optimal cell concentration.
6.2.2.3 Optim isation of antibody coating dilutions for use in the sandwich 
ELISAs
Two sandwich ELISAs were developed incorporating the two polyclonal antibodies, 
pAB 1 and pAB2, which were raised against the crude cytoplasmic lysate and whole 
B. abortus cells, respectively. Initially, development and standardisation o f the 
sandwich ELISAs involved the optimisation o f the polyclonal antibody coating 
dilution.
Figure 6,6 shows the results obtained for the sandwich ELISA incorporating pAB2 
and whole B. abortus 45/20 cells, where pAB2 antibody coating dilutions ranging 
from 1/250 -  1/2000 were investigated. It was apparent that a 1/500 dilution o f pAB2 
enabled the optimal discrimination between the standard Brucella-positive and 
negative sera. Similarly, pA Bl antibody coating dilutions ranging from 1/250 -  
1/2000 were investigated for use in the pA Bl sandwich ELISA  which incorporated 
the crude cytoplasmic lysate from B. abortus 45/20 cells as the capture antigen. In this
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case a 1/500 dilution o f  pABl enabled optimal discrimination between the standard 
Brucella-positive and negative sera (Data not shown).
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Figure 6.6: Optimisation o f  the pAB2 antibody coating dilution fo r  use in the pAB2 
sandwich ELISA. Antibody coating dilutions, ranging from  1/250 -  1/2000, were 
investigated to determine which dilution enabled optimal discrimination between the 
Brucella-positive and negative serum samples. A 1/500 dilution ofpA B2 was selected 
as optimal.
6.2.2.4 O ptim isation of antigen concentrations/dilutions for use in the sandwich 
ELISAs
The development and standardisation o f the sandwich ELISAs also involved 
optimisation o f the crude cytoplasmic lysate (CTY) dilution and whole cell 
concentration for use in the pABl and pAB2 sandwich ELISAs, respectively.
Figure 6.7 shows the results obtained for the sandwich ELISA incorporating pAB2 
and whole B. abortus 45/20 cells. Cell concentrations ranging from 1.6xl05 -  1.6xl09 
were investigated. 1.6xl08 cells/ml offered the optimal discrimination between the 
standard 2?n/ce//a-positive and negative sera. CTY dilutions ranging from neat -  1/16 
were investigated for use in the sandwich ELISA incorporating pABl and CTY. A 
1/16 dilution was chosen because it enabled discrimination between the standard
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Brucella-positive sera, the DeVeere Hunt Serum and the NSS, and the standard 
negative serum.
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Figure 6.7: Optimisation o f  the whole cell concentration fo r  use in the pAB2 
sandwich ELISA. Cell concentrations, ranging from  1.6x10s - 1.6xl09 cells/ml, were 
tested in order to determine which concentration enabled optimal discrimination 
between the Brucella-positive and negative serum samples. 1.6 x  l ( f  cells/ml was 
selected as the optimal cell concentration.
6.2.2.S Optim isation of bovine serum  dilutions for use in the indirect and 
sandwich ELISAs
Following optimisation o f the antigen / antibody coating concentrations and dilutions 
assay development and standardisation involved the determination o f the optimal 
bovine serum dilution for use in the indirect and sandwich ELISAs.
Bovine serum dilutions, ranging from 1/25 -  1/2500, were investigated for use in the 
indirect and sandwich ELISAs to determine which allowed the greatest degree of 
discrimination between the positive and negative serum samples. Figure 6.8 shows the 
results obtained for the pAB2 sandwich ELISA, where it is apparent that a 1/50 serum 
dilution enabled the optimal discrimination between the standard Brucella-positive 
sera, the DeVeere Hunt Serum and the NSS, and the standard negative serum. Similar 
results were obtained for the p i 8, bp26, CTY and whole cell indirect ELISAs and the
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pABl sandwich ELISA, where a 1/50 dilution o f the serum samples enabled the 
optimal discrimination between the standard Brucella-positive and negative sera (Data 
not shown).
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Figure 6.8: Optimisation o f  the serum dilution fo r  use in the pAb2 sandwich ELISA. 
Serum dilutions, ranging from  1/25 -  1/2500, were tested in order to determine which 
concentration enabled optimal discrimination between the standard positive serum, 
the DeVeere Hunt Serum and the NSS, and the standard negative serum. A 1/50 
dilution o f  the bovine serum samples was selected as optimal.
6.2.1.6 O ptim isation of anti-bovine secondary antibody dilution for use in the 
indirect and sandwich ELISAs
During assay development and standardisation it was also necessary to determine the 
optimal secondary anti-bovine antibody dilution for use in the indirect and sandwich 
ELISAs. The three standard serum samples, the DeVeere Hunt Serum, the NSS and 
the standard negative serum, were used with varying anti-bovine antibody dilutions in 
order to determine which serum dilution offered the best discriminatory capability.
Anti-bovine secondary antibody dilutions, ranging from 1/1000 -  1/16000, were 
investigated to determine which allowed the greatest degree o f discrimination 
between the positive and negative serum samples. Figure 6.9 shows the results 
obtained for the pAB2 sandwich ELISA  where a 1/2000 dilution o f the anti-bovine
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secondary antibody enabled the optimal discrimination between the standard 
Brucella-positive and negative sera. A 1/2000 dilution o f the anti-bovine secondary 
antibody also appeared to be optimum for use in the p i 8, bp26, CTY and whole cell 
indirect ELIS As and in the pABl sandwich ELISA (Data not shown).
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Figure 6.9: Optimisation o f  the anti-bovine antibody, dilution fo r  use in the pAb2  
sandwich ELISA. Anti-bovine antibody dilutions, ranging from  1/1000 -  1/16000, 
were tested in order to determine which concentration enabled optimal discrimination 
between the standard positive serum, the DeVeer e Hunt Serum and the NSS, and the 
standard negative serum. A 1/2000 dilution o f  the anti-bovine antibody was selected 
as optimal.
6.2.2.7 Initial estimates on the repeatability of the indirect and sandwich ELISAs
Following optimisation o f the various assay parameters estimates on the repeatability 
o f each indirect and sandwich ELISA were determined. This involved carrying out 
intra- and inter-day variability studies on the indirect and sandwich ELISAs. The three 
standard serum samples, the DeVeere Hunt Serum, the NSS and the standard negative 
serum, were used to estimate assay repeatability. Three replicates o f each standard 
were assayed over ten individual days to provide estimates on repeatability. 
Coefficients o f variation were determined by expressing the standard deviation o f the 
replicates over the mean o f the replicates, and generally values below 10% indicate 
adequate reproducibility (Jacobson, 1998). Estimates on the repeatability were
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determined for the p i 8, bp26, CTY and whole cell indirect ELIS As and on the pABl 
and pAB2 sandwich ELISAs.
Intra-day variability studies were carried out on each ELISA were three replicates of 
each standard were assayed and the coefficients o f  variation determined, in order to 
estimate variation between replicates within a day. The intra-day coefficients o f 
variation obtained for the p i 8, bp26, CTY and whole cell indirect ELISAs remained 
below 8.2%. Whereas, the intra-day coefficients of variation for the pABl and pAB2 
sandwich ELISAs ranged between 0.7 and 9.8%.
Inter-day variability studies were then carried out on the indirect and sandwich 
ELISAs where three replicates o f each standard were assayed over ten days and the 
coefficients o f variation determined, in order to estimate variation between replicates 
over a ten day period. Table 6.1 summarises the inter-day coefficients o f variation 
obtained for the p i 8, bp26, CTY and whole cell indirect ELISAs. The CVs for each 
indirect ELISA remained below 9.5%. Figure 6.10 shows the graphical representation 
o f the inter-day variability studies on p i 8, bp26, CTY and whole cell indirect 
ELISAs. Table 6.2 summarises the inter-day coefficients o f variation obtained for the 
pABl and pAB2 sandwich ELISAs. The CVs for each sandwich ELISA remained 
below 8.9%. Figure 6.11 shows the graphical representation o f the inter-day 
variability studies on the pABl and pAB2 sandwich ELISAs.
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Table 6.1: Inter-day assay coefficients o f  variation obtained fo r  the p i  8, bp26, CTY  
and whole cell indirect ELISAs. Three sets o f  each standard were assayed on ten 
different days and the coefficients o f  variation calculated
Serum p l8 bp26 CTY W hole cell
DeVeere 9.5% 7.2% 8.6% 8.6%
NSS 8.4% 6.6% 7.7% 9.2%
Negative 4.6% 5.0% 7.2% 8.2%
■  D eV eere
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Figure 6.10: Inter-day assay graph obtained fo r  the p i  8, bp26, CTY and whole cell 
(WC) indirect ELISAs. The optimised assay form ats were capable o f  discriminating 
between the Brucella-positive and negative standard serum samples. The bar graph 
represents the average normalised (A/A0)  results obtained over ten individual days. 
The error bars represent the standard deviation calculated between the ten-day 
replicates.
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Table 6.2: Inter-day assay coefficients o f  variation obtained fo r  p A B l and pAB2 
sandwich ELISAs. Three sets o f  each standard were assayed on ten different days and  
the coefficients o f  variation calculated.
Serum pA Bl pAB2
DeVeere 8.1% 7.1%
NSS 8.9% 7.6%
Negative 7.5% 6.7%
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Figure 6.11: Inter-day assay graph obtained fo r  the p A B l and pAB2 sandwich 
ELISAs. The optimised assay form ats were capable o f  discriminating between the 
Brucella-positive and negative standard serum samples. The bar graph represents the 
average normalised (A/Ao) results obtained over ten individual days. The error bars 
represent the standard deviation calculated between the ten-day replicates.
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6 .2 .3  C h a r a c te r is a t io n  o f  a s s a y  p e r fo r m a n c e
6.2.3.1 Perform ance characterisation on the indirect and sandwich ELISAs
Following optimisation o f the various parameters required to successfully carry out 
the indirect and sandwich the performance o f each assay was determined using a set 
o f reference Brucella-positive and negative serum samples. The indirect and sandwich 
ELISAs were carried out on the standard positive sera, the DeVeere Hunt Serum and 
the National Standard Serum, on the 18 reference positive sera, on the standard 
negative serum, and on the 50 reference negative sera. The indirect and sandwich 
ELISAs were carried out incorporating the optimised parameters as described in 
sections 2.6.1 and 2.6.2, respectively.
Figure 6.12 shows the ELISA results obtained for the p i 8 indirect ELISA. A cut-off 
point o f point o f 30% was chosen to enable optimal discrimination between the 
Brucella-positive and Brucella-negative reference samples, suggesting that serum 
samples with a value above 30% were positive for a Brucella infection and serum 
samples with a value below 30% were regarded as negative. 13 out of the 20 positive 
serum samples tested, displayed greater than or equalled to 30% of the absorbance 
value obtained for the DeVeere Hunt Serum. Whereas, 7 had values lower than 30% 
suggesting 7 false negatives. 36 out o f the 51 negative serum samples displayed 
values lower than 30% o f the DeVeere Hunt Serum. Whereas, 15 o f the negative 
reference samples had values above 30%, indicating 15 false positive results. The 
diagnostic sensitivity (DSn) and diagnostic specificity (DSp) were then calculated 
using a 2 x 2 table that associated infection status with test results from the 20 
infected and 51 uninfected reference animals (Table 6.3). The p l8  indirect ELISA 
yielded a diagnostic sensitivity o f  62% and a diagnostic specificity o f 70%.
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Figure 6.12: Characterisation o f  the p i 8 ELISA performance. The p i 8 indirect 
ELISA was assessed fo r  use as a diagnostic assay fo r  bovine brucellosis in serum 
samples. The indirect ELISA was performed using a panel o f  20 positive serum 
samples from  animal infected with Brucella and 50 negative reference samples that 
were uninfected. The absorbance value fo r  each sample was recorded at 405nm and  
the mean plotted as a percentage o f  the mean absorbance obtained fo r  the DeVeere 
Hunt Serum. A stringent cut-off point o f  30% was chosen to allow discrimination 
between the Brucella-positive and negative serum samples.
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Table 6.3: Calculations o f  diagnostic sensitivity (DSn) and diagnostic specificity 
(DSp) fo r  the p l8  indirect ELISA. A 2 x 2 table that associated infection status with 
test results from  the 20 infected and 51 uninfected reference animals was used to 
calculate the DSn and DSp. The p i 8 indirect ELISA yielded a diagnostic sensitivity o f  
62% and a diagnostic specificity o f  70%.
Reference animals o f  known infected status
Infected Uninfected
Positive 13 15
Test A B
result
Negative 7 C D 36
Diagnostic sensitivity Diagnostic specificity
A 13 D 36
- = 62% - = -----  = 70%
A + C  20 D + B 51
Figure 6.13 shows the ELISA results obtained for the bp26 indirect ELISA. A cut-off 
point o f point o f 35% was chosen to enable optimal discrimination between the 
Brucella-positive and Brucella-negative reference samples. 8 out of the 20 positive 
serum samples tested, displayed greater than or equalled to 35% of the absorbance 
value obtained for the DeVeere Hunt Serum. Whereas, 12 had values lower than 35% 
suggesting 13 false negatives. 45 out o f the 51 negative serum samples displayed 
values lower than 35% o f the DeVeere Hunt Serum. Whereas, 6 of the negative 
reference samples had values above 35%, indicating 6 false positive results. The 
diagnostic sensitivity (DSn) and diagnostic specificity (DSp) were then calculated 
using a 2 x 2 table that associated infection status with test results from the 20 
infected and 51 uninfected reference animals aided the calculations (Table 6.4). The 
bp26 indirect ELISA yielded a diagnostic sensitivity o f 38% and a diagnostic 
specificity o f 88%.
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Figure 6.13: Characterisation o f  the bp26 ELISA performance. The bp26 indirect 
ELISA was assessed fo r  use as a  diagnostic assay fo r  bovine brucellosis in serum  
samples. The indirect ELISA was performed using a panel o f  20 positive serum 
samples from  animals infected with Brucella and 50 negative reference samples that 
were uninfected. The absorbance value fo r  each sample was recorded at 405nm and  
the mean plotted as a  percentage o f  the mean absorbance obtained fo r  the DeVeere 
Hunt Serum. A  stringent cut-off point o f  35% was chosen to allow discrimination 
between the Brucella-positive and negative serum samples.
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Table 6.4: Calculations o f  diagnostic sensitivity (DSn) and diagnostic specificity 
(DSp) fo r  the bp26 indirect ELISA. A 2 x 2  table that associated infection status with 
test results from  the 20 infected and 51 uninfected reference animals was used to 
calculate the DSn and DSp. The bp26 indirect ELISA yielded a  diagnostic sensitivity 
o f  38% and a diagnostic specificity o f  88%.
Reference animals o f  known infected status
Infected Uninfected
Positive 8 6
Test A B
result
Negative 12 C D 45
Diagnostic sensitivity Diagnostic specijicity
A 8 D 45
= 38 °A - = -----  = 88%
A + C 20 D + B 51
Figure 6.14 shows the ELISA results obtained for the CTY indirect ELISA A cut-off 
point o f point o f 45% was chosen to enable optimal discrimination between the 
Brucella-positive and Brucella-negative reference samples Each of the 20 positive 
serum samples tested, displayed greater than or equalled to 45% o f the absorbance 
value obtained for the DeVeere Hunt Serum and 46 out o f the 51 negative serum 
samples displayed values lower than 45% o f the DeVeere Hunt Serum. Whereas, 5 of 
the negative reference samples had values above 45%, indicating only 5 false positive 
results. The diagnostic sensitivity (DSn) and diagnostic specificity (DSp) were then 
calculated using a 2 x 2 table that associated infection status with test results from the 
20 infected and 51 uninfected reference animals aided the calculations (Table 6.5). 
The CTY indirect ELISA yielded a diagnostic sensitivity o f 100% and a diagnostic 
specificity o f 90%.
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Figure 6.14: Characterisation o f  the CTY ELISA performance. The CTY indirect 
ELISA was assessed fo r  use as a diagnostic assay fo r  bovine brucellosis in serum 
sample. The indirect ELISA was performed using a panel o f  20 positive serum 
samples from  animals infected with Brucella and 50 negative reference samples that 
were uninfected. The absorbance value fo r  each sample was recorded at 405nm and  
the mean plotted as a percentage o f  the mean absorbance obtained fo r  the DeVeere 
Hunt Serum. A stringent cut-off point o f  45% was chosen to allow discrimination 
between the Brucella-positi ve and negative serum samples.
■  Positive sera
■  Standard positive sera
Negative sera 
1  Standard negative serum
305
Table 6.5: Calculations o f  diagnostic sensitivity (DSn) and diagnostic specificity 
(DSp) fo r  the CTY indirect ELISA. A 2 x 2  table that associated infection status with 
test results from  the 20 infected and 51 uninfected reference animals was used to 
calculate the DSn and DSp. The CTY indirect ELISA yielded a diagnostic sensitivity 
o f  100% and a diagnostic specificity o f  90%.
Reference animals o f  known infected status
Infected Uninfected
Test
result
Positive 20 5
A B
Negative 0 C D 46
Diagnostic sensitivity Diagnostic specificity
A  20 - 100°* ° 46. _ 90%
A + C  20 D + B 51
Figure 6.15 shows the ELISA results obtained for the whole cell indirect ELISA. A 
cut-off point o f point o f 55% was chosen to enable optimal discrimination between 
the Brucella-positive and Brucella-negative reference samples. 20 out o f the 20 
positive serum samples tested, displayed greater than or equalled to 55% of the 
absorbance value obtained for the DeVeere Hunt Serum and 48 out o f the 51 negative 
serum samples displayed values lower than 55% o f the DeVeere Hunt Serum. 
Whereas, only 3 values above 55%, indicating 3 false positive results. The diagnostic 
sensitivity (DSn) and diagnostic specificity (DSp) were then calculated using a 2 x 2 
table that associated infection status with test results from the 21 infected and 51 
uninfected reference animals aided the calculations (Table 6.6). The whole cell 
indirect ELISA yielded a diagnostic sensitivity o f 100% and a diagnostic specificity 
o f  94%.
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F igure 6.15: C haracterisation o f  the w hole cell indirect ELISA perform ance. The whole 
cell indirect ELISA was assessed fo r  use as a  diagnostic assay fo r  bovine brucellosis in  
serum  sam ples. The indirect ELISA w as perfo rm ed  using a  p a n el o f  20 positive serum  
sam ples fro m  anim als in fected  w ith B rucella  a nd  50 negative reference sam ples that were 
uninfected. The absorbance value fo r  each sam ple w as recorded a t 405nm  and  the m ean  
p lo tted  as a  percentage o f  the m ean absorbance obtained fo r  the D eVeere H unt Serum. A  
stringent c u t-o ff p o in t o f  55%  was chosen to allow  discrim ination between the Brucella­
positive and  negative serum  samples.
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Table 6.6: C alculations o f  diagnostic sensitivity (DSn) and  diagnostic specificity  
(DSp) fo r  the whole cell indirect ELISA. A  2 x 2  table tha t associated  infection status 
w ith test results fro m  the 20 in fected  and  51 uninfected reference anim als was used to 
calculate the D Sn and  DSp. The w hole cell indirect ELISA y ie ld ed  a  diagnostic 
sensitivity o f  100% and  a  diagnostic specificity o f  94%.
Reference anim als o f  known in fected  status
In fected U ninfected
Positive 20 3
Test A B
result
Negative 0 C D 48
Diagnostic sensitivity Diagnostic specificity
A  20 D 48 ftjn/- 100°/ .  = 9 4 %
A  +  C 20 D  +  B  51
Figure 6.16 shows the E L IS A  results obtained for the p A B l sandwich E L IS A . A  cut­
o ff  point o f  point o f  55%  was chosen to enable optimal discrimination between the 
B rucella-positive and B rucella-negative reference samples, suggesting that serum 
samples w ith  a value above 55%  were positive fo r a B rucella  infection and serum  
samples w ith  a value below  55%  were regarded as negative. 20 out o f  the 20 positive 
serum samples tested, displayed greater than or equalled to 55%  o f  the absorbance 
value obtained for the D eV eere H unt Serum. 49 out o f  the 51 negative serum samples 
displayed values low er than 55%  o f  the D eV eere H unt Serum. Whereas, 2  o f  the 
negative reference samples had values above 55% , indicating 2 false positive results. 
The diagnostic sensitivity (D S n ) and diagnostic specificity (D S p) were then calculated 
using a 2  x  2  table that associated infection status w ith  test results from the 20 
infected and 51 uninfected reference animals (Table 6.7). The p A B l sandwich E L IS A  
yielded a diagnostic sensitivity o f  100%  and a diagnostic specificity o f  96%.
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F igure 6.16: C haracterisation o f  the p A B l sandw ich ELISA perform ance. The p A B l 
sandw ich ELISA was assessed  fo r  use as a  diagnostic assay fo r  bovine brucellosis in 
serum  sample. The sandw ich ELISA was perform ed  using a  p a n e l o f  20 positive serum  
sam ples fro m  anim als in fected  w ith B rucella  a nd  50 negative reference sam ples tha t 
were uninfected. The absorbance value fo r  each sam ple was recorded a t 405nm a n d  
the m ean p lo tted  as a  percentage o f  the m ean absorbance obtained fo r  the D eVeer e 
H unt Serum. A stringent c u t-o ff p o in t o f  55%  was chosen to allow  discrim ination  
between the Brucella-positive  a n d  negative serum  samples.
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Table 6.7: C alculations o f  diagnostic sensitivity (DSn) and  diagnostic specificity  
(DSp) fo r  the p A B l sandwich ELISA. A 2 x  2 table that associated infection status 
w ith test results fro m  the 20 in fected a nd  51 uninfected reference anim als was used to 
calculate the D Sn and  DSp. The p A B l sandw ich ELISA y ie ld ed  a  diagnostic 
sensitivity o f  100% and  a  diagnostic specificity o f  96%.
Reference anim als o f  known in fected  status
In fected Uninfected
Positive 20 2
Test A B
result
Negative 0 C D 49
Diagnostic sensitivity Diagnostic specificity
A  20 D 4 9
A  +  C 20
-  100°/i1 D  + B  5 1  9 6 %
Figure 6.17 shows the E L IS A  results obtained for the pA B 2 sandwich E L IS A . A  cut­
o f f  point o f  point o f  50%  was chosen to enable optimal discrimination between the 
B rucella-positive  and B rucella-negative  reference samples. 20 out o f  the 20 positive 
serum samples tested, displayed greater than or equalled to 50%  o f  the absorbance 
value obtained for the D eVeere H unt Serum. 49 out o f  the 51 negative serum samples 
displayed values lower than 50%  o f  the D eVeere H unt Serum. Whereas, 2 o f  the 
negative reference samples had values above 50% , indicating 2 false positive results. 
The diagnostic sensitivity (D S n) and diagnostic specificity (D S p) were then calculated 
using a 2  x  2  table that associated infection status w ith test results from the 20 
infected and 51 uninfected reference animals aided the calculations (Table 6 .8). The 
pA B 2 sandwich E L IS A  yielded a diagnostic sensitivity o f  100%  and a diagnostic 
specificity o f  96% .
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F igure 6.17: C haracterisation o f  the pA B 2 sandw ich ELISA perform ance. The pA B 2  
sandwich ELISA was assessed fo r  use as a  diagnostic assay fo r  bovine brucellosis in  
serum  sample. The sandwich ELISA was perform ed  using a p a n e l o f 20 positive serum  
sam ples fro m  anim als in fected  w ith B rucella  and  50 negative reference sam ples that 
were un in fected  The absorbance value fo r  each sam ple w as recorded a t 405nm and  
the m ean p lo tted  as a  percentage o f  the m ean absorbance obtained fo r  the D eVeere 
H unt Serum. A  stringent cu t-o ff p o in t o f  50%  w as chosen to allow  discrim ination  
between the Brucella-positive and  negative serum  samples.
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Table 6.8: C alculations o f  diagnostic sensitivity (DSn) and  diagnostic specificity  
(DSp) fo r  the pA B 2 sandwich ELISA. A  2 x  2 table that associated infection status 
w ith test results fro m  the 20 infected a nd  51 uninfected  reference anim als was used to 
calculate the D Sn a nd  DSp. The pA B 2 sandw ich ELISA yie ld ed  a  diagnostic 
sensitivity o f  100%  a n d  a  diagnostic specificity o f  96%.
Reference anim als o f  known in fected  status
In fected U ninfected
Positive 20 2
Test A B
result
N egative 0 C D 49
Diagnostic sensitivity Diagnostic specificity
A  20 D 49
— - 1 0 0 ° / " 9 6 %
A  +  C  20 D  +  B  51
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6.3 Discussion
This chapter focused on the development and validation o f  enzyme-linked  
immunosorbent assays for the diagnosis o f  bovine brucellosis. Four indirect and two 
sandwich E L IS A s  were investigated for use as a diagnostic assay for brucellosis. The 
assay should be highly sensitive and specific, reproducible, capable o f  discriminating 
between cattle vaccinated w ith  attenuated B. abortus S19 and naturally infected cattle, 
and would also enable the detection o f  a B rucella  infection shortly after infection. 
Ideally there would be no cross-reactivity w ith  other gram-negative bacteria, e.g. 
Yersinia enterocolitica  0:9.
The indirect E L IS A s were based on the detection o f  anti -Brucella  serum antibodies 
specific for the recombinant p l 8 and bp26, the crude cytoplasmic lysate from  B. 
abortus 45 /20  and whole B. abortus 45 /20  cells, directly adsorbed on immunoplates. 
The sandwich E L IS A s  were based on the detection o f  anti -Brucella  serum antibodies 
specific for the crude cytoplasmic lysate from  B. abortus 45 /20  and whole B. abortus 
45/20  cells, which were captured on the immunoplate using the polyclonal antibodies 
p A B l and PA B 2, respectively. The E L IS A  validation was carried out based on O IE  
standards, using a method previously described for the validation o f  serological assays 
fo r the diagnosis o f  infectious diseases (Jacobson, 1998).
The E L IS A  validation was based on an incremental process, whereby assay 
parameters were established and characterised through the fo llow ing methods: ( 1) 
determining the feasibility o f  the method; (2 )  development o f  the assay through 
optimisation and standardisation o f  reagents and protocols; and (3 ) determining the 
performance characteristics o f  the assay.
The first stage in validating the indirect and sandwich E L IS A s  was the feasibility 
studies. Feasibility studies were carried out in order to determine i f  the selected 
reagents and protocols had the capacity to distinguish between B rucella-infected  and 
uninfected samples. The feasibility studies were conducted on the p i 8 , bp26, C T Y  
and w hole cell indirect E L IS A s  (Fig. 6.1 (A ))  and on the p A B l and pA B 2 sandwich 
E L IS A s  (F ig . 6 .1 (B ))  using tw o positive control sera, the D eVeere H unt Serum and 
the National Standard Serum, and one standard negative serum. The four indirect and 
tw o sandwich E L IS A s  were capable o f  discriminating between the tw o standard
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positive sera, the D eV eere H unt serum and the N SS , and the standard negative serum. 
The raw  test results (optical density) obtained were normalised by expressing the 
absorbance values as a percentage o f  the D eV eere H unt Serum (W right et al., 1993). 
Normalisation o f  the raw test results accounts for variability that may be introduced 
by ambient temperatures, test parameters and the photometric instrument.
Follow ing establishment o f  the feasibility o f  the p i 8, bp26, C T Y  and whole cell 
indirect E L IS A s  and the p B A l and pA B 2 sandwich E L IS A s the next step in assay 
validation involved assay development and standardisation. Assay development and 
standardisation involved tw o  main process: (1 ) Selection o f  optimal reagent 
concentrations and protocol parameters; and (2 ) Estimates on repeatability. 
Optimisation o f  the various assay parameters, including blocking reagent, optimal 
concentration /dilutions for antigen coating, serum samples and secondary antibody, 
was achieved through checkerboard titrations.
The choice o f  blocking reagent and serum /  antibody diluent can greatly influence the 
sensitivity o f  an assay. The polyclonal nature o f  the bovine serum samples increases 
the possibility o f  non-specific interactions between serum antibodies and the blocking  
reagent. Ovalbumin, bovine serum albumin and m ilk  marvel were investigated for use 
as the blocking reagent and serum /  antibody diluent. The use o f  ovalbumin (Fig. 6.3) 
and B S A  (Fig. 6 .4 ) as the blocking reagent resulted in a high-degree o f  non-specific 
interactions w ith  the bovine serum samples. How ever, the use o f  m ilk  marvel as both 
blocking reagent and serum /  antibody diluent (Fig. 6 .2 ) resulted in negligible non­
specific interactions. In  order to keep the non-specific interactions to a m inim um  4%  
m ilk  marvel was selected as the blocking reagent and diluent for the serum samples 
and secondary antibody, which needed to be pre-incubated at 37°C  for 1 hour (Data  
not shown).
The optimal antigen coating concentration/dilution, for use in the indirect ELISAs, 
was determined fo r p i 8, bp26, C T Y  and whole cells. The optimum concentration /  
dilution o f  the antigen adsorbed to  the immunoplate was optimised using 
checkerboard titrations. The optim um  coating concentration/ dilution was selected as 
the one that produced the best positive: negative ratio (i.e. the concentration /  dilution
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that enabled the greatest discrimination between the positive and negative serum 
samples). A n  optimum p l 8 coating concentration o f  25(ig /m l, a bp26 coating 
concentration o f  6.25(j.g/ml, a C T Y  coating dilution o f  1/4 and a whole cell coating 
concentration o f  1.6 x  10s cells/ml (Fig. 6 .5 ) were selected because they enabled the 
greatest discrimination between the positive and negative control sera.
In  order to develop a sensitive sandwich E L IS A  the capture antibody coating dilution  
and the captured antigen dilution /  concentration was optimised. Polyclonal antibody 
dilutions ranging from  1/250 -  1/2000 were adsorbed onto immunoplates and assayed 
to determine the optimal antibody coating dilution. Results for the p A B l and pA B 2  
(Fig. 6 .6)  sandwich E L IS A s  showed that a 1/500 dilution o f the polyclonal antibodies 
enabled optimal discrimination between the standard positive and negative sera. The 
optimum antigen concentration /  dilution was determined for use in the p A B l and 
pAB 2 sandwich E L IS A s. A  1/16 dilution o f  the C T Y  and a B. abortus cell 
concentration o f  1.6 x 108 cells/ml (Fig. 6 .7 ) enabled optimal discrimination between 
the standard positive and negative sera.
The next step involved in the incremental process for assay development and 
standardisation focused on the optimisation o f  the bovine serum sample dilution. The  
optimal serum dilution was independently determined for each o f  the four indirect 
E L IS A s  and the tw o  sandwich E L IS A s  using the standard positive sera, DeVeere  
H unt Serum and N SS , and standard negative serum. Bovine serum dilutions ranging 
from 1/25 -  1/2500 were assayed for the p i 8, bp26, C T Y  and whole cell indirect 
E L IS A s  and for the p A B l and pA B 2 (Fig. 6 .8)  sandwich E L IS A s. In  each case the 
serum samples diluted to 1/50 enabled the optimal discrimination between the 
standard positive sera, D eVeere H unt Serum and NSS, and standard negative serum.
During assay development and standardisation it was also necessary to determine the 
optimal secondary anti-bovine antibody dilution fo r use in the indirect and sandwich 
E LIS A s. A  horseradish peroxidase-labelled anti-bovine secondary antibody was 
selected fo r use in the development o f  the indirect and sandwich ELIS A s. The optimal 
working dilution was independently determined fo r each o f the indirect and sandwich 
E L IS A s using the standard positive sera, D eVeere Hunt Serum and NSS, and standard
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negative serum. A nti-bovine secondary antibody dilutions ranging from  1/1000 -  
1/16000 were assayed for the p i 8, bp26, C T Y  and whole cell indirect E L IS A s  and for 
the p A B l and pA B 2 (Fig. 6 .9) sandwich E L IS A s. In  each case a 1/2000 dilution o f  
the anti-bovine secondary antibody enabled the optimal discrimination between the 
standard positive sera, D eVeere Hunt Serum and N SS, and standard negative serum.
Estimates on assay repeatability were also determined as one o f  the main processes 
involved in the assay development and standardisation. The repeatability studies 
involved carrying out intra- and inter-day variability studies on the indirect and 
sandwich E L IS A s  using the three standard serum samples. Three replicates o f  each 
standard were assayed over ten individual days to  provide estimates on the 
repeatability. Coefficients o f  variation were determined by expressing the standard 
deviation o f  the replicates over the mean o f  the replicates. The intra-day coefficients 
o f  variation for the indirect E L IS A s  were calculated between the three replicates o f  
each standard and all remained below 8.21% . The intra-day coefficients o f  variation  
calculated for the sandwich E L IS A s remained below  9.82% . The inter-day variability  
studies on the p l 8 , bp28, C T Y  and whole cell indirect E L IS A s (Fig. 6 .10) resulted in 
co-efficients o f  variation between 4 .57  and 9.46%  (Table 6.1). The inter-day co­
efficients o f  variation for the p A B l and pA B 2 sandwich E L IS A s  (F ig  6 .11) ranged 
between 6.70 and 8 .90%  (Table 6.2). Jacobson (1998 ) recommended that coefficients 
o f  variation for normalised data from  the replicates o f  the standard serum should not 
exceed 10%. These results suggest that the indirect and sandwich E L IS A s are 
reproducible over a period o f  ten days.
The final stage o f  the assay validation involved characterising the assays in  
accordance to performance in categorising predetermined serum samples as positive 
and negative. Estimates o f  diagnostic sensitivity (D S n) and diagnostic specificity 
(D S p) are used to determine assay performance. The D S n  and D S p are derived from  
testing a panel o f  reference samples w ith  predetermined infectious status and history 
relative to the disease/infection in question. The D S n  is estimated as the proportion o f  
known infected animals that give a positive result to infected animals that yield  
negative results (false negative (F N )). Whereas, the D Sp is the proportion o f  
uninfected animals that give negative results to uninfected animals that display 
positive results (false positives (F P )). The number o f  infected and uninfected
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reference samples required can be calculated fo r determinations o f  D S n  and DSp  
within statistically defined limits. I t  is recommended that a m inim um  o f  
approximately 300 infected and 1000 -  5000 uninfected samples should be tested to 
provide added confidence in the estimates o f  DSn and D Sp (Jacobson, 1998). 
However, in our case it was d ifficult to find a large number o f  infected and uninfected  
reference samples. Therefore, it was necessary to start the validation process w ith  
small panels o f  infected and uninfected sera.
The indirect and sandwich E L IS A s  were carried out on 20 known B rucella-positive 
and 51 known B rucella-negative  serum samples using the optimised parameters 
discussed above. The results obtained were then used to calculate the diagnostic 
specificity (D S p) and diagnostic sensitivity (D S n ) o f  each E L IS A  format. The p l 8 
(Fig. 6 .12) and bp26 (F ig . 6 .13 ) indirect E L IS A s  appeared to be the least sensitive and 
specific, w ith  the p i 8 indirect E L IS A  yielding a diagnostic sensitivity o f  62%  and a 
diagnostic specificity o f  70%  (Table 6 .3 ) and the bp26 indirect E L IS A  yielding a 
diagnostic sensitivity o f  38%  and a diagnostic specificity o f  88%  (Table 6.4). The  
indirect E L IS A s incorporating the B rucella  cellular antigens appeared to offer 
improved diagnostic sensitivity and specificity over the recombinant proteins. The  
C T Y  indirect E L IS A  (Fig. 6 .14 ) resulted in a diagnostic sensitivity o f  100%  and a 
diagnostic specificity o f  90%  (Table 6.5). The whole cell indirect E L IS A  (Fig. 6.15) 
yielded a diagnostic sensitivity o f  100%  and a diagnostic specificity o f  94%  (Table  
6 .6 ). The p A B l and p A B 2  sandwich E L IS A s  offered increased diagnostic sensitivity 
and specificity over the four indirect EL IS A s. The p A B l (Fig. 6 .16) and pA B 2 (Fig. 
6.17) sandwich E L IS A s  both yielded diagnostic sensitivity o f  100%  and a diagnostic 
specificity o f  96%  (Tables 6 .7  and 6 .8 , respectively).
These results would suggest that the crude cytoplasmic lysate from  B. abortus 45 /20  
cells and the whole B. abortus 45 /20  cells offer improved discriminatory capabilities 
over the recombinant p i 8 and bp26 B rucella -specific proteins. Based on an indirect 
E L IS A  format the w hole B. abortus cells proved to be the most sensitive and specific 
antigen, out o f  the four antigens investigated, for the diagnosis o f  bovine brucellosis. 
The crude cytoplasmic lysate displayed a similar diagnostic sensitivity to the whole 
cells w ith  a slightly reduced diagnostic specificity. Whereas, the p A B l and pA B 2
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sandwich E L IS  As offer improved discriminatory capabilities over the indirect E L IS A  
when used for the diagnosis o f  bovine brucellosis in serum samples.
Published research has focused on the validation o f a variety o f  E L IS A  formats for the 
diagnosis o f  bovine brucellosis in serum samples. A n  indirect E L IS A  based on the 
detection o f  serum antibodies directed against a hot water/hot phenol-extracted B. 
abortus smooth lipopolysaccharide was described by Vanzin i and associates (1998). 
This indirect E L IS A  was validated using 562 infected and 2646 uninfected serum 
samples and yielded a relative sensitivity o f  99.6%  and specificity o f  98.6% . A  
competitive E L IS A  utilising immobilised lipopolysaccharide and a monoclonal 
antibody specific for the O-polysaccharide epitope has also been described for the 
diagnosis o f  brucellosis (N ielsen e t al., 1995). The specificity and sensitivity o f  this 
E L IS A  were 99.7 and 100%, respectively, using 1464 uninfected and 261 infected 
serum samples. Evidently, these E L IS A s  appear to offer improved sensitivity and 
specificity over the indirect and sandwich E L IS A s  developed in this chapter. 
However, this may be due to the fact that a lim ited number o f  infected and uninfected 
reference samples were available during the E L IS A  development and validation.
The most commonly used immunoassays for the detection o f  bovine brucellosis target 
the O-side chain o f  membrane-anchored lipopolysaccharides on the surface o f  smooth 
B rucella  strains. However, such assays frequently yield false positive serological 
reactions due to cross reactivity w ith  polysaccharide antigens o f  other micro­
organisms such as Yerisinia enterocolitica  0 .9 (Garin-Bastuji e t al., 1999). Problems 
have also been encountered w ith  these assays when trying to  discriminate between 
actively infected and vaccinated cattle (Goldbaum e t a l., 1993). However, the C T Y  
and w hole cell indirect E L IS A s  and the p A B l and pA B 2 sandwich E L IS A s  described 
in this chapter incorporate whole B. abortus 45 /20  whole cells or corresponding 
cellular extract. The B. abortus 45 /20  are a non-virulent rough stain o f  Brucella. 
Therefore, they lack the O-side chain on membrane-anchored lipopolysaccharides. 
This would suggest that the C T Y  and whole indirect E L IS A s  and the p A B l and pA B 2  
sandwich E L IS A S  would be less like ly  to exhibit false positives results, due to cross­
reactivity w ith  serum antibodies directed against Yersinia  and other structurally 
related bacterial cells containing a similar O-side chain.
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The 18kDa cytoplasmic protein, p l 8 (Goldbaum  e t a l ,  1993 and Hem m en e t a l, 
1995) and the 26kD a periplasmic protein, bp26 (Debbarh e t a l., 1996 and Rossetti e t 
al., 1996) were described as useful markers o f  an active B rucella  infection. Research 
has focused on the incorporation o f  these proteins in immunoassays for the detection 
o f  human (Goldbaum et a l, 1992), ovine (Debbarh e t a l,  1996 and Cloeckaert e t a l, 
2001), canine (Baldi e t a l, 1997) and caprine (Kittelberger e t a l,  1995, 1998 and 
Zygm unt e t a l, 2002) brucellosis. However, little research focused on their use in the 
development o f  diagnostic assays for bovine brucellosis. The research conducted in 
this chapter would therefore conclude that although the p i 8 and bp26 Brucella- 
specific proteins have proven useful as serological diagnostic markers for brucellosis 
they are unsuitable for the detection o f  a B. abortus infection.
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CHAPTER 7
Overall conclusions and future work
3 2 0
7.1 O vera ll conclusions and fu tu re  w o rk
The research discussed in this thesis focused on the development and characterisation 
o f immunoassays for the detection o f  aflatoxin B i (A F B i) and for the diagnosis o f  
bovine brucellosis.
Chapter 3 focused on the production and characterisation o f  three genetically derived 
aflatoxin B i (A FB i)-specific  scFv antibody fragments. The gene encoding the A F B i-  
specific scFv was isolated from a pre-immunised phage display library and 
subsequently expressed as a monomeric, dim eric and alkaline phosphatase-labelled 
scFv. The three scFvs were applied to  the development o f  competitive E L IS A s  for the 
detection o f  A F B i. The optimised competitive E L IS A s  were relatively sensitive w ith  
the dimeric and AP-labelled scFvs offering improved sensitivity over the monomeric 
scFv. The monomeric and dimeric scFvs displayed m inimal cross reactivity towards 
structurally related aflatoxins. However, the AP-labelled scFv showed a relatively  
high-level o f  cross-reactivity towards aflatoxin B 2 and G i. The monomeric and 
dimeric scFvs were then applied to the development o f  Biacore inhibition  
immunoassays fo r the detection o f  A F B i. The inhibition assays were conducted using 
a C M -5  chip directly immobilised w ith  an A F B i derivative and they offered improved  
sensitivity (0 .39  and 0 .19ng/ml for the monomeric and dimeric scFvs, respectively) 
over the competitive E L IS A s  (12  and 3ng/m l for the monomeric and dimeric, 
respectively). The monomeric and dim eric scFvs also exhibited m inim al cross­
reactivity towards the structurally related aflatoxins in the Biacore inhibition assay 
format. A  rapid lateral flo w  immunoassay was also developed for the detection o f  
A F B i, w hich incorporated an an ti-A FB i rat monoclonal antibody (obtained from  
collaborators at IF R  Norw ich, U K ). The monoclonal antibody was found to be 
relatively sensitive (1 .5ng/m l) in the L F IA  format.
The w o rk  described in Chapter 4  focused on the cloning and expression o f  two  
recombinant B. abortus proteins, p i 8 and bp26. The 18kDa cytoplasmic protein ( p i8) 
and the 26kD a  periplasmic protein (bp26) were cloned using a two-step cloning 
strategy incorporating T A  cloning and subsequent QIAexpress cloning. The  
recombinant proteins were successfully expressed from the high-level expression 
vector pQ E -60 in X L - 10 Gold E. coli cells. Several parameters affecting levels o f  
recombinant protein expression were optimised and then applied to  the large-scale
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expression o f  the p i 8 and bp26 recombinant proteins. The His-tagged recombinant 
proteins were purified using immobilised metal affin ity  chromatography ( IM A C ) and 
the ability o f  the proteins to discriminate between B rucella-positive  and negative 
serum samples was then confirmed using Western blotting and indirect ELISAs.
In  Chapter 5 the production and characterisation o f  B rucella-specific antibodies for 
use in the development o f  immunoassays fo r the detection o f  B rucella abortus was 
examined in  detail. Polyclonal antibodies were raised against the crude cytoplasmic 
lysate from  B. abortus 45 /20  and whole B. abortus 45 /20  cells. Saturated ammonium  
sulphate precipitation and protein G  affin ity  chromatography were used to isolate the 
polyclonal antibodies from  the crude anti-serum. The purified polyclonal antibodies 
were applied to  the development o f  competitive E L IS A s for the detection o f  B. 
abortus. The polyclonal antibodies proved to  be relatively sensitive and specific for 
the detection o f  B. abortus and the optimised E L IS A s were highly reproducible. 
Research also focused on the isolation o f  B rucella-specific scFv antibody fragments 
from  a naïve scFv phage display library. The B M V  library (obtained from  C A T , U K ) 
was panned against the recombinant B rucella-specific proteins, p l 8 and bp26 
(Chapter 4). Follow ing six rounds o f  panning a bp26-specific scFvs were isolated 
from  the B M V  library. The scFvs proved to be relatively sensitive and specific for 
bp26 in a competitive E L IS A  format. Follow ing six rounds o f  panning against p l 8, 
positive phage clones, expressing p i 8 -specific scFvs, were isolated. However, several 
attempts to  express the scFvs in a soluble form  were unsuccessful. Attempts made to 
express the soluble, p i 8-specific, scFvs may have been unsuccessful due to poor 
solubility or in vivo  degradation o f  the c-myc tag used for the detection o f  the soluble 
scFvs.
Chapter 6  focused on the development and validation o f  indirect and sandwich 
E LIS A s, incorporating the recombinant p l 8 and bp26 proteins and the B. abortus- 
specific  polyclonal antibodies, for the diagnosis o f  bovine brucellosis in serum 
samples. Four indirect E L IS A s  and tw o sandwich E L IS A s  were investigated as 
alternative sensitive and specific immunoassays for the diagnosis o f  bovine 
brucellosis. The indirect E L IS A s  w ere based on the detection o f  serum antibodies 
directed against the recombinant proteins p l 8 and bp26, the crude cytoplasmic lysate 
from  B. abortus 45 /20  and whole B. abortus 45 /20  cells, which were directly adsorbed
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onto immunoplates. Whereas, the sandwich E L IS A s  were based on the detection o f  
serum antibodies towards the crude cytoplasmic lysate from  B. abortus 45 /20  and 
whole B. abortus 45 /20  cells, which were captured on immunoplates using p AB 1 and 
pAB2, respectively. The indirect and sandwich E L IS A s  were developed and validated 
based on Organisation Internationale des Epizootics (O IE )  (W orld  Organisation for 
Anim al Health) standards, using a method described for the validation o f  serological 
assays for the diagnosis o f  infectious diseases (Jacobson, 1998). The diagnostic 
sensitivity and specificity o f  each E L IS A  was investigated using a panel o f  bovine 
sera w ith known infection status. The indirect E L IS A s, incorporating the p i  8 and 
bp26 recombinant proteins, displayed poor discriminatory capabilities when  
distinguishing between the B rucella -positive and negative samples, whereas, the 
indirect and sandwich E L IS A s  incorporating the C T Y  and whole cells adequately 
discriminated between the B rucella-positive  and negative serum samples.
In  summary, this w ork  highlights the potential use o f  immunoassays for the detection 
o f  food contaminants and the diagnosis o f  infectious diseases. I t  shows that a variety 
o f  genetically-derived antibody fragments can be engineered using appropriate 
expression vectors. The research also demonstrates the ease w ith  which scFv 
fragments, and their derivates, from  a pre-immunised phage display library can be 
applied to  a variety o f  sensitive and specific assay formats for the detection o f  A F B i. 
The use o f  a two-step cloning strategy also proved useful for the cloning, expression 
and purification o f  recombinant proteins. The relative ease w ith  which large non­
immunised phage display libraries could be used for the isolation o f  specific scFvs 
was also established. The use o f  an incremental process for the validation o f  
immunoassays also proved successful in the development o f  highly sensitive and 
specific E L IS A s  for the detection o f  bovine brucellosis.
Future w ork could entail the application o f  the A F B i immunoassays to the specific 
detection o f  A F B i in grain samples, which could then be used for routine and reliable 
sample analysis. I t  may also be possible to increase expression levels o f  the A F B i-  
specific scFvs and subsequently apply them to a L F IA  format. Research could also 
focus on the further validation o f  the indirect and sandwich E L IS A s  for the diagnosis 
o f bovine brucellosis. This w ould involve monitoring the valid ity o f  the E L IS A s using 
a pool o f  approximately 300 infected and 1000 -  5000 uninfected reference samples.
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Safety precautions
A fla to x in  B i
A flatoxin B i is a potent carcinogen that can cause heritable genetic damage. I t  is very  
toxic by inhalation, in contact w ith skin and i f  swallowed. A ll aflatoxin related w ork  
must be conducted within a fumehood. Personal protective clothing including gloves, 
safety goggles and a lab coat must be worn at all times. Spillages should be cleaned 
up immediately using 12% (v /v ) hypochlorite. A ll aflatoxin B i contaminated waste 
must be decontaminated as follow:
•  A n  equal volume o f  12%  (v /v ) hypochlorite is added to  the 
contaminated waste and left standing fo r 30 mins.
•  The p H  o f  the waste is then adjusted to 8.0 and left standing for 30 
mins.
•  Then 5%  (v /v ) acetone is added and the waste left standing for 30 
mins.
•  The decontaminated waste can then be disposed.
B rucella  abortus
B. abortus is a class H I pathogen and live  cultures must only be handled in a certified  
biological safety cabinet. Therefore, all B. abortus cells used during this research were 
received heat-killed from  the B lood Testing Laboratory, Department o f  Agriculture, 
Food and Fisheries, Cork.
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